trial_id	trialacronym	phase	recruitmentstatus	recruitmentstate	approvaldate	actualstartdate	drug_list	drug_classes	combo_list	combo_classes	secondaryid	studytitle	healthcondition	postcode	ext_weblink
ACTRN12614000365662	ACTRN12614000365662	Phase 1	Recruiting	NZ	7/04/2014	28/04/2014	Oraxol; Oraxol + Paclitaxel; Paclitaxel	taxane	Oraxol + Paclitaxel; Paclitaxel; Oraxol + Paclitaxel	taxane	Nil	Patients with cancer for whom IV paclitaxel (at a dose of 80 mg/m2 IV over 1 hour) is indicated will be treated with intravenous paclitaxel and Oraxol (Paclitaxel + HM30181AK-US) to evaluate bioavailability, safety and tolerability of Oraxol.	Cancer	Dunedin	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614000365662
ACTRN12614000789662	ACTRN12614000789662	Phase 2	Not yet recruiting	NSW	24/07/2014		Luminespib	HSP90_inhibitor	Luminespib	HSP90_inhibitor	Nil	A Randomised controlled Phase II trial of the pharmacodynamic effects of the heat shock protein 90 (Hsp90) inhibitor AUY922 in high-risk, localised prostate cancer	Prostate Cancer	2050 - Missenden Road	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614000789662
ACTRN12614001181695	BOSTON-II	Phase 1	Recruiting	VIC	11/11/2014	2/11/2015	Pembrolizumab; Radiotherapy	radiotherapy; anti-PD-1_monoclonal_antibody	Pembrolizumab; Radiotherapy	anti-PD-1_monoclonal_antibody; radiotherapy	Nil	A pilot study to assess the safety and feasibility of stereotactic ablative body radiosurgery combined with MK-3475 in patients with oligometastases from breast cancer.	Metastatic Breast Cancer (1-5 metastases)		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614001181695
ACTRN12614001248651	MesomiR-1	Phase 1	Recruiting	NSW	28/11/2014	29/09/2014	Dexamethasone; Dexamethasone + TargomiRs; TargomiRs	glucocorticoid + miR-16_miRNA_mimic; glucocorticoid; miR-16_miRNA_mimic	Dexamethasone; Dexamethasone + TargomiRs; TargomiRs; Dexamethasone + TargomiRs	glucocorticoid; glucocorticoid + miR-16_miRNA_mimic; miR-16_miRNA_mimic; glucocorticoid + miR-16_miRNA_mimic	Nil	MesomiR 1: A Phase I study of intravenously administered Epidermal Growth Factor Receptor (EGFR)-targeted, EnGeneIC Delivery Vehicle (EDV)-packaged, miR-16 mimic (TargomiRs) for patients with Malignant Pleural Mesothelioma (MPM) and advanced Non-Small Cell Lung Cancer (NSCLC) failing on standard therapy	Malignant Pleural Mesothelioma; Advanced Non Small Cell Lung Cancer	2050 - Camperdown; 2139 - Concord Repatriation Hospital; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614001248651
ACTRN12615000504516	NAP-CAPABIL	Phase 2	NOT_RECRUITING	NSW	20/05/2015		Capecitabine; Capecitabine + Nab-paclitaxel; Nab-paclitaxel; Paclitaxel	fluoropyrimidine; taxane; fluoropyrimidine + taxane	Capecitabine + Nab-paclitaxel; Capecitabine + Nab-paclitaxel	fluoropyrimidine + taxane; fluoropyrimidine + taxane	Nil	Patients with advanced biliary cancer to be treated with second line combination chemotherapy of NAB Paclitaxel and capecitabine in a single arm pilot study to assess feasibility	advanced biliary cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615000504516
ACTRN12615001088538	TIDAL-Melanoma	Phase 2	Recruiting	QLD	16/10/2015	6/01/2017	Diphencyprone; Diphencyprone + Imiquimod; Imiquimod	topical_immune_response_modifier	Diphencyprone; Diphencyprone + Imiquimod; Imiquimod; Diphencyprone + Imiquimod	topical_immune_response_modifier	Nil known	The effect of topical imiquimod or diphenylcyclopropenone on complete clinical response in patients with cutaneous in-transit melanoma metastases - A Phase II Single Centre Prospective Randomised Pilot Study.	Cutaneous in-transit melanoma metastases	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615001088538
ACTRN12615001328561	DESNET2	Phase 2	Not yet recruiting		4/12/2015		Octreotide; Octreotide + Pasireotide; Pasireotide	somatostatin_analog	Octreotide + Pasireotide; Pasireotide; Octreotide + Pasireotide	somatostatin_analog	Novartis Protocol Number: CSOM230FAU04T	Phase II study evaluating the efficacy of Pasireotide LAR (SOM230) dose escalation in patients with refractory non-functional GEP NETs	Gastro-entero-pancreatic neuroendocrine tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615001328561
ACTRN12616000008426	ACTRN12616000008426		Recruiting	NSW	12/01/2016	3/06/2015	RX108	sodium-potassium_ATPase_inhibitor	RX108	sodium-potassium_ATPase_inhibitor	None	A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RX108 in Patients with Advanced or Metastatic Solid Tumours.	Advanced or Metastatic Solid Tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000008426
ACTRN12616000228482	ACT001-AU-001	Phase 1	Recruiting	NSW, SA, VIC	19/02/2016	19/09/2016	ACT001	NFKB_inhibitor	ACT001	NFKB_inhibitor	ACT001-AU-001 (Sponsor protocol code)	A phase 1 dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors	Solid tumors	3004 - Melbourne; 2031 - Randwick; 5042 - Bedford Park; 3121 - Richmond	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000228482
ACTRN12616000420448	INTEGRATE-IIa	Phase 3	Recruiting	ACT, NSW, NT, NZ, QLD, SA, TAS, VIC, WA	1/04/2016	10/11/2016	Placebo; Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; placebo	Regorafenib; Placebo	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; placebo	AG0315OG  CTC0140	A Randomised Phase III Double-Blind Placebo-Controlled Study to determine if regorafenib improves overall survival in refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Advanced (metastatic or locally recurrent) Gastro-Oesophageal Cancer (AGOC)	6009 - Nedlands; 2444 - Port Macquarie; 4814 - Douglas; 2031 - Randwick; 4575 - Birtinya; 2139 - Concord; 4029 - Herston; 2145 - Westmead; 3690 - Wodonga; 3165 - East Bentleigh; 0810 - Tiwi; 2605 - Garran; 2065 - St Leonards; 5037 - Kurralta Park; 2485 - Tweed Heads; 2305 - New Lambton Heights; 6008 - Subiaco; 7000 - Hobart; 2010 - Darlinghurst; 2450 - Coffs Harbour; 5011 - Woodville; 2250 - Gosford; 2217 - Kogarah; 3168 - Clayton; 3084 - Heidelberg; 5042 - Bedford Park; 3355 - Wendouree	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000420448
ACTRN12616000440426	PRIME001	Phase 1 / Phase 2	NOT_RECRUITING; STATUS_UNKNOWN	NSW	6/04/2016	21/02/2017	Carboplatin; Carboplatin + Decitabine; Decitabine	DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor	Carboplatin + Decitabine; Carboplatin + Decitabine	DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent	None	Pilot Early phase II study of Decitabine and Carboplatin in patients with advanced melanoma	Metastatic melanoma	2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000440426
ACTRN12616000958482	NABNEC	Phase 2	Recruiting	NSW, NZ, QLD, SA, TAS, VIC, WA	21/07/2016	17/11/2016	Carboplatin; Carboplatin + Nab-paclitaxel; Nab-paclitaxel	taxane; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane	Carboplatin + Nab-paclitaxel; Carboplatin + Nab-paclitaxel	platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	AG0215NET	A phase II study to establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal Neuroendocrine Carcinomas.	Gastrointestinal Neuroendocrine Carcinomas		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000958482
ACTRN12616001019493	MoST-addendum-2	Phase 2	NOT_RECRUITING	NSW, WA	2/08/2016	16/12/2016	Durvalumab; Durvalumab + Tremelimumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Durvalumab + Tremelimumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	CTC0141 Addendum 2	Single arm, open label, signal seeking, phase IIa trial of the activity of Durvalumab (MEDI4736) in combination with Tremelimumab in patients with advanced rare or neglected cancers.	Cancer	2010 - Darlinghurst; 2217 - Kogarah; 6009 - Nedlands; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001019493
ACTRN12616001187437	MatchMel	Phase 2	NOT_RECRUITING	NSW	29/08/2016		Bortezomib; Cabozantinib; Ceritinib; Crizotinib; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Olaparib; Palbociclib; Pazopanib; Ramucirumab; Regorafenib; Sorafenib; Sunitinib; Trametinib; Vorinostat	FLT3_inhibitor; MET_inhibitor,type_1; HDAC_inhibitor; BCR-ABL1_inhibitor,first_generation; PDGFRA_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; CRAF_inhibitor; mTORC1_inhibitor; MET_inhibitor,type_2; ALK_inhibitor,first_generation; YES1_inhibitor; anti-VEGFR2_monoclonal_antibody; VEGFR_inhibitor; KIT_inhibitor,first_generation; KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; BCR-ABL1_inhibitor,second_generation; VEGFR2_inhibitor; ROS1_inhibitor; PDGFR_inhibitor; SRC_inhibitor; RET_inhibitor; CDK4/6_inhibitor; ERBB2_inhibitor,first_generation; MEK_inhibitor; AXL_inhibitor; EGFR_inhibitor,type_II; PARP_inhibitor; ALK/ROS1/IGF1R_inhibitor; proteasome_inhibitor; KIT_inhibitor,ATP-competitive; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; EGFR_inhibitor,first_generation	Bortezomib; Cabozantinib; Ceritinib; Crizotinib; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Olaparib; Palbociclib; Pazopanib; Ramucirumab; Regorafenib; Sorafenib; Sunitinib; Trametinib; Vorinostat	ALK/ROS1/IGF1R_inhibitor; ALK_inhibitor,first_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; BCR-ABL1_inhibitor,first_generation; BCR-ABL1_inhibitor,second_generation; CDK4/6_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; EGFR_inhibitor,first_generation; EGFR_inhibitor,type_II; ERBB2_inhibitor,first_generation; FLT3_inhibitor; HDAC_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT_inhibitor; KIT_inhibitor,ATP-competitive; KIT_inhibitor,first_generation; MEK_inhibitor; MET_inhibitor,type_1; MET_inhibitor,type_2; PARP_inhibitor; PDGFRA_inhibitor; PDGFR_inhibitor; RET_inhibitor; ROS1_inhibitor; SRC_inhibitor; VEGFR2_inhibitor; VEGFR_inhibitor; YES1_inhibitor; anti-VEGFR2_monoclonal_antibody; mTORC1_inhibitor; proteasome_inhibitor	Protocol Number MIA2015/174	Molecular profiling to identify patients with BRAF/NRAS wild type melanoma and the proportion of these patients that undergo matched targeted therapy as a result of extended molecular testing.	Metastatic Melanoma	2065 - Wollstonecraft; 2050 - Camperdown; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001187437
ACTRN12616001637437	ACTRN12616001637437	Phase 1	NOT_RECRUITING	ACT	25/11/2016	7/10/2016	Complete Freund’s Adjuvant; Pembrolizumab	immunopotentiator; anti-PD-1_monoclonal_antibody	Pembrolizumab; Complete Freund’s Adjuvant	anti-PD-1_monoclonal_antibody; immunopotentiator	Nil known	Phase I Study of the safety of Complete Freund’s Adjuvant (CFA) in Patients with Refractory and Relapsed Solid Tumours	Solid Tumours	2605 - Garran	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001637437
ACTRN12617000741381	Protocol-CA209-993ISR	Phase 1	Recruiting	NSW, SA, VIC	22/05/2017	31/08/2017	Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	Protocol CA209-993ISR	Nivolumab in renal transplant recipients with poor prognosis cancers - a safety study.	Renal Transplant; Cancer	2050 - Camperdown; 5000 - Adelaide; 3168 - Clayton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617000741381
ACTRN12617000855325	EMBRACE-study	Phase 2	NOT_RECRUITING	NSW, QLD, SA, VIC, WA	9/06/2017	12/09/2018	Olaparib	PARP_inhibitor	Olaparib	PARP_inhibitor	CTC0160	Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2: The EMBRACE study	High grade serous ovarian cancer; Triple negative breast cancer	3355 - Wendouree; 2217 - Kogarah; 4217 - Benowa; 2450 - Coffs Harbour; 5000 - Adelaide; 6150 - Murdoch; 2640 - Albury; 4066 - Auchenflower; 2065 - St Leonards; 3000 - Melbourne; 4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617000855325
ACTRN12617001000392	MoST-Addendum-3	Phase 2	NOT_RECRUITING	NSW, SA	11/07/2017	21/11/2017	Durvalumab; Durvalumab + Olaparib; Olaparib	anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; PARP_inhibitor	Durvalumab; Durvalumab + Olaparib; Durvalumab + Olaparib	PARP_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody	Nil	Single arm, open label, signal seeking, phase IIa trial of the activity of Olaparib in combination with Durvalumab in patients with tumours with homologous recombination repair defects	Cancer	5000 - Adelaide; 2217 - Kogarah; 2010 - Darlinghurst; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001000392
ACTRN12617001190392	PIT-Study	Phase 1 / Phase 2	STATUS_UNKNOWN	SA	15/08/2017		Irinotecan; Irinotecan + Panitumumab; Panitumumab; Trifluridine/Tipiracil	antimetabolite; anti-EGFR_monoclonal_antibody; Tipiracil Hydrochloride; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; topoisomerase_inhibitor; Trifluridine; thymidine_phosphorylase_inhibitor	Irinotecan + Panitumumab; Trifluridine/Tipiracil; Irinotecan + Panitumumab	Tipiracil Hydrochloride; Trifluridine; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; antimetabolite; thymidine_phosphorylase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor	None	An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer	colorectal cancer	5011 - Woodville; 5000 - Adelaide; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001190392
ACTRN12617001325392	DIAmOND	Phase 2	NOT_RECRUITING	NSW, QLD, SA, TAS, VIC, WA	15/09/2017	22/11/2018	Durvalumab; Durvalumab + Trastuzumab; Durvalumab + Trastuzumab + Tremelimumab; Durvalumab + Tremelimumab; Trastuzumab; Tremelimumab	anti-ERBB2_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab; Durvalumab + Trastuzumab; Durvalumab + Trastuzumab + Tremelimumab; Durvalumab + Tremelimumab; Trastuzumab; Tremelimumab; Durvalumab + Trastuzumab; Durvalumab + Trastuzumab + Tremelimumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	BCT 1703	BCT 1703 (DIAmOND): An investigator-initiated, non-randomised, phase II study of combination CTLA-4 and PD-L1 blockade in advanced HER2-positive breast cancers who have progressed on prior trastuzumab-based therapy.	Advanced HER2-positive breast cancer	7000 - Hobart; 3084 - Heidelberg; 2217 - Kogarah; 6150 - Murdoch; 5042 - Bedford Park; 4101 - South Brisbane; 2145 - Westmead; 4575 - Birtinya; 3000 - Melbourne; 3550 - Bendigo	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001325392
ACTRN12617001573347	ZU545102--CA209-9KJ	Phase 1	NOT_RECRUITING	NSW, QLD, SA, VIC	22/11/2017	24/10/2017	Nivolumab; Nivolumab + Pixatimod; Pixatimod	angiogenesis_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; angiogenesis_inhibitor	Nivolumab + Pixatimod; Nivolumab + Pixatimod	angiogenesis_inhibitor + anti-PD-1_monoclonal_antibody; angiogenesis_inhibitor + anti-PD-1_monoclonal_antibody	ZU545102  CA209-9KJ	An open-label, multi-centre Phase Ib study of the safety and tolerability of IV infused PG545 in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer	Colorectal cancer; Advanced solid tumours; Pancreatic Cancer	3004 - Prahran; 4029 - Herston; 2065 - St Leonards; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001573347
ACTRN12618000053224	PRIME002	Phase 2	NOT_RECRUITING	NSW, QLD	16/01/2018	22/03/2018	Avelumab; Azacitidine; Azacitidine + Carboplatin; Carboplatin	antimetabolite; anti-PD-L1_monoclonal_antibody; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor	Avelumab; Azacitidine + Carboplatin; Azacitidine + Carboplatin	DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	Nil known	PRIME002: Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy.	Metastatic melanoma; Immunotherapy resistant	2298 - Waratah; 4870 - Cairns	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000053224
ACTRN12618000233224	MONARCC	Phase 2	NOT_RECRUITING	NSW, QLD, SA, TAS, VIC, WA	14/02/2018	16/07/2018	Fluorouracil; Panitumumab	anti-EGFR_monoclonal_antibody; fluoropyrimidine	Panitumumab; Fluorouracil	anti-EGFR_monoclonal_antibody; fluoropyrimidine	AG0116CR / CTC 0151	MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer.	metastatic colorectal cancer	4575 - Birtinya; 4029 - Herston; 2541 - Nowra; 2065 - St Leonards; 2485 - Tweed Heads; 3690 - Wodonga; 2747 - Kingswood; 3021 - St Albans; 4102 - Woolloongabba; 7000 - Hobart; 2010 - Darlinghurst; 4215 - Southport; 4032 - Chermside; 5042 - Bedford Park; 2450 - Coffs Harbour; 5011 - Woodville; 3084 - Heidelberg; 3168 - Clayton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000233224
ACTRN12618000281291	MoST-Addendum-4	Phase 2	NOT_RECRUITING	ACT, NSW, NT, QLD, SA, TAS, VIC, WA	22/02/2018	7/12/2018	Vismodegib	SMO_inhibitor,first_generation	Vismodegib	SMO_inhibitor,first_generation	CTC0141-addendum 4	Single arm, open label, signal seeking, phase IIa trial of the activity of vismodegib in patients with tumours harbouring PTCH1 or SMO mutations	Cancer	2605 - Garran; 0810 - Tiwi; 2050 - Camperdown; 4102 - Woolloongabba; 3000 - Melbourne; 6009 - Nedlands; 2217 - Kogarah; 5000 - Adelaide; 2010 - Darlinghurst; 7000 - Hobart	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000281291
ACTRN12618000357257	MoST-Addendum-5	Phase 2	*NOT_RECRUITING	ACT, NSW, NT, QLD, SA, TAS, VIC, WA	9/03/2018	11/04/2019	Eribulin	macrocyclic_ketone_analogue	Eribulin	macrocyclic_ketone_analogue	CTC0141-addendum 5	Single arm, open label, signal seeking, phase IIa trial of the activity of eribulin in patients with advanced CD31 positive angiosarcoma and selected CD31 positive sarcomas.	Sarcoma; Cancer 306453 0; Angiosarcoma	7000 - Hobart; 2010 - Darlinghurst; 5000 - Adelaide; 2217 - Kogarah; 6009 - Nedlands; 2605 - Garran; 2050 - Camperdown; 0810 - Tiwi; 3000 - Melbourne; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000357257
ACTRN12618000686202	SOLACE-2	Phase 2	NOT_RECRUITING	NSW, QLD, SA, TAS, VIC	27/04/2018	8/05/2019	Cyclophosphamide; Cyclophosphamide + Durvalumab + Olaparib; Cyclophosphamide + Olaparib; Durvalumab; Durvalumab + Olaparib; Olaparib	alkylating_agent; PARP_inhibitor; PARP_inhibitor + alkylating_agent + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + alkylating_agent	Cyclophosphamide; Cyclophosphamide + Durvalumab + Olaparib; Cyclophosphamide + Olaparib; Durvalumab; Durvalumab + Olaparib; Olaparib; Cyclophosphamide + Durvalumab + Olaparib; Cyclophosphamide + Olaparib; Durvalumab + Olaparib	PARP_inhibitor; PARP_inhibitor + alkylating_agent; PARP_inhibitor + alkylating_agent + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; alkylating_agent; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + alkylating_agent; PARP_inhibitor + alkylating_agent + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody	CTC 0178 / ANZGOG 1723/2018	A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects.	Peritoneal cancer; Fallopian tube cancer; Ovarian cancer	2305 - New Lambton Heights; 2650 - Wagga Wagga; 7000 - Hobart; 3050 - Parkville; 2450 - Coffs Harbour; 5000 - Adelaide; 2250 - Gosford; 2217 - Kogarah; 5042 - Bedford Park; 3199 - Frankston; 4101 - South Brisbane; 2031 - Randwick; 3000 - Melbourne; 2065 - St Leonards; 2050 - Camperdown; 2485 - Tweed Heads	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000686202
ACTRN12618000941268	PLA001	Phase 0	Recruiting	NSW	4/06/2018	21/02/2018	PLA2 inhibitor	PLA2_inhibitor	PLA2 inhibitor	PLA2_inhibitor	None	Safety, tolerability, and pharmacokinetics of single and multiple doses of a PLA2 inhibitor (c2) in men with prostate cancer: A Phase 0 and limited dose-escalation trial	Prostate Cancer	2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000941268
ACTRN12618000954224	ICE-PAC	Phase 2	Recruiting	VIC	6/06/2018	1/12/2017	Avelumab; Avelumab + Radiotherapy; Radiotherapy	radiotherapy; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + radiotherapy	Avelumab + Radiotherapy; Avelumab + Radiotherapy	anti-PD-L1_monoclonal_antibody + radiotherapy; anti-PD-L1_monoclonal_antibody + radiotherapy	MS100070-0082	A phase II study of Avelumab + stereotactic ablative body radiosurgery (SABR) for metastatic castration-resistant prostate cancer (mCRPC). To assess radiographic progression-free survival (rPFS).	Metastatic castration-resistant prostate cancer (mCRPC).	3168 - Clayton; 3128 - Box Hill	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000954224
ACTRN12618001070224	AM-ATX101-01	Phase 1	Recruiting	NSW, SA, WA	27/06/2018	15/10/2018	ATX-101; Dexamethasone	cell_penetrating_peptide,PCNA-targeting; glucocorticoid	ATX-101; Dexamethasone	cell_penetrating_peptide,PCNA-targeting; glucocorticoid	AM ATX101-01	A phase 1 dose escalating study to determine incidence of dose limiting toxicities of single agent ATX-101 given by intravenous infusion every week in patients with advanced solid tumours	Advanced Solid Tumors	6009 - Nedlands; 2031 - Randwick; 5042 - Bedford Park; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001070224
ACTRN12618001073291	LuPin	Phase 1	Recruiting	NSW	27/06/2018	4/12/2017	Idronoxil; Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting; idronoxil_suppository	Idronoxil; Lu-177 vipivotide tetraxetan	idronoxil_suppository; radioligand,PSMA-targeting	Nil Known	Radionuclide therapy using 177Lu-PSMA: extension of a pilot study in men with castrate-resistant prostate cancer to determine the clinical benefit of combination therapy with idronoxil	Castrate-resistant prostate cancer	2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001073291
ACTRN12618001112257	AM-ATX101-02	Phase 1	Recruiting	NSW, SA, WA	5/07/2018	11/12/2018	ATX-101; Dexamethasone	cell_penetrating_peptide,PCNA-targeting; glucocorticoid	ATX-101; Dexamethasone	cell_penetrating_peptide,PCNA-targeting; glucocorticoid	AM ATX101-02	A long term follow up study, to evaluate the long term safety and efficacy, of single agent ATX-101 given by intravenous infusion once every week in patients with advanced solid tumours	Advanced Solid Tumors	5000 - Adelaide; 6009 - Nedlands; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001112257
ACTRN12618001121257	POPCORN	Phase 1 / Phase 2	Recruiting	QLD	6/07/2018	22/05/2019	Denosumab; Denosumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-RANK_L_monoclonal_antibody	Denosumab + Nivolumab; Nivolumab; Denosumab + Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody	20177440 Amgen ISS	Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) - a phase 1B/2 trial	Non-small cell lung cancer (NSCLC)	4032 - Chermside; 4102 - Woolloongabba; 4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001121257
ACTRN12618001337268	ACTRN12618001337268	Not Applicable	Not yet recruiting		8/08/2018						None	The safety and efficacy of immunotherapy with the activited T cells from from umbilical cord blood mononuclear cells ex vivo for small cell lung cancer,Kidney cancer and Primary liver cancer treatment	Histopathologically confirmed Liver cancer; Histopathologically confirmed Kidney cancer; Histopathologically confirmed small cell lung cancer (SCLC)		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001337268
ACTRN12618001480279	ALT-TRACC	Phase 2	Recruiting	VIC	4/09/2018	6/09/2018	Bevacizumab; Capecitabine; Fluorouracil; Irinotecan; Irinotecan + Oxaliplatin; Leucovorin; Oxaliplatin	fluoropyrimidine; topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; Fluorouracil; platinum-based_antineoplastic_agent; folinic_acid	Bevacizumab; Capecitabine; Fluorouracil; Irinotecan; Irinotecan + Oxaliplatin; Leucovorin; Oxaliplatin; Irinotecan + Oxaliplatin	anti-VEGF_monoclonal_antibody; fluoropyrimidine; folinic_acid; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; Fluorouracil; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Nil known	Alternating oxaliplatin and irinotecan doublet schedules versus continuous doublet chemotherapy in previously untreated metastatic colorectal cancer: A Treatment of Recurrent and Advanced Colorectal Cancer registry-based prospective randomised trial	Metastatic Colorectal Cancer	3084 - Heidelberg; 3280 - Warrnambool; 3844 - Traralgon; 3021 - St Albans; 3011 - Footscray; 3065 - Fitzroy; 3000 - Melbourne; 3076 - Epping; 3128 - Box Hill	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001480279
ACTRN12618001573246	CRIO	Phase 2	Not yet recruiting	QLD	20/09/2018		Carboplatin; Carboplatin + Durvalumab + Radiotherapy; Durvalumab; Radiotherapy	radiotherapy; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy	Carboplatin + Durvalumab + Radiotherapy; Carboplatin + Durvalumab + Radiotherapy	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy	Nil known	A prospective study investigating the efficacy and toxicity of definitive chemoradiation and immunotherapy (CRIO) in locally and/or regionally advanced cutaneous squamous cell carcinoma	squamous cell carcinoma; skin cancer	4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001573246
ACTRN12618001742268	ILLUMINATE	Phase 2	Recruiting	NSW, QLD, SA, TAS, VIC, WA	23/10/2018	4/04/2019	Carboplatin; Carboplatin + Cisplatin + Durvalumab + Pemetrexed + Tremelimumab; Cisplatin; Durvalumab; Durvalumab + Pemetrexed; Pemetrexed; Tremelimumab	antimetabolite; anti-CTLA-4_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Durvalumab + Pemetrexed + Tremelimumab; Durvalumab + Pemetrexed; Carboplatin + Cisplatin + Durvalumab + Pemetrexed + Tremelimumab; Durvalumab + Pemetrexed	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite	CTC 0209  ALTG 16/009	A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs) (ILLUMINATE).	EGFR mutant advanced non small cell lung cancer.	4102 - Woolloongabba; 3000 - Melbourne; 2170 - Liverpool; 3065 - Fitzroy; 6009 - Nedlands; 2200 - Bankstown; 3168 - Clayton; 2217 - Kogarah; 2250 - Gosford; 5042 - Bedford Park; 4032 - Chermside; 7000 - Hobart	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001742268
ACTRN12618001825246	2014-000259-99	Phase 2 / Phase 3	Recruiting	NSW, NZ, QLD, SA, VIC, WA	9/11/2018	25/11/2014	Carboplatin; Carboplatin + Etoposide; Cyclophosphamide; Cyclophosphamide + Topotecan; Docetaxel; Docetaxel + Gemcitabine + Irinotecan + Temozolomide; Etoposide; Gemcitabine; Ifosfamide; Irinotecan; Temozolomide; Topotecan	alkylating_agent; alkylating_agent + antimetabolite + taxane + topoisomerase_inhibitor; topoisomerase_inhibitor; gemcitabine; alkylating_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; taxane; platinum-based_antineoplastic_agent	Carboplatin + Etoposide; Cyclophosphamide + Topotecan; Docetaxel + Gemcitabine + Irinotecan + Temozolomide; Ifosfamide; Carboplatin + Etoposide; Cyclophosphamide + Topotecan; Docetaxel + Gemcitabine + Irinotecan + Temozolomide	alkylating_agent; alkylating_agent + antimetabolite + taxane + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; alkylating_agent + antimetabolite + taxane + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; gemcitabine; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	RG_13-277  ISRCTN36453794  EudraCT Number: 2014-000259-99	International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma	Ewing Sarcoma	2050 - Camperdown; 3000 - Melbourne; 4102 - Woolloongabba; 2145 - Westmead; 6009 - Nedlands; 2031 - Randwick; 3052 - Parkville; 5000 - Adelaide; 3168 - Clayton; 5006 - North Adelaide; 2305 - New Lambton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001825246
ACTRN12619000566134	OXTOX	Phase 2	Recruiting	NSW	10/04/2019	28/01/2021	Ibudilast; Ibudilast + Oxaliplatin; Oxaliplatin	PDE4_inhibitor + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; PDE4_inhibitor	Ibudilast + Oxaliplatin; Ibudilast + Oxaliplatin	PDE4_inhibitor + platinum-based_antineoplastic_agent; PDE4_inhibitor + platinum-based_antineoplastic_agent	None	OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study	Neurotoxicity caused by oxaliplatin in patients with metastatic colorectal cancer	2747 - Kingswood; 2065 - St Leonards; 2139 - Concord; 2800 - Orange; 2500 - Wollongong	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000566134
ACTRN12619000567123	EnzAdapt	Phase 1 / Phase 2	Recruiting	NSW	11/04/2019	29/08/2019	Enzalutamide	antiandrogen,nonsteroidal,second_generation	Enzalutamide	antiandrogen,nonsteroidal,second_generation	EnzAdapt	EnzAdapt: Feasibility, acceptability and safety of adaptive dosing of enzalutamide in men with metastatic castrate-resistant prostate cancer	castrate resistant prostate cancer; Prostate cancer	2340 - Tamworth; 2298 - Waratah; 2430 - Taree	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000567123
ACTRN12619000640101	ACTRN12619000640101	Phase 2	STATUS_UNKNOWN	ACT, NSW, QLD, VIC	30/04/2019	10/02/2020	PAX-1	sodium_arsenite	PAX-1	sodium_arsenite	None	A Phase 2, open label study of orally administered PAX-1 monotherapy in patients with recurrent glioblastoma.	Glioblastoma	3168 - Clayton; 2605 - Garran; 4120 - Greenslopes	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000640101
ACTRN12619000769189	ATTAC	Phase 1	Recruiting	WA	23/05/2019						None	A pilot study to evaluate the safety and immunogenicity of a personalised tumour neo-antigen peptide vaccine strategy in patients with completely resected non-small cell lung cancer.	Lung Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000769189
ACTRN12619000844145	ALKternate	Phase 1 / Phase 2	Recruiting	NSW, VIC	13/06/2019	14/06/2019	Crizotinib; Crizotinib + Lorlatinib; Lorlatinib	ALK_inhibitor,third_generation + ROS1_inhibitor; ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; MET_inhibitor,type_1; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,first_generation + ROS1_inhibitor; MET_inhibitor,type_1 + ROS1_inhibitor; ALK_inhibitor,third_generation; ALK_inhibitor,first_generation; ROS1_inhibitor	Crizotinib + Lorlatinib; Lorlatinib; Crizotinib + Lorlatinib	ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,third_generation; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,third_generation + ROS1_inhibitor; MET_inhibitor,type_1 + ROS1_inhibitor; ROS1_inhibitor; ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,third_generation + ROS1_inhibitor; MET_inhibitor,type_1 + ROS1_inhibitor	None	A single arm multi-centre translational proof of concept study investigating the safety and efficacy of alternating lorlatinib with crizotinib in a pre-treated advanced ALK-rearranged non-small cell lung cancer population with disease progression on a 2nd generation ALK tyrosine kinase inhibitor	ALK-rearranged advanced non-small cell lung cancer	3000 - Melbourne; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000844145
ACTRN12619000900112	AtTEnd	Phase 3	Not yet recruiting	NSW, NZ, QLD, SA, TAS, VIC, WA	27/06/2019		Atezolizumab; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Paclitaxel; Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; placebo	Atezolizumab + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin + Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; placebo; platinum-based_antineoplastic_agent + taxane	IRFMN-EN-7556  CTC 0246  ANZGOG 1807/2019	Phase III Double-Blind Randomized Placebo Controlled Trial of Atezolizumab in Combination with Paclitaxel and Carboplatin in Women with Advanced/Recurrent Endometrial Cancer.	Endometrial Cancer	3128 - Box Hill; 4101 - South Brisbane; 3199 - Frankston; 4029 - Herston; 2170 - Liverpool; 3000 - Melbourne; 3083 - Bundoora; 2298 - Waratah; 4350 - Toowoomba; 6008 - Subiaco; 2640 - Albury; Auckland; 7000 - Hobart; 4217 - Benowa; 5006 - North Adelaide; 2217 - Kogarah; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000900112
ACTRN12619001117101	CAPTURE	Phase 2	Recruiting	NSW, NT, QLD, SA, VIC, WA	12/08/2019	3/08/2020	Alpelisib; Alpelisib + Fulvestrant; Capecitabine; Fulvestrant; Goserelin	selective_estrogen_receptor_degrader; fluoropyrimidine; PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; GnRH_analogue	Alpelisib; Alpelisib + Fulvestrant; Goserelin; Alpelisib + Fulvestrant; Capecitabine	GnRH_analogue; PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; fluoropyrimidine	BCT 1901	BCT 1901 (CAPTURE): A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA.	Advanced Breast Cancer	2060 - North Sydney; 2145 - Westmead; 2444 - Port Macquarie; 3199 - Frankston; 2298 - Waratah; 5112 - Elizabeth Vale; 0810 - Tiwi; 3844 - Traralgon; 4102 - Woolloongabba; 3000 - Melbourne; 2170 - Liverpool; 2747 - Kingswood; 2010 - Darlinghurst; 3350 - Ballarat Central; 3135 - Ringwood East; 6008 - Subiaco; 3280 - Warrnambool; 2640 - Albury; 3168 - Clayton; 5011 - Woodville; 3121 - Richmond	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001117101
ACTRN12619001147178	MoST-Addendum-6	Phase 2	NOT_RECRUITING	ACT, NSW, NT, QLD, SA, TAS, VIC, WA	16/08/2019	2/11/2020	Larotrectinib	TRK_inhibitor,first_generation	Larotrectinib	TRK_inhibitor,first_generation	CTC0141-Addendum 6	Single arm, open label, signal seeking, phase IIa trial of the activity of Larotrectinib in patients with advanced NTRK1-3 positive tumours.	Cancer	5000 - Adelaide; 2217 - Kogarah; 7000 - Hobart; 2010 - Darlinghurst; 3000 - Melbourne; 4102 - Woolloongabba; 2605 - Garran; 2050 - Camperdown; 0810 - Tiwi; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001147178
ACTRN12619001185156	IGNITE	Phase 2	Recruiting	NSW, QLD, SA, TAS, VIC, WA	22/08/2019	26/03/2020	Adavosertib	WEE1_inhibitor	Adavosertib	WEE1_inhibitor	Nil known	A Phase II signal-seeking trial of Adavosertib (AZD1775) targeting recurrent high grade serous ovarian cancer (HGSC) with Cyclin E1 (CCNE1) over-expression with and without gene amplification to determine the clinical benefit rate.	Ovarian Cancer; Primary peritoneal cancer; Cancer of the falllopian tube	2145 - Westmead; 6009 - Nedlands; 4101 - South Brisbane; 2031 - Randwick; 2050 - Camperdown; 2065 - St Leonards; 3000 - Melbourne; 3021 - St Albans; 7000 - Hobart; 5042 - Bedford Park; 2800 - Orange	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001185156
ACTRN12619001265167	MoST-Addendum-8	Phase 2	Recruiting	ACT, NSW, NT, QLD, SA, TAS, VIC, WA	12/09/2019	25/06/2020	Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate	CTC0141-addendum 8	Single arm, open label, signal seeking, phase IIa trial of the activity of Trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2 amplifications or mutations	Cancer	6009 - Nedlands; 2605 - Garran; 2050 - Camperdown; 0810 - Tiwi; 4102 - Woolloongabba; 3000 - Melbourne; 2010 - Darlinghurst; 7000 - Hobart; 2217 - Kogarah; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001265167
ACTRN12619001298101	ASN-002-IL	Phase 2	Not yet recruiting	QLD	20/09/2019		Fluorouracil; Fluorouracil + Gusacitinib; Gusacitinib	SYK/JAK_inhibitor; Fluorouracil; SYK/JAK_inhibitor + fluoropyrimidine	Fluorouracil + Gusacitinib; Gusacitinib; Fluorouracil + Gusacitinib	SYK/JAK_inhibitor; SYK/JAK_inhibitor + fluoropyrimidine; Fluorouracil; SYK/JAK_inhibitor + fluoropyrimidine	SP-002	A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas	Basal Cell Nevus Syndrome (BCNS); Basal Cell Carcinoma	4000 - Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001298101
ACTRN12619001324101	ANTHEM	Phase 2	Recruiting	WA	27/09/2019	25/02/2020	Anamorelin; Placebo	GHSR_agonist; placebo	Anamorelin; Placebo	GHSR_agonist; placebo	Nil known	A single centre phase II, randomised placebo controlled cross over study to examine the effect of anamorelin on cancer cachexia in patients with mesothelioma	Mesothelioma	6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001324101
ACTRN12619001407189	QB46C-H03--CTRI-2019-11-022032	Phase 1 / Phase 2	Recruiting	NSW, QLD	14/10/2019	29/11/2019	Tigilanol Tiglate	protein_kinase_C_regulator	Tigilanol Tiglate	protein_kinase_C_regulator	QB46C-H03  CTRI/2019/11/022032	Exploratory Phase Ib/IIa Study of Intratumourally Administered Tigilanol Tiglate to Assess Safety, Tolerability and Tumour Response in Patients with Head and Neck Squamous Cell Carcinoma	Head and neck squamous cell carcinoma.	4102 - Woolloongabba; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001407189
ACTRN12619001527156	CESTEM-1	Phase 1	Recruiting	QLD	5/11/2019	1/06/2017	Cetuximab; Cetuximab + Prochlorperazine; Prochlorperazine	anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + antihistamine; antihistamine	Cetuximab + Prochlorperazine; Cetuximab + Prochlorperazine	anti-EGFR_monoclonal_antibody + antihistamine; anti-EGFR_monoclonal_antibody + antihistamine	None	Open-label Phase I study investigating the safety and efficacy of Cetuximab and prochlorperazine (STEMetil) combination therapy in patients with metastatic Head and Neck Squamous Cell Carcinoma and Triple Negative Breast Cancer (CESTEM study)	Cancer	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001527156
ACTRN12619001533189	FP101A	Phase 1	Recruiting	NSW	6/11/2019	9/03/2020	Deflexifol; Deflexifol + Fluorouracil + Leucovorin; Fluorouracil; Leucovorin	Fluorouracil; Fluorouracil + fluoropyrimidine + folinic_acid; folinic_acid	Deflexifol; Deflexifol + Fluorouracil + Leucovorin; Deflexifol + Fluorouracil + Leucovorin	Fluorouracil; Fluorouracil + fluoropyrimidine + folinic_acid; Fluorouracil + fluoropyrimidine + folinic_acid	TGA CT-2019-CTN-02849-1	A Phase 1 Study of Deflexifol: To determine pharmacokinetic (PK) in patients administered a combined dose of bolus and continuous 46hr infusion of Deflexifol in patients with advanced malignancy after failure of standard treatment	Advanced Malignant Cancer	2500 - Wollongong	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001533189
ACTRN12620000008921	CTIV1708	Phase 1	Recruiting	SA, VIC	8/01/2020	17/09/2020	MVR-T3011	oncolytic_HSV_virus	MVR-T3011	oncolytic_HSV_virus	Theravir Protocol Number: CTIV1708	A Phase I, Open-Label, Multiple Ascending Dose Study of the Safety and Tolerability of T3011 in advanced Cutaneous or Subcutaneous Malignancies	Any malignancy with cutaneous and/or subcutaneous tumours	5042 - Bedford Park; 3004 - St Kilda Road Melbourne; 3199 - Frankston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000008921
ACTRN12620000244909	VG161-A101	Phase 1	Recruiting	NSW, QLD, SA	26/02/2020	27/04/2020	VG-161	oncolytic_virus	VG-161	oncolytic_virus	VG161-A101	A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG161 in Subjects with Advanced Malignant Solid Tumors that are Refractory to Conventional Therapies	Advanced malignant solid tumors	4029 - Herston; 5042 - Bedford Park; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000244909
ACTRN12620000440921	ALMB-0168-AU-101	Phase 1	Recruiting	NSW, SA, VIC	6/04/2020	23/10/2020	ALMB-0168	anti-Cx43_agonistic_antibody	ALMB-0168	anti-Cx43_agonistic_antibody	ALMB-0168-AU-101	Phase 1, Multicenter, First-in-Human Dose Escalation Study of ALMB-0168 Administered IV as a Single Agent to Patients with Malignant Bone Disease	Osteosarcoma or any other solid tumor cancer with bone metastases	5042 - Bedford Park; 3199 - Frankston; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000440921
ACTRN12620000568910	MoST-Addendum-10	Phase 2	Recruiting	ACT, NSW, NT, QLD, SA, TAS, VIC, WA	15/05/2020	3/05/2021	Avelumab; Avelumab + Palbociclib; Palbociclib	anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor	Avelumab; Avelumab + Palbociclib; Palbociclib; Avelumab + Palbociclib	CDK4/6_inhibitor; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody	CTC0141-addendum 10	Single arm, open label, signal seeking, phase II trial of the activity of Palbociclib in combination with Avelumab in patients with tumours with amplified D-type cyclins or CDK4/6 or inactivation of CDKN2A.	Cancer	2050 - Camperdown; 0810 - Tiwi; 2605 - Garran; 3000 - Melbourne; 4102 - Woolloongabba; 6009 - Nedlands; 5000 - Adelaide; 7000 - Hobart	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000568910
ACTRN12620000583943	EOHC-1001-01	Phase 1 / Phase 2	Not yet recruiting	VIC	20/05/2020		EO1001	ERBB2_inhibitor,second_generation; EGFR_inhibitor,second_generation	EO1001	EGFR_inhibitor,second_generation; ERBB2_inhibitor,second_generation	EOHC-1001-01	An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.	ErbB-2(HER2) positive cancer; ErbB-1(EGFR) positive cancer; ERbB-4 (HER4) positive cancer	3168 - Clayton; 3144 - Malvern	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000583943
ACTRN12620000592943	GQCT001--GQ1001X2101	Phase 1	NOT_RECRUITING	NSW	21/05/2020	25/06/2020	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQCT001  GQ1001X2101	A Phase I, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously in Adult Patients with HER2-Positive Advanced Solid Tumors	HER2-Positive Advanced Solid Tumors	2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000592943
ACTRN12620000767909	MoST-Addendum-9	Phase 2	Recruiting	ACT, NSW, NT, QLD, SA, TAS, VIC, WA	27/07/2020		Trastuzumab; Trastuzumab + Tucatinib; Tucatinib	anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation	Trastuzumab; Trastuzumab + Tucatinib; Tucatinib; Trastuzumab + Tucatinib	ERBB2_inhibitor,third_generation; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody	CTC0141- addendum 9	Single arm, open label, signal seeking, phase II trial of the activity of tucatinib plus trastuzumab in patients with tumours harbouring HER2 amplifications or mutations	Cancer	6009 - Nedlands; 2605 - Garran; 0810 - Tiwi; 2050 - Camperdown; 4102 - Woolloongabba; 3000 - Melbourne; 2010 - Darlinghurst; 7000 - Hobart; 2217 - Kogarah; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000767909
ACTRN12620000849998	ACTRN12620000849998	Phase 1 / Phase 2	OLD_TRIAL	NSW, QLD	27/08/2020	12/05/2020	MG010; MG010 + Sorafenib; Sorafenib	PDGFR_inhibitor; FLT3_inhibitor; VEGFR_inhibitor; KIT_inhibitor; CRAF_inhibitor + KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor + PDGFR_inhibitor; CRAF_inhibitor + FLT3_inhibitor; CRAF_inhibitor; CRAF_inhibitor + VEGFR_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + CRAF_inhibitor	MG010 + Sorafenib; MG010 + Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + CRAF_inhibitor; CRAF_inhibitor; CRAF_inhibitor + FLT3_inhibitor; CRAF_inhibitor + KIT_inhibitor; CRAF_inhibitor + PDGFR_inhibitor; CRAF_inhibitor + VEGFR_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + CRAF_inhibitor; CRAF_inhibitor + FLT3_inhibitor; CRAF_inhibitor + KIT_inhibitor; CRAF_inhibitor + PDGFR_inhibitor; CRAF_inhibitor + VEGFR_inhibitor	Nil	A phase I/II, open label, multi-centre study to assess the safety, tolerability, and efficacy of MG010 in combination with sorafenib in subjects with solid tumours who have failed existing treatments.	Metastatic solid tumours having failed existing treatments.	4101 - South Brisbane; 2031 - Randwick; 2139 - Concord; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000849998
ACTRN12620000861954	MoST-Addendum-12	Phase 2	Recruiting	NSW	28/08/2020		Cobimetinib; Cobimetinib + Vemurafenib; Vemurafenib	BRAF_V600_inhibitor + MEK_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor	Cobimetinib + Vemurafenib; Cobimetinib + Vemurafenib	BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	CTC 0141 / ALTG 20/002 – addendum 12	Single arm, open label, phase II trial of vemurafenib and cobimetinib in patients with metastatic non-squamous non-small cell lung cancer and other tumours harbouring BRAF V600 mutations detected by comprehensive genomic profiling	non-small cell lung cancer; Cancer	2010 - Darlinghurst; 2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000861954
ACTRN12620000918921	MoST-addendum-7	Phase 2	Recruiting	ACT, NSW, NT, QLD, SA, TAS, VIC, WA	17/09/2020	30/11/2020	Tremelimumab	anti-CTLA-4_monoclonal_antibody	Tremelimumab	anti-CTLA-4_monoclonal_antibody	CTC0141 Addendum 7	Single arm, open label, signal seeking, phase IIa trial of the activity of Tremelimumab in patients with advanced rare or neglected cancers	cancer	5000 - Adelaide; 2010 - Darlinghurst; 7000 - Hobart; 0810 - Tiwi; 2605 - Garran; 2065 - St Leonards; 4102 - Woolloongabba; 3000 - Melbourne; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000918921
ACTRN12620000984998	MoST-Addendum-11	Phase 2	Recruiting	ACT, NSW, NT, QLD, SA, TAS, VIC, WA	30/09/2020	9/03/2021	Tildrakizumab	anti-IL-23_monoclonal_antibody	Tildrakizumab	anti-IL-23_monoclonal_antibody	CTC0141-addendum 11	Single arm, open label signal seeking, phase II trial to study the clinical activity of Tildrakizumab in patients with advanced osteosarcoma and soft tissue sarcomas	Soft Tissue Sarcoma; Advanced Osteosarcoma; Cancer	6009 - Nedlands; 4102 - Woolloongabba; 3000 - Melbourne; 2605 - Garran; 0810 - Tiwi; 2050 - Camperdown; 7000 - Hobart; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000984998
ACTRN12620001146987	ACTRN12620001146987	Phase 1	Recruiting	NSW, VIC, WA	2/11/2020		PMR-116	RNA_polymerase_I_transcription_inhibitor	PMR-116	RNA_polymerase_I_transcription_inhibitor	Nil known	Investigating the safety and tolerability of PMR-116 in Patients with Advanced Malignancies	Advanced solid tumours	3004 - Melbourne; 3000 - Melbourne; 2031 - Randwick; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620001146987
ACTRN12620001198910	MODERN-LUNG	Phase 2	Recruiting	NSW	10/11/2020	15/04/2021	Carboplatin; Carboplatin + Paclitaxel; Durvalumab; Paclitaxel; Radiotherapy	radiotherapy; anti-PD-L1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane	Carboplatin + Paclitaxel; Durvalumab; Radiotherapy; Carboplatin + Paclitaxel	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; radiotherapy; platinum-based_antineoplastic_agent + taxane	CMNDRO-2005	Phase 2 Study of a Moderately Hypofractionated Schedule of Chemoradiation followed by Immunotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer	lung cancer	2148 - Blacktown; 2560 - Campbelltown; 2298 - Waratah; 2170 - Liverpool; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620001198910
ACTRN12621000093886	ACT001-AU-004	Phase 2	Not yet recruiting	VIC	1/02/2021		ACT001; ACT001 + Radiotherapy; Radiotherapy	radiotherapy; NFKB_inhibitor; NFKB_inhibitor + radiotherapy	ACT001 + Radiotherapy; ACT001 + Radiotherapy	NFKB_inhibitor + radiotherapy; NFKB_inhibitor + radiotherapy	ACT001-AU-004	A Phase 2, open label, multicentre study assessing the safety and efficacy of ACT001 in combination with whole brain radiation therapy (WBRT) for brain metastases from solid tumours.	Solid Tumours; Metastatic Brain Cancer	3121 - Richmond	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000093886
ACTRN12621000156886	ACE-IT001	Phase 1 / Phase 2	Not yet recruiting	NSW	15/02/2021		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Perindopril	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ACE_inhibitor	Ipilimumab + Nivolumab; Perindopril; Ipilimumab + Nivolumab	ACE_inhibitor; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	NONE	A pilot study of Perindopril in combination with first line Ipilimumab and Nivolumab for patients with unresectable or metastatic melanoma- ACE-IT 001	Melanoma - Metastatic; Melanoma - Unresectable		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000156886
ACTRN12621000269831	HYNOVA	Not Applicable	Not yet recruiting	NSW, QLD, VIC	11/03/2021		Cisplatin	platinum-based_antineoplastic_agent	Cisplatin	platinum-based_antineoplastic_agent	CTC 0302  ANZGOG 1901 /2020	The safety of hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer (HYNOVA).	Fallopian tube cancer; Ovarian cancer; Primary peritoneal cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000269831
ACTRN12621000273886	ADELE	Phase 2	Not yet recruiting	NSW, VIC	11/03/2021		Carboplatin; Carboplatin + Paclitaxel + Tislelizumab; Paclitaxel; Tislelizumab	anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Carboplatin + Paclitaxel + Tislelizumab; Carboplatin + Paclitaxel + Tislelizumab	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	ANZGOG 1910/2020  CTC0299	The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer - ADELE: a randomised phase 2 trial	Endometrial Cancer	3052 - Parkville; 2031 - Randwick; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000273886
ACTRN12621000312842	MoST-Addendum-14	Phase 2	Recruiting	ACT, NSW, QLD, SA, TAS, VIC, WA	22/03/2021	3/09/2021	Alectinib	ALK/RET_inhibitor; ALK_inhibitor,second_generation	Alectinib	ALK/RET_inhibitor; ALK_inhibitor,second_generation	CTC 0141 – addendum 14	A Single arm, open label, phase II trial of tumour response to alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling	Cancer; Non-small cell lung cancer; ALK gene alterations	6009 - Nedlands; 2145 - Westmead; 4102 - Woolloongabba; 3000 - Melbourne; 2065 - St Leonards; 7000 - Hobart; 2217 - Kogarah; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000312842
ACTRN12621000479808	ATTACK-1-trial	Phase 1	*NOT_RECRUITING	NSW, SA, VIC	22/04/2021	16/06/2021	Auceliciclib; Auceliciclib + Temozolomide; Ifosfamide; Temozolomide	alkylating_agent; CDK4/6_inhibitor + alkylating_agent; CDK4/6_inhibitor	Auceliciclib; Auceliciclib + Temozolomide; Auceliciclib + Temozolomide; Ifosfamide	CDK4/6_inhibitor; CDK4/6_inhibitor + alkylating_agent; CDK4/6_inhibitor + alkylating_agent	Nil known	A Phase 1a/b, open-label, dose-exploration, combination/ expansion study to evaluate the safety, tolerability and pharmacokinetics of Auceliciclib in advanced solid tumours and in combination with temozolomide in recurrent or newly diagnosed Glioblastoma multiforme (GBM).	Ovarian cancer; Glioblastoma multiforme (GBM); Solid tumors; Cancer; Colorectal cancer	2170 - Liverpool; 5042 - Bedford Park; 3084 - Heidelberg	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000479808
ACTRN12621000507886	MoST-Addendum-15	Phase 2	Recruiting	QLD, SA	30/04/2021	7/09/2021	Acalabrutinib; Acalabrutinib + Durvalumab; Durvalumab	anti-PD-L1_monoclonal_antibody; BTK_inhibitor; BTK_inhibitor + anti-PD-L1_monoclonal_antibody	Acalabrutinib; Acalabrutinib + Durvalumab; Durvalumab; Acalabrutinib + Durvalumab	BTK_inhibitor; BTK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; BTK_inhibitor + anti-PD-L1_monoclonal_antibody	CTC0141- addendum 15	A single arm, open label, signal seeking, phase II trial of the activity of Durvalumab in combination with Acalabrutinib in patients with high-grade B cell lymphoma	Cancer; High grade B cell lymphoma	4029 - Herston; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000507886
ACTRN12621000611820	PICAASO	Phase 2	Not yet recruiting	NSW, VIC	21/05/2021		Dasatinib	BCR-ABL1_inhibitor,second_generation; SRC_inhibitor; YES1_inhibitor; KIT_inhibitor; PDGFRA_inhibitor	Dasatinib	BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; PDGFRA_inhibitor; SRC_inhibitor; YES1_inhibitor	Nil Known	Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstruction	metastatic castration-resistant prostate cancer	2010 - Darlinghurst; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000611820
ACTRN12621000639820	PARAGON-II	Phase 2	Not yet recruiting	NSW, QLD, TAS, VIC, WA	28/05/2021		Alpelisib; Alpelisib + Letrozole; Letrozole; Letrozole + Ribociclib; Ribociclib	PI3K_alpha_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor; aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor	Alpelisib + Letrozole; Letrozole; Letrozole + Ribociclib; Alpelisib + Letrozole; Letrozole + Ribociclib	CDK4/6_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor; aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor	None	The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (PARAGON-II) .	Endometrial cancer; Low grade epithelial cancers of ovary; Leiomyosarcomas; Platinum resistant high-grade epithelial cancers of ovary; Platinum resistant high-grade epithelial cancers of fallopian tube; Endometrial stromal sarcomas; Other gynaecological cancers (excluding endometrial cancers); Granulosa cell tumours; Platinum resistant high-grade epithelial cancers of primary peritoneum	2031 - Randwick; 4101 - South Brisbane; 6009 - Nedlands; 2145 - Westmead; 4029 - Herston; 3000 - Melbourne; 2050 - Camperdown; 2065 - St Leonards; 2305 - New Lambton Heights; 2640 - Albury; 7000 - Hobart; 3168 - Clayton; 2217 - Kogarah; 3052 - Parkville	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000639820
ACTRN12621000747820	TaxAdapt	Phase 1 / Phase 2	Not yet recruiting	NSW	11/06/2021		Docetaxel	taxane	Docetaxel	taxane	Nil known	TaxAdapt: Feasibility, acceptability and safety of adaptive dosing of docetaxel in men with metastatic castrate-resistant prostate cancer	Castration-resistant prostate cancer	2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000747820
ACTRN12621000762853	ACTRN12621000762853	Phase 1	Recruiting	QLD	18/06/2021	21/07/2021	Cyclophosphamide; Cyclophosphamide + Fludarabine + Tisagenlecleucel; Fludarabine; Tisagenlecleucel	antimetabolite; alkylating_agent; autologous_CAR-T-cell_therapy,CD19-targeting; alkylating_agent + antimetabolite + autologous_CAR-T-cell_therapy,CD19-targeting	Cyclophosphamide + Fludarabine + Tisagenlecleucel; Tisagenlecleucel; Cyclophosphamide + Fludarabine + Tisagenlecleucel	alkylating_agent + antimetabolite + autologous_CAR-T-cell_therapy,CD19-targeting; autologous_CAR-T-cell_therapy,CD19-targeting; alkylating_agent + antimetabolite + autologous_CAR-T-cell_therapy,CD19-targeting	None	Phase I Clinical Trial of MB.CART19.1 CD19 Chimeric Antigen Receptor (CAR) T Cells in Relapsed or Refractory CD19-Positive Haematological Malignancy	B cell blood cancers, including non-Hodgkin's lymphoma and leukaemia.	4029 - Herston; 4029 - Royal Brisbane Hospital	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000762853
ACTRN12621000802808	LU-TEMP	Phase 2	Not yet recruiting	NSW	25/06/2021		Temozolomide	alkylating_agent	Temozolomide	alkylating_agent	Nil	A pilot open label study of [177Lu]Lu-octretotate and temozolomide in the treatment of succinate dehydrogenase-associated locally advanced or metastatic pheochromocytoma and paraganglioma in adults.	Cancer	2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000802808
ACTRN12621000811808	MoST-Addendum-17	Phase 2	Recruiting	ACT, NSW, NT, QLD, SA, TAS, VIC, WA	28/06/2021	9/11/2021	Tepotinib	MET_inhibitor,type_1	Tepotinib	MET_inhibitor,type_1	CTC0141- addendum 17	A single arm, open label, signal-seeking, phase II trial of tepotinib in patients with advanced non-small cell lung cancer harbouring MET exon 14 skipping mutations detected by comprehensive genomic profiling	Advanced non-small cell lung cancer harbouring MET exon 14 skipping mutations	7000 - Hobart; 4032 - Chermside; 5000 - Adelaide; 2217 - Kogarah; 3084 - Heidelberg; 2145 - Westmead; 6009 - Nedlands; 2065 - St Leonards; 2605 - Garran; 0810 - Tiwi; 3065 - Fitzroy; 3000 - Melbourne; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000811808
ACTRN12621000991819	PDCCiHNC	Not Applicable	Not yet recruiting	NSW	28/07/2021		Carboplatin; Ceralasertib; Cisplatin; Crizotinib; Dactolisib; Dasatinib; Docetaxel; Doxorubicin; Erlotinib; Etoposide; Fluorouracil; Gemcitabine; Itraconazole; Methotrexate; Paclitaxel; Palbociclib; Pemetrexed; Ruxolitinib; Sorafenib; Vinorelbine; Vistusertib	antimetabolite; FLT3_inhibitor; MET_inhibitor,type_1; PI3K/mTOR_inhibitor; topoisomerase_inhibitor; gemcitabine; PDGFRA_inhibitor; CRAF_inhibitor; ALK_inhibitor,first_generation; YES1_inhibitor; fluoropyrimidine; SMO_inhibitor; VEGFR_inhibitor; KIT_inhibitor; JAK1/JAK2_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; Fluorouracil; BCR-ABL1_inhibitor,second_generation; mTORC1/mTORC2_inhibitor; ATR_inhibitor; ROS1_inhibitor; PDGFR_inhibitor; antifolate; SRC_inhibitor; anthracycline; CDK4/6_inhibitor; taxane; doxorubicin; platinum-based_antineoplastic_agent; vinca_alkaloid; EGFR_inhibitor,first_generation	Carboplatin; Ceralasertib; Cisplatin; Crizotinib; Dactolisib; Dasatinib; Docetaxel; Doxorubicin; Erlotinib; Etoposide; Fluorouracil; Gemcitabine; Itraconazole; Methotrexate; Paclitaxel; Palbociclib; Pemetrexed; Ruxolitinib; Sorafenib; Vinorelbine; Vistusertib	ALK_inhibitor,first_generation; ATR_inhibitor; BCR-ABL1_inhibitor,second_generation; CDK4/6_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; EGFR_inhibitor,first_generation; FLT3_inhibitor; JAK1/JAK2_inhibitor; KIT_inhibitor; MET_inhibitor,type_1; PDGFRA_inhibitor; PDGFR_inhibitor; PI3K/mTOR_inhibitor; ROS1_inhibitor; SMO_inhibitor; SRC_inhibitor; VEGFR_inhibitor; YES1_inhibitor; anthracycline; antifolate; antimetabolite; fluoropyrimidine; mTORC1/mTORC2_inhibitor; platinum-based_antineoplastic_agent; taxane; topoisomerase_inhibitor; vinca_alkaloid; Fluorouracil; doxorubicin; gemcitabine	Nil known	A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC)	Head and Neck Carcinoma	2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000991819
ACTRN12621001155886	PRIME005	Phase 1 / Phase 2	Recruiting	NSW, QLD	27/08/2021	13/09/2021	Azacitidine; Azacitidine + Carboplatin; Azacitidine + Carboplatin + Ipilimumab + Nivolumab; Carboplatin; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	antimetabolite; DNA_methyltransferase_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor	Azacitidine + Carboplatin; Azacitidine + Carboplatin + Ipilimumab + Nivolumab; Ipilimumab + Nivolumab; Azacitidine + Carboplatin; Azacitidine + Carboplatin + Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	DNA_methyltransferase_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	CA184-602	Phase Ib/II study of safety and clinical response to Azacitidine and Carboplatin priming for Ipilimumab and Nivolumab re-challenge in patients with advanced melanoma who are resistant to immunotherapy.	Advanced Melanoma	4870 - Cairns; 2298 - Waratah West; 2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001155886
ACTRN12621001172897	ACT001-AU-001	Phase 1	Recruiting	NSW, SA, VIC	31/08/2021	15/04/2021	ACT001; ACT001 + Pembrolizumab; Pembrolizumab	NFKB_inhibitor; anti-PD-1_monoclonal_antibody; NFKB_inhibitor + anti-PD-1_monoclonal_antibody	ACT001 + Pembrolizumab; ACT001 + Pembrolizumab	NFKB_inhibitor + anti-PD-1_monoclonal_antibody; NFKB_inhibitor + anti-PD-1_monoclonal_antibody	ACT001-AU-001 (Sponsor protocol code) - PART B	A phase 1 dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors (PART B).	Glioblastoma Multiforme	5042 - Bedford Park; 3121 - Richmond; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001172897
ACTRN12621001225808	MoST-Addendum-18	Phase 2	Recruiting	NSW	13/09/2021		Carboplatin; Carboplatin + Cisplatin + Etoposide; Cisplatin; Durvalumab; Etoposide	platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; topoisomerase_inhibitor; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Etoposide; Durvalumab; Carboplatin + Cisplatin + Etoposide	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	CTC0141- addendum 18	A single-arm, open-label, signal-seeking, phase II trial of durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma	Extra-pulmonary small cell carcinoma	2050 - Camperdown; 2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001225808
ACTRN12621001347853	SPEAR	Phase 2	Recruiting	NSW, QLD, SA, VIC, WA	7/10/2021		Sulfasalazine	SLC7A11_inhibitor	Sulfasalazine	SLC7A11_inhibitor	None	A phase 2, open-label, single-arm sulfasalazine monotherapy trial of progression-free survival in patients with pancreatic adenocarcinoma	Pancreatic cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001347853
ACTRN12621001403820	IMBO-Pilot-study	Phase 2	Not yet recruiting	NSW, VIC	18/10/2021		Dexamethasone; Placebo	glucocorticoid; placebo	Dexamethasone; Placebo	glucocorticoid; placebo	054/20	A phase II, multi-site, double blind, randomised placebo-controlled feasibility trial of crushed oral famotidine for management of Inoperable Malignant Bowel Obstruction (IMBO)	Malignant Bowel Obstruction; Bowel Obstruction; Bowel cancer	2010 - Darlinghurst; 3084 - Heidelberg; 2217 - Kogarah; 2176 - Prairiewood; 2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001403820
ACTRN12621001436864	CTB-02-01	Phase 1 / Phase 2	Not yet recruiting	NSW	25/10/2021		Cetuximab; Cetuximab + Cobimetinib + Palbociclib; Cobimetinib; Palbociclib	anti-EGFR_monoclonal_antibody; MEK_inhibitor; CDK4/6_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor	Cetuximab; Cetuximab + Cobimetinib + Palbociclib; Cobimetinib; Palbociclib; Cetuximab + Cobimetinib + Palbociclib	CDK4/6_inhibitor; CDK4/6_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; MEK_inhibitor; anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody	CTB-02-01	A two-part open label Phase 1/2 study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of the combination of cetuximab, cobimetinib and palbociclib in subjects with K-RAS wild-type BRAF V600E mutated, or K-RAS mutated, advanced or metastatic colorectal cancer who have failed all available standard therapies	Colorectal Cancer	2050 - Camperdown; 2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001436864
ACTRN12621001537842	NOX66-IS-002--CA209-66P,	Phase 1 / Phase 2	Recruiting	NSW	10/11/2021	25/10/2021	Idronoxil; Idronoxil + Nivolumab; Nivolumab	idronoxil_suppository; anti-PD-1_monoclonal_antibody + idronoxil_suppository; anti-PD-1_monoclonal_antibody	Idronoxil; Idronoxil + Nivolumab; Nivolumab; Idronoxil + Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + idronoxil_suppository; idronoxil_suppository; anti-PD-1_monoclonal_antibody + idronoxil_suppository	NOX66-IS-002  CA209-66P,	Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours – a pilot study (IONIC-1).	Patients with solid tumours	2217 - Kogarah; 2148 - Blacktown; 2076 - Wahroonga; 2228 - Miranda	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001537842
ACTRN12621001690842	MoST-addendum-19	Phase 2	Recruiting	NSW, SA, TAS, VIC, WA	10/12/2021		Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	CTC 0141 – addendum 19	Single arm, open label, signal-seeking phase II study of Sotorasib (AMG-510) in patients with solid tumours harbouring KRAS G12C mutation.	Cancer	2145 - Westmead; 6009 - Nedlands; 3000 - Melbourne; 2010 - Darlinghurst; 7000 - Hobart; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001690842
ACTRN12622000016730	HER2Pro-1B	Phase 1	Not yet recruiting	NSW, QLD	11/01/2022		Dexamethasone; Dexamethasone + Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel; Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Trastuzumab; Pertuzumab; Prochlorperazine; Trastuzumab	anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + glucocorticoid + taxane; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + taxane; antihistamine; glucocorticoid; taxane	Dexamethasone + Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Trastuzumab; Prochlorperazine; Dexamethasone + Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Trastuzumab	anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + glucocorticoid + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane; antihistamine; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + glucocorticoid + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane	None	Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study	Metastatic HER2-positive breast cancer	2010 - Darlinghurst; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000016730
ACTRN12622000405718	ONC201-104	Phase 1	Not yet recruiting	NZ	9/03/2022		ONC201	AKT_inhibitor; DRD2_antagonist; ERK_inhibitor	ONC201	AKT_inhibitor; DRD2_antagonist; ERK_inhibitor	ONC201-104	A Phase 1 study to evaluate the effect of renal impairment on the pharmacokinetics of ONC201	Renal Impairment; Cancer; Solid Tumours	Christchurch	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000405718
ACTRN12622000513718	GQ1007-101	Phase 1	Not yet recruiting	NSW, QLD, VIC	31/03/2022		Envafolimab; Envafolimab + GQ1007; GQ1007	anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-immune-agonist-conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-immune-agonist-conjugate	Envafolimab; Envafolimab + GQ1007; GQ1007; Envafolimab + GQ1007	anti-ERBB2_antibody-immune-agonist-conjugate; anti-ERBB2_antibody-immune-agonist-conjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-immune-agonist-conjugate + anti-PD-L1_monoclonal_antibody	GQ1007-101	A Phase I, First-In-Human, Multicenter, Open-Label, Dose Escalation and Expansion Study of GQ1007 Alone and in Combination with Envafolimab in Subjects with HER2-expressing Advanced Solid Tumors	Solid Tumors	2010 - Darlinghurst; 4217 - Benowa; 3168 - Clayton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000513718
ACTRN12622000973718	SHERLOCK	Phase 2	Not yet recruiting	NSW, QLD, TAS, VIC	11/07/2022		Bevacizumab; Carboplatin; Pemetrexed; Sotorasib	antimetabolite; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody	Carboplatin; Pemetrexed; Sotorasib; Bevacizumab	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; antimetabolite; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody	TOGA 21/011  CTC 0377	SHERLOCK: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation	advanced non-squamous non-small cell lung cancer with KRAS G12C mutation 326412 0		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000973718
ACTRN12622000993796	ACTRN12622000993796	Phase 1	Not yet recruiting	NSW, VIC, WA	14/07/2022		AXA-042	TLR2/6_agonist	AXA-042	TLR2/6_agonist	None	A Phase 1, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy in subjects with advanced solid tumors.	Advanced solid tumors	2031 - Randwick; 6009 - Nedlands; 3000 - Melbourne; 3175 - Dandenong	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000993796
ACTRN12622001003763	X22-0072	Phase 2	Not yet recruiting	NSW	18/07/2022		Evolocumab	anti-PCSK9_monoclonal_antibody	Evolocumab	anti-PCSK9_monoclonal_antibody	Protocol Number: X22-0072	A multi-centre, open label phase 2 trial investigating the effect of evolocumab in addition to chemotherapy or androgen receptor signalling inhibitor therapy on the circulating lipid profile of men with metastatic castration-resistant prostate cancer	Metastatic Castrate Resistant Prostate Cancer	2139 - Concord; 2050 - Camperdown; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001003763
ACTRN12622001339741	HH3806-A101	Phase 1	Not yet recruiting	VIC	18/10/2022		HH3806	BET_inhibitor	HH3806	BET_inhibitor	HH3806-A101	A Phase I, Open-label, Multicenter, First in Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients with Advanced Malignancies	relapsed/refractory Non-Hodgkin’s lymphomas (NHL); Solid Tumors	3199 - Frankston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001339741
ACTRN12622001378718	TheraPb-phase-I-II	Phase 1 / Phase 2	Not yet recruiting	QLD	26/10/2022						none	Phase I/II Dose Escalation and Toxicity Study of [212Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma (TheraPb – Phase I/II)	Metastatic Prostate Cancer	4029 - Royal Brisbane Hospital; 4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001378718
ACTRN12622001514796	KARPOS	Not Applicable	Not yet recruiting	SA	6/12/2022		Bevacizumab; Bevacizumab + GD2-iCAR-PBT; Cyclophosphamide; Cyclophosphamide + Fludarabine; Fludarabine; GD2-iCAR-PBT; Ifosfamide	antimetabolite; alkylating_agent; anti-VEGF_monoclonal_antibody; alkylating_agent + antimetabolite; anti-VEGF_monoclonal_antibody + autologous_CAR-T-cell_therapy,GD2-targeting; autologous_CAR-T-cell_therapy,GD2-targeting	Bevacizumab + GD2-iCAR-PBT; Cyclophosphamide + Fludarabine; GD2-iCAR-PBT; Bevacizumab + GD2-iCAR-PBT; Cyclophosphamide + Fludarabine; Ifosfamide	alkylating_agent + antimetabolite; anti-VEGF_monoclonal_antibody + autologous_CAR-T-cell_therapy,GD2-targeting; autologous_CAR-T-cell_therapy,GD2-targeting; alkylating_agent + antimetabolite; anti-VEGF_monoclonal_antibody + autologous_CAR-T-cell_therapy,GD2-targeting	Nil Known	KARPOS - A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme	Glioblastoma Multiforme	5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001514796
ACTRN12622001542785	Lewis-Y-Nivo-CAR-T	Phase 1	Not yet recruiting	VIC	13/12/2022		Cyclophosphamide; Cyclophosphamide + Fludarabine; Fludarabine; LeY-CAR-T; LeY-CAR-T + Nivolumab; Nivolumab	antimetabolite; alkylating_agent; anti-PD-1_monoclonal_antibody + autologous_CAR-T-cell_therapy,LeY-targeting; anti-PD-1_monoclonal_antibody; autologous_CAR-T-cell_therapy,LeY-targeting; alkylating_agent + antimetabolite	Cyclophosphamide + Fludarabine; LeY-CAR-T; LeY-CAR-T + Nivolumab; Nivolumab; Cyclophosphamide + Fludarabine; LeY-CAR-T + Nivolumab	alkylating_agent + antimetabolite; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + autologous_CAR-T-cell_therapy,LeY-targeting; autologous_CAR-T-cell_therapy,LeY-targeting; alkylating_agent + antimetabolite; anti-PD-1_monoclonal_antibody + autologous_CAR-T-cell_therapy,LeY-targeting	Nil known	A Pilot Study Assessing Safety and Tolerability of Lewis Y (LeY) targeting Chimeric Antigen Receptor (CAR) T cells in combination with Nivolumab in Patients With LeY Expressing Solid Tumours	LeY Expressing Advanced Solid Tumours	3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001542785
ACTRN12623000073606	SLAP-trial	Phase 0	Not yet recruiting	NSW	23/01/2023		Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting	Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting	None	A Single-Arm, Open-Label, Prospective, Phase 0 Trial Evaluating the Safety and Efficacy of Salvage 177Lu-PSMA-I&T in Prostate Specific Antigen (PSA) Biochemical Failure After Radical Prostatectomy for High-Risk Prostate Cancer	Prostate cancer 328693 0	2076 - Wahroonga	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000073606
ACTRN12623000096651	LUMOS2	Phase 2	Not yet recruiting	NSW, QLD, TAS, VIC	27/01/2023		AK104; Paxalisib; Selinexor	bispecific_PD-1/CTLA-4_antibody; dual_PI3K/mTOR_inhibitor; selective_inhibitor_of_nuclear_export	AK104; Paxalisib; Selinexor	bispecific_PD-1/CTLA-4_antibody; dual_PI3K/mTOR_inhibitor; selective_inhibitor_of_nuclear_export	CTC0837  COGNO2201	LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS	Grade 3 Glioma; Grade 2 Glioma	4029 - Herston; 2065 - St Leonards; 3065 - Fitzroy; 3000 - Melbourne; 7000 - Hobart; 2010 - Darlinghurst; 3084 - Heidelberg; 3168 - Clayton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000096651
ACTRN12623000108617	EMITT-1	Phase 1	Not yet recruiting	NSW, SA, VIC	31/01/2023		GRWD5769	ERAP1_inhibitor	GRWD5769	ERAP1_inhibitor	GRWD5769-ST-01	A modular, multi-part, multi-arm, open-label, Phase I/II Study to evaluate the safety and tolerability of GRWD5769 in patients with solid malignancies - Module 1.	Advanced solid malignancies		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000108617
ACTRN12623000174684	APG2449OG101	Phase 1	Not yet recruiting	NSW	21/02/2023		APG-2449; APG-2449 + Doxorubicin; Doxorubicin	FAK/ALK/ROS1_inhibitor; FAK_inhibitor; anthracycline; ALK_inhibitor,third_generation + anthracycline; doxorubicin; ALK_inhibitor,third_generation; FAK_inhibitor + anthracycline; FAK/ALK/ROS1_inhibitor + anthracycline	APG-2449; APG-2449 + Doxorubicin; APG-2449 + Doxorubicin	ALK_inhibitor,third_generation; ALK_inhibitor,third_generation + anthracycline; FAK/ALK/ROS1_inhibitor; FAK/ALK/ROS1_inhibitor + anthracycline; FAK_inhibitor; FAK_inhibitor + anthracycline; ALK_inhibitor,third_generation + anthracycline; FAK/ALK/ROS1_inhibitor + anthracycline; FAK_inhibitor + anthracycline; doxorubicin	APG2449OG101	Safety, tolerability, and efficacy of APG-2449 in Combination with Doxorubicin Hydrochloride Liposome in treating Patients with Platinum-resistant Ovarian Cancer	Ovarian Cancer	2148 - Blacktown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000174684
ACTRN12623000185662	SSO110-01	Phase 1	Not yet recruiting	NSW, QLD, VIC, WA	22/02/2023		Atezolizumab; Atezolizumab + Satoreotide Tetraxetan; Satoreotide Tetraxetan	anti-PD-L1_monoclonal_antibody; 177Lu-DOTA-radioconjugate + anti-PD-L1_monoclonal_antibody; 177Lu-DOTA-radioconjugate	Atezolizumab; Atezolizumab + Satoreotide Tetraxetan; Satoreotide Tetraxetan; Atezolizumab + Satoreotide Tetraxetan	177Lu-DOTA-radioconjugate; 177Lu-DOTA-radioconjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; 177Lu-DOTA-radioconjugate + anti-PD-L1_monoclonal_antibody	SSO110-01	A multicentre, open-label, Phase I study investigating the safety, tolerability, and efficacy of 177Lu-SSO110 with 68Ga-SSO120 companion imaging in participants with extensive stage small cell lung cancer (ES-SCLC) who are on maintenance treatment with atezolizumab	Extensive Stage Small Cell Lung Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000185662
ACTRN12623000202662	SON-DP-A002-ST	Phase 1	Not yet recruiting	SA	24/02/2023		Radiotherapy	radiotherapy	Radiotherapy	radiotherapy	SON-DP-A002-ST	A First-in-Human (FIH), Open-Label, Phase Ia Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Advanced/Metastatic Solid Tumours that have relapsed or are refractory/intolerant to standard of care therapies	Solid tumor malignancies	5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000202662
ACTRN12623000216617	RESCUE	Phase 1	Not yet recruiting	NZ	28/02/2023		177Lu-DOTA-rosopatamab; Lu-177 vipivotide tetraxetan; Radiotherapy	radioligand,PSMA-targeting; radiotherapy	177Lu-DOTA-rosopatamab; Lu-177 vipivotide tetraxetan; Radiotherapy	radioligand,PSMA-targeting; radiotherapy	Nil Known	A pilot, feasibility study of 177Lu-DOTA-Rosopatamab (TLX591) therapy in castrate resistant prostate adenocarcinoma patients showing progression on radioligand therapy using PSMA small molecule ligands	Metastatic Prostate Cancer	Auckland	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000216617
ACTRN12623000223639	iLSTA	Phase 1	Not yet recruiting	WA	2/03/2023		CEND-1; CEND-1 + Durvalumab + Gemcitabine + Nab-paclitaxel; Durvalumab; Gemcitabine; Nab-paclitaxel	antimetabolite; gemcitabine; anti-PD-L1_monoclonal_antibody; taxane; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane + tumor-homing_peptide_iRGD; tumor-homing_peptide_iRGD	CEND-1 + Durvalumab + Gemcitabine + Nab-paclitaxel; Durvalumab; CEND-1 + Durvalumab + Gemcitabine + Nab-paclitaxel	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane + tumor-homing_peptide_iRGD; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane + tumor-homing_peptide_iRGD; gemcitabine	Nil known	A Phase 1 single-blind study evaluating LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel as a first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC)	Cancer	6008 - Subiaco	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000223639
ACTRN12623000307606	NP-105	Phase 1	Not yet recruiting	NSW	21/03/2023		RX108	sodium-potassium_ATPase_inhibitor	RX108	sodium-potassium_ATPase_inhibitor	NP-105	A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of RX108-A Tablet in Patients with Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000307606
ACTRN12623000686606	IMRARP	Not Applicable	Not yet recruiting	VIC	26/06/2023						None	The effect of intrathecal morphine compared to standard care with oral and IV opioids on the quality of recovery after robotic-assisted radical prostatectomy	Bladder Spasms; Prostate Cancer 329956 0; Post-operative Pain	3000 - Melbourne; 3121 - Richmond	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000686606
ACTRN12623000739617	ACTRN12623000739617	Not Applicable	Not yet recruiting	ACT, NSW, NT, QLD, SA, TAS, VIC, WA	7/07/2023						Nil known	Comparing the effectiveness of two body image writing interventions against a neutral writing control in targeting positive body image in female cancer populations: A Randomised Controlled Trial	cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000739617
ACTRN12623000798662	HCC	Phase 1 / Phase 2	Not yet recruiting	NSW, SA	26/07/2023		BOS-342	bispecific_4-1BB/GPC3_antibody	BOS-342	bispecific_4-1BB/GPC3_antibody	Nil Known	A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of BOS-342 in Patients with Hepatocellular Carcinoma (HCC) and other GPC3-expressing Tumors	Other GPC3-expressing Tumors; Hepatocellular Carcinoma (HCC)	2050 - Camperdown; 5042 - Bedford Park; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000798662
ACTRN12623000874617	Biomarcer-2	Phase 2	Not yet recruiting	NSW, QLD, TAS, VIC, WA	15/08/2023		Cetuximab; Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Irinotecan; Fluorouracil; Irinotecan; Leucovorin	anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; topoisomerase_inhibitor; Fluorouracil; folinic_acid	Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Irinotecan; Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Irinotecan	anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; Fluorouracil; anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor	None	Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression	Advanced RAS Wild type right sided Colorectal cancer	3076 - Epping; 3000 - Melbourne; 3844 - Traralgon; 3011 - Footscray; 2298 - Waratah; 6150 - Murdoch; 3084 - Heidelberg; 3280 - Warrnambool; 2305 - New Lambton Heights; 7000 - Hobart	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000874617
ACTRN12623000956606	Australia	Unknown	Not yet recruiting	NSW, QLD, SA, VIC	4/09/2023		AT-0174	dual_IDO/TDO_inhibitor	AT-0174	dual_IDO/TDO_inhibitor	Antido Therapeutics (Australia) Protocol No. AT-0174-001	A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies	Locally Advanced Solid Tumours	3350 - Ballarat Central; 5000 - Adelaide; 4575 - Birtinya; 2228 - Miranda; 3065 - Fitzroy	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000956606
ACTRN12623001072606	LuCape	Unknown	Not yet recruiting	WA	6/10/2023		Capecitabine	fluoropyrimidine	Capecitabine	fluoropyrimidine	Nil known	A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC)	metastatic castration-resistant prostate cancer 331258 0	6150 - Murdoch	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001072606
ACTRN12623001077651	EMITT-1	Unknown	Not yet recruiting	NSW, SA, VIC	10/10/2023		Cemiplimab; Cemiplimab + GRWD5769; GRWD5769	anti-PD-1_monoclonal_antibody; ERAP1_inhibitor; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody	Cemiplimab; Cemiplimab + GRWD5769; GRWD5769; Cemiplimab + GRWD5769	ERAP1_inhibitor; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody	GRWD5769-ST-01 Module 2	A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies - Module 2.	Advanced solid malignancies	3004 - Melbourne; 5042 - Bedford Park; 3084 - Heidelberg; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001077651
ACTRN12623001126606	TCaP	Unknown	Not yet recruiting	QLD, VIC	1/11/2023		Cytarabine; Cytarabine + Pembrolizumab; Ifosfamide; Pembrolizumab	antimetabolite; alkylating_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite	Cytarabine + Pembrolizumab; Pembrolizumab; Cytarabine + Pembrolizumab; Ifosfamide	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite; alkylating_agent; anti-PD-1_monoclonal_antibody + antimetabolite	Nil known	Phase I/II clinical trial evaluating the safety and efficacy of allogeneic cytomegalovirus-specific T cells in combination with pembrolizumab for recurrent and newly diagnosed glioblastoma multiforme	Glioblastoma multiforme/astrocytoma grade 4	4006 - Bowen Hills; 4029 - Royal Brisbane Hospital; 3084 - Heidelberg; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001126606
ACTRN12623001164684	ACTRN12623001164684	Unknown	Not yet recruiting	QLD	9/11/2023		Atorvastatin; Hydroxychloroquine; Melatonin; Metformin	HMG-CoA_reductase_inhibitor; anti-malarial_agent; biguanide_antihyperglycaemic_agent; melatonin	Atorvastatin; Hydroxychloroquine; Melatonin; Metformin	HMG-CoA_reductase_inhibitor; anti-malarial_agent; biguanide_antihyperglycaemic_agent; melatonin	Nil	Assessing treatment effectiveness of the 'Repurposing-Drugs-in-Oncology' (ReDO) protocol for adult cancer by Circulating Tumour Cell (CTC) analysis: A case-series	Cancer	4209 - Willow Vale	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001164684
ACTRN12623001216606	MEHDSAM	Unknown	Not yet recruiting	NSW	27/11/2023		Sonidegib	SMO_inhibitor,first_generation	Sonidegib	SMO_inhibitor,first_generation	CT-2023-CTN-04330-1	Single-institution, single-arm, open-label phase II basket study investigating the effect of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies	Cancer	2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001216606
ACTRN12623001217695	ACTRN12623001217695	Unknown	Not yet recruiting	NSW	27/11/2023		IMD-101	IL2_conjugate	IMD-101	IL2_conjugate	AFB-105	An Open-Label Dose-Escalation Phase Ia Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of IMD-101 Injectable in Participants with Advanced Malignant Solid Tumours.	Advanced malignant solid tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001217695
ACTRN12623001219673	EN002-CN-001	Unknown	Recruiting	NSW, QLD	27/11/2023	22/08/2022					EN002-CN-001	A phase I-II clinical trial to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of EN002-gel in patients with non-melanoma skin cancer and precancerous lesions	Actinic keratosis; Bowen’s disease; Squamous cell carcinoma of the skin; Basal cell carcinoma	4102 - Woolloongabba; 2289 - Kotara	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001219673
ACTRN12623001333606	CCaLM	Unknown	Not yet recruiting	NSW	19/12/2023		Placebo	placebo	Placebo	placebo	Nil known	The Novel use of Labetuzumab as Adjuvant Immunotherapy in Patients with Primary Colon Adenocarcinoma with Intact PELPK Binding Motif in their CEACAM5 gene in a Phase II clinical trial regarding the Development of Metachronous Liver Metastases (i.e., those at ‘high-risk’ of metachronous CRCLMs)	Colon cancer	2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001333606
ACTRN12624000110583	SOCRATES-PILOT	Unknown	Not yet recruiting	NSW	8/02/2024		Abiraterone; Anastrozole; Apalutamide; Atorvastatin; Bevacizumab; Darolutamide; Enzalutamide; Letrozole; Lomustine; Nab-paclitaxel; Niraparib; Olaparib; Paclitaxel	CYP17A1_inhibitor; aromatase_inhibitor; taxane; alkylating_agent; PARP_inhibitor; anti-VEGF_monoclonal_antibody; HMG-CoA_reductase_inhibitor; antiandrogen,nonsteroidal,second_generation	Abiraterone; Anastrozole; Apalutamide; Atorvastatin; Bevacizumab; Darolutamide; Enzalutamide; Letrozole; Lomustine; Nab-paclitaxel; Niraparib; Olaparib; Paclitaxel	CYP17A1_inhibitor; HMG-CoA_reductase_inhibitor; PARP_inhibitor; alkylating_agent; anti-VEGF_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation; aromatase_inhibitor; taxane	CTC 0393	SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies	Cardio Vascular Disease; Cancer	2139 - Concord; 2031 - Randwick; 2050 - Missenden Road; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000110583
ACTRN12624000268549	LEPO	Unknown	Not yet recruiting	NSW	15/03/2024						ADRI002	LEPO: A phase 1 study of Leptospermum petersonii extract for patients with mesothelioma	Mesothelioma		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000268549
ACTRN12624000288527	REZOLV3R	Unknown	Not yet recruiting	NSW, QLD, VIC	20/03/2024		Bevacizumab	anti-VEGF_monoclonal_antibody	Bevacizumab	anti-VEGF_monoclonal_antibody	CTC 0398	Efficacy of intraperitoneal bevacizumab for decreasing or delaying re-accumulation of recurrent malignant ascites in chemotherapy resistant solid tumours: a randomised trial (REZOLV3R)	Chemotherapy resistant solid tumours; Recurrent malignant ascites		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000288527
ACTRN12624000478516	JBI-802-102	Unknown	Not yet recruiting	SA, WA	18/04/2024		JBI802	LSD1/HDAC6_inhibitor	JBI802	LSD1/HDAC6_inhibitor	JBI-802-102	Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis	Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN); Myeloproliferative Neoplasms (MPN); Essential Thrombocythemia (ET)	5000 - Adelaide; 6005 - West Perth; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000478516
ACTRN12624000532505	INTER-EWING-1	Unknown	Not yet recruiting	NSW, NZ, QLD, SA, TAS, VIC, WA	29/04/2024		Cyclophosphamide; Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Regorafenib + Vincristine; Cyclophosphamide + Vinorelbine; Doxorubicin; Etoposide; Ifosfamide; Radiotherapy; Regorafenib; Vincristine; Vinorelbine	alkylating_agent + vinca_alkaloid; alkylating_agent; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + anthracycline + topoisomerase_inhibitor + vinca_alkaloid; topoisomerase_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; radiotherapy; doxorubicin; vinca_alkaloid	Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Regorafenib + Vincristine; Cyclophosphamide + Vinorelbine; Radiotherapy; Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Regorafenib + Vincristine; Cyclophosphamide + Vinorelbine	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + anthracycline + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + vinca_alkaloid; radiotherapy; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + anthracycline + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + vinca_alkaloid; doxorubicin	ISRCTN17938906  RG_21-151	International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (INTER-EWING-1)	Ewing Sarcoma		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000532505
ACTRN12624000574549	ACTRN12624000574549	Unknown	Not yet recruiting	NZ	7/05/2024						Nil known	Using Digital Humans to Deliver Stress Management: Feasibility and Acceptability to Women with Breast Cancer and Healthcare Professionals.	Distress following breast cancer active-treatment		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000574549
ACTRN12624000588594	PORCUPINE2-Australian-Extension	Unknown	Not yet recruiting	NSW	8/05/2024		Denosumab; Denosumab + RXC004; RXC004	PORCN_inhibitor + anti-RANK_L_monoclonal_antibody; anti-RANK_L_monoclonal_antibody; PORCN_inhibitor	Denosumab + RXC004; RXC004; Denosumab + RXC004	PORCN_inhibitor; PORCN_inhibitor + anti-RANK_L_monoclonal_antibody; PORCN_inhibitor + anti-RANK_L_monoclonal_antibody	None	A Phase 2, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Pancreatic Cancer that have Progressed following Therapy with Current Standard of Care	Pancreatic Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000588594
NCT02365441	ALT-GIST	Phase 2	NOT_RECRUITING	ACT, NSW, QLD, SA, TAS, VIC, WA	19/02/2015	1/02/2015	Imatinib; Imatinib + Regorafenib; Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + KIT_inhibitor; BCR-ABL1_inhibitor,first_generation; KIT_inhibitor; PDGFRA_inhibitor; BCR-ABL1_inhibitor,first_generation + KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + PDGFRA_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Imatinib; Imatinib + Regorafenib; Imatinib + Regorafenib	BCR-ABL1_inhibitor,first_generation; BCR-ABL1_inhibitor,first_generation + KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + KIT_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + PDGFRA_inhibitor; KIT_inhibitor; PDGFRA_inhibitor; BCR-ABL1_inhibitor,first_generation + KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + KIT_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + PDGFRA_inhibitor	ACTRN12614000950662  AG1013GST	A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)	Gastrointestinal Stromal Tumour	2606 - Canberra; 5037 - Adelaide; 5042 - Adelaide; 2031 - Sydney; 3199 - Frankston; 7001 - Hobart; 2310 - Newcastle; 4120 - Brisbane; 3690 - Wodonga; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT02365441
NCT02516553	2015-001111-12--1367.1	Phase 1	NOT_RECRUITING	NSW	6/08/2015	8/07/2015	BI 894999	BET_inhibitor	BI 894999	BET_inhibitor	2015-001111-12  1367.1	An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit	Neoplasms; NUT Carcinoma	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT02516553
NCT02611960	Keynote-122	Phase 3	NOT_RECRUITING	NSW	19/11/2015	18/04/2016	Capecitabine; Capecitabine + Docetaxel + Gemcitabine; Docetaxel; Gemcitabine; Pembrolizumab	antimetabolite; anti-PD-1_monoclonal_antibody; fluoropyrimidine; taxane; gemcitabine; antimetabolite + fluoropyrimidine + taxane	Capecitabine + Docetaxel + Gemcitabine; Pembrolizumab; Capecitabine + Docetaxel + Gemcitabine	anti-PD-1_monoclonal_antibody; antimetabolite + fluoropyrimidine + taxane; antimetabolite + fluoropyrimidine + taxane; gemcitabine	MK-3475-122  3475-122	A Two-arm, Open-label, Randomized Phase III Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)	Nasopharyngeal Neoplasms	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02611960
NCT02702414	KEYNOTE-224	Phase 2	NOT_RECRUITING	NSW, VIC	3/03/2016	31/05/2016	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2015-004566-28  3475-224	A Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Advanced Hepatocellular Carcinoma (KEYNOTE-224)	Hepatocellular Carcinoma	3168 - Melbourne; 3004 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02702414
NCT02705482	D6060C00002	Phase 1	NOT_RECRUITING	NSW, QLD, VIC	4/03/2016	30/03/2016	Durvalumab; Durvalumab + Tavolimab; Immune Therapeutic Agent; Tavolimab; Tavolimab + Tremelimumab; Tremelimumab	anti-OX40_agonistic_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; immune_checkpoint_blockade	Durvalumab + Tavolimab; Tavolimab + Tremelimumab; Durvalumab + Tavolimab; Immune Therapeutic Agent; Tavolimab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; immune_checkpoint_blockade	D6060C00002	A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors	Select Advanced Solid Tumors	2217 - Kogarah; 3168 - Clayton; 2109 - Macquarie University; 4068 - Woolloongabba; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02705482
NCT02775435	KEYNOTE-407	Phase 3	NOT_RECRUITING	NSW	15/05/2016	9/06/2016	Carboplatin; Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Dexamethasone; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; glucocorticoid; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; placebo	Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Dexamethasone; Placebo	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; glucocorticoid; placebo; platinum-based_antineoplastic_agent + taxane	2016-000229-38  3475-407	A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)	Non-small Cell Lung Cancer	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02775435
NCT02787005	KEYNOTE-199	Phase 2	NOT_RECRUITING	NSW	26/05/2016	1/07/2016	Enzalutamide; Enzalutamide + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation	Enzalutamide + Pembrolizumab; Pembrolizumab; Enzalutamide + Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation	2015-003644-40  3475-199	Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)	Metastatic Castration-resistant Prostate Cancer	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02787005
NCT02964013	MK-7684-001--7684-001	Phase 1	NOT_RECRUITING	NSW	15/11/2016	13/12/2016	Carboplatin; Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Carboplatin + Pembrolizumab + Pemetrexed + Vibostolimab; Cisplatin; Etoposide; Pembrolizumab; Pembrolizumab + Vibostolimab; Pemetrexed; Vibostolimab	antimetabolite; topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Carboplatin + Pembrolizumab + Pemetrexed + Vibostolimab; Pembrolizumab + Vibostolimab; Vibostolimab; Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Carboplatin + Pembrolizumab + Pemetrexed + Vibostolimab; Pembrolizumab + Vibostolimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	MK-7684-001  7684-001	A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Neoplasms	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02964013
NCT03286842	D0816C00018	Phase 3	NOT_RECRUITING	NSW	14/09/2017	17/01/2018	Olaparib	PARP_inhibitor	Olaparib	PARP_inhibitor	D0816C00018	A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations.	Somatic BRCA1/2 Mutations; HER2-ve Metastatic Breast Cancer; Germline BRCA1/2 Mutations	NSW 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT03286842
NCT03363776	2017-002199-24--CA034-001	Phase 1/Phase 2	NOT_RECRUITING	NSW, QLD, VIC	6/12/2017	24/11/2017	BMS-986277; BMS-986277 + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; replication-competent_oncolytic_adenovirus; anti-PD-1_monoclonal_antibody + replication-competent_oncolytic_adenovirus	BMS-986277; BMS-986277 + Nivolumab; BMS-986277 + Nivolumab	anti-PD-1_monoclonal_antibody + replication-competent_oncolytic_adenovirus; replication-competent_oncolytic_adenovirus; anti-PD-1_monoclonal_antibody + replication-competent_oncolytic_adenovirus	2017-002199-24  CA034-001	Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors	Cancer	2050 - Camperdown; 4029 - Herston; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT03363776
NCT03430063	2017-003684-35--R2810-ONC-1763	Phase 2	NOT_RECRUITING	NSW	9/02/2018	29/05/2018	Cemiplimab; Ipilimumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Cemiplimab; Ipilimumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2017-003684-35  R2810-ONC-1763	A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer	Advanced Non-Small Cell Lung Carcinoma	- Wollongong	https://clinicaltrials.gov/ct2/show/NCT03430063
NCT03811652	D8540C00002	Phase 1	NOT_RECRUITING	VIC	21/01/2019	20/12/2018	Abiraterone; Abiraterone + Enzalutamide; Capecitabine; Capecitabine + Fluorouracil + Irinotecan + Oxaliplatin + Raltitrexed + Tegafur; Enzalutamide; Fluorouracil; Irinotecan; MEDI7247; Oxaliplatin; Raltitrexed; Tegafur	antimetabolite; fluoropyrimidine; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; topoisomerase_inhibitor; antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; Fluorouracil; anti-ASCT2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; antiandrogen,nonsteroidal,second_generation	Abiraterone + Enzalutamide; Capecitabine + Fluorouracil + Irinotecan + Oxaliplatin + Raltitrexed + Tegafur; Abiraterone + Enzalutamide; Capecitabine + Fluorouracil + Irinotecan + Oxaliplatin + Raltitrexed + Tegafur; MEDI7247	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; Fluorouracil; anti-ASCT2_antibody-drug_conjugate; antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	D8540C00002	A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors	Pancreatic Ductal Adenocarcinoma (PDAC); Small Cell Lung Cancer (SCLC); Metastatic Castration-resistant Prostate Cancer (mCRPC); Colorectal Cancer (CRC); Head and Neck Squamous Cell Carcinoma (HNSCC); Non Small Cell Lung Cancer Squamous (NSCLC-Sq)	3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03811652
NCT03878719	C4221011--ARRAY-162-115	Phase 1	NOT_RECRUITING	NSW, NZ, VIC	18/03/2019	13/08/2020	Binimetinib; Binimetinib + Encorafenib; Encorafenib	BRAF_V600_inhibitor + MEK_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor	Binimetinib + Encorafenib; Binimetinib + Encorafenib	BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	C4221011  ARRAY-162-115	A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma	Melanoma	2031 - Sydney; Wellington; 3168 - Clayton; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT03878719
NCT04077463	Chrysalis-2	Unknown	NOT_RECRUITING		4/09/2019	4/09/2019	Amivantamab; Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + Osimertinib; Amivantamab + Osimertinib; Carboplatin; Lazertinib; Osimertinib; Pemetrexed	antimetabolite; EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; bispecific_cMET/EGFR_monoclonal_antibody; platinum-based_antineoplastic_agent	Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + Osimertinib; Amivantamab + Osimertinib; Lazertinib; Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + Osimertinib; Amivantamab + Osimertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody	73841937NSC1001  CR108656	An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung		https://clinicaltrials.gov/ct2/show/NCT04077463
NCT04164199	2019-002554-23--BGB-A317-290-LTE1	Phase 3	ENROLLING_BY_INVITATION	NSW, NZ, QLD, SA, VIC	15/11/2019	19/12/2019	Capecitabine; Capecitabine + Tislelizumab; Pamiparib; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Pemetrexed; Pemetrexed + Tislelizumab; Temozolomide; Tislelizumab	antimetabolite; alkylating_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody; fluoropyrimidine; PARP_inhibitor; anti-PD-1_monoclonal_antibody + fluoropyrimidine; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite; PARP_inhibitor + alkylating_agent	Capecitabine + Tislelizumab; Pamiparib; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Pemetrexed + Tislelizumab; Tislelizumab; Capecitabine + Tislelizumab; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Pemetrexed + Tislelizumab	PARP_inhibitor; PARP_inhibitor + alkylating_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + fluoropyrimidine; PARP_inhibitor + alkylating_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + fluoropyrimidine	2019-002554-23  BGB-A317-290-LTE1	An Open Label, Multicentre, Long-Term Extension Study of Tislelizumab- Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies	Advanced Malignancies	2298 - Waratah; 4101 - Brisbane; - East Melbourne; 3168 - Clayton; 2031 - Randwick; 5011 - Woodville; Auckland; 2065 - Saint Leonards	https://clinicaltrials.gov/ct2/show/NCT04164199
NCT04170283	BGB-3111-LTE1	Phase 3	RECRUITING	NSW, QLD, SA, TAS, VIC, WA	20/11/2019	21/01/2020	Tislelizumab; Tislelizumab + Zanubrutinib; Zanubrutinib	anti-PD-1_monoclonal_antibody; BTK_inhibitor; BTK_inhibitor + anti-PD-1_monoclonal_antibody	Tislelizumab + Zanubrutinib; Zanubrutinib; Tislelizumab + Zanubrutinib	BTK_inhibitor; BTK_inhibitor + anti-PD-1_monoclonal_antibody; BTK_inhibitor + anti-PD-1_monoclonal_antibody	BGB-3111-LTE1	An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies	B-cell Malignancies	- Hobart; - Concord; - Wodonga; 5037 - Kurralta Park; - Kogarah; 4120 - Greenslopes; - Geelong; - Woolloongabba; - Westmead; - Clayton; - Sydney; - Melbourne; 3004 - Melbourne; - Malvern; - Perth	https://clinicaltrials.gov/ct2/show/NCT04170283
NCT04282018	BGB-A317-3111-10188-101	Phase 1/Phase 2	NOT_RECRUITING	NSW, SA, VIC, WA	24/02/2020	25/05/2020	BGB-10188; BGB-10188 + Tislelizumab; BGB-10188 + Zanubrutinib; Tislelizumab; Zanubrutinib	anti-PD-1_monoclonal_antibody; PI3K_delta_inhibitor; BTK_inhibitor + PI3K_delta_inhibitor; BTK_inhibitor; PI3K_delta_inhibitor + anti-PD-1_monoclonal_antibody	BGB-10188; BGB-10188 + Tislelizumab; BGB-10188 + Zanubrutinib; BGB-10188 + Tislelizumab; BGB-10188 + Zanubrutinib	BTK_inhibitor + PI3K_delta_inhibitor; PI3K_delta_inhibitor; PI3K_delta_inhibitor + anti-PD-1_monoclonal_antibody; BTK_inhibitor + PI3K_delta_inhibitor; PI3K_delta_inhibitor + anti-PD-1_monoclonal_antibody	BGB-A317-3111-10188-101	A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kd) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors	Marginal Zone Lymphoma; Diffuse Large B Cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Advanced Solid Tumor; Mantle Cell Lymphoma; Metastatic Melanoma; Non-small Cell Lung Cancer; Follicular Lymphoma	- West Perth; - Heidelberg; - Darlinghurst; 4029 - Herston; 2148 - Blacktown; - Clayton; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04282018
NCT04427072	GeoMETry-III	Phase 3	NOT_RECRUITING	VIC	11/06/2020	25/09/2020	Capmatinib; Docetaxel	MET_inhibitor,type_1; taxane	Capmatinib; Docetaxel	MET_inhibitor,type_1; taxane	CINC280A2301	A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib Versus SoC Docetaxel Chemotherapy in Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (MET?ex14).	Carcinoma, Non-Small-Cell Lung	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04427072
NCT04603001	2020-002830-33--LOXO-IDH-20001	Phase 1	NOT_RECRUITING	VIC, WA	26/10/2020	1/12/2020	LY3410738	IDH1_R132_inhibitor,covalent	LY3410738	IDH1_R132_inhibitor,covalent	2020-002830-33  LOXO-IDH-20001	A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations	Myelodysplastic Syndrome (MDS); Myeloproliferative Neoplasms (MPNs); Chronic Myelomonocytic Leukemia (CMML); Acute Myeloid Leukemia (AML)	3000 - Melbourne; 6009 - Nedlands; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04603001
NCT04612751	2021-000274-28--DS1062-A-U104	Phase 1	RECRUITING	NSW, SA	3/11/2020	6/11/2020	Carboplatin; Cisplatin; Datopotamab deruxtecan; Datopotamab deruxtecan + Durvalumab; Durvalumab	anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent	Datopotamab deruxtecan + Durvalumab; Carboplatin; Cisplatin; Datopotamab deruxtecan + Durvalumab	anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent	2021-000274-28  DS1062-A-U104	A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Data-DXd) in Combination With Durvalumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)	Advanced or Metastatic NSCLC	2500 - Wollongong; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04612751
NCT04784715	D967UC00001	Phase 3	NOT_RECRUITING	NSW, QLD	5/03/2021	26/04/2021	Pertuzumab; Pertuzumab + Trastuzumab Deruxtecan; Placebo; Trastuzumab; Trastuzumab Deruxtecan	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; placebo; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	Pertuzumab + Trastuzumab Deruxtecan; Pertuzumab + Trastuzumab Deruxtecan; Placebo	anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; placebo	D967UC00001	Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)	HER2-positive; Metastatic; Breast Cancer	2109 - Macquarie University; 4066 - Auchenflower; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT04784715
NCT04819100	LIBRETTO-432	Phase 3	RECRUITING	NSW, QLD, VIC	26/03/2021	20/12/2021	Placebo; Selpercatinib	placebo; RET-selective_inhibitor	Selpercatinib; Placebo	RET-selective_inhibitor; placebo	J2G-MC-JZJX  18126	LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC	Carcinoma, Non-Small-Cell Lung	4814 - Douglas; 3350 - Ballarat; 2640 - Albury; 3630 - Shepparton; 3280 - Warrambool; 3550 - Bendigo; 4700 - Rockhampton; 4575 - Birtinya	https://clinicaltrials.gov/ct2/show/NCT04819100
NCT05006716	BGB-16673-101	Phase 1	RECRUITING	VIC, WA	16/08/2021		BGB-16673	BTK_PROTAC_degrader	BGB-16673	BTK_PROTAC_degrader	BGB-16673-101	A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies	B-cell Malignancy; Marginal Zone Lymphoma; Waldenström Macroglobulinemia; Non-hodgkin Lymphoma; Follicular Lymphoma	6005 - West Perth; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05006716
NCT05440864	NEOTOMA	Unknown	RECRUITING		1/07/2022		Durvalumab; Durvalumab + Tremelimumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Durvalumab + Tremelimumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	22-5353	Perioperative Therapy With Durvalumab Plus Tremelimumab for Patients With Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)	Hepatocellular Carcinoma		https://clinicaltrials.gov/ct2/show/NCT05440864
NCT05498428	PALOMA-2	Phase 2	RECRUITING	VIC, WA	12/08/2022	11/11/2022	Amivantamab; Amivantamab + Carboplatin + Lazertinib + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Amivantamab + Lazertinib; Carboplatin; Lazertinib; Osimertinib; Pemetrexed	antimetabolite; EGFR_inhibitor,third_generation; antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; bispecific_cMET/EGFR_monoclonal_antibody; platinum-based_antineoplastic_agent	Amivantamab + Carboplatin + Lazertinib + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Carboplatin + Lazertinib + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Amivantamab + Lazertinib	EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent	2022-000526-21  CR109264	A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer	Carcinoma, Non-small-Cell Lung	6009 - Nedlands; VIC 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT05498428
NCT05618028	M23-324	Phase 1	RECRUITING	VIC	16/11/2022		ABBV-525	MALT1_inhibitor	ABBV-525	MALT1_inhibitor	M23-324	A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies	Diffuse Large B-Cell Lymphoma; Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma; B Cell Malignancies	3168 - Clayton; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05618028
NCT05712356	BOLSTER	Unknown	RECRUITING	SA	3/02/2023	24/08/2023	CEND-1; Cisplatin; Durvalumab; Gemcitabine; Paclitaxel; Placebo	antimetabolite; gemcitabine; anti-PD-L1_monoclonal_antibody; taxane; tumor-homing_peptide_iRGD; platinum-based_antineoplastic_agent; placebo	CEND-1; Cisplatin; Durvalumab; Gemcitabine; Paclitaxel; Placebo	tumor-homing_peptide_iRGD; anti-PD-L1_monoclonal_antibody; antimetabolite; gemcitabine; placebo; platinum-based_antineoplastic_agent; taxane	2023-503740-14  LSTA1-P02	A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors	Hypopharynx Cancer; Cancer of the Head and Neck; Gall Bladder Cancer; Bile Duct Cancer; HNSCC; Oropharynx Cancer; Advanced Head and Neck Squamous Cell Carcinoma; Squamous Cell Carcinoma of the Larynx; Gallbladder Carcinoma; Oral Cavity Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Larynx Squamous Cell Carcinoma; Squamous Cell Carcinoma of the Oropharynx; Intrahepatic Cholangiocarcinoma; Squamous Cell Carcinoma of the Head and Neck; Hypopharynx Squamous Cell Carcinoma; Larynx Cancer; Gall Bladder Carcinoma; Oropharynx Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Cholangiocarcinoma; Head and Neck Cancer; Squamous Cell Carcinoma of the Hypopharynx; Extrahepatic Cholangiocarcinoma; Oral Cavity Cancer; Gallbladder Cancer; Squamous Cell Carcinoma of the Oral Cavity	5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT05712356
NCT05830084	REGO-EWING	Unknown	RECRUITING		13/04/2023	27/03/2023	Radiotherapy; Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; radiotherapy	Radiotherapy; Regorafenib	radiotherapy; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	2022/3545  2022-002874-10	Phase Ib Study of the Combination of Regorafenib With Conventional Chemotherapy for the Treatment of Newly Diagnosed Patients With Multimetastatic Ewing Sarcoma	Bone Cancer		https://clinicaltrials.gov/ct2/show/NCT05830084
NCT02408861	NCI-2015-00461	Phase 1	RECRUITING	NSW	2015-04-03	2015-10-21	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	NCI-2015-00461	A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma	Advanced Malignant Solid Neoplasm; Anal Carcinoma; HIV Infection; Kaposi Sarcoma; Lung Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma; Unresectable Solid Neoplasm	2010 - Darlinghurst - Saint Vincent's Hospital - (SUSPENDED); 2052 - Sydney - University of New South Wales	https://clinicaltrials.gov/ct2/show/NCT02408861
NCT02419417	BET	Phase 1/Phase 2	NOT_RECRUITING	VIC	2015-04-14	2015-06-19	BMS-986158; BMS-986158 + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; BET_inhibitor + anti-PD-1_monoclonal_antibody; BET_inhibitor	BMS-986158; BMS-986158 + Nivolumab; BMS-986158 + Nivolumab	BET_inhibitor; BET_inhibitor + anti-PD-1_monoclonal_antibody; BET_inhibitor + anti-PD-1_monoclonal_antibody	CA011-001	A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies	Advanced Tumors	3004 - Melbourne - Nucleus Network	https://clinicaltrials.gov/ct2/show/NCT02419417
NCT02477826	CheckMate-227	Phase 3	NOT_RECRUITING	ACT, Australian Capital Territory, NSW, QLD, SA, VIC, WA	2015-06-18	2015-08-05	Carboplatin; Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed; Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed; Cisplatin; Gemcitabine; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Paclitaxel; Pemetrexed	antimetabolite; anti-CTLA-4_monoclonal_antibody; gemcitabine; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed; Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed; Ipilimumab + Nivolumab; Nivolumab; Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed; Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent + taxane; gemcitabine	CA209-227	An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	Non-Small Cell Lung Cancer	2148 - Blacktown - Local Institution - 0301; 2250 - Gosford - Local Institution - 0300; 2340 - Tamworth - Local Institution - 0183; 2605 - Garran - Local Institution - 0182; 3065 - Fitzroy - Local Institution - 0042; 3168 - Clayton - Local Institution - 0043; 4102 - Brisbane - Local Institution - 0045; 5112 - Elizabeth Vale - Local Institution - 0046; 6150 - Murdoch - Local Institution - 0040; 6150 - Perth - Local Institution - 0180	https://clinicaltrials.gov/ct2/show/NCT02477826
NCT02503033	2015-523-00AU1	Phase 1	UNKNOWN	ACT, Australian Capital Territory, NSW, QLD, SA, VIC, WA	2015-07-16	2015-11	HMPL-523	SYK_inhibitor	HMPL-523	SYK_inhibitor	2015-523-00AU1	A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Hematologic Malignancies	Hematologic Malignancies	2640 - Albury - Border Medical Oncology Research Unit; 3144 - Melbourne - Cabrini Health; 3220 - Geelong - Barwon Health; 3350 - Ballarat - Ballarat Regional Integrated Cancer Centre; 4814 - Townsville - Townsville Hospital; 6000 - Perth - Royal Perth Hospital; Adelaide - Royal Adelaide Hospital; Canberra - Canberra Hospital; Fitzroy - St Vincent's Hospital; Frankston - Peninsula & South Eastern Haematology and Oncology Group; Heidelberg - Austin Hospital; Liverpool - Liverpool Hospital	https://clinicaltrials.gov/ct2/show/NCT02503033
NCT02503774	D6070C00001	Phase 1	NOT_RECRUITING	NSW, QLD	2015-07-17	2015-07-24	Durvalumab; Durvalumab + Oleclumab; Oleclumab	anti-PD-L1_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD73_monoclonal_antibody	Durvalumab + Oleclumab; Oleclumab; Durvalumab + Oleclumab	anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	D6070C00001	A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors	Solid Tumors	2050 - Camperdown - Research Site; 2065 - St Leonards - Research Site; 3050 - Parkville - Research Site; 4068 - Woolloongabba - Research Site	https://clinicaltrials.gov/ct2/show/NCT02503774
NCT02554812	B9991004	Phase 1/Phase 2	NOT_RECRUITING	NSW, VIC	2015-09-17	2015-11-09	Avelumab; Avelumab + CMP-001; Avelumab + CMP-001 + PF-04518600; Avelumab + CMP-001 + Utomilumab; Avelumab + PD-0360324; Avelumab + PF-04518600; Avelumab + PF-04518600 + Utomilumab; Avelumab + Utomilumab; CMP-001; PD-0360324; PF-04518600; Utomilumab	anti-4-1BB_agonistic_antibody; TLR9_agonist + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CSF1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-CSF1_monoclonal_antibody; TLR9_agonist; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-4-1BB_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody	Avelumab + CMP-001; Avelumab + CMP-001 + PF-04518600; Avelumab + CMP-001 + Utomilumab; Avelumab + PD-0360324; Avelumab + PF-04518600; Avelumab + PF-04518600 + Utomilumab; Avelumab + Utomilumab; Avelumab + CMP-001; Avelumab + CMP-001 + PF-04518600; Avelumab + CMP-001 + Utomilumab; Avelumab + PD-0360324; Avelumab + PF-04518600; Avelumab + PF-04518600 + Utomilumab; Avelumab + Utomilumab	TLR9_agonist + anti-4-1BB_agonistic_antibody + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-CSF1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-4-1BB_agonistic_antibody + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-CSF1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody	B9991004	A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES	Advanced Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2060 - North Sydney - Melanoma Institute Australia; 2060 - North Sydney - The Mater Hospital; 2109 - Macquarie University - Macquarie University; 2109 - New South Wales - Macquarie Heart; 2146 - Old Toongabie - Baxter Healthcare; 3084 - Heidelberg - Austin Health; 3144 - Malvern - Cabrini Hospital; 3144 - Malvern - Cabrini Hospital Malvern; 3144 - Malvern - Malvern Medical Imaging; 3186 - Brighton - Brighton Medical Imaging; 3186 - Brighton - Cabrini Hospital Brighton	https://clinicaltrials.gov/ct2/show/NCT02554812
NCT02568267	STARTRK-2	Phase 2	NOT_RECRUITING	NSW, SA, VIC	2015-10-02	2015-11-19	Crizotinib; Crizotinib + Entrectinib; Entrectinib	MET_inhibitor,type_1; ALK_inhibitor,first_generation + TRK_inhibitor,first_generation; ROS1_inhibitor + TRK_inhibitor,first_generation; MET_inhibitor,type_1 + ROS1_inhibitor; ALK_inhibitor,third_generation + ROS1_inhibitor; ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,first_generation + ROS1_inhibitor; MET_inhibitor,type_1 + TRK_inhibitor,first_generation; ALK_inhibitor,third_generation; TRK_inhibitor,first_generation; ROS1_inhibitor	Crizotinib + Entrectinib; Entrectinib; Crizotinib + Entrectinib	ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,first_generation + TRK_inhibitor,first_generation; ALK_inhibitor,third_generation; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,third_generation + ROS1_inhibitor; MET_inhibitor,type_1 + ROS1_inhibitor; MET_inhibitor,type_1 + TRK_inhibitor,first_generation; ROS1_inhibitor; ROS1_inhibitor + TRK_inhibitor,first_generation; TRK_inhibitor,first_generation; ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,first_generation + TRK_inhibitor,first_generation; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,third_generation + ROS1_inhibitor; MET_inhibitor,type_1 + ROS1_inhibitor; MET_inhibitor,type_1 + TRK_inhibitor,first_generation; ROS1_inhibitor + TRK_inhibitor,first_generation	RXDX-101-02	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor	2170 - Liverpool - Liverpool Hospital; 2305 - New Lambton Heights - Newcastle Private Hospital; 3084 - Heidelberg - Austin Health; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT02568267
NCT02582697	P3BEP	Phase 3	UNKNOWN	Auckland, NSW, NZ, Palmerston North, QLD, SA, TAS, VIC, WA	2015-10-19	2014-02	Bleomycin; Bleomycin + Cisplatin + Etoposide + Filgrastim + Pegfilgrastim; Cisplatin; Etoposide; Filgrastim; Pegfilgrastim	antineoplastic_antibiotic + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; antineoplastic_antibiotic; topoisomerase_inhibitor; granulocyte_colony_stimulating_factor; platinum-based_antineoplastic_agent	Bleomycin + Cisplatin + Etoposide + Filgrastim + Pegfilgrastim; Bleomycin + Cisplatin + Etoposide + Filgrastim + Pegfilgrastim	antineoplastic_antibiotic + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; antineoplastic_antibiotic + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	ANZUP1302	Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours	Germ Cell Tumor	1023 - Grafton - Starship Children's Hospital; 1142 - Grafton - Auckland Hospital; 2031 - Sydney - Prince of Wales Hospital; 2050 - Sydney - Chris O'Brien Lifehouse; 2065 - St Leonards - Royal North Shore Hospital; 2076 - Wahroonga - SAN Clinical Trials Unit; 2109 - Sydney - Macquarie Cancer Clinical Trials; 2139 - Sydney - Concord Repatriation General Hospital; 2145 - Sydney - Westmead Hospital - (WITHDRAWN); 2298 - Newcastle - Calvary Mater Newcastle; 2485 - Tweed Heads - Tweed Hospital; 2751 - Sydney - Nepean Hospital; 3002 - East Melbourne - Peter MacCallum Cancer Centre; 3021 - St Albans - Sunshine Hospital - (WITHDRAWN); 3084 - Heidelberg - Austin Health; 3128 - Box Hill - Box Hill Hospital; 3690 - Wodonga - Border Medical Oncology; 4029 - Brisbane - Royal Brisbane & Women's Hospital; 4101 - South Brisbane - Queensland Children's Hospital; 4102 - Woolloongabba - Princess Alexandra; 4442 - Roslyn - Palmerston North Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6847 - Murdoch - Fiona Stanley Hospital; 7000 - Hobart - Royal Hobart Hospital; 8011 - Christchurch - Christchurch Hospital; 9054 - Dunedin - Dunedin Hospital - (WITHDRAWN)	https://clinicaltrials.gov/ct2/show/NCT02582697
NCT02601950	EZH-202	Phase 2	NOT_RECRUITING	NSW, QLD	2015-11-09	2015-12-22	Tazemetostat	EZH2_inhibitor	Tazemetostat	EZH2_inhibitor	EZH-202	A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma	Malignant Rhabdoid Tumors (MRT); Rhabdoid Tumors of the Kidney (RTK); Atypical Teratoid Rhabdoid Tumors (ATRT); Selected Tumors With Rhabdoid Features; Synovial Sarcoma; INI1-negative Tumors; Malignant Rhabdoid Tumor of Ovary; Renal Medullary Carcinoma; Epithelioid Sarcoma; Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval); Any Solid Tumor With an EZH2 GOF Mutation	2050 - Camperdown - Chris O'Brien Lifehouse; QLD 4102 - Woolloongabba - Metro South Hospital and Health Service via Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT02601950
NCT02628067	KEYNOTE-158	Phase 2	RECRUITING	NSW	2015-12-09	2015-12-18	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	3475-158	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	Advanced Cancer; Anal Carcinoma; Anal Cancer; Biliary Cancer; Cholangiocarcinoma; Bile Duct Cancer; Neuroendocrine Tumor; Carcinoid Tumor; Endometrial Carcinoma; Endometrial Cancer; Cervical Carcinoma; Cervical Cancer; Vulvar Carcinoma; Vulvar Cancer; Small Cell Lung Carcinoma; Small Cell Lung Cancer (SCLC); Mesothelioma; Thyroid Carcinoma; Thyroid Cancer; Salivary Gland Carcinoma; Salivary Gland Cancer; Salivary Cancer; Parotid Gland Cancer; Advanced Solid Tumors; Colorectal Carcinoma	North Ryde - MSD Australia	https://clinicaltrials.gov/ct2/show/NCT02628067
NCT02645149	MatchMel	Phase 2	RECRUITING	NSW	2015-12-30	2021-11-22	Ceritinib; Ribociclib; Ribociclib + Trametinib; Trametinib	ALK/ROS1/IGF1R_inhibitor; CDK4/6_inhibitor + MEK_inhibitor; CDK4/6_inhibitor; MEK_inhibitor	Ribociclib + Trametinib; Trametinib; Ceritinib; Ribociclib + Trametinib	CDK4/6_inhibitor + MEK_inhibitor; MEK_inhibitor; ALK/ROS1/IGF1R_inhibitor; CDK4/6_inhibitor + MEK_inhibitor	MIA2015/174	Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma	Melanoma	2145 - Westmead - Westmead Hospital; 2260 - Wollstonecraft - Melanoma Institute Australia	https://clinicaltrials.gov/ct2/show/NCT02645149
NCT02660034	BGB-A317-BGB-290-Study-001	Phase 1	NOT_RECRUITING	ACT, Australian Capital Territory, NSW, NZ, QLD, VIC, WA	2016-01-17	2016-02-02	Pamiparib; Pamiparib + Tislelizumab; Tislelizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; PARP_inhibitor	Pamiparib + Tislelizumab; Pamiparib + Tislelizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody	BGB-A317/BGB-290_Study_001	A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors	Solid Tumors	1023 - Auckland - Auckland City Hospital; 2065 - St Leonards - Northern Cancer Institute; 2298 - Newcastle - Calvary Mater Newcastle; 2450 - Coffs Harbour - Mid North Coast Cancer Institute; 2605 - Garran - The Canberra Hospital; 4101 - Brisbane - Icon Cancer Care; 6021 - Wellington - Capital and Coast District Health Board; Clayton - Monash Health; Melbourne - Peter MacCallum Cancer Centre; Nedlands - Linear Clinical Research Ltd; Parramatta - Westmead Hospital; Randwick - Prince of Wales	https://clinicaltrials.gov/ct2/show/NCT02660034
NCT02671435	D419NC00001	Phase 1/Phase 2	NOT_RECRUITING	NSW, NZ, VIC	2016-01-28	2016-02-22	Bevacizumab; Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Monalizumab + Oxaliplatin; Cetuximab; Cetuximab + Durvalumab + Fluorouracil + Leucovorin + Monalizumab + Oxaliplatin; Cetuximab + Durvalumab + Monalizumab; Cetuximab + Monalizumab; Durvalumab; Durvalumab + Monalizumab; Fluorouracil; Leucovorin; Monalizumab; Oxaliplatin	anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; folinic_acid; anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody; anti-VEGF_monoclonal_antibody; Fluorouracil; platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody	Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Monalizumab + Oxaliplatin; Cetuximab + Durvalumab + Fluorouracil + Leucovorin + Monalizumab + Oxaliplatin; Cetuximab + Durvalumab + Monalizumab; Cetuximab + Monalizumab; Durvalumab + Monalizumab; Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Monalizumab + Oxaliplatin; Cetuximab + Durvalumab + Fluorouracil + Leucovorin + Monalizumab + Oxaliplatin; Cetuximab + Durvalumab + Monalizumab; Cetuximab + Monalizumab; Durvalumab + Monalizumab	anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	D419NC00001	A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors	Advanced Solid Tumors	1023 - Grafton - Research Site; 2148 - Blacktown - Research Site; 2298 - Waratah - Research Site; 3168 - Clayton - Research Site	https://clinicaltrials.gov/ct2/show/NCT02671435
NCT02723955	GSK3359609-204691	Phase 1	NOT_RECRUITING	VIC, WA	2016-03-24	2016-06-23	Bintrafusp Alfa; Bintrafusp Alfa + GSK3359609; Carboplatin; Carboplatin + Cisplatin + Docetaxel + Fluorouracil + GSK3359609 + Gemcitabine + Paclitaxel + Pemetrexed; Cisplatin; Cobolimab; Cobolimab + Dostarlimab + GSK3359609; Docetaxel; Dostarlimab; Dostarlimab + GSK3359609; Fluorouracil; GSK3174998; GSK3174998 + GSK3359609; GSK3359609; GSK3359609 + Pembrolizumab; Gemcitabine; Paclitaxel; Pembrolizumab; Pemetrexed	antimetabolite; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody; gemcitabine; anti-ICOS_agonistic_antibody + anti-OX40_agonistic_antibody; taxane; anti-PD-L1/TGF-beta_fusion_protein; anti-ICOS_agonistic_antibody + anti-PD-L1/TGF-beta_fusion_protein; anti-TIM3_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-ICOS_agonistic_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + taxane; Fluorouracil; anti-PD-1_monoclonal_antibody; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-ICOS_agonistic_antibody	Bintrafusp Alfa + GSK3359609; Carboplatin + Cisplatin + Docetaxel + Fluorouracil + GSK3359609 + Gemcitabine + Paclitaxel + Pemetrexed; Cobolimab + Dostarlimab + GSK3359609; Dostarlimab + GSK3359609; GSK3174998 + GSK3359609; GSK3359609; GSK3359609 + Pembrolizumab; Bintrafusp Alfa + GSK3359609; Carboplatin + Cisplatin + Docetaxel + Fluorouracil + GSK3359609 + Gemcitabine + Paclitaxel + Pemetrexed; Cobolimab + Dostarlimab + GSK3359609; Dostarlimab + GSK3359609; GSK3174998 + GSK3359609; GSK3359609 + Pembrolizumab	anti-ICOS_agonistic_antibody; anti-ICOS_agonistic_antibody + anti-OX40_agonistic_antibody; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-ICOS_agonistic_antibody + anti-PD-L1/TGF-beta_fusion_protein; anti-ICOS_agonistic_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + taxane; Fluorouracil; anti-ICOS_agonistic_antibody + anti-OX40_agonistic_antibody; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-ICOS_agonistic_antibody + anti-PD-L1/TGF-beta_fusion_protein; anti-ICOS_agonistic_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + taxane; gemcitabine	204691	A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors	Neoplasms	3000 - Melbourne - GSK Investigational Site; 3084 - Heidelberg - GSK Investigational Site; 6009 - Nedlands - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT02723955
NCT02747342	SHR3680-002	Phase 1	NOT_RECRUITING	NSW, QLD	2016-04-20	2016-09	Fuzuloparib; Fuzuloparib + Rezvilutamide; Rezvilutamide	PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor; antiandrogen,nonsteroidal,second_generation	Fuzuloparib + Rezvilutamide; Fuzuloparib + Rezvilutamide	PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor + antiandrogen,nonsteroidal,second_generation	SHR3680-002	A Phase 1 Trial of SHR3680 With or Without SHR3162 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Neoplasm; Prostate Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2145 - Sydney - Westmead Hospital; 2170 - Liverpool - Liverpool Hospital; 2217 - Kogarah - St George Hospital; 2640 - Albury - Border Medical Oncology; 4101 - South Brisbane - Icon Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT02747342
NCT02754141	CA013-004	Phase 1/Phase 2	NOT_RECRUITING	NSW, VIC	2016-04-25	2016-06-21	BMS-986179; BMS-986179 + Nivolumab; BMS-986179 + rHuPH20; Nivolumab; rHuPH20	anti-CD73_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; recombinant_human_hyaluronidase; anti-CD73_monoclonal_antibody	BMS-986179; BMS-986179 + Nivolumab; BMS-986179 + rHuPH20; BMS-986179 + Nivolumab; BMS-986179 + rHuPH20	anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody + recombinant_human_hyaluronidase; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody + recombinant_human_hyaluronidase	CA013-004	A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors	Malignant Solid Tumor	2010 - Sydney - Local Institution - 0017; 2031 - Randwick - Local Institution - 0019; 3004 - Melbourne - Local Institution - 0018	https://clinicaltrials.gov/ct2/show/NCT02754141
NCT02773524	INTEGRATEIIa	Phase 3	UNKNOWN	ACT, Australian Capital Territory, NSW, NT, NZ, QLD, SA, TAS, VIC, WA	2016-05-12	2016-11	Placebo; Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; placebo	Regorafenib; Placebo	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; placebo	AG0315OG	A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Gastro-Oesophageal Cancer	0810 - Tiwi - Royal Darwin Hospital; 1023 - Auckland - Auckland Hospital; 2010 - Darlinghurst - St Vincent's Public Hospital; 2031 - Randwick - Prince of Wales Hospital; 2035 - New Lambton Heights - Newcastle Private Hospital; 2139 - Concord - Concord Repatriation General Hospital; 2145 - Westmead - Westmead Hospital; 2217 - Kogarah - St George Hospital; 2250 - Gosford - Gosford Hospital; 2444 - Port Macquarie - Port Macquarie Base Hospital; 2450 - Coffs Harbour - Coffs Harbour Health Campus; 2485 - Tweed Heads - The Tweed Hospital; 2640 - Albury - Border Medical Oncology; 3084 - Heidelberg - Austin Hospital; 3168 - Clayton - Monash Medical Centre; 3355 - Wendouree - Ballarat Oncology and Haematology Services; 4029 - Herston - Royal Brisbane and Womens Hospital; 4560 - Sunshine Coast - Sunshine Coast University Hospital; 4814 - Douglas - The Townsville Hospital; 5011 - Woodville South - The Queen Elizabeth Hospital; 5035 - Ashford - Ashford Cancer Centre Research; 5042 - Bedford Park - Flinders Medical Centre; 6008 - Subiaco - St John of God Hospital Subiaco; 6009 - Nedlands - Sir Charles Gairdner Hospital; 700 - Hobart - Royal Hobart Hospital; Canberra - Canberra Hospital; Saint Leonards - Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT02773524
NCT02821013	STOP-GAP	Phase 3	RECRUITING	Mildura, NSW, QLD, SA, South A., VIC	2016-06-29	2016-10-31					ME13	A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma	Unresectable/Metastatic Melanoma	2145 - Westmead - Westmead Hospital; 2298 - Waratah - Calvary Mater Newcastle Hospital; 2450 - Coffs Harbour - Coffs Habour Health Campus - NCCI; 2650 - Wagga Wagga - Riverina Cancer Care Centre Wagga Wagga; 3004 - Melbourne - Alfred Hospital; 3168 - Clayton - Monash Medical Centre; 3500 - Victoria - Mildura Base Public Hospital; 4029 - Herston - Royal Brisbane and Womens Hospital; 4102 - Brisbane - Princess Alexandra Hospital; 4215 - Southport - Gold Coast University Hospital; 4575 - Birtinya - Sunshine Coast University Hospital; 4870 - Cairns - Cairns Hospital; 5011 - Woodville - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT02821013
NCT02824965	ONJ2015-001	Phase 1	UNKNOWN	VIC	2016-07-06	2017-08-09	Coxsackievirus A21; Coxsackievirus A21 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing; oncolytic_Coxsackie_virus,ICAM_overexpressing; anti-PD-1_monoclonal_antibody	Coxsackievirus A21 + Pembrolizumab; Coxsackievirus A21 + Pembrolizumab	anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing; anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing	ONJ2015-001	A Phase I/II Open-label Trial of Intravenous CAVATAK^TM in Combination With Pembrolizumab for the Treatment of Patients With Advanced NSCLC	Non-Small Cell Lung Cancer	3078 - Heidelberg - Austin Health	https://clinicaltrials.gov/ct2/show/NCT02824965
NCT02854436	Galahad	Phase 2	NOT_RECRUITING	NSW, SA, VIC, WA	2016-08-01	2016-08-31	Niraparib	PARP_inhibitor	Niraparib	PARP_inhibitor	CR108208	A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies	Prostatic Neoplasms	Camperdown; Darlinghurst; East Albury; Kurralta Park; Macquarie University; Melbourne; Murdoch; Port Macquarie; Randwick; Wahroonga	https://clinicaltrials.gov/ct2/show/NCT02854436
NCT02857270	NCT02857270	Phase 1	NOT_RECRUITING	NSW, WA	2016-08-03	2016-09-29	Abemaciclib; Abemaciclib + LY3214996; Cetuximab; Cetuximab + Encorafenib + LY3214996; Encorafenib; Gemcitabine; Gemcitabine + LY3214996 + Nab-paclitaxel; LY3214996; LY3214996 + Midazolam; Midazolam; Nab-paclitaxel	ERK_inhibitor + benzodiazepam; gemcitabine; CDK4/6_inhibitor + ERK_inhibitor; BRAF_V600_inhibitor; CDK4/6_inhibitor; taxane; ERK_inhibitor; anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + ERK_inhibitor + anti-EGFR_monoclonal_antibody; benzodiazepam; ERK_inhibitor + antimetabolite + taxane	Abemaciclib + LY3214996; Cetuximab + Encorafenib + LY3214996; Gemcitabine + LY3214996 + Nab-paclitaxel; LY3214996; LY3214996 + Midazolam; Abemaciclib + LY3214996; Cetuximab + Encorafenib + LY3214996; Gemcitabine + LY3214996 + Nab-paclitaxel; LY3214996 + Midazolam	BRAF_V600_inhibitor + ERK_inhibitor + anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor + ERK_inhibitor; ERK_inhibitor; ERK_inhibitor + antimetabolite + taxane; ERK_inhibitor + benzodiazepam; BRAF_V600_inhibitor + ERK_inhibitor + anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor + ERK_inhibitor; ERK_inhibitor + antimetabolite + taxane; ERK_inhibitor + benzodiazepam; gemcitabine	16419	A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer	Advanced Cancer; Metastatic Melanoma; Metastatic Non-small Cell Lung Cancer; Colorectal Cancer	2010 - Sydney - St Vincent's Hospital; 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT02857270
NCT02861573	KEYNOTE-365	Phase 1/Phase 2	RECRUITING	NSW, NZ	2016-08-05	2016-11-17	Abiraterone; Abiraterone + Pembrolizumab + Prednisone; Belzutifan; Belzutifan + Pembrolizumab; Carboplatin; Carboplatin + Etoposide; Carboplatin + Etoposide + Pembrolizumab; Dexamethasone; Dexamethasone + Docetaxel + Pembrolizumab + Prednisone; Docetaxel; Enzalutamide; Enzalutamide + Pembrolizumab; Etoposide; Lenvatinib; Lenvatinib + Pembrolizumab; Olaparib; Olaparib + Pembrolizumab; Pembrolizumab; Pembrolizumab + Vibostolimab; Prednisone; Vibostolimab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; CYP17A1_inhibitor; topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; taxane; CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; PARP_inhibitor; VEGF_inhibitor; anti-TIGIT_monoclonal_antibody; glucocorticoid; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; platinum-based_antineoplastic_agent; antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; HIF2a_inhibitor	Abiraterone + Pembrolizumab + Prednisone; Belzutifan + Pembrolizumab; Carboplatin + Etoposide; Carboplatin + Etoposide + Pembrolizumab; Dexamethasone + Docetaxel + Pembrolizumab + Prednisone; Enzalutamide + Pembrolizumab; Lenvatinib + Pembrolizumab; Olaparib + Pembrolizumab; Pembrolizumab + Vibostolimab; Abiraterone + Pembrolizumab + Prednisone; Belzutifan + Pembrolizumab; Carboplatin + Etoposide; Carboplatin + Etoposide + Pembrolizumab; Dexamethasone + Docetaxel + Pembrolizumab + Prednisone; Enzalutamide + Pembrolizumab; Lenvatinib + Pembrolizumab; Olaparib + Pembrolizumab; Pembrolizumab + Vibostolimab	CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	3475-365	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)	Metastatic Castration-Resistant Prostate Cancer	Auckland - Merck Sharp & Dohme (New Zealand) Ltd.,; North Ryde - MSD Australia	https://clinicaltrials.gov/ct2/show/NCT02861573
NCT02875548	TRuST	Phase 1/Phase 2	ENROLLING_BY_INVITATION	VIC	2016-08-17	2016-08-30	Tazemetostat	EZH2_inhibitor	Tazemetostat	EZH2_inhibitor	EZH-501	Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study	Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma (FL); Synovial Sarcoma; Epitheliod Sarcoma (ES); Mesothelioma; Advanced Solid Tumors; Renal Medullary Carcinoma; Non-Hodgkin Lymphoma (NHL)	3002 - Melbourne - Peter MacCallum Cancer Institute; 3168 - Clayton - Monash Medical Centre- Monash Campus; Geelong - Geelong Hospital	https://clinicaltrials.gov/ct2/show/NCT02875548
NCT02913313	CA020-002	Phase 1/Phase 2	NOT_RECRUITING	WA	2016-09-21	2016-11-30	BMS-986207; BMS-986207 + Ipilimumab + Nivolumab; BMS-986207 + Nivolumab; Ipilimumab; Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	BMS-986207; BMS-986207 + Ipilimumab + Nivolumab; BMS-986207 + Nivolumab; BMS-986207 + Ipilimumab + Nivolumab; BMS-986207 + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	CA020-002	Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors	Broad Solid Tumor	6009 - Nedlands - Local Institution - 0006	https://clinicaltrials.gov/ct2/show/NCT02913313
NCT02937272	NCT02937272	Phase 1	NOT_RECRUITING	NSW, QLD	2016-10-17	2016-11-21	Cisplatin; Cisplatin + Intensity Modulated Radiotherapy + LY3200882; Gemcitabine; Gemcitabine + LY3200882 + Nab-paclitaxel; Intensity Modulated Radiotherapy; LY3200882; LY3200882 + Lodapolimab; Lodapolimab; Nab-paclitaxel	gemcitabine; TGFBR1_inhibitor + antimetabolite + taxane; radiotherapy; anti-PD-L1_monoclonal_antibody; TGFBR1_inhibitor + platinum-based_antineoplastic_agent + radiotherapy; TGFBR1_inhibitor; TGFBR1_inhibitor + anti-PD-L1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Cisplatin + Intensity Modulated Radiotherapy + LY3200882; Gemcitabine + LY3200882 + Nab-paclitaxel; LY3200882; LY3200882 + Lodapolimab; Cisplatin + Intensity Modulated Radiotherapy + LY3200882; Gemcitabine + LY3200882 + Nab-paclitaxel; LY3200882 + Lodapolimab	TGFBR1_inhibitor; TGFBR1_inhibitor + anti-PD-L1_monoclonal_antibody; TGFBR1_inhibitor + antimetabolite + taxane; TGFBR1_inhibitor + platinum-based_antineoplastic_agent + radiotherapy; TGFBR1_inhibitor + anti-PD-L1_monoclonal_antibody; TGFBR1_inhibitor + antimetabolite + taxane; TGFBR1_inhibitor + platinum-based_antineoplastic_agent + radiotherapy; gemcitabine	16185	A Phase 1 Study of LY3200882 in Patients With Solid Tumors	Solid Tumor	2010 - Sydney - St Vincent's Hospital Sydney; 2298 - Newcastle - Calvary Mater Newcastle; 4120 - Greenslopes - Greenslopes Private Hospital	https://clinicaltrials.gov/ct2/show/NCT02937272
NCT02960022	9785-CL-0123	Phase 2	RECRUITING	NSW, NZ, VIC, WA	2016-11-07	2016-12-22	Abiraterone; Abiraterone + Enzalutamide + Prednisone; Enzalutamide; Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation	Abiraterone + Enzalutamide + Prednisone; Enzalutamide; Abiraterone + Enzalutamide + Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid	9785-CL-0123	A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study	Prostate Cancer	2076 - Wahroonga - Site AU61017; 2145 - Westmead - Site AU61004; 2485 - Tweed Heads - Site AU61001 - (COMPLETED); 2640 - Albury - Site AU61014 - (COMPLETED); 3021 - St Albans - Site AU61016; 3165 - East Bentleigh - Site AU61007; 3350 - Ballarat - Site AU61019; 9016 - Dunedin - Site NZ64005; Ashford - Site AU61006; Hamilton - Site NZ64001; Malvern - Site AU61009 - (COMPLETED); Parkville - Site AU61021; South Brisbane - Site AU61008 - (COMPLETED); V2S 3N5 - Auckland - Site NZ64002; Westmead - Site AU61004 - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT02960022
NCT02964507	GSK525762-201973	Phase 1	NOT_RECRUITING	NSW, SA, VIC	2016-11-12	2017-02-02	Fulvestrant; Fulvestrant + Molibresib; Molibresib	selective_estrogen_receptor_degrader; BET_inhibitor + selective_estrogen_receptor_degrader; BET_inhibitor	Fulvestrant; Fulvestrant + Molibresib; Fulvestrant + Molibresib	BET_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; BET_inhibitor + selective_estrogen_receptor_degrader	201973	A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer	Neoplasms	2444 - Port Macquarie - GSK Investigational Site; 3084 - Heidelberg - GSK Investigational Site; 5042 - Bedford Park - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT02964507
NCT02985957	CheckMate-650	Phase 2	NOT_RECRUITING	NSW, QLD, SA, VIC	2016-12-05	2017-03-26	Cabazitaxel; Cabazitaxel + Prednisone; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Prednisone	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; glucocorticoid + taxane; glucocorticoid; anti-PD-1_monoclonal_antibody; taxane	Cabazitaxel + Prednisone; Ipilimumab; Ipilimumab + Nivolumab; Cabazitaxel + Prednisone; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; glucocorticoid + taxane; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; glucocorticoid + taxane	CA209-650	A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2076 - Wahroonga - Local Institution - 0059; 2145 - Westmead - Local Institution - 0029; 2250 - Gosford - Local Institution - 0027; 3168 - Clayton - Local Institution - 0031; 4012 - Woolloongabba - Local Institution - 0043; 4215 - Southport - Local Institution - 0028; 5112 - Elizabeth Vale - Local Institution - 0030	https://clinicaltrials.gov/ct2/show/NCT02985957
NCT03000257	M15-891	Phase 1	NOT_RECRUITING	NSW, VIC, WA	2016-12-19	2016-12-14	Budigalimab; Budigalimab + Rovalpituzumab Tesirine; Budigalimab + Rovalpituzumab Tesirine + Venetoclax; Budigalimab + Venetoclax; Rovalpituzumab Tesirine; Venetoclax	anti-DLL3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; Bcl2_inhibitor; anti-PD-1_monoclonal_antibody; anti-DLL3_antibody-drug_conjugate; Bcl2_inhibitor + anti-DLL3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; Bcl2_inhibitor + anti-PD-1_monoclonal_antibody	Budigalimab + Rovalpituzumab Tesirine; Budigalimab + Rovalpituzumab Tesirine + Venetoclax; Budigalimab + Venetoclax; Budigalimab + Rovalpituzumab Tesirine; Budigalimab + Rovalpituzumab Tesirine + Venetoclax; Budigalimab + Venetoclax	Bcl2_inhibitor + anti-DLL3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; Bcl2_inhibitor + anti-PD-1_monoclonal_antibody; anti-DLL3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; Bcl2_inhibitor + anti-DLL3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; Bcl2_inhibitor + anti-PD-1_monoclonal_antibody; anti-DLL3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	M15-891	A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181 as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	2148 - Blacktown - Blacktown Hospital /ID# 167386; 3065 - Fitzroy Melbourne - St Vincent's Hospital Melbourne /ID# 167552; 6000 - Nedlands - Linear Clinical Research /ID# 170797	https://clinicaltrials.gov/ct2/show/NCT03000257
NCT03052608	B7461006	Phase 3	NOT_RECRUITING	VIC	2017-02-09	2017-04-27	Crizotinib; Lorlatinib	MET_inhibitor,type_1; ALK_inhibitor,third_generation; ALK_inhibitor,first_generation; ROS1_inhibitor	Crizotinib; Lorlatinib	ALK_inhibitor,first_generation; ALK_inhibitor,third_generation; MET_inhibitor,type_1; ROS1_inhibitor	B7461006	A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER	Carcinoma, Non-Small-Cell Lung	3000 - Melbourne - Peter MacCallum Cancer Centre; 3550 - Bendigo - Bendigo Day Surgery Collection Centre and Laboratory; 3550 - Bendigo - Bendigo Medical Imaging, Bendigo Hospital; 3550 - Bendigo - Melbourne Pathology	https://clinicaltrials.gov/ct2/show/NCT03052608
NCT03085095	HERO	Phase 3	NOT_RECRUITING	NSW, NZ, QLD	2017-03-14	2017-04-18	Leuprolide Acetate; Relugolix	GnRH_antagonist; synthetic_gonadotropin-releasing_hormone; GnRH_analogue	Leuprolide Acetate; Relugolix	GnRH_analogue; GnRH_antagonist; synthetic_gonadotropin-releasing_hormone	MVT-601-3201	HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer	Prostate Cancer	2050 - Camperdown - Camperdown; 2076 - Wahroonga - Wahroonga; 2485 - Tweed Heads - Tweed Heads; 3112 - Tauranga - Tauranga; 3204 - Hamilton - Hamilton; 4020 - Redcliffe - Redcliffe; 4215 - Southport - Southport; 8013 - Christchurch - Christchurch; 9016 - Dunedin - Dunedin	https://clinicaltrials.gov/ct2/show/NCT03085095
NCT03088540	R2810-ONC-1624	Phase 3	NOT_RECRUITING	NSW, SA, WA	2017-03-16	2017-05-29	Carboplatin; Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed; Cemiplimab; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed	antimetabolite; gemcitabine; antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed; Cemiplimab; Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed	anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent + taxane; gemcitabine	R2810-ONC-1624	A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer	Carcinoma，Non-Small-Cell Lung; Lung Carcinomas, Non-Small-Cell; Non-small-cell Lung Carcinoma; Nonsmall Cell Lung Cancer	Albury - Clinical Study Site; Fitzroy - Clinical Study Site; Wollongong - Clinical Study Site	https://clinicaltrials.gov/ct2/show/NCT03088540
NCT03088813	RESILIENT	Phase 3	NOT_RECRUITING	NSW, QLD, VIC	2017-03-17	2018-04-25	Irinotecan; Liposomal Irinotecan; Topotecan	topoisomerase_inhibitor	Irinotecan; Topotecan; Liposomal Irinotecan	topoisomerase_inhibitor	MM-398-01-03-04	RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy	Small Cell Lung Cancer	2640 - Albury - Border Medical Oncology Research Unit; 3280 - Warrnambool - South West Healthcare; Wollongong - Southern Medical Day Care Centre; Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT03088813
NCT03093116	TRIDENT-1	Phase 1/Phase 2	RECRUITING	NSW, SA, VIC	2017-03-21	2017-03-07	Repotrectinib	TRK_inhibitor,second_generation; ALK_inhibitor,third_generation; ROS1_inhibitor	Repotrectinib	ALK_inhibitor,third_generation; ROS1_inhibitor; TRK_inhibitor,second_generation	CA127-1024	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Locally Advanced Solid Tumors; Metastatic Solid Tumors	2050 - Camperdown - Local Institution - 6102; 3000 - Melbourne - Local Institution - 6101; 5042 - Adelaide - Local Institution - 6103	https://clinicaltrials.gov/ct2/show/NCT03093116
NCT03126110	INCAGN-1876-201	Phase 1/Phase 2	NOT_RECRUITING	NSW, QLD, VIC, WA	2017-04-21	2017-04-25	INCAGN01876; INCAGN01876 + Ipilimumab; INCAGN01876 + Ipilimumab + Nivolumab; INCAGN01876 + Nivolumab; Ipilimumab; Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	INCAGN01876 + Ipilimumab; INCAGN01876 + Ipilimumab + Nivolumab; INCAGN01876 + Nivolumab; INCAGN01876 + Ipilimumab; INCAGN01876 + Ipilimumab + Nivolumab; INCAGN01876 + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	INCAGN 1876-201	A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies	Advanced Malignancies; Metastatic Cancer	2148 - Blacktown - Blacktown Cancer and Haematology Centre; 2148 - Randwick - Scientia Clinical Research; 3084 - Heidelberg - Austin Hospital; 4120 - Brisbane - Greenslopes Private Hospital; 6009 - Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT03126110
NCT03146468	NIVALLO	Phase 2	UNKNOWN	VIC	2017-05-07	2017-05-08	Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	RMH 2016.281	Pilot Study of the Tolerability of Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Haematopoietic Stem Cell Transplantation	Haematological Malignancy	3050 - Parkville - Royal Melbourne Hospital	https://clinicaltrials.gov/ct2/show/NCT03146468
NCT03148795	MDV3800-06	Phase 2	NOT_RECRUITING	NSW, QLD, VIC	2017-05-09	2017-07-04	Abiraterone; Enzalutamide; Prednisone; Talazoparib	glucocorticoid; PARP_inhibitor; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation	Talazoparib; Abiraterone; Enzalutamide; Prednisone	PARP_inhibitor; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation; glucocorticoid	MDV3800-06	TALAPRO-1: A PHASE 2, OPEN-LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE)	Prostate Cancer	2010 - Darlinghurst - Medical Imaging St Vincent's Hospital Sydney; 2010 - Darlinghurst - St Vincent's Hospital Sydney, The Kinghorn Cancer Centre; 2145 - Westmead - PRP Diagnostic Imaging; 2145 - Westmead - Westmead Hospital; 3084 - Heidelberg - Olivia Newton John Cancer Wellness & Research Centre Austin Health; 3128 - Box Hill - Eastern Clinical Research Unit; 3128 - Box Hill - Eastern Health Pathology Service; 3168 - Clayton - Monash Medical Centre; 3199 - Frankston - Peninsula Health; 4032 - Chermside - Icon Cancer Care Chermside; 4066 - Auchenflower - Icon Cancer Care Wesley; 4101 - South Brisbane - Icon Cancer Care; 4101 - South Brisbane - Icon Cancer Care South Brisbane; 4101 - South Brisbane - Intergrated Clinical Oncology Network (ICON); 4215 - Southport - Icon Cancer Care Southport; 4870 - Cairns - Liz Plummer Cancer Care Center	https://clinicaltrials.gov/ct2/show/NCT03148795
NCT03150056	GSK525762-204697	Phase 1	NOT_RECRUITING	NSW, VIC	2017-05-09	2017-07-18	Abiraterone; Abiraterone + Molibresib + Prednisone; Enzalutamide; Enzalutamide + Molibresib; Molibresib; Prednisone	BET_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; glucocorticoid; antiandrogen,nonsteroidal,second_generation; BET_inhibitor + CYP17A1_inhibitor + glucocorticoid; BET_inhibitor	Abiraterone + Molibresib + Prednisone; Enzalutamide + Molibresib; Abiraterone + Molibresib + Prednisone; Enzalutamide + Molibresib	BET_inhibitor + CYP17A1_inhibitor + glucocorticoid; BET_inhibitor + antiandrogen,nonsteroidal,second_generation; BET_inhibitor + CYP17A1_inhibitor + glucocorticoid; BET_inhibitor + antiandrogen,nonsteroidal,second_generation	204697	A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)	Solid Tumours	2050 - Sydney - GSK Investigational Site; 3000 - Melbourne - GSK Investigational Site; 3168 - Clayton - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT03150056
NCT03150810	BGB-290-103	Phase 1/Phase 2	NOT_RECRUITING	NSW, QLD, VIC	2017-05-10	2017-06-28	Pamiparib; Pamiparib + Temozolomide; Temozolomide	alkylating_agent; PARP_inhibitor; PARP_inhibitor + alkylating_agent	Pamiparib + Temozolomide; Pamiparib + Temozolomide	PARP_inhibitor + alkylating_agent; PARP_inhibitor + alkylating_agent	BGB-290-103	A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors	2010 - Darlinghurst - Saint Vincent's Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 4032 - Chermside - Icon Cancer Centre Chermside; 4066 - Auchenflower - Icon Cancer Centre Wesley; 4101 - South Brisbane - Icon Cancer Centre South Brisbane; 4215 - Southport - Icon Cancer Centre Southport; 4509 - North Lakes - Icon Cancer Centre North Lakes	https://clinicaltrials.gov/ct2/show/NCT03150810
NCT03157128	LIBRETTO-001	Phase 1/Phase 2	RECRUITING	NSW, VIC	2017-05-15	2017-05-02	Selpercatinib	RET-selective_inhibitor	Selpercatinib	RET-selective_inhibitor	17477	A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)	Non-Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Any Solid Tumor	2065 - St. Leonards - Royal North Shore Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03157128
NCT03161756	CHARLI	Phase 1/Phase 2	UNKNOWN	NSW, QLD, TAS, VIC, WA	2017-05-18	2017-12-07	Denosumab; Denosumab + Ipilimumab + Nivolumab; Denosumab + Nivolumab; Ipilimumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-RANK_L_monoclonal_antibody	Denosumab + Ipilimumab + Nivolumab; Denosumab + Nivolumab; Denosumab + Ipilimumab + Nivolumab; Denosumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody	01.15	A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma	Melanoma Stage Iv; Melanoma Stage Iii; Melanoma	2298 - Waratah - Calvary Mater Newcastle; 2640 - Albury - Border Medical Oncology Research Unit; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - Alfred Health; 3084 - Heidelberg - Austin Health; 3128 - Box Hill - Box Hill Hospital; 3550 - Bendigo - Bendigo Health; 4029 - Herston - Royal Brisbane and Women's Hospital; 6009 - Nedlands - Sir Charles Gairdner Hospital; 7000 - Hobart - Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT03161756
NCT03175224	SPARTA	Phase 2	RECRUITING	SA, VIC, WA	2017-06-01	2017-09-27	Vebreltinib	MET_inhibitor,type_1	Vebreltinib	MET_inhibitor,type_1	APL-101-01	Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Solid Tumors; Advanced Cancer; Renal Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; NSCLC; Lung Cancer; Brain Tumor; Glioblastoma Multiforme; EGFR Gene Mutation; MET Amplification; HGF; Thyroid Cancer; Pancreatic Cancer; Colon Cancer; MET Alteration; MET Fusion; Exon 14 Skipping	Albury - Border Medical Oncology; Bedford Park - Flinders Medical Centre; Frankston - Peninsula and Southeast Oncology; Melbourne - St Vincents Hospital Melbourne; Nedlands - Sir Charles Gairdner Hospital; North Adelaide - Calvary Central Districts Hospita	https://clinicaltrials.gov/ct2/show/NCT03175224
NCT03177239	UNISoN	Phase 2	UNKNOWN	NSW, QLD, SA, VIC, WA	2017-06-04	2017-10-19	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	ANZUP 1602	A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).	Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 1; Papillary Renal Cell Carcinoma Type 2; Chromophobe Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Xp11 Translocation Carcinoma	2010 - Darlinghurst - St Vincents Hospital; 2031 - Randwick - Prince of Wales Hospital; 2050 - Camperdown - Chris O'Brien Lifehouse; 2086 - Frenchs Forest - Northern Cancer Institute; 2145 - Westmead - Westmead Hospital; 2217 - Kogarah - St. George Hospital; 2298 - Newcastle - Calvary Mater Newcastle; 2340 - Tamworth - Tamworth Hospital - North West Cancer Centre; 2444 - Port Macquarie - Port Macquarie Base Hospital; 2460 - Albury - Border Medical Oncology; 2560 - Campbelltown - Campbelltown Hospital; 3128 - Box Hill - Box Hill Hospital - Eastern Health; 3168 - Clayton - Monash Medical Centre; 3355 - Ballarat - Ballarat Oncology & Haematology Services; 4000 - Brisbane - Royal Brisbane & Women's Hospital; 4575 - Birtinya - Sunshine Coast University Hospital; 5000 - Adelaide - Flinders Medical Centre; 5037 - Adelaide - Ashford Cancer Centre; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT03177239
NCT03178552	B-FAST	Phase 2/Phase 3	NOT_RECRUITING	NSW, NZ, QLD, SA, VIC, WA	2017-06-05	2017-09-22	Alectinib; Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed; Atezolizumab + Cobimetinib + Vemurafenib; Bevacizumab; Carboplatin; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Cobimetinib; Divarasib; Divarasib + Docetaxel; Docetaxel; Entrectinib; Gemcitabine; Pemetrexed; Vemurafenib	antimetabolite; gemcitabine; BRAF_V600_inhibitor; anti-PD-L1_monoclonal_antibody; taxane; MEK_inhibitor; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; ALK/RET_inhibitor; antimetabolite + platinum-based_antineoplastic_agent; ALK_inhibitor,third_generation; platinum-based_antineoplastic_agent; TRK_inhibitor,first_generation; ROS1_inhibitor; ALK_inhibitor,second_generation	Alectinib; Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed; Atezolizumab + Cobimetinib + Vemurafenib; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Pemetrexed; Divarasib + Docetaxel; Entrectinib; Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed; Atezolizumab + Cobimetinib + Vemurafenib; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Pemetrexed; Divarasib + Docetaxel	ALK/RET_inhibitor; ALK_inhibitor,second_generation; ALK_inhibitor,third_generation; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + taxane; ROS1_inhibitor; TRK_inhibitor,first_generation; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	BO29554	A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)	Non-Small Cell Lung Cancer	1023 - Auckland - Auckland City Hospital; 2065 - St Leonards - Royal North Shore Hospital; Department of Medical Oncology; 3084 - Heidelberg - Austin Hospital; Medical Oncology; 4032 - Chermside - The Prince Charles Hospital; Oncology Dept. - (COMPLETED); 5037 - Kurralta Park - Ashford Cancer Center Research - (TERMINATED); 6009 - Nedlands - Sir Charles Gairdner Hospital - (WITHDRAWN)	https://clinicaltrials.gov/ct2/show/NCT03178552
NCT03179436	1308-001	Phase 1/Phase 2	NOT_RECRUITING	Canterbury, NSW, NZ, QLD, SA, VIC	2017-06-05	2017-07-02	Pembrolizumab; Pembrolizumab + Quavonlimab; Quavonlimab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Pembrolizumab + Quavonlimab; Pembrolizumab + Quavonlimab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	1308-001	A Phase 1 / 2 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	1023 - Auckland - Auckland City Hospital ( Site 0016); 2065 - Wollstonecraft - Melanoma Institute Australia ( Site 0017); 2148 - Blacktown - Blacktown Hospital. Western Sydney local health district ( Site 0009); 2298 - Waratah - Calvary Mater Newcastle ( Site 0025); 3004 - Melbourne - Alfred Health ( Site 0018); 3350 - Ballarat - Ballarat Health Services ( Site 0022); 4120 - Brisbane - Gallipoli Medical Research Foundation-GMRF CTU ( Site 0019); 4870 - Cairns - Cairns and Hinterland Hospital and Health Service ( Site 0020); 5037 - Kurralta Park - Ashford Cancer Centre Research ( Site 0012); 8011 - Christchurch - Canterbury District Health Board ( Site 0023)	https://clinicaltrials.gov/ct2/show/NCT03179436
NCT03184870	CV202-103	Phase 1/Phase 2	NOT_RECRUITING	VIC	2017-06-09	2017-08-08	BMS-813160; BMS-813160 + Fluorouracil + Irinotecan + Leucovorin; BMS-813160 + Gemcitabine + Nab-paclitaxel; BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab; BMS-813160 + Nivolumab; Fluorouracil; Fluorouracil + Irinotecan + Leucovorin; Gemcitabine; Gemcitabine + Nab-paclitaxel; Irinotecan; Leucovorin; Nab-paclitaxel; Nivolumab	CCR2/CCR5_antagonist + antimetabolite + taxane; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; topoisomerase_inhibitor; gemcitabine; CCR2/CCR5_antagonist; taxane; CCR2/CCR5_antagonist + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; folinic_acid; antimetabolite + taxane; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody; Fluorouracil; anti-PD-1_monoclonal_antibody; fluoropyrimidine + folinic_acid + topoisomerase_inhibitor	BMS-813160; BMS-813160 + Fluorouracil + Irinotecan + Leucovorin; BMS-813160 + Gemcitabine + Nab-paclitaxel; BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab; BMS-813160 + Nivolumab; Fluorouracil + Irinotecan + Leucovorin; Gemcitabine + Nab-paclitaxel; BMS-813160 + Fluorouracil + Irinotecan + Leucovorin; BMS-813160 + Gemcitabine + Nab-paclitaxel; BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab; BMS-813160 + Nivolumab; Fluorouracil + Irinotecan + Leucovorin; Gemcitabine + Nab-paclitaxel	CCR2/CCR5_antagonist; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; CCR2/CCR5_antagonist + antimetabolite + taxane; CCR2/CCR5_antagonist + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; antimetabolite + taxane; fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; CCR2/CCR5_antagonist + antimetabolite + taxane; CCR2/CCR5_antagonist + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; antimetabolite + taxane; fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; gemcitabine	CV202-103	A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors	Colorectal Cancer; Pancreatic Cancer	0 - Clayton - Local Institution - 0028	https://clinicaltrials.gov/ct2/show/NCT03184870
NCT03188159	GY01-05-16	Phase 2	UNKNOWN	VIC	2017-06-14	2017-07-01	Vinorelbine	vinca_alkaloid	Vinorelbine	vinca_alkaloid	GY01/05/16	Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer (VIP)	Ovarian Cancer; Fallopian Tube Cancer	Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03188159
NCT03192345	TCD14678	Phase 1	NOT_RECRUITING	VIC	2017-06-16	2017-06-09	Cemiplimab; Cemiplimab + SAR439459; SAR439459	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; anti-TGF-beta_monoclonal_antibody	Cemiplimab + SAR439459; SAR439459; Cemiplimab + SAR439459	anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; anti-TGF-beta_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody	TCD14678	A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid Tumors	Malignant Solid Tumor	3000 - Melbourne - Investigational Site Number :0360001; 3081 - Heidelberg West - Investigational Site Number :0360002	https://clinicaltrials.gov/ct2/show/NCT03192345
NCT03207867	CNIR178X2201	Phase 2	NOT_RECRUITING	NSW	2017-06-30	2017-08-28	NIR178; NIR178 + Spartalizumab; Spartalizumab	adenosine_A2A_receptor_antagonist + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist	NIR178 + Spartalizumab; NIR178 + Spartalizumab	adenosine_A2A_receptor_antagonist + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-PD-1_monoclonal_antibody	CNIR178X2201	A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma	NSCLC, Non Small Cell Lung Cancer; RCC, Renal Cell Cancer; Pancreatic Cancer; Urothelial Cancer; Head and Neck Cancer; DLBCL, Diffused Large B Cell Lymphoma; MSS, Microsatellite Stable Colon Cancer; TNBC, Triple Negative Breast Cancer; Melanoma; mCRPC, Metastatic Castration Resistant Prostate Cancer	2148 - Blacktown - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT03207867
NCT03212404	CK-301-101	Phase 1	RECRUITING	NSW, NZ, QLD, VIC	2017-07-06	2017-09-20	Cosibelimab	anti-PD-L1_monoclonal_antibody	Cosibelimab	anti-PD-L1_monoclonal_antibody	CK-301-101	A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers	Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Malignant Mesothelioma, Advanced; Head and Neck Cancer; Melanoma; Merkel Cell Carcinoma; Renal Cell Carcinoma; Urothelial Carcinoma; Classical Hodgkin Lymphoma; Cutaneous Squamous Cell Carcinoma; Non Hodgkin Lymphoma; Endometrial Cancer	2500 - Wollongong - Research Site; 3128 - Box Hill - Research Site; 3144 - Malvern - Research Site; 4101 - South Brisbane - Research Site; 4102 - Woolloongabba - Research Site; 4120 - Greenslopes - Research Site; 4217 - Benowa - Research Site; 4556 - Buderim - Research Site; 8140 - Christchurch - Research Site	https://clinicaltrials.gov/ct2/show/NCT03212404
NCT03215706	CheckMate-9LA	Phase 3	NOT_RECRUITING	NSW, SA, VIC, WA	2017-07-11	2017-08-24	Carboplatin; Carboplatin + Cisplatin + Ipilimumab + Nivolumab + Paclitaxel + Pemetrexed; Carboplatin + Cisplatin + Paclitaxel + Pemetrexed; Cisplatin; Ipilimumab; Nivolumab; Paclitaxel; Pemetrexed	antimetabolite; anti-CTLA-4_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Ipilimumab + Nivolumab + Paclitaxel + Pemetrexed; Carboplatin + Cisplatin + Paclitaxel + Pemetrexed; Carboplatin + Cisplatin + Ipilimumab + Nivolumab + Paclitaxel + Pemetrexed; Carboplatin + Cisplatin + Paclitaxel + Pemetrexed	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent + taxane	CA209-9LA	A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	2250 - Gosford - Local Institution - 0086; 3084 - Heidelberg - Local Institution - 0036; 3128 - Box Hill - Local Institution - 0089; 5042 - Bedford Park - Local Institution - 0040; 6150 - Murdoch - Local Institution - 0078	https://clinicaltrials.gov/ct2/show/NCT03215706
NCT03219268	CP-MGD013-01	Phase 1	NOT_RECRUITING	NSW, VIC	2017-07-14	2017-08-18	Margetuximab; Margetuximab + Tebotelimab; Tebotelimab	anti-ERBB2_monoclonal_antibody + humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein; anti-ERBB2_monoclonal_antibody; humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein	Margetuximab + Tebotelimab; Tebotelimab; Margetuximab + Tebotelimab	anti-ERBB2_monoclonal_antibody + humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein; humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein; anti-ERBB2_monoclonal_antibody + humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein	CP-MGD013-01	A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms	Advanced Solid Tumors; Hematologic Neoplasms; Ovarian Cancer; HER2-positive Advanced Solid Tumors; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Cholangiocarcinoma; Cervical Cancer; TNBC - Triple-Negative Breast Cancer	2010 - Darlinghurst - St Vincent's Hospital Sydney; 2298 - Waratah - Calvary Mater Newcastle; 2500 - Wollongong - Southern Medical Day Care Centre; 3084 - Heidelberg - Austin Health Melbourne	https://clinicaltrials.gov/ct2/show/NCT03219268
NCT03229200	PCYC-1145-LT	Phase 4	ENROLLING_BY_INVITATION	Auckland, NSW, NZ, QLD, SA, VIC	2017-07-24	2017-05-22	Ibrutinib	BTK_inhibitor	Ibrutinib	BTK_inhibitor	PCYC-1145-LT	Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.	Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, B-cell; Graft Vs Host Disease; Solid Tumor	0622 - Auckland - North Shore Hospital; 2025 - Papatoetoe - Middlemore Hospital; 2139 - Sydney - Concord Repatriation General Hospital - Haematology Clinical Trials; 2217 - Kogarah - St. George Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3065 - Fitzroy - St Vincent Hospital; 3128 - Box Hill - Eastern Health; 3168 - Clayton - Monash Health-Monash Medical Centre; 3350 - Ballarat - Ballarat Health Services; 4102 - Woolloongabba - Princess Alexandra Hospital; 5067 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT03229200
NCT03234712	M16-438	Phase 1	NOT_RECRUITING	NSW, VIC	2017-07-27	2017-10-10	Serclutamab Talirine	anti-EGFR/PBD_antibody-drug_conjugate	Serclutamab Talirine	anti-EGFR/PBD_antibody-drug_conjugate	M16-438	A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)	Advanced Solid Tumors Cancer	2065 - St Leonards - Northern Cancer Institute /ID# 166138; 3084 - Heidelberg - Austin Hospital /ID# 166137; 3168 - Clayton - Monash Health /ID# 217435	https://clinicaltrials.gov/ct2/show/NCT03234712
NCT03256344	NCT03256344	Phase 1	NOT_RECRUITING	NSW, VIC, WA	2017-08-17	2018-03-19	Atezolizumab; Atezolizumab + Talimogene Laherparepvec; Talimogene Laherparepvec	anti-PD-L1_monoclonal_antibody + oncolytic_HSV_virus; anti-PD-L1_monoclonal_antibody; oncolytic_HSV_virus	Atezolizumab + Talimogene Laherparepvec; Atezolizumab + Talimogene Laherparepvec	anti-PD-L1_monoclonal_antibody + oncolytic_HSV_virus; anti-PD-L1_monoclonal_antibody + oncolytic_HSV_virus	20140299	A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases	Metastatic Triple Negative Breast Cancer; Metastatic Colorectal Cancer	2170 - Liverpool - Liverpool Hospital; 3168 - Clayton - Monash Medical Centre; 6009 - Nedlands - Breast Cancer Research Centre - WA; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT03256344
NCT03261011	AK104-101	Phase 1	STATUS_UNKNOWN	VIC, WA	2017-08-22	2017-10-03	AK104	bispecific_PD-1/CTLA-4_antibody	AK104	bispecific_PD-1/CTLA-4_antibody	AK104-101	A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors	Advanced Cancer	3002 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Heidelberg - Austin Health; 3168 - Clayton - Monash Health; 6009 - Nedlands - Linear Clinical Research/Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT03261011
NCT03273153	CO39722	Phase 3	NOT_RECRUITING	QLD, TAS, WA	2017-09-01	2017-12-11	Atezolizumab; Atezolizumab + Cobimetinib; Cobimetinib; Pembrolizumab	anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Cobimetinib; Pembrolizumab; Atezolizumab + Cobimetinib	MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	CO39722	A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma	Advanced BRAFV600 Wild-type Melanoma	4102 - Woolloongabba - Princess Alexandra Hospital; 4184 - Douglas - Townsville General Hospital; 4870 - Cairns - Cairns Base Hospital; 6150 - Murdoch - Fiona Stanley Hospital; 7000 - Hobart - Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT03273153
NCT03278717	ICON9	Phase 3	NOT_RECRUITING	ACT, NSW, NZ, QLD, SA, TAS, VIC	2017-09-07	2018-06-15	Cediranib; Cediranib + Olaparib; Olaparib	PARP_inhibitor + VEGF_inhibitor; PARP_inhibitor; VEGF_inhibitor	Cediranib + Olaparib; Olaparib; Cediranib + Olaparib	PARP_inhibitor; PARP_inhibitor + VEGF_inhibitor; PARP_inhibitor + VEGF_inhibitor	UCL/14/0795	International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy	Ovarian Cancer	Albury - Border Medical Oncology; Auckland - Auckland City Hospital; Bedford Park - Flinders Medical Centre; Benowa - Pindara Private Hospital; Camperdown - Chris O'Brien Lifehouse; Canberra - Canberra Hospital; Christchurch - Christchurch Hospital; Clayton - Monash Health; Gosford - Gosford Hospital; Hobart - Royal Hobart Hospital; Melbourne - Peter MacCallum Cancer Centre; South Brisbane - ICON Cancer Centre; South Brisbane - Mater Cancer Centre; Sydney - Calvary Mater Hospital; Sydney - Campbelltown Hospital; Sydney - Prince of Wales Hospital; Townsville - Townsville Hospital; Westmead - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT03278717
NCT03287427	MYPHISMO	Phase 1	NOT_RECRUITING	VIC	2017-09-15	2018-08-22	TetMYB; TetMYB + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; MYB-targeting_vaccine; MYB-targeting_vaccine + anti-PD-1_monoclonal_antibody	TetMYB + Tislelizumab; TetMYB + Tislelizumab	MYB-targeting_vaccine + anti-PD-1_monoclonal_antibody; MYB-targeting_vaccine + anti-PD-1_monoclonal_antibody	MYPHISMO	First-in-human Phase I Clinical Trial of a Combined Immune Modulatory Approach Using TetMYB Vaccine and Anti-PD1 Antibody in Patients With Advanced Solid Cancer Including Colorectal or Adenoid Cystic Carcinoma.	Colorectal Cancer; Adenoid Cystic Carcinoma	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03287427
NCT03296696	NCT03296696	Phase 1	NOT_RECRUITING	NSW, VIC	2017-09-27	2018-04-18	AMG 404; AMG 404 + AMG 596; AMG 596	anti-PD-1_monoclonal_antibody; bispecific_T-cell_engager,EGFRvIII-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,EGFRvIII-targeting	AMG 404 + AMG 596; AMG 404 + AMG 596	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,EGFRvIII-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,EGFRvIII-targeting	20160132	Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)	Glioblastoma or Malignant Glioma	2065 - St Leonards - Royal North SHore Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03296696
NCT03317496	B9991023	Phase 1/Phase 2	NOT_RECRUITING	NSW, VIC	2017-10-17	2017-12-21	Avelumab; Avelumab + Carboplatin + Pemetrexed; Avelumab + Cisplatin + Gemcitabine; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed	antimetabolite; gemcitabine; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Avelumab + Carboplatin + Pemetrexed; Avelumab + Cisplatin + Gemcitabine; Avelumab + Carboplatin + Pemetrexed; Avelumab + Cisplatin + Gemcitabine	anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	B9991023	A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES	Non-small Cell Lung Cancer; Urothelial Cancer	2010 - Darlinghurst - St Vincent's Hospital Sydney; 2010 - Darlinghurst - St Vincent's Public Hospital Sydney; 2050 - Camperdown - Chris O'Brien Lifehouse; 3021 - St Albans - Western Health, Sunshine Hospital	https://clinicaltrials.gov/ct2/show/NCT03317496
NCT03319940	NCT03319940	Phase 1	RECRUITING	NSW	2017-10-19	2017-12-26	Pembrolizumab; Pembrolizumab + Tarlatamab; Tarlatamab	bispecific_T-cell_engager,DLL3-targeting; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting	Pembrolizumab + Tarlatamab; Tarlatamab; Pembrolizumab + Tarlatamab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; bispecific_T-cell_engager,DLL3-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting	20160323	A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)	Small Cell Lung Carcinoma	2050 - Camperdown - Chris OBrien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT03319940
NCT03330405	B9991025	Phase 1/Phase 2	NOT_RECRUITING	NSW, QLD, WA	2017-10-30	2017-10-19	Avelumab; Avelumab + Talazoparib; Talazoparib	anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; PARP_inhibitor	Avelumab + Talazoparib; Avelumab + Talazoparib	PARP_inhibitor + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody	B9991025	A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY(ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS	Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors	2065 - St. Leonards - Northern Cancer Institute; 2065 - Sydney - Northern Cancer Institute; 2109 - North Ryde - Macquarie University; 4101 - Brisbane - Mater Misericordiae Ltd; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT03330405
NCT03332797	GO39932	Phase 1	NOT_RECRUITING	NSW, VIC	2017-11-01	2017-11-27	Brilanestrant; Brilanestrant + Giredestrant; Giredestrant; Giredestrant + LHRH Agonist; Giredestrant + LHRH Agonist + Palbociclib; Giredestrant + Palbociclib; LHRH Agonist; Palbociclib	selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + LHRH_agonist + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; LHRH_agonist; LHRH_agonist + selective_estrogen_receptor_degrader	Brilanestrant + Giredestrant; Giredestrant; Giredestrant + LHRH Agonist; Giredestrant + LHRH Agonist + Palbociclib; Giredestrant + Palbociclib; Brilanestrant + Giredestrant; Giredestrant + LHRH Agonist; Giredestrant + LHRH Agonist + Palbociclib; Giredestrant + Palbociclib	CDK4/6_inhibitor + LHRH_agonist + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; LHRH_agonist + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + LHRH_agonist + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; LHRH_agonist + selective_estrogen_receptor_degrader	GO39932	A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer	Breast Cancer	2010 - Darlinghurst - St Vincent's Hospital Sydney; 3000 - Melbourne - Peter Maccallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03332797
NCT03337724	IPATunity130	Phase 3	NOT_RECRUITING	NSW, QLD, VIC, WA	2017-11-07	2018-01-06	Ipatasertib; Ipatasertib + Paclitaxel; Paclitaxel; Placebo	pan-AKT_inhibitor + taxane; taxane; placebo; pan-AKT_inhibitor	Ipatasertib + Paclitaxel; Paclitaxel; Ipatasertib + Paclitaxel; Placebo	pan-AKT_inhibitor + taxane; taxane; pan-AKT_inhibitor + taxane; placebo	CO40016	A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer	Breast Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2145 - Wentworthville - Westmead Hospital; Medical Oncology; 2298 - Waratah - Calvary Mater Newcastle; Medical Oncology; 3144 - Malvern - Cabrini Medical Centre; Oncology; 4101 - South Brisbane - Mater Hospital; Cancer Services; 6149 - Bull Creek - Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit	https://clinicaltrials.gov/ct2/show/NCT03337724
NCT03338790	CheckMate-9KD	Phase 2	NOT_RECRUITING	NSW, QLD, SA, VIC	2017-11-08	2017-12-19	Docetaxel; Docetaxel + Nivolumab + Prednisone; Enzalutamide; Enzalutamide + Nivolumab; Nivolumab; Nivolumab + Rucaparib; Prednisone; Rucaparib	PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; PARP_inhibitor; glucocorticoid; anti-PD-1_monoclonal_antibody; taxane; antiandrogen,nonsteroidal,second_generation	Docetaxel + Nivolumab + Prednisone; Enzalutamide + Nivolumab; Nivolumab + Rucaparib; Docetaxel + Nivolumab + Prednisone; Enzalutamide + Nivolumab; Nivolumab + Rucaparib	PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane	CA209-9KD	A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer	Prostate Cancer	0 - Clayton - Local Institution - 0050; 2050 - Camperdown - Local Institution - 0015; 2145 - Westmead - Local Institution - 0017; 3084 - Heidelberg - Local Institution - 0013; 4101 - South Brisbane - Local Institution - 0014; 5112 - Elizabeth Vale - Local Institution - 0016	https://clinicaltrials.gov/ct2/show/NCT03338790
NCT03352531	AK105-101	Phase 1	*STATUS_UNKNOWN	NSW, QLD, SA	2017-11-21	2017-12-22	Penpulimab	anti-PD-1_monoclonal_antibody	Penpulimab	anti-PD-1_monoclonal_antibody	AK105-101	A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors	Advanced Cancer	2010 - Darlinghurst - St Vincent's Hospital, Sydney (The Kinghorn Cancer Centre); 2170 - Liverpool - Liverpool Hospital; 2640 - East Albury - Border Medical Oncology; 4101 - South Brisbane - ICON Cancer Foundation; 5037 - Adelaide - Ashford Cancer Centre Research	https://clinicaltrials.gov/ct2/show/NCT03352531
NCT03358875	BGB-A317-303	Phase 3	NOT_RECRUITING	NZ	2017-11-27	2017-11-30	Docetaxel; Tislelizumab	anti-PD-1_monoclonal_antibody; taxane	Docetaxel; Tislelizumab	anti-PD-1_monoclonal_antibody; taxane	BGB-A317-303	A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen	Non-small Cell Lung Cancer	1023 - Grafton - Auckland City Hospital; 3112 - Tauranga - Tauranga Hospital; Hamilton - Waikato Hospital	https://clinicaltrials.gov/ct2/show/NCT03358875
NCT03377361	CheckMate-9N9	Phase 1/Phase 2	NOT_RECRUITING	NSW, QLD, SA, VIC	2017-12-14	2018-02-01	Ipilimumab; Ipilimumab + Nivolumab + Trametinib; Nivolumab; Nivolumab + Trametinib; Regorafenib; Trametinib	anti-CTLA-4_monoclonal_antibody; MEK_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; MEK_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MEK_inhibitor	Ipilimumab + Nivolumab + Trametinib; Nivolumab + Trametinib; Regorafenib; Ipilimumab + Nivolumab + Trametinib; Nivolumab + Trametinib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; MEK_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-PD-1_monoclonal_antibody	CA209-9N9	A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers	Colorectal Cancer; Colorectal Tumors; Colorectal Carcinoma; Colorectal Neoplasm	0 - Clayton - Local Institution - 0055; 05112 - Elizabeth Vale - Local Institution - 0068; 2148 - Blacktown - Local Institution - 0044; 3084 - Heidelberg - Local Institution - 0069; 4215 - Southport - Local Institution - 0043	https://clinicaltrials.gov/ct2/show/NCT03377361
NCT03391778	NCT03391778	Phase 1	RECRUITING	VIC	2018-01-02	2018-04-09					208750	Long-Term Follow-Up (LTFU) of Participants Treated With GSK Adoptive Cell Therapies	Neoplasms	3000 - Melbourne - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT03391778
NCT03424005	Morpheus-panBC	Phase 1/Phase 2	NOT_RECRUITING	VIC, WA	2018-02-05	2018-04-02	Abemaciclib; Abemaciclib + Fulvestrant + Inavolisib; Atezolizumab; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Bevacizumab; Capecitabine; Carboplatin; Eribulin; Fulvestrant; Fulvestrant + Inavolisib + Ribociclib; Gemcitabine; Inavolisib; Inavolisib + Trastuzumab Deruxtecan; Ipatasertib; Ladiratuzumab Vedotin; Nab-paclitaxel; Ribociclib; Sacituzumab Govitecan; Selicrelumab; Tocilizumab; Trastuzumab Deruxtecan	selective_estrogen_receptor_degrader; anti-LIV1_antibody-drug_conjugate; gemcitabine; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; pan-AKT_inhibitor; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; fluoropyrimidine; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-IL-6_monoclonal_antibody; anti-LIV1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + taxane; anti-Trop2_antibody-drug_conjugate; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor; CDK4/6_inhibitor; taxane; PI3K_alpha_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; anti-CD40_agonistic_antibody; macrocyclic_ketone_analogue; platinum-based_antineoplastic_agent	Abemaciclib + Fulvestrant + Inavolisib; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Capecitabine; Fulvestrant + Inavolisib + Ribociclib; Inavolisib + Trastuzumab Deruxtecan; Abemaciclib + Fulvestrant + Inavolisib; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Fulvestrant + Inavolisib + Ribociclib; Inavolisib + Trastuzumab Deruxtecan	CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-LIV1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; fluoropyrimidine; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-LIV1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; gemcitabine	CO40115	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (Morpheus-panBC)	Breast Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre-East Melbourne; 6150 - Murdoch - Fiona Stanley Hospital - Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT03424005
NCT03427814	BGB-290-303	Phase 2	NOT_RECRUITING	NSW, QLD, VIC	2018-02-08	2018-07-03	Pamiparib; Placebo	PARP_inhibitor; placebo	Pamiparib; Placebo	PARP_inhibitor; placebo	BGB-290-303	A Phase 2, Double-blind, Randomized Study of BGB-290 Versus Placebo as Maintenance Therapy in Patients With Inoperable Locally Advanced or Metastatic Gastric Cancer That Responded to Platinum-based First-line Chemotherapy	Advanced or Inoperable Gastric Cancer	2250 - Gosford - Central Coast Local Health District; 3076 - Epping - Northern Hospital; 3168 - Clayton - Monash Health; 3355 - Wendouree - Ballarat Oncology and Haematology Services; 4814 - Douglas - The Townsville Hospital and Health Service	https://clinicaltrials.gov/ct2/show/NCT03427814
NCT03446040	CA031-002	Phase 1/Phase 2	NOT_RECRUITING	NSW, VIC	2018-02-21	2018-03-08	BMS-986258; BMS-986258 + Nivolumab; BMS-986258 + rHuPH20; Nivolumab; rHuPH20	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; recombinant_human_hyaluronidase; anti-TIM3_monoclonal_antibody + recombinant_human_hyaluronidase; anti-TIM3_monoclonal_antibody	BMS-986258; BMS-986258 + Nivolumab; BMS-986258 + rHuPH20; BMS-986258 + Nivolumab; BMS-986258 + rHuPH20	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-TIM3_monoclonal_antibody; anti-TIM3_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-TIM3_monoclonal_antibody + recombinant_human_hyaluronidase	CA031-002	A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors	Advanced Cancer	2145 - Westmead - Local Institution - 0013; 3084 - Melbourne - Local Institution - 0015	https://clinicaltrials.gov/ct2/show/NCT03446040
NCT03448042	GO40311	Phase 1	NOT_RECRUITING	VIC	2018-02-26	2018-06-06	Runimotamab; Runimotamab + Tocilizumab + Trastuzumab; Tocilizumab; Trastuzumab	bispecific_T-cell_engager,ERBB2-targeting; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-IL-6_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting; anti-IL-6_monoclonal_antibody	Runimotamab + Tocilizumab + Trastuzumab; Runimotamab + Tocilizumab + Trastuzumab	anti-ERBB2_monoclonal_antibody + anti-IL-6_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting; anti-ERBB2_monoclonal_antibody + anti-IL-6_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting	GO40311	A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers	Solid Tumors	3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT03448042
NCT03454451	CPI-006-001	Phase 1	NOT_RECRUITING	NSW, QLD, VIC	2018-03-02	2018-04-25	CPI-006; CPI-006 + Ciforadenant; CPI-006 + Pembrolizumab; Ciforadenant; Pembrolizumab	adenosine_A2aR_and_A2bR_antagonist + anti-CD73_monoclonal_antibody; anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody	CPI-006; CPI-006 + Ciforadenant; CPI-006 + Pembrolizumab; CPI-006 + Ciforadenant; CPI-006 + Pembrolizumab	adenosine_A2aR_and_A2bR_antagonist + anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CPI-006-001	A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS	Non-Small Cell Lung Cancer; Renal Cell Cancer; Colorectal Cancer; Triple Negative Breast Cancer; Cervical Cancer; Ovarian Cancer; Pancreatic Cancer; Endometrial Cancer; Sarcoma; Squamous Cell Carcinoma of the Head and Neck; Bladder Cancer; Metastatic Castration Resistant Prostate Cancer; Non-hodgkin Lymphoma	2010 - Darlinghurst - St. Vincent's Hospital; 2050 - Camperdown - Lifehouse; 3168 - Clayton - Monash Hospital; 3168 - Westmead - Westmead; 4029 - Herston - Royal Brisbane	https://clinicaltrials.gov/ct2/show/NCT03454451
NCT03459222	CA224-048	Phase 1/Phase 2	NOT_RECRUITING	NSW, WA	2018-03-02	2018-05-30	Ipilimumab; Ipilimumab + Nivolumab + Relatlimab; Linrodostat; Linrodostat + Nivolumab + Relatlimab; Nivolumab; Relatlimab	anti-CTLA-4_monoclonal_antibody; IDO1_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; IDO1_inhibitor	Ipilimumab + Nivolumab + Relatlimab; Linrodostat + Nivolumab + Relatlimab; Ipilimumab + Nivolumab + Relatlimab; Linrodostat + Nivolumab + Relatlimab	IDO1_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CA224-048	A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors	Advanced Cancer	2065 - Wollstonecraft - Local Institution - 0012; 6009 - Nedlands - Local Institution - 0011	https://clinicaltrials.gov/ct2/show/NCT03459222
NCT03473925	7123-034	Phase 2	NOT_RECRUITING	NSW, VIC	2018-03-15	2018-04-10	Navarixin; Navarixin + Pembrolizumab; Pembrolizumab	CXCR2_antagonist; anti-PD-1_monoclonal_antibody; CXCR2_antagonist + anti-PD-1_monoclonal_antibody	Navarixin + Pembrolizumab; Navarixin + Pembrolizumab	CXCR2_antagonist + anti-PD-1_monoclonal_antibody; CXCR2_antagonist + anti-PD-1_monoclonal_antibody	7123-034	A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors	Solid Tumors; Non-small Cell Lung Cancer; Castration Resistant Prostate Cancer; Microsatellite Stable Colorectal Cancer	2031 - Randwick - Scientia Clinical Research ( Site 0021); 2148 - Blacktown - Blacktown Hospital Western Sydney Local Health District ( Site 0024); 3000 - Melbourne - Peter MacCallum Cancer Centre ( Site 0023)	https://clinicaltrials.gov/ct2/show/NCT03473925
NCT03475251	CS1003-101	Phase 1	NOT_RECRUITING	NSW	2018-03-22	2018-05-09	CS1003; CS1003 + Regorafenib; Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-1_monoclonal_antibody	CS1003; CS1003 + Regorafenib; CS1003 + Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-1_monoclonal_antibody	CS1003-101	A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors	Advanced Cancer	2031 - Randwick - Scientia Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT03475251
NCT03477175	E7080-G000-604	Phase 2	NOT_RECRUITING	VIC	2018-03-20	2018-08-16	Lenvatinib; Lenvatinib + Sorafenib; Sorafenib	PDGFR_inhibitor + VEGF_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + VEGF_inhibitor; VEGF_inhibitor; CRAF_inhibitor; KIT_inhibitor + VEGF_inhibitor; VEGFR_inhibitor + VEGF_inhibitor; FLT3_inhibitor + VEGF_inhibitor; CRAF_inhibitor + VEGF_inhibitor	Lenvatinib; Lenvatinib + Sorafenib; Lenvatinib + Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + VEGF_inhibitor; CRAF_inhibitor + VEGF_inhibitor; FLT3_inhibitor + VEGF_inhibitor; KIT_inhibitor + VEGF_inhibitor; PDGFR_inhibitor + VEGF_inhibitor; VEGFR_inhibitor + VEGF_inhibitor; VEGF_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + VEGF_inhibitor; CRAF_inhibitor + VEGF_inhibitor; FLT3_inhibitor + VEGF_inhibitor; KIT_inhibitor + VEGF_inhibitor; PDGFR_inhibitor + VEGF_inhibitor; VEGFR_inhibitor + VEGF_inhibitor	E7080-G000-604	An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety of Lenvatinib Monotherapy or Lenvatinib Combination Regimen or Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials	Solid Tumors	3004 - Melbourne - The Alfred Hospital	https://clinicaltrials.gov/ct2/show/NCT03477175
NCT03486873	3475-587	Phase 3	RECRUITING	Canterbury, NSW, NZ, QLD, SA, VIC, WA, Waikato	2018-03-29	2018-08-21	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor	Lenvatinib + Pembrolizumab; Pembrolizumab; Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	3475-587	A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab	Solid Tumors; Hematologic Malignancies	1023 - Auckland - Auckland City Hospital ( Site 1503); 2050 - Camperdown - Chris OBrien Lifehouse ( Site 3003); 2050 - Camperdown - Royal Prince Alfred Hospital-A.W. Morrow Gastroenterology and Liver Centre ( Site 3016); 2060 - North Sydney - Mater Hospital Sydney ( Site 3007); 2065 - St Leonards - Royal North Shore Hospital-Medical Oncology Clinical Trials ( Site 3025); 2065 - Wollstonecraft - Melanoma Institute Australia ( Site 3001); 2109 - Macquarie University - Macquarie University ( Site 3010); 2145 - Westmead - Westmead Hospital ( Site 3000); 2170 - Liverpool - Liverpool Hospital-Medical Oncology ( Site 3021); 2298 - Waratah - Calvary Mater Newcastle ( Site 3005); 2444 - Port Macquarie - Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3020); 2800 - Orange - Orange Hospital-Clinical Trials Unit ( Site 3027); 3000 - Melbourne - Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 3008); 3021 - St Albans - Western Health-Sunshine & Footscray Hospitals ( Site 3023); 3065 - Melbourne - St Vincent's Hospital-Oncology Clinical Trials ( Site 3018); 3084 - Heidelberg - Austin Health-Austin Hospital ( Site 3004); 3168 - Clayton - Monash Health ( Site 3015); 3204 - Hamilton - Waikato Hospital ( Site 1502); 3355 - Wendouree - Ballarat Oncology & Haematology Services ( Site 3022); 4029 - Herston - Royal Brisbane and Women s Hospital ( Site 3009); 4101 - Brisbane - Mater Misericordiae Limited-Medical Oncology ( Site 3019); 4102 - Woolloongabba - Princess Alexandra Hospital ( Site 3002); 4120 - Brisbane - Gallipoli Medical Research Ltd ( Site 3011); 4215 - Southport - Tasman Oncology Research Pty Ltd ( Site 3012); 4814 - Townsville - The Townsville Hospital ( Site 3017); 5000 - Adelaide - Royal Adelaide Hospital ( Site 3014); 5011 - Woodville - The Queen Elizabeth Hospital ( Site 3026); 6008 - Subiaco - St John of God Subiaco Hospital ( Site 3013); 6009 - Nedlands - Sir Charles Gairdner Hospital ( Site 3006); 6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital ( Site 1501); 8011 - Christchurch - Canterbury Regional Cancer & Blood Service ( Site 1500)	https://clinicaltrials.gov/ct2/show/NCT03486873
NCT03497767	OUTRUN	Phase 2	*NOT_RECRUITING - IN FOLLOW UP	NSW, QLD, SA, VIC, WA	2018-04-12	2019-08-15	Osimertinib	EGFR_inhibitor,third_generation	Osimertinib	EGFR_inhibitor,third_generation	TROG 17.02	A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases	Metastatic Non Small Cell Lung Cancer	2002 - Sydney - Liverpool Hospital; 2010 - Sydney - St. Vincents Hospital; 2145 - Sydney - Westmead Hospital; 2148 - Sydney - Blacktown Hospital; 2217 - Sydney - St George Hospital; 2298 - Newcastle - Calvary Mater; 3002 - Melbourne - Peter MacCallum Cancer Center; 3175 - Melbourne - Monash Health; 4102 - Brisbane - Princess Alexandra Hospital; 4120 - Brisbane - ICON Cancer Centre Greenslopes; Adelaide - Royal Adelaide Hospital; Perth - Sir Charles Gairdner	https://clinicaltrials.gov/ct2/show/NCT03497767
NCT03507543	IMP4297-2016-AU01	Phase 1	NOT_RECRUITING	NSW, VIC	2018-04-15	2017-02-03	Senaparib	PARP_inhibitor	Senaparib	PARP_inhibitor	IMP4297-2016-AU01	A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors	Advanced Solid Tumours; Breast Cancer; Ovarian Cancer; Prostate Cancer; Primary Peritoneal Cancer	2148 - Blacktown - Blacktown Hospital; 3004 - Melbourne - Nucleus Network; Kogarah - St George Private Hospital	https://clinicaltrials.gov/ct2/show/NCT03507543
NCT03515824	1697-001	Phase 1	NOT_RECRUITING	NSW	2018-04-23	2018-08-13	MK-1697	bispecific_PD-1/LAG3_antibody	MK-1697	bispecific_PD-1/LAG3_antibody	1697-001	A Phase 1 Study of MK-1697 in Participants With Advanced Solid Tumors	Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms	2031 - Randwick - Scientia Clinical Research ( Site 0100)	https://clinicaltrials.gov/ct2/show/NCT03515824
NCT03515837	KEYNOTE-789	Phase 3	NOT_RECRUITING	NSW, VIC	2018-04-23	2018-06-29	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Pembrolizumab; Pemetrexed	antimetabolite; anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	3475-789	A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)	Non-small Cell Lung Cancer	2050 - Camperdown - Chris OBrien Lifehouse ( Site 0200); 2145 - Westmead - Westmead Hospital ( Site 0201); 3084 - Heidelberg - Austin Health ( Site 0203); 3128 - Box Hill - Eastern Health ( Site 0202)	https://clinicaltrials.gov/ct2/show/NCT03515837
NCT03516123	CS3006-101	Phase 1	NOT_RECRUITING	NSW	2018-05-02	2018-06-14	CS3006	MEK_inhibitor	CS3006	MEK_inhibitor	CS3006-101	A Phase I, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, PK and Antitumor Activities of the MEK Inhibitor CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors	Solid Tumor, Adult	2010 - Sydney - St Vincent's hospital	https://clinicaltrials.gov/ct2/show/NCT03516123
NCT03522064	HiTeCH	Phase 2	RECRUITING	NSW	2018-05-10	2018-07-30	Carboplatin; Carboplatin + Testosterone Enanthate; Testosterone Enanthate	platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + testosterone; testosterone	Carboplatin + Testosterone Enanthate; Carboplatin + Testosterone Enanthate	platinum-based_antineoplastic_agent + testosterone; platinum-based_antineoplastic_agent + testosterone	HiTECH	High Dose Testosterone + Carboplatin in Men With Advanced Prostate Cancer	Castration-resistant Prostate Cancer; Homologous Recombination Deficiency	2010 - Sydney - Kinghorn Cancer Centre, St. Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT03522064
NCT03522246	ATHENA	Phase 3	NOT_RECRUITING	NSW, NZ, QLD, SA, VIC, WA	2018-04-30	2018-05-14	Nivolumab; Nivolumab + Rucaparib; Placebo; Rucaparib	PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; PARP_inhibitor; placebo	Nivolumab; Nivolumab + Rucaparib; Rucaparib; Nivolumab + Rucaparib; Placebo	PARP_inhibitor; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; placebo	CO-338-087/GOG-3020/ENGOT-ov45	ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)	Epithelial Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancer; Newly Diagnosed; FIGO Stage III-IV; Partial Response; Complete Response	1023 - Auckland - Auckland City Hospital; 2031 - Sydney - Prince of Wales Hospital; 2065 - Saint Leonards - Northern Cancer Institute St Leonards; 2145 - New Lambton Heights - Newcastle Private Hospital; 2145 - Westmead - Westmead Hospital; 3000 - Melbourne - Peter MacCallum Cancer Center; 3112 - Tauranga - Tauranga Hospital; 3204 - Hamilton - Waikato Hospital; 4020 - Brisbane - Royal Brisbane and Women's Hospital; 4442 - Palmerston North - Palmerston North Hospital; 5065 - Toorak Gardens - Brian Fricker Oncology Centre, Burnside Hospital; 6005 - Subiaco - St John of God Subiaco Hospital; 8011 - Christchurch - Christchurch Hospital	https://clinicaltrials.gov/ct2/show/NCT03522246
NCT03523585	DS8201-A-U301	Phase 3	NOT_RECRUITING	ACT, NSW, QLD, SA, VIC, WA	2018-05-01	2018-08-01	Capecitabine; Capecitabine + Lapatinib + Trastuzumab Emtansine; Capecitabine + Trastuzumab + Trastuzumab Emtansine; Lapatinib; Trastuzumab; Trastuzumab Deruxtecan; Trastuzumab Deruxtecan + Trastuzumab Emtansine; Trastuzumab Emtansine	EGFR_inhibitor,type_II; fluoropyrimidine; anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,first_generation + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody + fluoropyrimidine; EGFR_inhibitor,type_II + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine	Capecitabine + Lapatinib + Trastuzumab Emtansine; Capecitabine + Trastuzumab + Trastuzumab Emtansine; Trastuzumab Deruxtecan + Trastuzumab Emtansine; Capecitabine + Lapatinib + Trastuzumab Emtansine; Capecitabine + Trastuzumab + Trastuzumab Emtansine; Trastuzumab Deruxtecan + Trastuzumab Emtansine	EGFR_inhibitor,type_II + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; ERBB2_inhibitor,first_generation + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody + fluoropyrimidine; EGFR_inhibitor,type_II + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; ERBB2_inhibitor,first_generation + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody + fluoropyrimidine	DS8201-A-U301	A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1	Breast Cancer	2010 - Darlinghurst - St Vincent's Hospital Sydney; 2109 - Sydney - Macquarie University Hospital; 2170 - Liverpool - Liverpool Hospital; 2485 - Tweed Heads - The Tweed Hospital; 2614 - Bruce - Calvary North Adelaide Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3021 - Saint Albans - Sunshine Hospital; 3084 - Heidelberg - Austin Health; 3128 - Box Hill - Box Hill Hospital; 3199 - Frankston - Frankston Hospital; 3199 - Frankston - Peninsula and South Eastern Haematology & Oncology Group; 3280 - Warrnambool - South West Oncology; 3355 - Wendouree - Ballarat Oncology & Haematology Service; 4102 - Woolloongabba - Princess Alexandra Hospital; 5037 - Kurralta Park - Ashford Cancer Centre Research; 6008 - Subiaco - St John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT03523585
NCT03529110	DS8201-A-U302	Phase 3	NOT_RECRUITING	NSW, QLD, VIC, WA	2018-05-07	2018-08-09	Trastuzumab; Trastuzumab + Trastuzumab Deruxtecan; Trastuzumab + Trastuzumab Emtansine; Trastuzumab Deruxtecan; Trastuzumab Emtansine	anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody	Trastuzumab + Trastuzumab Deruxtecan; Trastuzumab + Trastuzumab Emtansine; Trastuzumab + Trastuzumab Deruxtecan; Trastuzumab + Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody	DS8201-A-U302	A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane	Breast Cancer	2485 - Tweed Heads - The Tweed Hospital; 3000 - Melbourne - Peter MacCallum Cancer; 3128 - Box Hill - Box Hill Hospital; 3199 - Frankston - Peninsula and South Eastern Haematology & Oncology Group; 4102 - Woolloongabba - Princess Alexandra Hospital; 6008 - Subiaco - St John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT03529110
NCT03529526	KN046-AUS-001	Phase 1	STATUS_UNKNOWN	QLD	2018-05-17	2018-05-21	KN046	bispecific_PD-L1/CTLA-4_antibody	KN046	bispecific_PD-L1/CTLA-4_antibody	KN046-AUS-001	An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	4125 - Southport - ICON Cancer Care	https://clinicaltrials.gov/ct2/show/NCT03529526
NCT03537482	APG2575-001	EARLY_Phase 1	RECRUITING	VIC	2018-05-15	2018-08-07	Lisaftoclax	Bcl2_inhibitor	Lisaftoclax	Bcl2_inhibitor	APG2575-001	A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies	Hematologic Malignancies	3065 - Fitzroy - St. Vincent Hospital; 3121 - Richmond - Epworth Healthcare	https://clinicaltrials.gov/ct2/show/NCT03537482
NCT03539536	M14-239	Phase 2	NOT_RECRUITING	NSW, QLD, WA	2018-05-17	2018-10-10	Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	M14-239	Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer	2010 - Darlinghurst - The Kinghorn Cancer Centre /ID# 207666; 2305 - Lambton Heights - Newcastle Private Hospital /ID# 206600; 2485 - Tweed Heads - The Tweed Hospital /ID# 206601; 4101 - South Brisbane - Mater Misericordiae Limited /ID# 229639; 6008 - Subiaco - St John Of God Subiaco Hospital /ID# 226943	https://clinicaltrials.gov/ct2/show/NCT03539536
NCT03549000	CNZV930X2101	Phase 1	NOT_RECRUITING	VIC	2018-05-25	2018-07-18	NIR178; NIR178 + NZV930; NIR178 + NZV930 + Spartalizumab; NZV930; NZV930 + Spartalizumab; Spartalizumab	anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody; anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist	NIR178 + NZV930; NIR178 + NZV930 + Spartalizumab; NZV930; NZV930 + Spartalizumab; NIR178 + NZV930; NIR178 + NZV930 + Spartalizumab; NZV930 + Spartalizumab	adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CNZV930X2101	A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.	Non-small Cell Lung Cancer (NSCLC); Triple Negative Breast Cancer (TNBC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer Microsatellite Stable (MSS); Ovarian Cancer; Renal Cell Carcinoma (RCC); Metastatic Castration Resistant Prostate Cancer (mCRPC)	3000 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT03549000
NCT03551626	COMBI-APlus	Phase 3	NOT_RECRUITING	QLD	2018-05-28	2018-08-29	Dabrafenib; Dabrafenib + Trametinib; Trametinib	BRAF_V600_inhibitor + MEK_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor	Dabrafenib + Trametinib; Dabrafenib + Trametinib	BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	CDRB436F2410	COMBI-APlus: Open-label, Phase IIIb Study of Dabrafenib in COMBInation With Trametinib in the Adjuvant Treatment of Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes of an Adapted Pyrexia AE-management Algorithm (Plus)	Malignant Melanoma	4102 - Woolloongabba - Novartis Investigative Site; QLD 4870 - Cairns - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT03551626
NCT03555149	CO39612	Phase 1/Phase 2	NOT_RECRUITING	VIC	2018-05-31	2018-09-27	Atezolizumab; Atezolizumab + Bevacizumab + PGG Beta-Glucan; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Etrumadenant + Regorafenib; Atezolizumab + Idasanutlin; Atezolizumab + Isatuximab; Atezolizumab + Regorafenib; Bevacizumab; Etrumadenant; Idasanutlin; Isatuximab; PGG Beta-Glucan; Regorafenib; Selicrelumab	adenosine_A2aR_and_A2bR_antagonist; dectin_receptor_agonist; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; anti-PD-L1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor; anti-CD38_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-CD38_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + dectin_receptor_agonist; anti-VEGF_monoclonal_antibody; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody	Atezolizumab; Atezolizumab + Bevacizumab + PGG Beta-Glucan; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Etrumadenant + Regorafenib; Atezolizumab + Idasanutlin; Atezolizumab + Isatuximab; Atezolizumab + Regorafenib; Regorafenib; Atezolizumab + Bevacizumab + PGG Beta-Glucan; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Etrumadenant + Regorafenib; Atezolizumab + Idasanutlin; Atezolizumab + Isatuximab; Atezolizumab + Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody; anti-CD38_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + dectin_receptor_agonist; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody; anti-CD38_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + dectin_receptor_agonist	CO39612	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)	Colorectal Cancer	3051 - North Melbourne - Peter MacCallum Cancer Center	https://clinicaltrials.gov/ct2/show/NCT03555149
NCT03557619	M16-185	Phase 1	RECRUITING	VIC	2018-06-14	2019-07-30	Venetoclax	Bcl2_inhibitor	Venetoclax	Bcl2_inhibitor	M16-185	A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies	Hematologic Malignancies	3002 - East Melbourne - Peter MacCallum Cancer Centre-East Melbourne /ID# 225247	https://clinicaltrials.gov/ct2/show/NCT03557619
NCT03564340	R4018-ONC-1721	Phase 1/Phase 2	RECRUITING	NSW, VIC	2018-06-08	2018-05-21	Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	R4018-ONC-1721	A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers	Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Recurrent Primary Peritoneal Cancer; Recurrent Endometrial Cancer	3000 - Melbourne - Peter MacCallum Cancer Center; NSW 2031 - Randwick - Prince of Wales Hospital	https://clinicaltrials.gov/ct2/show/NCT03564340
NCT03584009	Veronica	Phase 2	NOT_RECRUITING	NSW, QLD, VIC	2018-07-10	2018-09-06	Fulvestrant; Fulvestrant + Venetoclax; Venetoclax	selective_estrogen_receptor_degrader; Bcl2_inhibitor + selective_estrogen_receptor_degrader; Bcl2_inhibitor	Fulvestrant; Fulvestrant + Venetoclax; Fulvestrant + Venetoclax	Bcl2_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; Bcl2_inhibitor + selective_estrogen_receptor_degrader	WO40181	A Phase II, Multicenter, Randomized Study To Compare The Efficacy Of Venetoclax Plus Fulvestrant Versus Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy	Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer	2059 - North Sydney - Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research; 3051 - North Melbourne - Peter MacCallum Cancer Center; 4101 - South Brisbane - Mater Misericordiae Limited	https://clinicaltrials.gov/ct2/show/NCT03584009
NCT03611868	APG-115-US-002	Phase 1/Phase 2	RECRUITING	QLD, SA, VIC	2018-07-27	2018-08-29	Alrizomadlin; Alrizomadlin + Pembrolizumab; Pembrolizumab	p53-HDM2_interaction_inhibitor; anti-PD-1_monoclonal_antibody; MDM2_inhibitor; anti-PD-1_monoclonal_antibody + p53-HDM2_interaction_inhibitor; MDM2_inhibitor + anti-PD-1_monoclonal_antibody	Alrizomadlin + Pembrolizumab; Alrizomadlin + Pembrolizumab	MDM2_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + p53-HDM2_interaction_inhibitor; MDM2_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + p53-HDM2_interaction_inhibitor	APG-115-US-002	A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors	Unresectable or Metastatic Melanoma or Advanced Solid Tumors; Melanoma; Uveal Melanoma; P53 Mutation; MDM2 Gene Mutation; MPNST; Cutaneous Melanoma; Mucosal Melanoma; Malignant Peripheral Nerve Sheath Tumors	4101 - South Brisbane - Queensland Children's Hospital; 5042 - Bedford Park - Flinders Medical Centre; Brisbane - Metro South Hospital and Health Services via Princess Alexandra Hospital; Heidelberg - Austin Health	https://clinicaltrials.gov/ct2/show/NCT03611868
NCT03629756	ARC-5	Phase 1	NOT_RECRUITING	NSW, QLD, VIC	2018-08-10	2018-07-24	Etrumadenant; Etrumadenant + Zimberelimab; Zimberelimab	anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist	Etrumadenant + Zimberelimab; Etrumadenant + Zimberelimab	adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody	ARC-5 (AB928CSP0005)	A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies	Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck; Breast Cancer; Colorectal Cancer; Melanoma; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Merkel Cell Carcinoma; GastroEsophageal Cancer; Renal Cell Carcinoma; Castration-resistant Prostate Cancer	2217 - Kogarah - St. George Private Hospital; 3144 - Malvern - Cabrini Health Limited; 4120 - Greenslopes - Gallipoli Medical Research Foundation	https://clinicaltrials.gov/ct2/show/NCT03629756
NCT03631199	CANOPY-1	Phase 3	NOT_RECRUITING	NSW, QLD, VIC, WA	2018-08-10	2018-12-21	Canakinumab; Canakinumab + Carboplatin + Cisplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin; Cisplatin; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed; Placebo	antimetabolite; anti-IL-1beta_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; placebo; anti-IL-1beta_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	Canakinumab + Carboplatin + Cisplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab + Pemetrexed; Canakinumab + Carboplatin + Cisplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab + Pemetrexed; Placebo	anti-IL-1beta_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-IL-1beta_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; placebo	CACZ885U2301	A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)	Non-small Cell Lung Cancer	2145 - Westmead - Novartis Investigative Site; 3000 - Melbourne - Novartis Investigative Site; 4102 - Wooloongabba - Novartis Investigative Site; 6150 - Murdoch - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT03631199
NCT03631784	KEYNOTE-799	Phase 2	NOT_RECRUITING	NSW, NZ, VIC	2018-08-13	2018-10-19	Carboplatin; Carboplatin + Paclitaxel + Pembrolizumab + Radiotherapy + Thoracic Radiation Therapy; Cisplatin; Cisplatin + Pembrolizumab + Pemetrexed + Thoracic Radiation Therapy; Paclitaxel; Pembrolizumab; Pemetrexed; Radiotherapy; Thoracic Radiation Therapy	antimetabolite; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy + taxane; radiotherapy; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy	Carboplatin + Paclitaxel + Pembrolizumab + Radiotherapy + Thoracic Radiation Therapy; Cisplatin + Pembrolizumab + Pemetrexed + Thoracic Radiation Therapy; Carboplatin + Paclitaxel + Pembrolizumab + Radiotherapy + Thoracic Radiation Therapy; Cisplatin + Pembrolizumab + Pemetrexed + Thoracic Radiation Therapy	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy + taxane	3475-799	A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)	Non-small Cell Lung Cancer	1023 - Auckland - Auckland City Hospital ( Site 0700); 2148 - Blacktown - Blacktown Hospital Western Sydney Local Health District ( Site 0204); 2444 - Port Macquarie - MNCCI Port Macquarie Base Hospital ( Site 0200); 2500 - Wollongong - Southern Medical Day Care Centre ( Site 0201); 3350 - Ballarat - Ballarat Health Services ( Site 0206)	https://clinicaltrials.gov/ct2/show/NCT03631784
NCT03639714	GO-004	Phase 1/Phase 2	NOT_RECRUITING	VIC	2018-08-18	2019-02-13	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	GO-004	An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors	Non Small Cell Lung Cancer; Colorectal Cancer; Gastroesophageal Adenocarcinoma; Urothelial Carcinoma	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03639714
NCT03647839	MODULATE	Phase 2	NOT_RECRUITING	NSW, QLD, SA, VIC	2018-08-23	2018-09-06	BNC-105; BNC-105 + Nivolumab; Napabucasin; Napabucasin + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody + tubulin_polymerization_inhibitor_and_vascular_disruption_agents; anti-PD-1_monoclonal_antibody; tubulin_polymerization_inhibitor_and_vascular_disruption_agents; cancer_stemness_inhibitor; anti-PD-1_monoclonal_antibody + cancer_stemness_inhibitor	BNC-105 + Nivolumab; Napabucasin + Nivolumab; BNC-105 + Nivolumab; Napabucasin + Nivolumab	anti-PD-1_monoclonal_antibody + cancer_stemness_inhibitor; anti-PD-1_monoclonal_antibody + tubulin_polymerization_inhibitor_and_vascular_disruption_agents; anti-PD-1_monoclonal_antibody + cancer_stemness_inhibitor; anti-PD-1_monoclonal_antibody + tubulin_polymerization_inhibitor_and_vascular_disruption_agents	CA209-99U	Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer	Colorectal Cancer Metastatic	2065 - St Leonards - Northern Cancer Institute; 2145 - Westmead - Westmead Hospital; 2640 - Albury - Border Cancer Hospital; 3021 - Saint Albans - Western Health; 3084 - Heidelberg - Olivia Newton-John Cancer Wellness and Research Centre; 3168 - Clayton - Monash Health; 4029 - Herston - Royal Brisbane Hospital; 5011 - Woodville South - Queen Elizabeth Hospital; 5037 - Kurralta Park - Ashford Cancer Centre Research; 5042 - Bedford Park - Flinders Medical Centre; Ballarat - Ballarat Health Service; Box Hill - Eastern Health; Mornington Peninsula - Peninsula Health/Frankston Hospital; Newcastle - Newcastle Private Hospital	https://clinicaltrials.gov/ct2/show/NCT03647839
NCT03656718	CA209-8KX	Phase 1/Phase 2	NOT_RECRUITING	Bay Of Plenty, NZ, VIC, WA, Wellington	2018-08-31	2018-10-31	Nivolumab; Nivolumab + rHuPH20; rHuPH20	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase; recombinant_human_hyaluronidase	Nivolumab; Nivolumab + rHuPH20; Nivolumab + rHuPH20	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase	CA209-8KX	Phase I/II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy	Neoplasms by Site	3046 - Rotorua - Local Institution - 0040; 3112 - Tauranga - Local Institution - 0015; 6021 - Newtown - Local Institution - 0018; 9012 - Dunedin - Local Institution - 0014	https://clinicaltrials.gov/ct2/show/NCT03656718
NCT03658447	PRINCE	Phase 1/Phase 2	NOT_RECRUITING	NSW, VIC	2018-09-04	2019-07-12	Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan + Pembrolizumab; Pembrolizumab	radioligand,PSMA-targeting; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + radioligand,PSMA-targeting	Lu-177 vipivotide tetraxetan + Pembrolizumab; Lu-177 vipivotide tetraxetan + Pembrolizumab	anti-PD-1_monoclonal_antibody + radioligand,PSMA-targeting; anti-PD-1_monoclonal_antibody + radioligand,PSMA-targeting	PeterMac project no. 18/114	Phase Ib/II Study of Radionuclide 177Lutetium-PSMA-617 Therapy in Combination With Pembrolizumab for Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)	Metastatic Castration Resistant Prostate Cancer	2010 - Sydney - St Vincent's Hospital Sydney; 2050 - Sydney - Chris O'Brien Lifehouse; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3128 - Melbourne - Box Hill Hospital	https://clinicaltrials.gov/ct2/show/NCT03658447
NCT03659136	1280-0022	Phase 2	NOT_RECRUITING	NSW, VIC	2018-09-03	2018-11-28	Everolimus; Everolimus + Exemestane; Everolimus + Exemestane + Xentuzumab; Exemestane; Placebo; Xentuzumab	aromatase_inhibitor + mTORC1_inhibitor; aromatase_inhibitor; mTORC1_inhibitor; anti-IGF_ligand_monoclonal_antibody + aromatase_inhibitor + mTORC1_inhibitor; anti-IGF_ligand_monoclonal_antibody; placebo	Everolimus + Exemestane; Everolimus + Exemestane + Xentuzumab; Everolimus + Exemestane; Everolimus + Exemestane + Xentuzumab; Placebo	anti-IGF_ligand_monoclonal_antibody + aromatase_inhibitor + mTORC1_inhibitor; aromatase_inhibitor + mTORC1_inhibitor; anti-IGF_ligand_monoclonal_antibody + aromatase_inhibitor + mTORC1_inhibitor; aromatase_inhibitor + mTORC1_inhibitor; placebo	1280-0022	XENERA™1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease	Breast Neoplasms	2485 - Tweed Heads - The Tweed Hospital; 3199 - Frankston - Peninsula Haematology & Oncology	https://clinicaltrials.gov/ct2/show/NCT03659136
NCT03666143	BGB-900-103	Phase 1	NOT_RECRUITING	NSW, QLD, VIC, WA	2018-09-09	2018-11-01	Sitravatinib; Sitravatinib + Tislelizumab; Tislelizumab	KIT/PDGFR/RET/VEGFR_inhibitor; PDGFR_inhibitor; RET_inhibitor; KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor; KIT_inhibitor; RET_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody	Sitravatinib + Tislelizumab; Sitravatinib + Tislelizumab	KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody	BGB-900-103	A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumors	Blacktown - Blacktown Cancer and Haematology Centre; Heidelberg - Austin Hospital; Melbourne - Monash Health; Melbourne - Nucleus Network; Perth - Linear Clinical Research Limited; South Brisbane - ICON Cancer Foundation	https://clinicaltrials.gov/ct2/show/NCT03666143
NCT03666988	GSK3368715-207675	Phase 1	NOT_RECRUITING	VIC	2018-09-10	2018-10-22	GSK3368715	type_1_PRMT_inhibitor	GSK3368715	type_1_PRMT_inhibitor	207675	A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL	Neoplasms	3000 - Melbourne - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT03666988
NCT03673501	INTRIGUE	Phase 3	NOT_RECRUITING	NSW, QLD, SA, VIC	2018-09-14	2019-02-08	Imatinib; Ripretinib; Sunitinib	PDGFR_inhibitor; BCR-ABL1_inhibitor,first_generation; VEGFR_inhibitor; KIT_inhibitor,first_generation; KIT_inhibitor; PDGFRA_inhibitor; KIT_inhibitor,switch_control_kinase_inhibitor	Ripretinib; Sunitinib; Imatinib	KIT_inhibitor,first_generation; KIT_inhibitor,switch_control_kinase_inhibitor; PDGFRA_inhibitor; PDGFR_inhibitor; VEGFR_inhibitor; BCR-ABL1_inhibitor,first_generation	DCC-2618-03-002	A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib	Gastrointestinal Stromal Tumors	2031 - Randwick - Prince of Wales Hospital; 3004 - Melbourne - The Alfred Hospital; 5037 - Kurralta Park - Ashford Cancer Centre Research; Albury - Border Medical Oncology Research Unit; Kurralta Park - Ashford Cancer Centre Research; Woolloongabba - Princess Alexandara Hospital; Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT03673501
NCT03674567	FLX475-02	Phase 1/Phase 2	NOT_RECRUITING	VIC, WA	2018-09-14	2018-09-25	FLX475; FLX475 + Pembrolizumab; Pembrolizumab	CCR4_inhibitor; anti-PD-1_monoclonal_antibody; CCR4_inhibitor + anti-PD-1_monoclonal_antibody	FLX475; FLX475 + Pembrolizumab; FLX475 + Pembrolizumab	CCR4_inhibitor; CCR4_inhibitor + anti-PD-1_monoclonal_antibody; CCR4_inhibitor + anti-PD-1_monoclonal_antibody	FLX475-02	Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer	Advanced Cancer	3084 - Heidelberg - Austin Hospital; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT03674567
NCT03684811	2102-ONC-102	Phase 1/Phase 2	NOT_RECRUITING	VIC	2018-09-24	2018-11-01	Azacitidine; Azacitidine + Olutasidenib; Cisplatin; Cisplatin + Gemcitabine + Olutasidenib; Gemcitabine; Nivolumab; Nivolumab + Olutasidenib; Olutasidenib	antimetabolite; IDH1_R132_inhibitor + antimetabolite; DNA_methyltransferase_inhibitor + IDH1_R132_inhibitor; gemcitabine; IDH1_R132_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; IDH1_R132_inhibitor; platinum-based_antineoplastic_agent; IDH1_R132_inhibitor + anti-PD-1_monoclonal_antibody	Azacitidine + Olutasidenib; Cisplatin + Gemcitabine + Olutasidenib; Nivolumab + Olutasidenib; Olutasidenib; Azacitidine + Olutasidenib; Cisplatin + Gemcitabine + Olutasidenib; Nivolumab + Olutasidenib	DNA_methyltransferase_inhibitor + IDH1_R132_inhibitor; IDH1_R132_inhibitor; IDH1_R132_inhibitor + anti-PD-1_monoclonal_antibody; IDH1_R132_inhibitor + antimetabolite; IDH1_R132_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + IDH1_R132_inhibitor; IDH1_R132_inhibitor + anti-PD-1_monoclonal_antibody; IDH1_R132_inhibitor + antimetabolite; IDH1_R132_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	2102-ONC-102	A Phase 1b/2 Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation	Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme); Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 3a and 3b: Chondrosarcoma; Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma; Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations	3084 - Heidelberg - Austin Hospital; VIC 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03684811
NCT03685448	UNICAB	Phase 2	UNKNOWN	NSW, QLD, SA, VIC	2018-09-25	2019-04-11	Cabozantinib	RET_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; AXL_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; VEGFR2_inhibitor; ROS1_inhibitor	Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor	ANZUP1802	A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802)	Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 1; Papillary Renal Cell Carcinoma Type 2; Chromophobe Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Xp11.2 Translocation-Related Renal Cell Carcinoma	2109 - Macquarie Park - Macquarie University Hospital; 2460 - Albury - Border Medical Oncology Research Unit / The Border Cancer Hospital; 2560 - Campbelltown - Campbelltown Hospital; 3128 - Box Hill - Box Hill Hospital - Eastern Health; 3630 - Shepparton - Goulburn Valley Health, as a satellite site under the supervision of Border Medical Oncology Research Unit, via the Tele-trial model; 5037 - Kurralta Park - Adelaide Cancer Centre / Ashford Cancer Centre Research / Cancer Care SA; 5042 - Bedford Park - Flinders Medical Centre; Clayton - Monash Medical Centre; Herston - Royal Brisbane & Women's Hospital; Kogarah - St George Hospital; Newcastle - Calvary Mater Newcastle	https://clinicaltrials.gov/ct2/show/NCT03685448
NCT03690154	FN-1501-UP1	Phase 1	NOT_RECRUITING	VIC	2018-09-27	2018-07-23	FN-1501	CDK2/4/6/FLT3_inhibitor	FN-1501	CDK2/4/6/FLT3_inhibitor	FN-1501-UP1	A Phase 1, Multi-center, Open-label, Single-arm, Dose-escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia (AML)	Advanced Cancer; Solid Tumors; Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse	3144 - Malvern - Cabrini Malvern Hospital	https://clinicaltrials.gov/ct2/show/NCT03690154
NCT03694522	FIGHT	Phase 2	NOT_RECRUITING	NSW, SA	2018-10-01	2018-09-14	Bemarituzumab	anti-FGFR2_monoclonal_antibody	Bemarituzumab	anti-FGFR2_monoclonal_antibody	FPA144-004 Phase 2	FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1	Gastric Cancer	Camperdown - Chris O'brien Lifehouse; Douglas - The Townsville Hospital; Wahroonga - Sydney Adventist Hospital	https://clinicaltrials.gov/ct2/show/NCT03694522
NCT03720431	PMC-TTAC-0001-05	Phase 1	NOT_RECRUITING	NSW, WA	2018-10-24	2019-01-03	Olinvacimab; Olinvacimab + Pembrolizumab; Pembrolizumab	anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	Olinvacimab + Pembrolizumab; Olinvacimab + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	PMC_TTAC-0001_05	A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer	Triple Negative Breast Cancer	2170 - Liverpool - Liverpool Hospital; 6009 - Nedlands - Hollywood Private Hospital	https://clinicaltrials.gov/ct2/show/NCT03720431
NCT03720678	ARC-3	Phase 1	NOT_RECRUITING	NSW, VIC	2018-10-24	2018-11-18	Etrumadenant	adenosine_A2aR_and_A2bR_antagonist	Etrumadenant	adenosine_A2aR_and_A2bR_antagonist	ARC-3 (AB928CSP0003)	A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies	GastroEsophageal Cancer; Colorectal Cancer	2010 - Darlinghurst - The Kinghorn Cancer Centre; 2050 - Camperdown - Chris O'Brien Lifehouse; 2109 - Macquarie Park - Macquarie University Hospital; 2217 - Kogarah - St. George Private Hospital; 2640 - Albury - Border Medical Oncology; 3144 - Malvern - Cabrini Hospital; 3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT03720678
NCT03729245	17-214-09	Phase 3	NOT_RECRUITING	NSW, NZ, SA, VIC	2018-10-31	2018-12-18	Bempegaldesleukin; Bempegaldesleukin + Nivolumab; Cabozantinib; Cabozantinib + Sunitinib; Nivolumab; Sunitinib	PDGFR_inhibitor + ROS1_inhibitor; KIT_inhibitor + PDGFR_inhibitor; IL-2_variant + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor + VEGFR2_inhibitor; KIT_inhibitor,first_generation + VEGFR2_inhibitor; MET_inhibitor,type_2; IL-2_variant; MET_inhibitor,type_2 + VEGFR_inhibitor; VEGFR_inhibitor; KIT_inhibitor,first_generation; KIT_inhibitor + VEGFR_inhibitor; KIT_inhibitor; anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2 + PDGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + PDGFR_inhibitor; VEGFR2_inhibitor; ROS1_inhibitor; AXL_inhibitor + VEGFR_inhibitor; PDGFR_inhibitor; KIT_inhibitor + KIT_inhibitor,first_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR_inhibitor; PDGFR_inhibitor + RET_inhibitor; AXL_inhibitor + KIT_inhibitor,first_generation; RET_inhibitor; ROS1_inhibitor + VEGFR_inhibitor; KIT_inhibitor,first_generation + MET_inhibitor,type_2; AXL_inhibitor + PDGFR_inhibitor; AXL_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + KIT_inhibitor,first_generation; VEGFR2_inhibitor + VEGFR_inhibitor; KIT_inhibitor,first_generation + RET_inhibitor; RET_inhibitor + VEGFR_inhibitor; KIT_inhibitor,first_generation + ROS1_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor	Bempegaldesleukin + Nivolumab; Cabozantinib + Sunitinib; Bempegaldesleukin + Nivolumab; Cabozantinib + Sunitinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + KIT_inhibitor,first_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + PDGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR_inhibitor; AXL_inhibitor + KIT_inhibitor,first_generation; AXL_inhibitor + PDGFR_inhibitor; AXL_inhibitor + VEGFR_inhibitor; IL-2_variant + anti-PD-1_monoclonal_antibody; KIT_inhibitor + KIT_inhibitor,first_generation; KIT_inhibitor + PDGFR_inhibitor; KIT_inhibitor + VEGFR_inhibitor; KIT_inhibitor,first_generation + MET_inhibitor,type_2; KIT_inhibitor,first_generation + RET_inhibitor; KIT_inhibitor,first_generation + ROS1_inhibitor; KIT_inhibitor,first_generation + VEGFR2_inhibitor; MET_inhibitor,type_2 + PDGFR_inhibitor; MET_inhibitor,type_2 + VEGFR_inhibitor; PDGFR_inhibitor + RET_inhibitor; PDGFR_inhibitor + ROS1_inhibitor; PDGFR_inhibitor + VEGFR2_inhibitor; RET_inhibitor + VEGFR_inhibitor; ROS1_inhibitor + VEGFR_inhibitor; VEGFR2_inhibitor + VEGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + KIT_inhibitor,first_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + PDGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR_inhibitor; AXL_inhibitor + KIT_inhibitor,first_generation; AXL_inhibitor + PDGFR_inhibitor; AXL_inhibitor + VEGFR_inhibitor; IL-2_variant + anti-PD-1_monoclonal_antibody; KIT_inhibitor + KIT_inhibitor,first_generation; KIT_inhibitor + PDGFR_inhibitor; KIT_inhibitor + VEGFR_inhibitor; KIT_inhibitor,first_generation + MET_inhibitor,type_2; KIT_inhibitor,first_generation + RET_inhibitor; KIT_inhibitor,first_generation + ROS1_inhibitor; KIT_inhibitor,first_generation + VEGFR2_inhibitor; MET_inhibitor,type_2 + PDGFR_inhibitor; MET_inhibitor,type_2 + VEGFR_inhibitor; PDGFR_inhibitor + RET_inhibitor; PDGFR_inhibitor + ROS1_inhibitor; PDGFR_inhibitor + VEGFR2_inhibitor; RET_inhibitor + VEGFR_inhibitor; ROS1_inhibitor + VEGFR_inhibitor; VEGFR2_inhibitor + VEGFR_inhibitor	17-214-09	A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma	Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma	1023 - Auckland - Auckland City Hospital; 2065 - Saint Leonards - Royal North Shore Hospital; 2109 - Sydney - Macquarie University; 2800 - Orange - Orange Cancer Centre; 3050 - Parkville - Barwon Health; 5037 - Kurralta Park - Adelaide Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03729245
NCT03729596	CP-MGC018-01	Phase 1/Phase 2	NOT_RECRUITING	NSW, QLD, VIC	2018-10-31	2018-11-21	Retifanlimab; Vobramitamab duocarmazine	anti-PD-1_monoclonal_antibody; anti-B7H3_antibody-drug_conjugate	Vobramitamab duocarmazine; Retifanlimab	anti-B7H3_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	CP-MGC018-01	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors	Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer; Melanoma; Advanced Solid Tumor, Adult; Metastatic Castrate Resistant Prostate Cancer; Non Small Cell Lung Cancer	2010 - Darlinghurst - St Vincent's Health Network (Kinghorn Cancer Centre); 2298 - Waratah - Calvary Mater NewCastle; 3084 - Heidelberg - Austin Health - Olivia Newton John Cancer Center; 4105 - Woolloongabba - The University of Queensland - Princess Alexandra Hospital (PAH)	https://clinicaltrials.gov/ct2/show/NCT03729596
NCT03742895	7339-002	Phase 2	RECRUITING	NSW, WA	2018-11-14	2018-12-12	Olaparib	PARP_inhibitor	Olaparib	PARP_inhibitor	7339-002	A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer	Advanced Solid Neoplasms	2010 - Darlinghurst - Kinghorn Cancer Centre ( Site 2200); 2444 - Port Macquarie - MNCCI Port Macquarie Base Hospital ( Site 2201) - (COMPLETED); 6009 - Nedlands - Linear Clinical Research Ltd ( Site 2202) - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT03742895
NCT03744468	BGB-900-102	Phase 1/Phase 2	NOT_RECRUITING	NSW, QLD, SA, VIC, WA	2018-11-15	2018-11-13	BGB-A425; BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab; LBL-007; Tislelizumab	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-TIM3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody	BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab; BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody	BGB-900-102	Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors	Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2	2170 - Liverpool - Sydney Southwest Private Hospital; 3021 - St Albans - Western Health Sunshine Hospital; 3128 - Box Hill - Box Hill Hospital; 3144 - Malvern - Cabrini Research and Education Institute; 4215 - Southport - Gold Coast University Hospital; 4575 - Birtinya - Sunshine Coast Hospital and Health Service; 5006 - North Adelaide - Calvary North Adelaide Hospital; 5112 - Elizabeth Vale - Lyell McEwin Hospital; 6009 - Nedlands - Hollywood Private Hospital	https://clinicaltrials.gov/ct2/show/NCT03744468
NCT03746431	FPX-01-01	Phase 1/Phase 2	RECRUITING	SA, VIC	2018-11-15	2019-01-17	FPI-1175; FPI-1175 + FPI-1547; FPI-1547	IGF1R-radionucleotide_conjugate	FPI-1175 + FPI-1547; FPI-1547; FPI-1175 + FPI-1547	IGF1R-radionucleotide_conjugate	FPX-01-01	A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours	Advanced Solid Tumours; Endometrial Cancer; Cervical Cancer; Ovarian Cancer; Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Adrenocortical Carcinoma; Uveal Melanoma	3084 - Heidelberg - Austin Hospital; 5000 - Adelaide - Royal Adelaide Hospital - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT03746431
NCT03755791	COSMIC-312	Phase 3	NOT_RECRUITING	Auckland, NSW, NZ, QLD, SA, VIC, WA, Wellington	2018-11-26	2018-06-10	Atezolizumab; Atezolizumab + Cabozantinib; Cabozantinib; Sorafenib	RET_inhibitor + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; FLT3_inhibitor; RET_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; CRAF_inhibitor; anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR_inhibitor; KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; VEGFR2_inhibitor; ROS1_inhibitor	Atezolizumab + Cabozantinib; Sorafenib; Atezolizumab + Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; KIT_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody	XL184-312	A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy	Hepatocellular Carcinoma	1023 - Grafton - Exelixis Clinical Site #60; 2010 - Darlinghurst - Exelixis Clinical Site #165; 2050 - Camperdown - Exelixis Clinical Site #78; 2145 - Westmead - Exelixis Clinical Site #155; 2217 - Kogarah - Exelixis Clinical Site #126; 2747 - Kingswood - Exelixis Clinical Site #171; 3050 - Parkville - Exelixis Clinical Site #72; 3084 - Heidelberg - Exelixis Clinical Site #166; 3128 - Box Hill - Exelixis Clinical Site #107; 4120 - Greenslopes - Exelixis Clinical Site #142; 6009 - Nedlands - Exelixis Clinical Site #190; 6021 - Newton - Exelixis Clinical Site #62; Kurralta Park - Exelixis Clinical Site #17	https://clinicaltrials.gov/ct2/show/NCT03755791
NCT03768063	IMbrella-B	Phase 3	RECRUITING	NSW, QLD, VIC	2018-12-05	2019-02-28	Alectinib; Alectinib + Atezolizumab + Bevacizumab + Cabozantinib + Cobimetinib + Emactuzumab + Enzalutamide + Niraparib + Paclitaxel + Pemetrexed + Rucaparib + Vemurafenib + Venetoclax; Atezolizumab; Bevacizumab; Cabozantinib; Cobimetinib; Cobimetinib + Enzalutamide + Niraparib + Paclitaxel + Pembrolizumab + Pemetrexed + Sunitinib + Vemurafenib + Venetoclax; Emactuzumab; Enzalutamide; Niraparib; Paclitaxel; Pembrolizumab; Pemetrexed; Rucaparib; Sunitinib; Vemurafenib; Venetoclax	antimetabolite; BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + VEGFR_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; BRAF_V600_inhibitor + Bcl2_inhibitor + KIT_inhibitor,first_generation + MEK_inhibitor + PARP_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; anti-PD-L1_monoclonal_antibody; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + VEGFR2_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + MET_inhibitor,type_2 + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + RET_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; anti-CSF1R_monoclonal_antibody; anti-VEGF_monoclonal_antibody; VEGFR_inhibitor; KIT_inhibitor,first_generation; Bcl2_inhibitor; ALK/RET_inhibitor; anti-PD-1_monoclonal_antibody; ALK/RET_inhibitor + AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + RET_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + KIT_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; antiandrogen,nonsteroidal,second_generation; BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + PDGFR_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + MET_inhibitor,type_2 + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; PDGFR_inhibitor; ALK/RET_inhibitor + AXL_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; BRAF_V600_inhibitor; ALK_inhibitor,second_generation + AXL_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; RET_inhibitor; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + VEGFR2_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + ROS1_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; taxane; MEK_inhibitor; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + ROS1_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; PARP_inhibitor; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + KIT_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane	Alectinib + Atezolizumab + Bevacizumab + Cabozantinib + Cobimetinib + Emactuzumab + Enzalutamide + Niraparib + Paclitaxel + Pemetrexed + Rucaparib + Vemurafenib + Venetoclax; Atezolizumab; Cobimetinib + Enzalutamide + Niraparib + Paclitaxel + Pembrolizumab + Pemetrexed + Sunitinib + Vemurafenib + Venetoclax; Alectinib + Atezolizumab + Bevacizumab + Cabozantinib + Cobimetinib + Emactuzumab + Enzalutamide + Niraparib + Paclitaxel + Pemetrexed + Rucaparib + Vemurafenib + Venetoclax; Cobimetinib + Enzalutamide + Niraparib + Paclitaxel + Pembrolizumab + Pemetrexed + Sunitinib + Vemurafenib + Venetoclax	ALK/RET_inhibitor + AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + AXL_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + KIT_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + MET_inhibitor,type_2 + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + RET_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + ROS1_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + VEGFR2_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + AXL_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + KIT_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + MET_inhibitor,type_2 + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + RET_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + ROS1_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + VEGFR2_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; BRAF_V600_inhibitor + Bcl2_inhibitor + KIT_inhibitor,first_generation + MEK_inhibitor + PARP_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + PDGFR_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + VEGFR_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; anti-PD-L1_monoclonal_antibody; ALK/RET_inhibitor + AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + AXL_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + KIT_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + MET_inhibitor,type_2 + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + RET_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + ROS1_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK/RET_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + VEGFR2_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + AXL_inhibitor + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + KIT_inhibitor + MEK_inhibitor + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + MET_inhibitor,type_2 + PARP_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + RET_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + ROS1_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; ALK_inhibitor,second_generation + BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + VEGFR2_inhibitor + anti-CSF1R_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; BRAF_V600_inhibitor + Bcl2_inhibitor + KIT_inhibitor,first_generation + MEK_inhibitor + PARP_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + PDGFR_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane; BRAF_V600_inhibitor + Bcl2_inhibitor + MEK_inhibitor + PARP_inhibitor + VEGFR_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + antimetabolite + taxane	BO40729	An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)	Cancer	2010 - Darlinghurst - St Vincent'S Hospital; 2050 - Camperdown - Chris O'Brien Lifehouse - (WITHDRAWN); 3144 - Malvern - Cabrini Hospital Malvern - (WITHDRAWN); 4032 - Chermside - The Prince Charles Hospital; Oncology Dept. - (WITHDRAWN); 4810 - Townsville - Townsville Hospital; 4814 - Douglas - The Townsville Hospital - (WITHDRAWN)	https://clinicaltrials.gov/ct2/show/NCT03768063
NCT03778931	EMERALD	Phase 3	NOT_RECRUITING	NSW, QLD, VIC	2018-12-14	2019-05-10	Anastrozole; Anastrozole + Exemestane + Fulvestrant + Letrozole; Elacestrant; Exemestane; Fulvestrant; Letrozole	selective_estrogen_receptor_degrader; aromatase_inhibitor; aromatase_inhibitor + selective_estrogen_receptor_degrader	Anastrozole + Exemestane + Fulvestrant + Letrozole; Elacestrant; Anastrozole + Exemestane + Fulvestrant + Letrozole	aromatase_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; aromatase_inhibitor + selective_estrogen_receptor_degrader	RAD1901-308	Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial	Breast Cancer	2560 - Campbelltown - Macarthur Cancer Therapy; 3065 - Fitzroy - St Vincent's Hospital Melbourne; 4101 - Brisbane - Mater Misericordiae Ltd Mater Cancer Care Centre; 4575 - Birtinya - Sunshine Coast University Hospital	https://clinicaltrials.gov/ct2/show/NCT03778931
NCT03785925	PIVOT-10	Phase 2	NOT_RECRUITING	NSW, QLD, SA, VIC, WA	2018-12-20	2019-04-29	Bempegaldesleukin; Bempegaldesleukin + Nivolumab; Cisplatin; Nivolumab	anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody; IL-2_variant; platinum-based_antineoplastic_agent	Bempegaldesleukin + Nivolumab; Bempegaldesleukin + Nivolumab; Cisplatin	IL-2_variant + anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent	18-214-10	A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients	Urinary Bladder Neoplasm; Neoplasm Metastasis	2010 - Darlinghurst - St Vincent's Hospital Sydney; 3165 - Bentleigh East - Monash Health, Monash Medical Centre; 4215 - Southport - Tasman Health Care; 5037 - Kurralta Park - Adelaide Cancer Centre; 6009 - Nedlands - St John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT03785925
NCT03787602	KRT-232-103	Phase 1/Phase 2	RECRUITING	QLD	2018-12-21	2019-03-19	Avelumab; Avelumab + Navtemadlin; Navtemadlin	anti-PD-L1_monoclonal_antibody; MDM2_inhibitor; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody	Avelumab + Navtemadlin; Navtemadlin; Avelumab + Navtemadlin	MDM2_inhibitor; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody	KRT-232-103	A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve	Merkel Cell Carcinoma	Woolloongabba - Princess Alexandra Hospital Oncology	https://clinicaltrials.gov/ct2/show/NCT03787602
NCT03792841	NCT03792841	Phase 1	NOT_RECRUITING	NSW, VIC	2019-01-02	2019-02-05	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	20180101	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager Acapatamab in Subjects With Metastatic Castration-resistant Prostate Cancer	Metastatic Castration-resistant Prostate Cancer; Prostate Cancer	2031 - Randwick - Scientia Clinical Research Ltd; 2050 - Camperdown - Chris OBrien Lifehouse; 3050 - Parkville - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03792841
NCT03797326	LEAP-005	Phase 2	Recruiting	QLD, VIC, WA	2019-01-07	2019-02-12	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor	Lenvatinib; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	7902-005	A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)	Advanced Solid Tumors; Triple Negative Breast Cancer; Ovarian Cancer; Gastric Cancer; Colorectal Cancer; Glioblastoma; Biliary Tract Cancers; Pancreatic Cancer	3004 - Melbourne - Alfred Health ( Site 0902); 4029 - Herston - Royal Brisbane and Women s Hospital ( Site 0901); 6009 - Nedlands - Sir Charles Gairdner Hospital ( Site 0903)	https://clinicaltrials.gov/ct2/show/NCT03797326
NCT03800836	CO40151	Phase 1	NOT_RECRUITING	NSW, VIC	2019-01-09	2018-02-13	Atezolizumab; Atezolizumab + Cyclophosphamide + Doxorubicin + Ipatasertib + Paclitaxel; Atezolizumab + Ipatasertib; Atezolizumab + Ipatasertib + Nab-paclitaxel; Atezolizumab + Ipatasertib + Paclitaxel; Cyclophosphamide; Doxorubicin; Ipatasertib; Nab-paclitaxel; Paclitaxel	alkylating_agent; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody; taxane; doxorubicin; pan-AKT_inhibitor; alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane	Atezolizumab + Cyclophosphamide + Doxorubicin + Ipatasertib + Paclitaxel; Atezolizumab + Ipatasertib; Atezolizumab + Ipatasertib + Nab-paclitaxel; Atezolizumab + Ipatasertib + Paclitaxel; Atezolizumab + Cyclophosphamide + Doxorubicin + Ipatasertib + Paclitaxel; Atezolizumab + Ipatasertib; Atezolizumab + Ipatasertib + Nab-paclitaxel; Atezolizumab + Ipatasertib + Paclitaxel	alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; doxorubicin	CO40151	A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer	Breast Cancer	2010 - Darlinghurst - St Vincents Hospital; Cardiopulmonary transplant Ambulatory Care Dept; 3002 - East Melbourne - Peter MacCallum Cancer Center; 3084 - Heidelberg - Austin Hospital	https://clinicaltrials.gov/ct2/show/NCT03800836
NCT03806764	CReSCT	NA	ENROLLING_BY_INVITATION	VIC	2019-01-15	2018-04-17					CReSCT	Assessing the Impact and Complications of Cytomegalovirus (CMV) Reactivation in a Multi-site Study of Allogeneic Haematopoietic Stem Cell Transplant Recipient	Cytomegalovirus Infections; Haematological Malignancy; Organ or Tissue Transplant; Complications; Immune Suppression	3050 - Parkville - Royal Melbourne Hospital	https://clinicaltrials.gov/ct2/show/NCT03806764
NCT03821935	M19-345	Phase 1	RECRUITING	NSW, QLD	2019-01-28	2019-02-21	ABBV-151; Budigalimab	anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody	Budigalimab; ABBV-151	anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody	M19-345	A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumors Cancer	2050 - Camperdown - Chris O'Brien Lifehouse /ID# 213236; 4101 - South Brisbane - Icon Cancer Centre /ID# 224961	https://clinicaltrials.gov/ct2/show/NCT03821935
NCT03829319	LEAP-006	Phase 3	NOT_RECRUITING	Bay Of Plenty, NSW, NZ, QLD, VIC	2019-02-01	2019-03-25	Carboplatin; Carboplatin + Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed; Cisplatin; Lenvatinib; Pembrolizumab; Pemetrexed; Placebo	antimetabolite; VEGF_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; VEGF_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo	Carboplatin + Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed; Placebo	VEGF_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; VEGF_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; placebo	7902-006	A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)	Nonsquamous Non-small Cell Lung Cancer	1023 - Auckland - Auckland City Hospital ( Site 0011); 2050 - Sydney - Chris OBrien Lifehouse ( Site 0006); 2145 - Sydney - Westmead Hospital ( Site 0009); 2148 - Blacktown - Blacktown Hospital Western Sydney Local Health District ( Site 0008); 2444 - Port Macquarie - Port Macquarie Base Hospital ( Site 0001); 3112 - Tauranga - Tauranga Hospital ( Site 0004); 3350 - Ballarat - Ballarat Health Services ( Site 0003); 4032 - Chermside - The Prince Charles Hospital ( Site 0010); 4870 - Cairns - Cairns Hospital ( Site 0002)	https://clinicaltrials.gov/ct2/show/NCT03829319
NCT03829332	LEAP-007	Phase 3	NOT_RECRUITING	NSW, QLD, VIC, WA	2019-02-01	2019-03-13	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor	Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	7902-007	A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)	Non-small Cell Lung Cancer	2500 - Wollongong - Wollongong Private Hospital ( Site 0005); 2800 - Orange - Orange Health Services ( Site 0002); 3355 - Wendouree - Ballarat Oncology and Haematology Services ( Site 0008); 4032 - Chermside - The Prince Charles Hospital ( Site 0011); 6150 - Perth - St John of God Murdoch Medical Clinic ( Site 0001)	https://clinicaltrials.gov/ct2/show/NCT03829332
NCT03833154	PACIFIC-4	Phase 3	RECRUITING	NSW, SA, VIC	2019-02-05	2019-03-06	Durvalumab; Osimertinib; Placebo; Radiotherapy	radiotherapy; anti-PD-L1_monoclonal_antibody; EGFR_inhibitor,third_generation; placebo	Durvalumab; Osimertinib; Placebo; Radiotherapy	EGFR_inhibitor,third_generation; anti-PD-L1_monoclonal_antibody; placebo; radiotherapy	D9103C00001	A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation	Carcinoma, Non-Small-Cell Lung	2148 - Blacktown - Research Site - (WITHDRAWN); 3168 - Clayton - Research Site; 5112 - Elizabeth Vale - Research Site - (WITHDRAWN)	https://clinicaltrials.gov/ct2/show/NCT03833154
NCT03834519	KEYLYNK-010	Phase 3	NOT_RECRUITING	NSW, NZ, QLD, VIC, WA	2019-02-06	2019-05-02	Abiraterone; Abiraterone + Enzalutamide + Prednisolone + Prednisone; Enzalutamide; Olaparib; Olaparib + Pembrolizumab; Pembrolizumab; Prednisolone; Prednisone	PARP_inhibitor + anti-PD-1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; PARP_inhibitor; CYP17A1_inhibitor; glucocorticoid; anti-PD-1_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation	Abiraterone + Enzalutamide + Prednisolone + Prednisone; Olaparib + Pembrolizumab; Abiraterone + Enzalutamide + Prednisolone + Prednisone; Olaparib + Pembrolizumab	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; PARP_inhibitor + anti-PD-1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; PARP_inhibitor + anti-PD-1_monoclonal_antibody	7339-010	A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)	Prostatic Neoplasms	1023 - Auckland - Auckland City Hospital ( Site 0193); 2010 - Darlinghurst - St. Vincent's Hospital ( Site 0158); 2109 - Macquarie University - Macquarie University ( Site 0151); 2298 - Waratah - Calvary Mater Newcastle ( Site 0148); 2444 - Port Macquarie - Port Macquarie Base Hospital ( Site 0153); 2500 - Wollongong - Southern Medical Day Care Centre ( Site 0160); 3000 - Melbourne - Peter MacCallum Cancer Centre ( Site 0152); 3128 - Box Hill - Box Hill Hospital ( Site 0146); 4029 - Herston - Royal Brisbane and Women s Hospital ( Site 0155); 4224 - Tugun - John Flynn Hospital & Medical Centre ( Site 0164); 6150 - Murdoch - Fiona Stanley Hospital ( Site 0162)	https://clinicaltrials.gov/ct2/show/NCT03834519
NCT03840200	BO40933	Phase 1	NOT_RECRUITING	NSW, VIC	2019-02-11	2019-06-12	Abiraterone; Abiraterone + Apalutamide + Enzalutamide + Ipatasertib + Rucaparib; Apalutamide; Enzalutamide; Ipatasertib; Ipatasertib + Rucaparib; Rucaparib	PARP_inhibitor; CYP17A1_inhibitor; CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation + pan-AKT_inhibitor; PARP_inhibitor + pan-AKT_inhibitor; pan-AKT_inhibitor; antiandrogen,nonsteroidal,second_generation	Abiraterone + Apalutamide + Enzalutamide + Ipatasertib + Rucaparib; Ipatasertib + Rucaparib; Abiraterone + Apalutamide + Enzalutamide + Ipatasertib + Rucaparib; Ipatasertib + Rucaparib	CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation + pan-AKT_inhibitor; PARP_inhibitor + pan-AKT_inhibitor; CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation + pan-AKT_inhibitor; PARP_inhibitor + pan-AKT_inhibitor	BO40933	A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer	Breast Cancer; Prostate Cancer; Ovarian Cancer	2010 - Darlinghurst - Kinghorn Cancer Centre; St Vincents Hospital; 2109 - Macquarie Park - Macquarie University Hospital; 3144 - Malvern - Cabrini Hospital Malvern	https://clinicaltrials.gov/ct2/show/NCT03840200
NCT03851146	LeY-CAR-T	Phase 1	NOT_RECRUITING	VIC	2019-02-20	2016-11-24	LeY-CAR-T	autologous_CAR-T-cell_therapy,LeY-targeting	LeY-CAR-T	autologous_CAR-T-cell_therapy,LeY-targeting	LeYPh1-02	A Phase I Investigation of the Safety, Tolerability and Immunological Effects of T Lymphocytes Transduced With an Anti-Lewis Y (LeY) Chimeric Antigen Receptor Gene (LeY-CAR-T) in Patients With LeY Antigen Expressing Advanced Solid Tumours	Advanced Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03851146
NCT03858972	CONTESSA-2	Phase 2	NOT_RECRUITING	NSW	2019-02-28	2019-02-05	Capecitabine; Capecitabine + Tesetaxel; Tesetaxel	fluoropyrimidine; taxane; fluoropyrimidine + taxane	Capecitabine + Tesetaxel; Capecitabine + Tesetaxel	fluoropyrimidine + taxane; fluoropyrimidine + taxane	ODO-TE-B201	Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane	Breast Cancer	2640 - Albury - Border Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT03858972
NCT03869892	SOLSTICE	Phase 3	NOT_RECRUITING	NSW, VIC	2019-03-08	2019-03-21	Bevacizumab; Bevacizumab + Capecitabine; Bevacizumab + Trifluridine/Tipiracil; Capecitabine; Trifluridine/Tipiracil	antimetabolite; Tipiracil Hydrochloride; fluoropyrimidine; anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody; Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor; Trifluridine; thymidine_phosphorylase_inhibitor; Trifluridine + anti-VEGF_monoclonal_antibody	Bevacizumab + Capecitabine; Bevacizumab + Trifluridine/Tipiracil; Bevacizumab + Capecitabine; Bevacizumab + Trifluridine/Tipiracil	Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor; Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor	CL3-95005-006	An Open-label, Randomised, Phase III Study cOmparing trifLuridine/Tipiracil (S 95005) in Combination With Bevacizumab to Capecitabine in Combination With Bevacizumab in firST-line Treatment of Patients With metastatIC Colorectal Cancer Who Are Not candidatE for Intensive Therapy (SOLSTICE Study)	Metastatic Colorectal Cancer	2076 - Wahroonga - Adventist HealthCare Integrated Cancer Centre; 2148 - Blacktown - Blacktown Hospital Cancer and Haematology Centre; 2217 - Kogarah - St George Hospital St George Hospital Cancer Care Centre; 2290 - Gateshead - Lake Macquarie Private Hospital; 2500 - Wollongong - Southern Medical Day Care Centre; 3199 - Frankston - Frankston Private Peninsula and Southeast Oncology Group	https://clinicaltrials.gov/ct2/show/NCT03869892
NCT03874884	LuPARP	Phase 1	RECRUITING	NSW, VIC	2019-03-12	2019-07-09	Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan + Olaparib; Olaparib	radioligand,PSMA-targeting; PARP_inhibitor + radioligand,PSMA-targeting; PARP_inhibitor	Lu-177 vipivotide tetraxetan + Olaparib; Lu-177 vipivotide tetraxetan + Olaparib	PARP_inhibitor + radioligand,PSMA-targeting; PARP_inhibitor + radioligand,PSMA-targeting	Peter Mac project no.18/216	177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer	Metastatic Castration Resistant Prostate Cancer (mCRPC)	2010 - Sydney - St Vincent's Hospital Sydney; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03874884
NCT03875079	BP41054	Phase 1	NOT_RECRUITING	NSW, VIC	2019-03-13	2019-06-24	Pembrolizumab; Pembrolizumab + RO-6874281; RO-6874281	anti-PD-1_monoclonal_antibody; anti-FAP/IL-2_fusion_protein; anti-FAP/IL-2_fusion_protein + anti-PD-1_monoclonal_antibody	Pembrolizumab + RO-6874281; Pembrolizumab + RO-6874281	anti-FAP/IL-2_fusion_protein + anti-PD-1_monoclonal_antibody; anti-FAP/IL-2_fusion_protein + anti-PD-1_monoclonal_antibody	BP41054	An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), In Combination With Pembrolizumab (Anti-PD-1), In Participants With Advanced Or Metastatic Melanoma	Metastatic Melanoma	2060 - North Sydney - Melanoma Institute Australia; 3000 - Melbourne - Peter Maccallum Cancer Institute; Clinical Trial Unit	https://clinicaltrials.gov/ct2/show/NCT03875079
NCT03900442	PTX-100-PD-012017	Phase 1	UNKNOWN_STATUS	VIC	2019-03-30	2019-09-01	PTX-100	geranylgeranyl_transferase_inhibitor	PTX-100	geranylgeranyl_transferase_inhibitor	PTX-100-PD-012017	Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies	Advanced Cancer; PTCL	3002 - Melbourne - Epworth Healthcare; 3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT03900442
NCT03905148	BGB-283-PD-0325901-AU-001	Phase 1	RECRUITING	NSW, VIC, WA	2019-04-04	2019-05-01	Lifirafenib; Lifirafenib + Mirdametinib; Mirdametinib	MEK_inhibitor; EGFR/RAF_dimer_inhibitor + MEK_inhibitor; EGFR/RAF_dimer_inhibitor	Lifirafenib + Mirdametinib; Lifirafenib + Mirdametinib	EGFR/RAF_dimer_inhibitor + MEK_inhibitor; EGFR/RAF_dimer_inhibitor + MEK_inhibitor	BGB-283/PD-0325901-AU-001	A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors	Solid Tumor, Adult	2031 - Randwick - The Prince of Wales Private Hospital - Specialist Medical Randwick; 2148 - Blacktown - Blacktown Cancer and Haematology Centre; 3000 - Melbourne - Peter MacCallum Cancer Centre; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT03905148
NCT03906331	NCT03906331		AVAILABLE	NSW, NZ, QLD, WA	2019-04-04		Selpercatinib	RET-selective_inhibitor	Selpercatinib	RET-selective_inhibitor	17494	Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration	2050 - Camperdown - NSW Health - Sydney Local Health District - (AVAILABLE); 2065 - St. Leonards - Royal North Shore Hospital - (AVAILABLE); 4032 - Chermside - Queensland Health - Metro North Hospital and Health Service - (AVAILABLE); 6009 - Nedlands - Linear Clinical Research - (AVAILABLE); 91346 - Auckland - University of Auckland - (AVAILABLE)	https://clinicaltrials.gov/ct2/show/NCT03906331
NCT03936959	NCT03936959	Phase 1	NOT_RECRUITING	NSW	2019-05-02	2019-05-24	LY3434172	bispecific_PD-1/PD-L1_antibody	LY3434172	bispecific_PD-1/PD-L1_antibody	17101	A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors	Advanced Cancer	2010 - Sydney - St Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT03936959
NCT03947385	IDE196-001	Phase 1/Phase 2	RECRUITING	NSW	2019-05-09	2019-06-28	Binimetinib; Binimetinib + Darovasertib; Crizotinib; Crizotinib + Darovasertib; Darovasertib	MET_inhibitor,type_1; PKC_inhibitor + ROS1_inhibitor; MEK_inhibitor + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor; MEK_inhibitor; PKC_inhibitor	Binimetinib + Darovasertib; Crizotinib + Darovasertib; Darovasertib; Binimetinib + Darovasertib; Crizotinib + Darovasertib	ALK_inhibitor,first_generation + PKC_inhibitor; MEK_inhibitor + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor; MEK_inhibitor + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor	IDE196-001	A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions	Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors	Sydney - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT03947385
NCT03948763	V941-001	Phase 1	NOT_RECRUITING	Canterbury, NSW, NZ, SA, VIC	2019-05-10	2019-06-26	Pembrolizumab; Pembrolizumab + mRNA-5671; mRNA-5671	anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,KRAS-targeting; anti-PD-1_monoclonal_antibody; mRNA_personalised_cancer_vaccine,KRAS-targeting	Pembrolizumab + mRNA-5671; mRNA-5671; Pembrolizumab + mRNA-5671	anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,KRAS-targeting; mRNA_personalised_cancer_vaccine,KRAS-targeting; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,KRAS-targeting	V941-001	A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma	Neoplasms; Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms; Colorectal Neoplasms	1023 - Auckland - Auckland City Hospital ( Site 6500); 2010 - Darlinghurst - Kinghorn Cancer Centre ( Site 6000); 3168 - Clayton - Monash Health-Monash Medical Centre ( Site 6001); 5042 - Bedford Park - Southern Oncology Clinical Research Unit SOCRU ( Site 6002); 8011 - Christchurch - New Zealand Clinical Research (Christchurch) ( Site 6501)	https://clinicaltrials.gov/ct2/show/NCT03948763
NCT03964727	TROPiCS-03	Phase 2	NOT_RECRUITING	NSW, QLD, SA, VIC	2019-05-24	2019-10-15	Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate	Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate	IMMU-132-11	A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors	Metastatic Solid Tumor	2109 - North Ryde - Macquarie University; 2145 - Westmead - Blacktown Hospital; 2298 - Waratah - Calvary Mater Newcastle Hospital; 2576 - Bowral - Southern Highlands Cancer Center; 3168 - Clayton - Monash Medical Centre, Monash Health; 3220 - Geelong - The Andrew Love Cancer Centre, Geelong Hospital; 4101 - South Brisbane - Mater Cancer Centre, Mater Misericordiae Limited; 4217 - Benowa - Pindara Private Hospital; 5112 - Elizabeth Vale - Lyell McEwin Hospital	https://clinicaltrials.gov/ct2/show/NCT03964727
NCT03970447	GBM-AGILE	Phase 2/Phase 3	RECRUITING	NSW, QLD, VIC	2019-05-30	2019-07-30	Lomustine; Lomustine + Radiotherapy + Temozolomide; Paxalisib; Paxalisib + Radiotherapy + Temozolomide; Pegargiminase; Pegargiminase + Temozolomide; Radiotherapy; Radiotherapy + Regorafenib + Temozolomide; Radiotherapy + Temozolomide; Radiotherapy + Temozolomide + VAL-083; Regorafenib; Temozolomide; VAL-083	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + radiotherapy; dual_PI3K/mTOR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; radiotherapy; alkylating_agent; alkylating_agent + radiotherapy; alkylating_agent + dual_PI3K/mTOR_inhibitor + radiotherapy; arginine_deiminase-polyethylene_glycol_conjugate; alkylating_agent + arginine_deiminase-polyethylene_glycol_conjugate	Lomustine + Radiotherapy + Temozolomide; Paxalisib + Radiotherapy + Temozolomide; Pegargiminase; Pegargiminase + Temozolomide; Radiotherapy + Regorafenib + Temozolomide; Radiotherapy + Temozolomide; Radiotherapy + Temozolomide + VAL-083; Temozolomide; Lomustine + Radiotherapy + Temozolomide; Paxalisib + Radiotherapy + Temozolomide; Pegargiminase + Temozolomide; Radiotherapy + Regorafenib + Temozolomide; Radiotherapy + Temozolomide; Radiotherapy + Temozolomide + VAL-083	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + radiotherapy; alkylating_agent; alkylating_agent + arginine_deiminase-polyethylene_glycol_conjugate; alkylating_agent + dual_PI3K/mTOR_inhibitor + radiotherapy; alkylating_agent + radiotherapy; arginine_deiminase-polyethylene_glycol_conjugate; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + radiotherapy; alkylating_agent + arginine_deiminase-polyethylene_glycol_conjugate; alkylating_agent + dual_PI3K/mTOR_inhibitor + radiotherapy; alkylating_agent + radiotherapy	GCAR-7213	GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM	Glioblastoma	2065 - St Leonards - Northern Sydney Cancer Centre/Royal North Shore Hospital; 2298 - Waratah - Calvary Mater Newcastle; 3084 - Heidelberg - Austin Health; 4029 - Herston - Royal Brisbane and Women's Hospital; Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03970447
NCT03975647	SGNTUC-016	Phase 3	RECRUITING	NSW, Other, VIC, WA	2019-06-04	2019-10-02	Placebo; Trastuzumab Emtansine; Trastuzumab Emtansine + Tucatinib; Tucatinib	anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,third_generation; placebo; ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate	Trastuzumab Emtansine; Trastuzumab Emtansine + Tucatinib; Placebo; Trastuzumab Emtansine + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; placebo	SGNTUC-016	Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)	HER2-positive Breast Cancer	2060 - Sydney - Mater Hospital; 2145 - Westmead - Westmead Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Melbourne - Austin Health; 6009 - Nedlands - Breast Cancer Research Centre	https://clinicaltrials.gov/ct2/show/NCT03975647
NCT03976323	7339-006	Phase 3	NOT_RECRUITING	Manawatu-Wanganui, NSW, NZ, QLD, VIC	2019-06-03	2019-06-28	Carboplatin; Carboplatin + Cisplatin + Olaparib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Olaparib; Pembrolizumab; Pemetrexed	antimetabolite; PARP_inhibitor; PARP_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Olaparib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Olaparib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed	PARP_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	7339-006	A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Non-squamous Non-Small-Cell Lung Cancer (NSCLC)	Carcinoma, Non-squamous Non-small-cell Lung	2170 - Liverpool - Liverpool Hospital ( Site 1201); 2500 - Wollongong - Southern Medical Day Care Centre ( Site 1200); 3168 - Clayton - Monash Cancer Centre ( Site 1205); 4414 - Palmerston North - MidCentral DHB Palmerston North Hospital ( Site 1102); 4814 - Townsville - Townsville General Hospital ( Site 1202); 6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital ( Site 1101)	https://clinicaltrials.gov/ct2/show/NCT03976323
NCT04008030	CheckMate-8HW	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2019-07-02	2019-08-05	Bevacizumab; Bevacizumab + Cetuximab + Fluorouracil + Ipilimumab + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin; Cetuximab; Fluorouracil; Ipilimumab; Ipilimumab + Nivolumab; Irinotecan; Leucovorin; Nivolumab; Oxaliplatin	anti-EGFR_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; Fluorouracil; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent; folinic_acid	Bevacizumab + Cetuximab + Fluorouracil + Ipilimumab + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin; Ipilimumab + Nivolumab; Nivolumab; Bevacizumab + Cetuximab + Fluorouracil + Ipilimumab + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; Fluorouracil; anti-CTLA-4_monoclonal_antibody + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CA209-8HW	A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	2145 - Westmead - Local Institution - 0019; 3084 - Heidelberg - Local Institution - 0017; 3168 - Clayton - Local Institution - 0041; 4102 - Woolloongabba - Local Institution - 0053; 5112 - Elizabeth Vale - Local Institution - 0018	https://clinicaltrials.gov/ct2/show/NCT04008030
NCT04047290	AK112-101	Phase 1	RECRUITING	NSW, QLD, SA, VIC	2019-08-05	2019-09-20	Ivonescimab	bispecific_PD-1/VEGF_monoclonal_antibody	Ivonescimab	bispecific_PD-1/VEGF_monoclonal_antibody	AK112-101	A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects With Advanced Solid Tumors	Neoplasms Malignant	Albury - Border Medical Oncology - (COMPLETED); Clayton - Monash Health; Kurralta Park - Adelaide Cancer Centre; Melbourne - Peter MacCallum Cancer Centre; Randwick - Scientia Clinical Research Ltd; South Brisbane - ICON Cancer Foundation; Sydney - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT04047290
NCT04049617	GS-US-494-5484	Phase 1	NOT_RECRUITING	NZ	2019-08-06	2019-08-26	GS-4224	anti-PD-L1_monoclonal_antibody	GS-4224	anti-PD-L1_monoclonal_antibody	GS-US-494-5484	A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	1010 - Grafton, Auckland - Auckland Clinical Studies Ltd; 1023 - Auckland - Auckland City Hospital; 8011 - Christchurch - Christchurch Clinical Studies Trust, LLC	https://clinicaltrials.gov/ct2/show/NCT04049617
NCT04051827	TAK-788-1004	Phase 1	NOT_RECRUITING	NSW, SA, VIC	2019-08-08	2019-12-23	Midazolam; Midazolam + Mobocertinib; Mobocertinib	EGFR_inhibitor,exon_20_selective + benzodiazepam; ERBB2_inhibitor,exon_20_selective; benzodiazepam; ERBB2_inhibitor,exon_20_selective + benzodiazepam; EGFR_inhibitor,exon_20_selective	Midazolam + Mobocertinib; Mobocertinib; Midazolam + Mobocertinib	EGFR_inhibitor,exon_20_selective; EGFR_inhibitor,exon_20_selective + benzodiazepam; ERBB2_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective + benzodiazepam; EGFR_inhibitor,exon_20_selective + benzodiazepam; ERBB2_inhibitor,exon_20_selective + benzodiazepam	TAK-788-1004	A Phase 1, Open-Label, Multicenter, Drug-Drug Interaction Study of TAK-788 and Midazolam, a Sensitive CYP3A Substrate, in Patients With Advanced Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung; Lung Neoplasms	2065 - St Leonards - Royal North Shore Hospital; 3004 - Melbourne - Nucleus Network; 3199 - Frankston - Peninsula and Southeast Oncology; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04051827
NCT04052971	ABN401-001	Phase 1	RECRUITING	NSW, WA	2019-08-08	2019-08-01	ABN401	MET_inhibitor,type_1	ABN401	MET_inhibitor,type_1	ABN401-001	A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Pilot Expansion in Patients With Non-Small Cell Lung Cancer Harboring c-MET Dysregulation	Advanced Solid Tumors	2031 - Randwick - Scientia Clinical Research; 2170 - Liverpool - Sydney Southwest Private Hospital; 2217 - Kogarah - ST George Private Hospital; 6009 - Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04052971
NCT04060862	IPATunity150	Phase 3	NOT_RECRUITING	VIC	2019-08-15	2019-11-15	Fulvestrant; Fulvestrant + Ipatasertib + Palbociclib; Fulvestrant + Palbociclib; Ipatasertib; Palbociclib; Placebo	selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; placebo; pan-AKT_inhibitor; CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader	Fulvestrant + Ipatasertib + Palbociclib; Fulvestrant + Palbociclib; Fulvestrant + Ipatasertib + Palbociclib; Fulvestrant + Palbociclib; Placebo	CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; placebo	CO41012	A Phase Ib/III Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer	Breast Cancer	3021 - St Albans - Sunshine Hospital; 3144 - Malvern - Cabrini Medical Centre; Oncology	https://clinicaltrials.gov/ct2/show/NCT04060862
NCT04064060	ACE-536-LTFU-001	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2019-08-19	2019-08-12	Luspatercept	recombinant_human_ActRIIb_fusion_protein	Luspatercept	recombinant_human_ActRIIb_fusion_protein	ACE-536-LTFU-001	A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials	Myelodysplastic Syndromes (MDS); Beta-thalassemia; Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis	2050 - Camperdown - Royal Prince Alfred Hospital; 3168 - Clayton - Local Institution - 102; 4101 - South Brisbane - Local Institution - 100 - (COMPLETED); 5000 - Adelaide - Local Institution - 103	https://clinicaltrials.gov/ct2/show/NCT04064060
NCT04068610	D910CC00001	Phase 1/Phase 2	NOT_RECRUITING	VIC	2019-08-23	2019-09-13	Bevacizumab; Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Durvalumab; Fluorouracil; Leucovorin; Oleclumab; Oxaliplatin	anti-VEGF_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; Fluorouracil; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; folinic_acid	Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin	anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	D910CC00001	A Phase Ib/II, Open-label, Multicenter Study of Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)	Metastatic Microsatellite-stable Colorectal Cancer	3000 - Melbourne - Research Site; 3084 - Heidelberg - Research Site; 3168 - Clayton - Research Site	https://clinicaltrials.gov/ct2/show/NCT04068610
NCT04106492	SQ3370-001	Phase 1/Phase 2	RECRUITING	NSW, SA	2019-09-25	2020-08-01	SQ3370	anthracycline	SQ3370	anthracycline	SQ3370-001	A Multicenter Phase 1/2a, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors	Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - Sydney - Royal North Shore Hospital; 5000 - Adelaide - Cancer Research Institute	https://clinicaltrials.gov/ct2/show/NCT04106492
NCT04109456	IN10018-004-01	Phase 1	RECRUITING	NSW, VIC, WA	2019-09-27	2020-03-16	Atezolizumab; Atezolizumab + Cobimetinib; Cobimetinib	anti-PD-L1_monoclonal_antibody; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Cobimetinib; Cobimetinib; Atezolizumab + Cobimetinib	MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	IN10018-004-01	A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma	Metastatic Melanoma	Melbourne - The Alfred Hospital; Nedlands - Linear Clinical Research; Sydney - St Vincent Hospital Sydney	https://clinicaltrials.gov/ct2/show/NCT04109456
NCT04122339	Maxinovel-10181-001	Phase 1	UNKNOWN	WA	2019-10-08	2020-02-11	MAX-10181	PD-L1_inhibitor,oral	MAX-10181	PD-L1_inhibitor,oral	Maxinovel-10181-001	A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor	Solid Tumor	6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04122339
NCT04139317	CINC280I12201	Phase 2	NOT_RECRUITING	NSW, SA, VIC	2019-10-23	2020-01-22	Capmatinib; Capmatinib + Pembrolizumab; Pembrolizumab	MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1	Capmatinib + Pembrolizumab; Pembrolizumab; Capmatinib + Pembrolizumab	MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody	CINC280I12201	A Randomized, Open Label, Multicenter Phase II Study Evaluating the Efficacy and Safety of Capmatinib (INC280) Plus Pembrolizumab Versus Pembrolizumab Alone as First Line Treatment for Locally Advanced or Metastatic Non-small Cell Lung Cancer With PD-L1≥ 50%	Non-small Cell Lung Cancer (NSCLC)	2500 - Wollongong - Novartis Investigative Site; 3630 - Shepparton - Novartis Investigative Site; 5006 - North Adelaide - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04139317
NCT04140526	PRESERVE-001	Phase 1/Phase 2	RECRUITING	NSW, QLD, SA	2019-10-24	2020-09-16	Docetaxel; Docetaxel + ONC392; ONC392; ONC392 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; taxane; anti-CTLA-4_monoclonal_antibody + taxane; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Docetaxel + ONC392; ONC392; ONC392 + Pembrolizumab; Docetaxel + ONC392; ONC392 + Pembrolizumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + taxane; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + taxane	ONC-392-001	Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)	Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma	2305 - New Lambton Heights - Newcastle Private Hospital; 4120 - Southport - Tasman Oncology Research; 5000 - Adelaide - Cancer Research SA; 5042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT04140526
NCT04148937	NCT04148937	Phase 1	*NOT_RECRUITING	VIC	2019-11-01	2020-01-16	LY3475070; LY3475070 + Pembrolizumab; Pembrolizumab	CD73_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; CD73_inhibitor	LY3475070; LY3475070 + Pembrolizumab; LY3475070 + Pembrolizumab	CD73_inhibitor; CD73_inhibitor + anti-PD-1_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody	17504	A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies	Advanced Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04148937
NCT04162301	CS3002-101	Phase 1	NOT_RECRUITING	NSW, VIC	2019-11-11	2019-12-30	CS3002	CDK4/6_inhibitor	CS3002	CDK4/6_inhibitor	CS3002-101	A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activities of CS3002, a CDK4/6 Inhibitor, in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2050 - Camperdown - Chris O'Brien Lifehouse; 3199 - Heidelberg - Peninsula and South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT04162301
NCT04177108	CO41101	Phase 3	NOT_RECRUITING	NSW, NZ, QLD, SA, VIC, WA	2019-11-22	2019-11-25	Atezolizumab; Atezolizumab + Ipatasertib + Paclitaxel; Ipatasertib; Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; taxane; placebo; pan-AKT_inhibitor	Atezolizumab + Ipatasertib + Paclitaxel; Atezolizumab + Ipatasertib + Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; placebo	CO41101	A Phase III, Double-blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer	Triple-Negative Breast Cancer	1023 - Auckland - Auckland City Hospital, Cancer and Blood Research; 2065 - St Leonards - Royal North Shore Hospital; Department of Medical Oncology; 2109 - Macquarie Park - Macquarie University Hospital; 2298 - Waratah - Calvary Mater Newcastle; Medical Oncology; 2444 - Port Macquarie - Mid North Coast Cancer Institute; 3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology; 3112 - Tauranga - Tauranga Hospital, Clinical Trials Unit; BOP Clinical School; 3168 - Clayton - Monash Health Monash Medical Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; 5037 - Kurralta Park - Adelaide Cancer Centre; 6008 - Subiaco - St John of God Hospital; Bendat Cancer Centre; 6021 - Wellington - Wellington Regional Hospital; Clinical Trials Unit; St Albans - Sunshine Hospital; Oncology Research	https://clinicaltrials.gov/ct2/show/NCT04177108
NCT04185883	NCT04185883	Phase 1	RECRUITING	NSW, QLD, SA, WA	2019-12-03	2019-12-17	AMG 404; AMG 404 + Sotorasib; Afatinib; Afatinib + Sotorasib; Atezolizumab; Atezolizumab + Sotorasib; BI 1701963; BI 1701963 + Sotorasib; Bevacizumab; Bevacizumab + Sotorasib; Carboplatin; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed + Sotorasib; Docetaxel; Everolimus; Everolimus + Sotorasib; Paclitaxel; Palbociclib; Palbociclib + Sotorasib; Panitumumab; Panitumumab + Sotorasib; Panitumumab + Sotorasib + Trametinib; Pembrolizumab; Pembrolizumab + Sotorasib; Pemetrexed; RMC-4630; RMC-4630 + Sotorasib; Sotorasib; Sotorasib + TNO155; TNO155; Trametinib	antimetabolite; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; CDK4/6_inhibitor + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; mTORC1_inhibitor; anti-PD-L1_monoclonal_antibody; SHP2_inhibitor; EGFR_inhibitor,second_generation; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; SOS1-KRAS_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; CDK4/6_inhibitor; taxane; MEK_inhibitor; anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; platinum-based_antineoplastic_agent; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + mTORC1_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody	AMG 404 + Sotorasib; Afatinib + Sotorasib; Atezolizumab + Sotorasib; BI 1701963 + Sotorasib; Bevacizumab + Sotorasib; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed + Sotorasib; Everolimus + Sotorasib; Palbociclib + Sotorasib; Panitumumab + Sotorasib; Panitumumab + Sotorasib + Trametinib; Pembrolizumab + Sotorasib; RMC-4630 + Sotorasib; Sotorasib; Sotorasib + TNO155; AMG 404 + Sotorasib; Afatinib + Sotorasib; Atezolizumab + Sotorasib; BI 1701963 + Sotorasib; Bevacizumab + Sotorasib; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed + Sotorasib; Everolimus + Sotorasib; Palbociclib + Sotorasib; Panitumumab + Sotorasib; Panitumumab + Sotorasib + Trametinib; Pembrolizumab + Sotorasib; RMC-4630 + Sotorasib; Sotorasib + TNO155	CDK4/6_inhibitor + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + mTORC1_inhibitor; CDK4/6_inhibitor + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + mTORC1_inhibitor	20190135	A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)	Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation	2065 - St Leonards - GenesisCare -North Shore Oncology; 2747 - Kingswood - Nepean Cancer Centre; 4101 - South Brisbane - Icon Cancer Care South Brisbane; 5011 - Woodville South - The Queen Elizabeth Hospital; 6008 - Subiaco - St John of God Healthcare	https://clinicaltrials.gov/ct2/show/NCT04185883
NCT04191499	INAVO120	Phase 2/Phase 3	NOT_RECRUITING	NSW, NZ, QLD, VIC	2019-12-06	2020-01-29	Fulvestrant; Fulvestrant + Inavolisib + Palbociclib; Fulvestrant + Palbociclib; Inavolisib; Palbociclib; Placebo	selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; placebo	Fulvestrant + Inavolisib + Palbociclib; Fulvestrant + Palbociclib; Fulvestrant + Inavolisib + Palbociclib; Fulvestrant + Palbociclib; Placebo	CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; placebo	WO41554	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer	Breast Cancer	2113 - Macquarie Park - Macquarie University Hospital; 2145 - Westmead - Westmead Hospital; Medical Oncology and Pallative Care; 2500 - Wollongong - Southern Medical Day Care Centre; 3065 - Fitzroy - Western Health; 3199 - Frankston - Peninsula and South Eastern Haematology and Oncology Group; 4101 - South Brisbane - Mater Adult Hospital; Oncology; 4102 - Woolloongabba - Princess Alexandra Hospital; Cancer Trials Unit; 4442 - Palmerston North - Palmerston North Hospital; Regional Cancer Treatment Service	https://clinicaltrials.gov/ct2/show/NCT04191499
NCT04221035	HR-NBL2	Phase 3	RECRUITING	NSW, NZ, Randwick, VIC, WA	2020-01-06	2019-11-05	Busulfan; Busulfan + Melphalan + Thiotepa; Carboplatin; Carboplatin + Cisplatin + Cyclophosphamide + Dacarbazine + Dinutuximab + Doxorubicin + Etoposide + Ifosfamide + Irinotecan + Temozolomide + Vincristine; Cisplatin; Cyclophosphamide; Dacarbazine; Dinutuximab; Dinutuximab + Radiotherapy; Doxorubicin; Etoposide; Ifosfamide; Irinotecan; Melphalan; Radiotherapy; Temozolomide; Thiotepa; Vincristine	topoisomerase_inhibitor; radiotherapy; anti-GD2_monoclonal_antibody + radiotherapy; alkylating_agent; anti-GD2_monoclonal_antibody; doxorubicin; platinum-based_antineoplastic_agent; vinca_alkaloid; alkylating_agent + anthracycline + anti-GD2_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid	Busulfan + Melphalan + Thiotepa; Carboplatin + Cisplatin + Cyclophosphamide + Dacarbazine + Dinutuximab + Doxorubicin + Etoposide + Ifosfamide + Irinotecan + Temozolomide + Vincristine; Dinutuximab + Radiotherapy; Busulfan + Melphalan + Thiotepa; Carboplatin + Cisplatin + Cyclophosphamide + Dacarbazine + Dinutuximab + Doxorubicin + Etoposide + Ifosfamide + Irinotecan + Temozolomide + Vincristine; Dinutuximab + Radiotherapy	alkylating_agent; alkylating_agent + anthracycline + anti-GD2_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; anti-GD2_monoclonal_antibody + radiotherapy; alkylating_agent + anthracycline + anti-GD2_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; anti-GD2_monoclonal_antibody + radiotherapy; doxorubicin	2019-001068-31	High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)	High-Risk Neuroblastoma; Patient With Insufficient Response Chemoimmunotherapy	NSW, 2031 - Sydney - Australian and New Zealand Children's Hematology/oncology Group; NSW, 2031 - Sydney - Sydney children Hospital; NSW, 2031 - Sydney - sydney children Hospital; NSW, 2145, - Westmead - Cancer Centre for Children, The Children's Hospital; NSW, 2305 - New Lambton Heights - Children's Cancer & Haematology Services, John Hunter Children's Hospital; VIC 3168 - Clayton - Children's Cancer Centre, Monash Children's Hospital; WA, 6009 - Nedlands - Oncology/Haematology Department, Perth Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT04221035
NCT04221542	NCT04221542	Phase 1	RECRUITING	NSW, VIC	2020-01-06	2020-03-04	Abiraterone; Abiraterone + Enzalutamide + Xaluritamig; Enzalutamide; Xaluritamig	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,STEAP1-targeting; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation; bispecific_T-cell_engager,STEAP1-targeting	Abiraterone + Enzalutamide + Xaluritamig; Xaluritamig; Abiraterone + Enzalutamide + Xaluritamig	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,STEAP1-targeting; bispecific_T-cell_engager,STEAP1-targeting; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,STEAP1-targeting	20180146	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2050 - Camperdown - Chris OBrien Lifehouse; 3168 - Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04221542
NCT04222972	AcceleRET-Lung	Phase 3	NOT_RECRUITING	NSW, SA	2020-01-07	2020-07-24	Carboplatin; Carboplatin + Cisplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab + Pemetrexed; Cisplatin; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed; Pralsetinib	antimetabolite; gemcitabine; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; RET-selective_inhibitor	Carboplatin + Cisplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab + Pemetrexed; Pralsetinib; Carboplatin + Cisplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab + Pemetrexed	RET-selective_inhibitor; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; gemcitabine	BO42864	A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer	RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Diseases; Head and Neck Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue	2065 - St Leonards - Royal North Shore Hospital; Department of Medical Oncology; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04222972
NCT04223856	EV-302	Phase 3	NOT_RECRUITING	NSW, QLD, SA, VIC	2020-01-08	2020-03-30	Carboplatin; Carboplatin + Cisplatin + Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Cisplatin; Enfortumab Vedotin; Enfortumab Vedotin + Pembrolizumab; Gemcitabine; Pembrolizumab	anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; gemcitabine; anti-NECTIN4_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Enfortumab Vedotin + Pembrolizumab	anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	SGN22E-003	An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer	Urothelial Cancer	2109 - Macquarie Park - Site AUS61002; 3084 - Heidelberg - Site AUS61004; 3128 - Box Hill - Site AU61003; 4101 - South Brisbane - Site AU61005; 4814 - Douglas - Site AUS61001; 5112 - South Australia - Site AUS61006	https://clinicaltrials.gov/ct2/show/NCT04223856
NCT04246489	MS200647-0017	Phase 2	NOT_RECRUITING	NSW, VIC, WA	2020-01-28	2020-03-30	Bintrafusp Alfa	anti-PD-L1/TGF-beta_fusion_protein	Bintrafusp Alfa	anti-PD-L1/TGF-beta_fusion_protein	MS200647_0017	A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy	Uterine Cervical Neoplasms	Melbourne - Peter MacCallum Cancer Centre-East Melbourne; Nedlands - Linear Clinical Research Limited; Waratah - Calvary Mater Newcastle	https://clinicaltrials.gov/ct2/show/NCT04246489
NCT04249843	BGB-3245-AU-001	Phase 1	RECRUITING	NSW, Perth, VIC, WA	2020-01-29	2020-02-17	BGB-3245	RAF_dimer_inhibitor	BGB-3245	RAF_dimer_inhibitor	BGB-3245-AU-001	A First-in-Human, Phase 1a/1b, Open Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients With Advanced or Refractory Tumors	Solid Tumor; B-Raf Mutation-Related Tumors	2010 - Melbourne - Peter MacCallum Cancer Centre; 2010 - Sydney - The Kinghorn Cancer Centre, St Vincent Hospital Sydney; 2148 - Blacktown - Blacktown Hospital; 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04249843
NCT04250155	GO41596	Phase 1	RECRUITING	VIC	2020-01-29	2020-03-09	Atezolizumab; Atezolizumab + XmAb24306; XmAb24306	anti-PD-L1_monoclonal_antibody; IL-15/IL-15R_Fc-fusion_protein; IL-15/IL-15R_Fc-fusion_protein + anti-PD-L1_monoclonal_antibody	Atezolizumab + XmAb24306; XmAb24306; Atezolizumab + XmAb24306	IL-15/IL-15R_Fc-fusion_protein; IL-15/IL-15R_Fc-fusion_protein + anti-PD-L1_monoclonal_antibody; IL-15/IL-15R_Fc-fusion_protein + anti-PD-L1_monoclonal_antibody	GO41596	A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Solid Tumors	3002 - East Melbourne - Peter Mac Callum Cancer Center	https://clinicaltrials.gov/ct2/show/NCT04250155
NCT04251117	GT-30	Phase 1/Phase 2	NOT_RECRUITING	NZ	2020-01-30	2020-03-01	GNOS-PV02; GNOS-PV02 + INO-9012 + Pembrolizumab; INO-9012; Pembrolizumab	anti-PD-1_monoclonal_antibody; DNA_plasmid_encoding_IL-12; personalized_neoantigen_vaccine; DNA_plasmid_encoding_IL-12 + anti-PD-1_monoclonal_antibody + personalized_neoantigen_vaccine	GNOS-PV02 + INO-9012 + Pembrolizumab; GNOS-PV02 + INO-9012 + Pembrolizumab	DNA_plasmid_encoding_IL-12 + anti-PD-1_monoclonal_antibody + personalized_neoantigen_vaccine; DNA_plasmid_encoding_IL-12 + anti-PD-1_monoclonal_antibody + personalized_neoantigen_vaccine	GT-30	An Open-label, Multi-center, Phase I/IIa Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) in Combination With Pembrolizumab (MK-3475) in Subjects With Advanced Hepatocellular Carcinoma	HCC	Auckland - Auckland Clinical Studies	https://clinicaltrials.gov/ct2/show/NCT04251117
NCT04256421	SKYSCRAPER-02	Phase 3	NOT_RECRUITING	NSW, NZ, QLD, SA	2020-02-03	2020-02-04	Atezolizumab; Atezolizumab + Carboplatin + Etoposide; Atezolizumab + Carboplatin + Etoposide + Tiragolumab; Carboplatin; Etoposide; Placebo; Tiragolumab	topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Atezolizumab + Carboplatin + Etoposide; Atezolizumab + Carboplatin + Etoposide + Tiragolumab; Atezolizumab + Carboplatin + Etoposide; Atezolizumab + Carboplatin + Etoposide + Tiragolumab; Placebo	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; placebo	GO41767	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Cancer	1023 - Auckland - Auckland City Hospital; Clinical Oncology; 2050 - Camperdown - Chris O'Brien Lifehouse; 2747 - Kingswood - Nepean Hospital; Nepean Cancer Care Centre; 4575 - Birtinya - Sunshine Coast University Hospital; The Adem Crosby Centre; 5112 - Elizabeth Vale - Lyell McEwin Hospital; Oncology Clinical Trials, Chemotherapy Day Unit	https://clinicaltrials.gov/ct2/show/NCT04256421
NCT04262466	IMC-F106C-101	Phase 1/Phase 2	RECRUITING	NSW, NZ, VIC, WA	2020-02-07	2020-02-25	Bevacizumab; Bevacizumab + IMC-F106C + Pembrolizumab; Bevacizumab + IMC-F106C + Tebentafusp; IMC-F106C; IMC-F106C + Pembrolizumab; Pembrolizumab; Tebentafusp	anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting; bispecific_T-cell_engager,PRAME-targeting; anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting; anti-PD-1_monoclonal_antibody; anti-CD3/scFv_fusion_protein,gp100-targeting + anti-VEGF_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting; anti-CD3/scFv_fusion_protein,gp100-targeting	Bevacizumab + IMC-F106C + Pembrolizumab; Bevacizumab + IMC-F106C + Tebentafusp; IMC-F106C; IMC-F106C + Pembrolizumab; Bevacizumab + IMC-F106C + Pembrolizumab; Bevacizumab + IMC-F106C + Tebentafusp; IMC-F106C + Pembrolizumab	anti-CD3/scFv_fusion_protein,gp100-targeting + anti-VEGF_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting; bispecific_T-cell_engager,PRAME-targeting; anti-CD3/scFv_fusion_protein,gp100-targeting + anti-VEGF_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting	IMC-F106C-101	Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers	Select Advanced Solid Tumors	2031 - Randwick - Scientia Clinical Research; 2065 - Wollstonecraft - Melanoma Institute Australia (MIA) - The Poche Centre; 3004 - Melbourne - The Alfred Hospital; 6009 - Nedlands - Linear Clinical Research; 92697 - Auckland - New Zealand Clinical Research-Auckland	https://clinicaltrials.gov/ct2/show/NCT04262466
NCT04277637	BGB-11417-101	Phase 1	NOT_RECRUITING	NSW, NZ, QLD, SA, VIC, WA	2020-02-18	2020-03-24	BGB-11417; BGB-11417 + Obinutuzumab + Zanubrutinib; BGB-11417 + Zanubrutinib; Obinutuzumab; Zanubrutinib	BTK_inhibitor + Bcl2_inhibitor + anti-CD20_monoclonal_antibody; BTK_inhibitor + Bcl2_inhibitor; BTK_inhibitor; anti-CD20_monoclonal_antibody; Bcl2_inhibitor	BGB-11417; BGB-11417 + Obinutuzumab + Zanubrutinib; BGB-11417 + Zanubrutinib; BGB-11417 + Obinutuzumab + Zanubrutinib; BGB-11417 + Zanubrutinib	BTK_inhibitor + Bcl2_inhibitor; BTK_inhibitor + Bcl2_inhibitor + anti-CD20_monoclonal_antibody; Bcl2_inhibitor; BTK_inhibitor + Bcl2_inhibitor; BTK_inhibitor + Bcl2_inhibitor + anti-CD20_monoclonal_antibody	BGB-11417-101	A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies	Mature B-Cell Malignancies	0622 - Takapuna - North Shore Hospital; 1023 - Auckland - Auckland City Hospital; 2139 - Concord - Concord Repatriation General Hospital; 2800 - Orange - Orange Health Service (Central West Cancer Care Centre); 3000 - Melbourne - Peter Maccallum Cancer Centre; 3004 - Melbourne - The Alfred Hospital; 3065 - Fitzroy - St Vincents Hospital Melbourne; 3128 - Box Hill - Box Hill Hospital; 3168 - Clayton - Monash Health; 4217 - Benowa - Pindara Private Hospital; 4224 - Tugun - John Flynn Private Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 5042 - Bedford PK - Flinders Medical Centre; 6009 - Nedlands - Linear Clinical Research; 6021 - Wellington - Wellington Regional Hospital (Ccdhb)	https://clinicaltrials.gov/ct2/show/NCT04277637
NCT04294810	SKYSCRAPER-01	Phase 3	NOT_RECRUITING	QLD, VIC	2020-03-02	2020-03-04	Atezolizumab; Atezolizumab + Tiragolumab; Placebo; Tiragolumab	anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; placebo; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Atezolizumab; Atezolizumab + Tiragolumab; Atezolizumab + Tiragolumab; Placebo	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo	GO41717	A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	3000 - Melbourne - Peter Maccallum Cancer Centre; 3084 - Heidelberg - Austin Hospital Olivia Newton John Cancer Centre; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT04294810
NCT04303780	NCT04303780	Phase 3	NOT_RECRUITING	NSW, QLD, SA, VIC, WA	2020-03-09	2020-06-04	Docetaxel; Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; taxane	Docetaxel; Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; taxane	20190009	A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C	KRAS p, G12c Mutated /Advanced Metastatic NSCLC	2050 - Camperdown - Chris OBrien Lifehouse; 2148 - Blacktown - Blacktown Hospital; 2170 - Liverpool - Liverpool Hospital; 2217 - Kogarah - St George Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3168 - Clayton - Monash Medical Centre; 4032 - Chermside - Prince Charles Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 5011 - Woodville South - The Queen Elizabeth Hospital; 6008 - Subiaco - St John of God Healthcare	https://clinicaltrials.gov/ct2/show/NCT04303780
NCT04305054	3475-02B	Phase 1/Phase 2	RECRUITING	NSW, QLD, WA	2020-03-09	2020-07-01	Favezelimab; Favezelimab + Pembrolizumab; Favezelimab + Pembrolizumab + Vibostolimab; Lenvatinib; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab; Pembrolizumab + Vibostolimab; Quavonlimab; Vibostolimab	VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Favezelimab + Pembrolizumab; Favezelimab + Pembrolizumab + Vibostolimab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab; Pembrolizumab + Vibostolimab; Favezelimab + Pembrolizumab; Favezelimab + Pembrolizumab + Vibostolimab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab + Quavonlimab; Pembrolizumab + Vibostolimab	VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	3475-02B	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B	Melanoma	2065 - Wollstonecraft - Melanoma Institute Australia ( Site 2402); 2298 - Waratah - Calvary Mater Newcastle-Medical Oncology ( Site 2404); 4120 - Southport - Tasman Oncology Research Pty Ltd ( Site 2403); 6150 - Murdoch - Fiona Stanley Hospital ( Site 2401)	https://clinicaltrials.gov/ct2/show/NCT04305054
NCT04305249	ERASER	Phase 1	RECRUITING	NSW, VIC	2020-03-10	2020-08-15	ATG-017; ATG-017 + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; ERK_inhibitor + anti-PD-1_monoclonal_antibody; ERK_inhibitor	ATG-017; ATG-017 + Nivolumab; ATG-017 + Nivolumab	ERK_inhibitor; ERK_inhibitor + anti-PD-1_monoclonal_antibody; ERK_inhibitor + anti-PD-1_monoclonal_antibody	ATG-017-001	A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Patients With Advanced Solid Tumors and Hematological Malignancies	Solid Tumor; Hematological Malignancy	3002 - East Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - Alfred Hospital; 3084 - Heidelberg - Austin Hospital; Randwick - Scientia Clinical Research; Sydney - Chris O'Brien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT04305249
NCT04311710	CheckMate-76U	Phase 1	NOT_RECRUITING	NZ	2020-03-16	2020-06-25	Ipilimumab; Ipilimumab + Nivolumab; Ipilimumab + Nivolumab + rHuPH20; Nivolumab; rHuPH20	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; recombinant_human_hyaluronidase	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab + rHuPH20; Ipilimumab + Nivolumab; Ipilimumab + Nivolumab + rHuPH20	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase	CA209-76U	A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination With Subcutaneous Nivolumab	Tumor	1023 - Auckland - Local Institution - 0010	https://clinicaltrials.gov/ct2/show/NCT04311710
NCT04322318	AREN1921	Phase 2	RECRUITING	Auckland, NSW, NZ, QLD, SA, VIC, WA	2020-03-24	2020-10-19	Carboplatin; Carboplatin + Cyclophosphamide + Doxorubicin + Etoposide + Irinotecan + Radiotherapy + Vincristine; Carboplatin + Cyclophosphamide + Etoposide + Ifosfamide + Radiotherapy + Topotecan; Cyclophosphamide; Doxorubicin; Etoposide; Ifosfamide; Irinotecan; Radiotherapy; Topotecan; Vincristine	topoisomerase_inhibitor; radiotherapy; alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + topoisomerase_inhibitor; alkylating_agent; alkylating_agent + anthracycline + platinum-based_antineoplastic_agent + radiotherapy + topoisomerase_inhibitor + vinca_alkaloid; doxorubicin; platinum-based_antineoplastic_agent; vinca_alkaloid	Carboplatin + Cyclophosphamide + Doxorubicin + Etoposide + Irinotecan + Radiotherapy + Vincristine; Carboplatin + Cyclophosphamide + Etoposide + Ifosfamide + Radiotherapy + Topotecan; Carboplatin + Cyclophosphamide + Doxorubicin + Etoposide + Irinotecan + Radiotherapy + Vincristine; Carboplatin + Cyclophosphamide + Etoposide + Ifosfamide + Radiotherapy + Topotecan	alkylating_agent + anthracycline + platinum-based_antineoplastic_agent + radiotherapy + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + topoisomerase_inhibitor; alkylating_agent + anthracycline + platinum-based_antineoplastic_agent + radiotherapy + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + topoisomerase_inhibitor; doxorubicin	AREN1921	Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)	Anaplastic Kidney Wilms Tumor; Recurrent Kidney Wilms Tumor; Stage II Kidney Wilms Tumor; Stage III Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor	1145 - Grafton - Starship Children's Hospital; 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 2310 - Hunter Regional Mail Centre - John Hunter Children's Hospital; 3052 - Parkville - Royal Children's Hospital; 3168 - Clayton - Monash Medical Center-Clayton Campus - (SUSPENDED); 4101 - South Brisbane - Queensland Children's Hospital; 5006 - North Adelaide - Women's and Children's Hospital-Adelaide; 6009 - Perth - Perth Children's Hospital; 8011 - Christchurch - Christchurch Hospital	https://clinicaltrials.gov/ct2/show/NCT04322318
NCT04322539	FRESCO-2	Phase 3	NOT_RECRUITING	QLD, SA, VIC	2020-03-25	2020-08-12	Fruquintinib; Placebo	VEGFR1/2/3_inhibitor; placebo	Fruquintinib; Placebo	VEGFR1/2/3_inhibitor; placebo	2019-013-GLOB1	A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer	Metastatic Colorectal Cancer; Metastatic Colon Cancer	3021 - Melbourne - Western Health; 3084 - Melbourne - Austin Hopistal Medical Oncology Unit; 3168 - Melbourne - Monash Health; 4001 - Brisbane - Integrated Clinical Oncology Network Pty Ltd (Icon); 5011 - Adelaide - The Queen Elizabeth Hospital; 5042 - Adelaide - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04322539
NCT04390763	daNIS-1	Phase 2	NOT_RECRUITING	NSW, VIC	2020-05-14	2020-10-16	Gemcitabine; Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel + Spartalizumab; Gemcitabine + Nab-paclitaxel; NIS793; Nab-paclitaxel; Spartalizumab	antimetabolite + taxane; antimetabolite; anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; gemcitabine; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-PD-1_monoclonal_antibody; taxane; anti-TGF-beta_monoclonal_antibody	Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel + Spartalizumab; Gemcitabine + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel + Spartalizumab; Gemcitabine + Nab-paclitaxel	anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; gemcitabine	CNIS793B12201	A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	Metastatic Pancreatic Ductal Adenocarcinoma	2145 - Westmead - Novartis Investigative Site; 3000 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04390763
NCT04402073	PersoMed-I	Phase 2	RECRUITING	NSW, QLD, VIC, WA	2020-05-20	2022-11-11	Cisplatin; Cisplatin + Lomustine + Radiotherapy + Sonidegib + Vincristine; Lomustine; Radiotherapy; Sonidegib; Vincristine	alkylating_agent; SMO_inhibitor,first_generation + alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; SMO_inhibitor,first_generation; radiotherapy; platinum-based_antineoplastic_agent; vinca_alkaloid	Cisplatin + Lomustine + Radiotherapy + Sonidegib + Vincristine; Cisplatin + Lomustine + Radiotherapy + Sonidegib + Vincristine	SMO_inhibitor,first_generation + alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; SMO_inhibitor,first_generation + alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid	1634	Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I)	Medulloblastoma	Adelaide - Royal Adelaide Hospital; Brisbane - Princess Alexandra Hospital - University Of Queensland; Melbourne - Austin Health - Austin hospital; Melbourne - Peter Maccallum Cancer Institute; Nedlands - Sir Charles Gairdner Hospital; New Lambton Heights - John Hunter Children's Hospital; Sydney - Prince Of Wales Hospital; Sydney - Royal North Shore Hospital; Sydney - Sydney Children's Hospital; Westmead - Westmead Hospital - Crown Princess Mary Cancer Center	https://clinicaltrials.gov/ct2/show/NCT04402073
NCT04418661	TCD16210	Phase 1/Phase 2	*NOT_RECRUITING	NSW, QLD, VIC	2020-06-02	2020-06-09	Adagrasib; Adagrasib + RMC-4630; Pembrolizumab; Pembrolizumab + RMC-4630; RMC-4630	SHP2_inhibitor + anti-PD-1_monoclonal_antibody; SHP2_inhibitor; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor	Adagrasib + RMC-4630; Pembrolizumab + RMC-4630; Adagrasib + RMC-4630; Pembrolizumab + RMC-4630	KRAS_G12C_inhibitor + SHP2_inhibitor; SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor; SHP2_inhibitor + anti-PD-1_monoclonal_antibody	TCD16210	A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of SAR442720 in Combination With Other Agents in Participants With Advanced Malignancies	Metastatic Neoplasm	2031 - Randwick - Investigational Site Number : 0360002; 3081 - Heidelberg West - Investigational Site Number : 0360003; 4102 - Woolloongabba - Investigational Site Number : 0360001	https://clinicaltrials.gov/ct2/show/NCT04418661
NCT04423029	CA101-001	Phase 1/Phase 2	RECRUITING	VIC	2020-06-05	2020-07-13	DF6002; DF6002 + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; IL-12_Fc-fusion_protein + anti-PD-1_monoclonal_antibody; IL-12_Fc-fusion_protein	DF6002; DF6002 + Nivolumab; DF6002 + Nivolumab	IL-12_Fc-fusion_protein; IL-12_Fc-fusion_protein + anti-PD-1_monoclonal_antibody; IL-12_Fc-fusion_protein + anti-PD-1_monoclonal_antibody	CA101-001	A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications	Solid Tumors	3084 - Heidelberg - Local Institution - 0022 - (WITHDRAWN); 3128 - Box Hill - Local Institution - 0023 - (WITHDRAWN)	https://clinicaltrials.gov/ct2/show/NCT04423029
NCT04428151	LEAP-009	Phase 2	RECRUITING	NSW, QLD, SA, VIC	2020-06-09	2020-08-06	Capecitabine; Capecitabine + Cetuximab + Docetaxel + Paclitaxel; Cetuximab; Docetaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Paclitaxel; Pembrolizumab	anti-EGFR_monoclonal_antibody; fluoropyrimidine; anti-EGFR_monoclonal_antibody + fluoropyrimidine + taxane; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane	Capecitabine + Cetuximab + Docetaxel + Paclitaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Capecitabine + Cetuximab + Docetaxel + Paclitaxel; Lenvatinib + Pembrolizumab	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + fluoropyrimidine + taxane; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + fluoropyrimidine + taxane	7902-009	A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)	Squamous Cell Carcinoma of Head and Neck	2148 - Sydney - Blacktown Hospital ( Site 0101); 2444 - Port Macquarie - Mid North Coast Cancer Institute ( Site 0109) - (COMPLETED); 3168 - Clayton - Monash Health ( Site 0102); 4120 - Greenslopes - Gallipoli Medical Research Ltd-GMRF CTU ( Site 0105); 4814 - Douglas - The Townsville Hospital ( Site 0107) - (COMPLETED); 5000 - Adelaide - Royal Adelaide Hospital ( Site 0110)	https://clinicaltrials.gov/ct2/show/NCT04428151
NCT04430842	QBS-72S-1001	Phase 1	NOT_RECRUITING	NSW	2020-06-10	2020-07-20	QBS10072S	amino_acid_analogue,LAT1-targeting	QBS10072S	amino_acid_analogue,LAT1-targeting	QBS-72S-1001	A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma	Astrocytoma; Brain Cancer; Brain Metastases; Bladder Cancer; Breast Cancer; Cervical Cancer; Cholangiocarcinoma; Colorectal Cancer; Esophagus Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Liver Cancer; Lung Cancer; Melanoma; Ovarian Cancer; Pancreatic Cancer; Pleural Mesothelioma; Prostate Cancer; Sarcoma; Tongue Cancer; Thymic Carcinoma; Urinary Tract Cancer	2170 - Liverpool - Sydney Southwest Private Hospital; 2217 - Kogarah - St George Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04430842
NCT04434482	IMP4297-106	Phase 1/Phase 2	RECRUITING	NSW, VIC	2020-06-14	2020-08-07	Senaparib; Senaparib + Temozolomide; Temozolomide	alkylating_agent; PARP_inhibitor; PARP_inhibitor + alkylating_agent	Senaparib + Temozolomide; Senaparib + Temozolomide	PARP_inhibitor + alkylating_agent; PARP_inhibitor + alkylating_agent	IMP4297-106	A Phase Ib/II, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer	Advanced Solid Tumours; Small Cell Lung Cancer	2148 - Blacktown - Blacktown Hospital; 2640 - Albury - Border Medical Oncology; 2800 - Orange - Orange Hospital; 3199 - Frankston - Peninsula Health Frankston Hospital	https://clinicaltrials.gov/ct2/show/NCT04434482
NCT04446260	SHR-A1811-I-101	Phase 1	RECRUITING	NSW, SA, VIC	2020-06-22	2020-09-03	SHR-A1811	anti-ERBB2_antibody-drug_conjugate	SHR-A1811	anti-ERBB2_antibody-drug_conjugate	SHR-A1811-I-101	A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects	Advanced Solid Tumors	2109 - Macquarie - Macquarie University Hospital; 3004 - Melbourne - Alfred Hospital; 3004 - Melbourne - Nucleus Network; 3199 - Frankston - Peninsula and South Eastern Haematology & Oncology Group; 5042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT04446260
NCT04449874	GO42144	Phase 1	RECRUITING	NSW, NZ, VIC, WA	2020-06-24	2020-07-29	Atezolizumab; Atezolizumab + Divarasib; Bevacizumab; Bevacizumab + Divarasib; Cetuximab; Cetuximab + Divarasib; Divarasib; Divarasib + Erlotinib; Divarasib + Inavolisib; Divarasib + RLY-1971; Erlotinib; Inavolisib; RLY-1971	KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor; PI3K_alpha_inhibitor; anti-PD-L1_monoclonal_antibody; SHP2_inhibitor; KRAS_G12C_inhibitor + PI3K_alpha_inhibitor; KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; anti-VEGF_monoclonal_antibody; EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; EGFR_inhibitor,first_generation	Atezolizumab + Divarasib; Bevacizumab + Divarasib; Cetuximab + Divarasib; Divarasib; Divarasib + Erlotinib; Divarasib + Inavolisib; Divarasib + RLY-1971; Atezolizumab + Divarasib; Bevacizumab + Divarasib; Cetuximab + Divarasib; Divarasib + Erlotinib; Divarasib + Inavolisib; Divarasib + RLY-1971	EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + PI3K_alpha_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + PI3K_alpha_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody	GO42144	A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation	Non-Small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumors	1023 - Auckland - Auckland City Hospital; 1023 - Auckland - Auckland City Hospital, Cancer and Blood Research; 2010 - Darlinghurst - St Vincent's Hospital Sydney; 2080 - Mount Kuring-gai - Slade Health Inward goods; 3004 - Melbourne - Alfred Health; 3051 - North Melbourne - Peter MacCallum Cancer Center; 6009 - Nedlands - Linear Clinical Research Limited; 8011 - Christchurch - New Zealand Clinical Research - Christchurch	https://clinicaltrials.gov/ct2/show/NCT04449874
NCT04450732	GQ1001X2101	Phase 1	NOT_RECRUITING	NSW, VIC	2020-06-25	2020-07-07	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQ1001X2101	A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors	HER2-positive Breast Cancer; HER2-positive Biliary Tract Cancer; HER2-Positive Salivary Gland Carcinomas; HER2-Positive Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research Limited; 3050 - Melbourne - Cabrini Institute in Melbourne, Australia - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT04450732
NCT04458259	C4201002	Phase 1	NOT_RECRUITING	NSW	2020-07-02	2020-09-24	Axitinib; Axitinib + PF-07265807 + Sasanlimab; Methotrexate; Methotrexate + PF-07265807; PF-07265807; PF-07265807 + Sasanlimab; Sasanlimab	antimetabolite; AXL/MER_inhibitor + KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor; AXL/MER_inhibitor + antifolate; VEGFR/PDGFR_inhibitor; anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + antimetabolite	Axitinib + PF-07265807 + Sasanlimab; Methotrexate + PF-07265807; PF-07265807; PF-07265807 + Sasanlimab; Axitinib + PF-07265807 + Sasanlimab; Methotrexate + PF-07265807; PF-07265807 + Sasanlimab	AXL/MER_inhibitor; AXL/MER_inhibitor + KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + antifolate; AXL/MER_inhibitor + antimetabolite; AXL/MER_inhibitor + KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + antifolate; AXL/MER_inhibitor + antimetabolite	C4201002	A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF 07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES	Neoplasm Metastasis	2010 - Darlinghurst - HPS Pharmacies Darlinghurst; 2010 - Sydney - St Vincent's Hospital; 2109 - Macquarie University - Macquarie University; 2298 - Waratah - Calvary Mater Newcastle	https://clinicaltrials.gov/ct2/show/NCT04458259
NCT04460456	SBT6050-101	Phase 1	UNKNOWN	NSW, VIC, WA	2020-07-06	2020-07-27	Cemiplimab; Cemiplimab + SBT6050; Pembrolizumab; Pembrolizumab + SBT6050; SBT6050	anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	Cemiplimab + SBT6050; Pembrolizumab + SBT6050; SBT6050; Cemiplimab + SBT6050; Pembrolizumab + SBT6050	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	SBT6050-101	A Phase 1/1B, Open-Label, Dose Escalation and Expansion Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced Solid Tumors Expressing HER2	HER2 Positive Solid Tumors	2109 - Sydney - Macquarie University Hospital Clinical Trials Unit; 3000 - Melbourne - Peter MacCallum Cancer Centre; 6009 - Nedlands - Breast Cancer Research Centre - WA	https://clinicaltrials.gov/ct2/show/NCT04460456
NCT04464226	NCT04464226	Phase 3	RECRUITING	SA	2020-07-07	2020-10-20	Darolutamide	antiandrogen,nonsteroidal,second_generation	Darolutamide	antiandrogen,nonsteroidal,second_generation	20321	An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies	Cancer	5037 - Kurralta Park - Adelaide Cancer Centre Research Pty Ltd - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT04464226
NCT04468607	GO41751	Phase 1	NOT_RECRUITING	VIC	2020-07-08	2020-08-31	BLYG8824A	bispecific_T-cell_engager,LY6G6D-targeting	BLYG8824A	bispecific_T-cell_engager,LY6G6D-targeting	GO41751	A Phase I, Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of BLYG8824A Administered Intravenously In Patients With Locally Advanced Or Metastatic Colorectal Cancer	Colorectal Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT04468607
NCT04482309	DPT02	Phase 2	RECRUITING	NSW, QLD, VIC, WA	2020-07-20	2020-08-18	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	D967VC00001	A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)	Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer; Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer	2050 - Camperdown - Research Site; 2148 - Blacktown - Research Site; 3000 - Melbourne - Research Site; 3084 - Heidelberg - Research Site; 4066 - Auchenflower - Research Site - (COMPLETED); 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT04482309
NCT04487080	MARIPOSA	Phase 3	NOT_RECRUITING	NSW, QLD, SA, VIC, WA	2020-07-23	2020-09-30	Amivantamab; Amivantamab + Lazertinib; Lazertinib; Lazertinib + Osimertinib; Osimertinib	bispecific_cMET/EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody	Amivantamab + Lazertinib; Lazertinib + Osimertinib; Amivantamab + Lazertinib; Lazertinib + Osimertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody	CR108856	A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.	Carcinoma, Non-Small-Cell Lung	2145 - Westmead - Westmead Hospital; 2500 - Wollongong - Southern Medical Day Care Centre; 3084 - Heidelberg - Austin Hospital; 3144 - Malvern - Cabrini Medical Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - Sir Charles Gairdner Hospital; 6150 - Murdoch - St John of God Hospital Murdoch	https://clinicaltrials.gov/ct2/show/NCT04487080
NCT04494425	DB-06	Phase 3	NOT_RECRUITING	NSW, QLD, SA, WA	2020-07-28	2020-07-24	Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel; Paclitaxel; Trastuzumab Deruxtecan	fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate; taxane; fluoropyrimidine + taxane	Capecitabine + Nab-paclitaxel + Paclitaxel; Trastuzumab Deruxtecan; Capecitabine + Nab-paclitaxel + Paclitaxel	anti-ERBB2_antibody-drug_conjugate; fluoropyrimidine + taxane; fluoropyrimidine + taxane	D9670C00001	A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)	Advanced or Metastatic Breast Cancer	2010 - Darlinghurst - Research Site; 2065 - St Leonards - Research Site; 2298 - Waratah - Research Site; 4101 - South Brisbane - Research Site; 4575 - Birtinya - Research Site; 5000 - Adelaide - Research Site; 6150 - Murdoch - Research Site	https://clinicaltrials.gov/ct2/show/NCT04494425
NCT04503278	BNT211-01	Phase 1	RECRUITING	VIC	2020-08-04	2020-09-16	CLDN6 CAR-T; CLDN6 RNA-LPX	mRNA_vaccine,CLDN6-targeting; autologous_CAR-T-cell_therapy,CLDN6-targeting	CLDN6 CAR-T; CLDN6 RNA-LPX	autologous_CAR-T-cell_therapy,CLDN6-targeting; mRNA_vaccine,CLDN6-targeting	BNT211-01	Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumors	Solid Tumor	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04503278
NCT04516447	ZN-c3-002	Phase 1	RECRUITING	QLD, SA, VIC, WA	2020-08-14	2020-10-26	Azenosertib; Azenosertib + Bevacizumab; Azenosertib + Carboplatin; Azenosertib + Gemcitabine; Azenosertib + Paclitaxel; Azenosertib + Pegylated liposomal doxorubicin; Bevacizumab; Carboplatin; Gemcitabine; Paclitaxel; Pegylated liposomal doxorubicin	WEE1_inhibitor + antimetabolite; gemcitabine; WEE1_inhibitor + anthracycline; anthracycline; WEE1_inhibitor; taxane; anti-VEGF_monoclonal_antibody; WEE1_inhibitor + taxane; WEE1_inhibitor + anti-VEGF_monoclonal_antibody; platinum-based_antineoplastic_agent; WEE1_inhibitor + platinum-based_antineoplastic_agent	Azenosertib + Bevacizumab; Azenosertib + Carboplatin; Azenosertib + Gemcitabine; Azenosertib + Paclitaxel; Azenosertib + Pegylated liposomal doxorubicin; Azenosertib + Bevacizumab; Azenosertib + Carboplatin; Azenosertib + Gemcitabine; Azenosertib + Paclitaxel; Azenosertib + Pegylated liposomal doxorubicin	WEE1_inhibitor + anthracycline; WEE1_inhibitor + anti-VEGF_monoclonal_antibody; WEE1_inhibitor + antimetabolite; WEE1_inhibitor + platinum-based_antineoplastic_agent; WEE1_inhibitor + taxane; WEE1_inhibitor + anthracycline; WEE1_inhibitor + anti-VEGF_monoclonal_antibody; WEE1_inhibitor + antimetabolite; WEE1_inhibitor + platinum-based_antineoplastic_agent; WEE1_inhibitor + taxane; gemcitabine	ZN-c3-002	A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer	Solid Tumor; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer	3144 - Melbourne - Site 2706; 4101 - South Brisbane - Site 2707; 4556 - Sunshine Coast - Site 2708; 5000 - Adelaide - Site 2709; 6009 - Nedlands - Site 2705	https://clinicaltrials.gov/ct2/show/NCT04516447
NCT04522323	D7980C00003	Phase 1	RECRUITING	NSW, VIC	2020-08-19	2020-08-05	Axitinib; Axitinib + Lenvatinib + MEDI5752; Lenvatinib; MEDI5752	bispecific_PD-L1/CTLA-4_antibody; VEGFR/PDGFR_inhibitor; KIT_inhibitor,ATP-competitive + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; KIT_inhibitor,ATP-competitive; VEGF_inhibitor; VEGFR/PDGFR_inhibitor + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody	Axitinib + Lenvatinib + MEDI5752; Axitinib + Lenvatinib + MEDI5752	KIT_inhibitor,ATP-competitive + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGFR/PDGFR_inhibitor + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; KIT_inhibitor,ATP-competitive + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGFR/PDGFR_inhibitor + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody	D7980C00003	A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination With Axitinib in Subjects With Advanced Renal Cell Carcinoma	Advanced Renal Cell Carcinoma	2298 - Waratah - Research Site - (COMPLETED); 3000 - Melbourne - Research Site - (WITHDRAWN); 3199 - Frankston - Research Site - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT04522323
NCT04524871	GO42216	Phase 1/Phase 2	RECRUITING	NZ	2020-08-21	2020-11-02	ADG126; ADG126 + Atezolizumab + Bevacizumab; Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + TPST-1120; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab + Tocilizumab; Bevacizumab; Bevacizumab + Tobemstomig; TPST-1120; Tiragolumab; Tobemstomig; Tocilizumab	bispecific_PD-1/LAG3_antibody; PPAR-alpha_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; anti-CTLA-4_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; PPAR-alpha_inhibitor	ADG126 + Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + TPST-1120; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab + Tocilizumab; Bevacizumab + Tobemstomig; ADG126 + Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + TPST-1120; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab + Tocilizumab; Bevacizumab + Tobemstomig	PPAR-alpha_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; PPAR-alpha_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/LAG3_antibody	GO42216	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	Advanced Liver Cancers	1023 - Auckland - Auckland City Hospital	https://clinicaltrials.gov/ct2/show/NCT04524871
NCT04534205	AHEAD-MERIT	Phase 2	RECRUITING	NSW, QLD, SA, VIC	2020-08-27	2021-01-07	EO1001; Pembrolizumab	ERBB2_inhibitor,second_generation; anti-PD-1_monoclonal_antibody; EGFR_inhibitor,second_generation	Pembrolizumab; EO1001	anti-PD-1_monoclonal_antibody; EGFR_inhibitor,second_generation; ERBB2_inhibitor,second_generation	BNT113-01	An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT)	Unresectable Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer	2065 - Saint Leonards - Royal North Shore Hospital; 2200 - Bankstown - Bankstown-Lidcombe Hospital - (WITHDRAWN); 2450 - Coffs Harbour - Coffs Harbour Hospital; 2500 - Wollongong - Southern Medical Day Care Centre; 4224 - Tugun - John Flynn Private Hospital; 5000 - Adelaide - Cancer Research SA; 5042 - Bedford Park - Flinders Medical Centre; VIC 3065 - Fitzroy - St Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT04534205
NCT04565275	ICP-CL-00303	Phase 1/Phase 2	RECRUITING	NSW, QLD, VIC	2020-09-21	2021-02-01	Gunagratinib	pan-FGFR_inhibitor	Gunagratinib	pan-FGFR_inhibitor	ICP-CL-00303	A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations	Advanced Solid Tumors; Urothelial Carcinoma; Cholangiocarcinoma	1590 - St Leonards - GenesisCare - North Shore; 2109 - Macquarie Park - Macquarie University Hospital; 2145 - Westmead - Westmead Hospital; 3084 - Melbourne - Olivia Newton-John Cancer Research Institute; 3168 - Clayton - Monash Medical Centre Clayton; 3199 - Frankston - Peninsula & South Eastern Haematology & Oncology Group; 4217 - Benowa - Pindara Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04565275
NCT04585750	PMV-586-101	Phase 1/Phase 2	RECRUITING	NSW, VIC, WA	2020-10-07	2020-10-29	Pembrolizumab; Pembrolizumab + Rezatapopt; Rezatapopt	mutant_p53_reactivator,Y220C-selective; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + mutant_p53_reactivator,Y220C-selective	Pembrolizumab + Rezatapopt; Rezatapopt; Pembrolizumab + Rezatapopt	anti-PD-1_monoclonal_antibody + mutant_p53_reactivator,Y220C-selective; mutant_p53_reactivator,Y220C-selective; anti-PD-1_monoclonal_antibody + mutant_p53_reactivator,Y220C-selective	PMV-586-101	A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)	Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Cancer; Ovarian Cancer; Endometrial Cancer; Prostate Cancer; Colorectal Cancer; Breast Cancer; Other Cancer; Locally Advanced; Head and Neck Cancer	Camperdown - Chris O'Brien Lifehouse Hospital; Clayton - Monash Medical Centre; Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04585750
NCT04586335	CYH33-G102	Phase 1	NOT_RECRUITING	NSW, QLD, VIC	2020-10-07	2020-09-28	CYH33; CYH33 + Olaparib; Olaparib	PARP_inhibitor + PI3K_alpha_inhibitor; PI3K_alpha_inhibitor; PARP_inhibitor	CYH33 + Olaparib; CYH33 + Olaparib	PARP_inhibitor + PI3K_alpha_inhibitor; PARP_inhibitor + PI3K_alpha_inhibitor	CYH33-G102	Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Ovarian Cancer; Breast Cancer; Solid Tumor; Prostate Cancer; Endometrial Cancer	2031 - Sydney - Scientia Cancer Centre; 3168 - Melbourne - Monash Cancer Centre; 4101 - Brisbane - Integrated Oncology Network PTY LTD	https://clinicaltrials.gov/ct2/show/NCT04586335
NCT04589845	BO41932	Phase 2	RECRUITING	NSW, NT, NZ, QLD, VIC	2020-10-11	2021-01-18	Alectinib; Atezolizumab; Belvarafenib; Camonsertib; Divarasib; Entrectinib; Idasanutlin; Inavolisib; Ipatasertib; Pralsetinib; Trastuzumab Emtansine	pan-RAF_inhibitor; PI3K_alpha_inhibitor; anti-PD-L1_monoclonal_antibody; MDM2_inhibitor; pan-AKT_inhibitor; KRAS_G12C_inhibitor; anti-ERBB2_antibody-drug_conjugate; ALK/RET_inhibitor; ALK_inhibitor,third_generation; TRK_inhibitor,first_generation; ATR_inhibitor; ROS1_inhibitor; RET-selective_inhibitor; ALK_inhibitor,second_generation	Alectinib; Atezolizumab; Belvarafenib; Camonsertib; Divarasib; Entrectinib; Idasanutlin; Inavolisib; Ipatasertib; Pralsetinib; Trastuzumab Emtansine	ALK/RET_inhibitor; ALK_inhibitor,second_generation; ALK_inhibitor,third_generation; ATR_inhibitor; KRAS_G12C_inhibitor; MDM2_inhibitor; PI3K_alpha_inhibitor; RET-selective_inhibitor; ROS1_inhibitor; TRK_inhibitor,first_generation; anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody; pan-AKT_inhibitor; pan-RAF_inhibitor	BO41932	Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	Solid Tumors	0810 - Tiwi - Royal Darwin Hospital; Alan Walker Cancer Centre; 1023 - Auckland - Auckland City Hospital, Cancer and Blood Research; 2010 - Darlinghurst - Kinghorn Cancer Centre; St Vincents Hospital; 2031 - Randwick - Sydney Children's Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology; 3052 - Parkville - Royal Children's Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; Christchurch - Christchurch Hospital; Dept of Oncology - (WITHDRAWN)	https://clinicaltrials.gov/ct2/show/NCT04589845
NCT04597411	PSMA-617-100	Phase 1	RECRUITING	NSW	2020-10-16	2021-04-01	225Ac-PSMA-617; 225Ac-PSMA-617 + Abiraterone + Enzalutamide; 225Ac-PSMA-617 + Lu-177 vipivotide tetraxetan; Abiraterone; Abiraterone + Enzalutamide + Lu-177 vipivotide tetraxetan; Enzalutamide; Lu-177 vipivotide tetraxetan	CYP17A1_inhibitor; radioligand,PSMA-targeting; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + radioligand,PSMA-targeting	225Ac-PSMA-617 + Abiraterone + Enzalutamide; 225Ac-PSMA-617 + Lu-177 vipivotide tetraxetan; Abiraterone + Enzalutamide + Lu-177 vipivotide tetraxetan; 225Ac-PSMA-617 + Abiraterone + Enzalutamide; 225Ac-PSMA-617 + Lu-177 vipivotide tetraxetan; Abiraterone + Enzalutamide + Lu-177 vipivotide tetraxetan	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + radioligand,PSMA-targeting; radioligand,PSMA-targeting; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + radioligand,PSMA-targeting	PSMA-617-100	AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy	Prostatic Neoplasms, Castration-Resistant	Darlinghurst - St. Vincent's Hospital Research Office-Translational Research Center	https://clinicaltrials.gov/ct2/show/NCT04597411
NCT04606446	KAT6	Phase 1	RECRUITING	NSW, SA, VIC, WA	2020-10-22	2020-11-16	Fulvestrant; Fulvestrant + PF-07220060 + PF-07248144; Fulvestrant + PF-07248144; Letrozole; Letrozole + PF-07248144 + Palbociclib; PF-07220060; PF-07248144; Palbociclib	selective_estrogen_receptor_degrader; KAT6_inhibitor + selective_estrogen_receptor_degrader; KAT6_inhibitor; CDK4/6_inhibitor + KAT6_inhibitor + aromatase_inhibitor; aromatase_inhibitor; CDK4_selective_inhibitor; CDK4/6_inhibitor; CDK4_selective_inhibitor + KAT6_inhibitor + selective_estrogen_receptor_degrader	Fulvestrant + PF-07220060 + PF-07248144; Fulvestrant + PF-07248144; Letrozole + PF-07248144 + Palbociclib; PF-07248144; Fulvestrant + PF-07220060 + PF-07248144; Fulvestrant + PF-07248144; Letrozole + PF-07248144 + Palbociclib	CDK4/6_inhibitor + KAT6_inhibitor + aromatase_inhibitor; CDK4_selective_inhibitor + KAT6_inhibitor + selective_estrogen_receptor_degrader; KAT6_inhibitor; KAT6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + KAT6_inhibitor + aromatase_inhibitor; CDK4_selective_inhibitor + KAT6_inhibitor + selective_estrogen_receptor_degrader; KAT6_inhibitor + selective_estrogen_receptor_degrader	C4551001	A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.	Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer	2050 - Camperdown - Chris O'Brien Lifehouse - (TERMINATED); 3000 - Melbourne - Peter MacCallum Cancer Centre; 3021 - St Albans - Western Health-Sunshine & Footscray Hospitals; 3050 - Parkville - Royal Melbourne Hospital; 5000 - Adelaide - Cancer Research South Australia; 6008 - Subiaco - St. John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT04606446
NCT04607421	C4221015	Phase 3	RECRUITING	BAY OF Plenty, NSW, NZ, QLD, SA, VIC	2020-10-22	2020-12-21	Bevacizumab; Bevacizumab + Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Capecitabine; Cetuximab; Cetuximab + Encorafenib; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin; Encorafenib; Fluorouracil; Irinotecan; Leucovorin; Oxaliplatin	anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; BRAF_V600_inhibitor; folinic_acid; anti-EGFR_monoclonal_antibody; fluoropyrimidine; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; anti-VEGF_monoclonal_antibody; Fluorouracil; platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	Bevacizumab + Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin; Bevacizumab + Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin	BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor	C4221015	AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER	Neoplasms	1023 - Auckland - Auckland City Hospital; 1023 - Auckland - Auckland District Health Board Charitable Trust; 2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - St Leonards - GenesisCare - North Shore; 2065 - St Leonards - GenesisCare North Shore; 2080 - Mount Kuring-Gai - Slade Pharmacy; 2170 - Liverpool - Liverpool Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - Alfred Health; 3084 - Heidelberg - Austin Health; 3112 - Tauranga - Tauranga Hospital; 3168 - Clayton - Monash Health; 4029 - Herston - Royal Brisbane & Women's Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 5011 - Adelaide - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT04607421
NCT04613596	CA239-0009	Phase 2/Phase 3	RECRUITING	ACT, NSW, QLD, SA, VIC	2020-10-30	2020-12-02	Adagrasib; Adagrasib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor	Adagrasib; Adagrasib + Pembrolizumab; Pembrolizumab; Adagrasib + Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	CA239-0009	A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation	Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer	2500 - Wollongong - Cancer Care Wollongong; 2605 - Garran - Local Institution - 007-006; 3168 - Clayton - Local Institution - 007-004 - (WITHDRAWN); 3350 - Ballarat - Ballarat Regional Integrated Cancer Center; 4102 - Woolloongabba - Princess Alexandra Hospital; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04613596
NCT04624204	7339-013	Phase 3	RECRUITING	NSW, QLD, VIC	2020-11-05	2020-12-08	Etoposide; Etoposide + Olaparib + Pembrolizumab + Radiotherapy; Olaparib; Pembrolizumab; Placebo; Radiotherapy	PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor; PARP_inhibitor; topoisomerase_inhibitor; radiotherapy; anti-PD-1_monoclonal_antibody; placebo	Etoposide + Olaparib + Pembrolizumab + Radiotherapy; Etoposide + Olaparib + Pembrolizumab + Radiotherapy; Placebo	PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor; PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor; placebo	7339-013	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)	Small Cell Lung Cancer	2298 - Waratah - Calvary Mater Newcastle ( Site 3000); 2560 - Campbelltown - Campbelltown Hospital ( Site 3002); 2747 - Kingswood - Nepean Hospital ( Site 3001); 3021 - St Albans - Western Health-Sunshine Hospital ( Site 3004) - (COMPLETED); 3084 - Heidelberg - Austin Health-Austin Hospital ( Site 3006); 3199 - Frankston - Frankston Hospital-Oncology and Haematology ( Site 3007); 4215 - Southport - Gold Coast University Hospital ( Site 3003)	https://clinicaltrials.gov/ct2/show/NCT04624204
NCT04631731	ICEMELT	Phase 1/Phase 2	RECRUITING	NSW	2020-11-10	2020-12-15					2020/PID02542	Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity	Lung Cancer, Nonsmall Cell; Renal Cell Carcinoma; Melanoma; Gastric Cancer; Hepatocellular Carcinoma; Endometrial Cancer; Mesothelioma	2145 - Sydney - Westmead Hospital; 2148 - Sydney - Blacktown Mt Druitt Hospital	https://clinicaltrials.gov/ct2/show/NCT04631731
NCT04644068	PETRA	Phase 1/Phase 2	RECRUITING	VIC	2020-11-19	2020-11-12	Camizestrant; Camizestrant + Saruparib; Carboplatin; Carboplatin + Paclitaxel + Saruparib; Datopotamab deruxtecan; Datopotamab deruxtecan + Saruparib; Paclitaxel; Paclitaxel + Saruparib; Saruparib; Saruparib + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan	selective_estrogen_receptor_degrader; PARP1-selective_inhibitor + selective_estrogen_receptor_degrader; PARP_inhibitor + taxane; PARP_inhibitor + selective_estrogen_receptor_degrader; PARP1-selective_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP1-selective_inhibitor + anti-Trop2_antibody-drug_conjugate; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP1-selective_inhibitor; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate; taxane; PARP_inhibitor + anti-Trop2_antibody-drug_conjugate; PARP_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; PARP_inhibitor; PARP1-selective_inhibitor + taxane; anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent	Camizestrant + Saruparib; Carboplatin + Paclitaxel + Saruparib; Datopotamab deruxtecan + Saruparib; Paclitaxel + Saruparib; Saruparib; Saruparib + Trastuzumab Deruxtecan; Camizestrant + Saruparib; Carboplatin + Paclitaxel + Saruparib; Datopotamab deruxtecan + Saruparib; Paclitaxel + Saruparib; Saruparib + Trastuzumab Deruxtecan	PARP1-selective_inhibitor; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-Trop2_antibody-drug_conjugate; PARP1-selective_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP1-selective_inhibitor + selective_estrogen_receptor_degrader; PARP1-selective_inhibitor + taxane; PARP_inhibitor; PARP_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP_inhibitor + anti-Trop2_antibody-drug_conjugate; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + selective_estrogen_receptor_degrader; PARP_inhibitor + taxane; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-Trop2_antibody-drug_conjugate; PARP1-selective_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP1-selective_inhibitor + selective_estrogen_receptor_degrader; PARP1-selective_inhibitor + taxane; PARP_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP_inhibitor + anti-Trop2_antibody-drug_conjugate; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + selective_estrogen_receptor_degrader; PARP_inhibitor + taxane	D9720C00001	A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies	Ovarian Cancer; Breast Cancer; Pancreatic Cancer; Prostate Cancer; Additional Indications Below for Module 4 and 5; Non-small Cell Lung Cancer; Colorectal Cancer; Bladder Cancer; Gastric Cancer; Biliary Cancer; Cervical Cancer; Endometrial Cancer; Small Cell Lung Cancer Only in Module 5	3000 - Melbourne - Research Site; 3084 - Heidelberg - Research Site	https://clinicaltrials.gov/ct2/show/NCT04644068
NCT04645069	ADG126-1001	Phase 1/Phase 2	RECRUITING	NSW, QLD, VIC, WA	2020-11-20	2021-03-15	ADG106; ADG106 + ADG126; ADG126	anti-4-1BB_agonistic_antibody; anti-4-1BB_agonistic_antibody + anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	ADG106 + ADG126; ADG126; ADG106 + ADG126	anti-4-1BB_agonistic_antibody + anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-CTLA-4_monoclonal_antibody	ADG126-1001	A First-in-Human (FIH), Open-Label, Phase 1/2 Dose Escalation and Expansion Study of ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Patients With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	2228 - Miranda - Southside Cancer Care Centre; 3144 - Malvern - Cabrini Health Limited; 4575 - Birtinya - Sunshine Coast University Private Hospital; 6009 - Nedlands - One Clinical Research Pty Ltd; Sydney - Macquarie University Hospital	https://clinicaltrials.gov/ct2/show/NCT04645069
NCT04649385	BGB-A317-15025-101	Phase 1	RECRUITING	NSW, NZ, SA, VIC, WA	2020-11-25	2021-03-04	BGB-15025; BGB-15025 + Tislelizumab; Tislelizumab	HPK1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; HPK1_inhibitor	BGB-15025 + Tislelizumab; BGB-15025 + Tislelizumab	HPK1_inhibitor + anti-PD-1_monoclonal_antibody; HPK1_inhibitor + anti-PD-1_monoclonal_antibody	BGB-A317-15025-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	1023 - Auckland - Auckland City Hospital; 2031 - Randwick - Prince of Wales Hospital; 3000 - Melbourne - Peter Maccallum Cancer Centre; 5087 - Windsor Gardens - Ashford Cancer Centre Research Northeast; 6009 - Nedlands - Linear Clinical Research; 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04649385
NCT04665206	VT3989-001	Phase 1/Phase 2	RECRUITING	VIC, WA	2020-12-10	2021-03-24	VT3989	TEAD_palmitoylation_inhibitor	VT3989	TEAD_palmitoylation_inhibitor	VT3989-001	Phase 1, Multi-Center, Open-Label Study of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the Neurofibromatosis Type 2 Gene (Mutant NF2 or mNF2)	Solid Tumor, Adult; Mesothelioma	3000 - Melbourne - Peter MacCullum Cancer Centre; 3168 - Clayton - Monash Health; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04665206
NCT04672460	C3441037	Phase 1	NOT_RECRUITING	NSW, VIC	2020-12-11	2020-12-21	Talazoparib	PARP_inhibitor	Talazoparib	PARP_inhibitor	C3441037	A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO ESTABLISH BIOEQUIVALENCE BETWEEN THE PROPOSED SOFT GEL TALAZOPARIB CAPSULE FORMULATION AND THE CURRENT TALAZOPARIB COMMERCIAL FORMULATION AND TO ESTIMATE THE FOOD EFFECT ON PHARMACOKINETICS OF THE PROPOSED TALAZOPARIB SOFT GEL CAPSULE FORMULATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS	Advanced Solid Tumors; Solid Tumors; Ovarian Cancer; Breast Cancer; Prostate Cancer; NSCLC; Pancreatic Cancer; Colorectal Cancer	2170 - Liverpool - Liverpool Cancer Therapy Centre; 2170 - Liverpool - Liverpool Hospital; 3002 - East Melbourne - Epworth Healthcare; 3002 - East Melbourne - Epworth Healthcare (Epworth Freemasons Hospital); 3121 - Richmond - Epworth Healthcare; 3121 - Richmond - Epworth Richmond Hospital (Epworth Healthcare); 3168 - Clayton - Monash Health	https://clinicaltrials.gov/ct2/show/NCT04672460
NCT04675294	AT148003	Phase 2	RECRUITING	NSW, QLD, VIC, WA	2020-12-15	2021-04-02	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	AT148003	A Phase 2 Study of ALX148 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)	Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma	2146 - Sydney - St. Vincent's; 3051 - Melbourne - Peter MacCallum Cancer Centre; 4029 - Brisbane - Royal Brisbane and Womens Hospital; 6009 - Perth - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT04675294
NCT04675333	AT148004	Phase 2	RECRUITING	SA	2020-12-17	2021-05-10	Carboplatin; Carboplatin + Cisplatin + Fluorouracil + Pembrolizumab; Cisplatin; Fluorouracil; Pembrolizumab	Fluorouracil; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Fluorouracil + Pembrolizumab; Carboplatin + Cisplatin + Fluorouracil + Pembrolizumab	anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent	AT148004	A Phase 2 Study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)	Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma	5037 - Adelaide - Ashford Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04675333
NCT04686305	DL03	Phase 1	RECRUITING	SA, VIC, WA	2020-12-22	2021-03-09	AZD2936; AZD2936 + Carboplatin + Rilvegostomig + Trastuzumab Deruxtecan; AZD2936 + Rilvegostomig + Trastuzumab Deruxtecan; Carboplatin; Carboplatin + Durvalumab + Trastuzumab Deruxtecan; Carboplatin + Trastuzumab Deruxtecan; Cisplatin; Cisplatin + Durvalumab + Trastuzumab Deruxtecan; Durvalumab; Durvalumab + Pemetrexed + Trastuzumab Deruxtecan; MEDI5752; Pemetrexed; Rilvegostomig; Trastuzumab Deruxtecan	antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + antimetabolite; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; bispecific_PD-L1/CTLA-4_antibody; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; bispecific_PD-1/TIGIT_antibody	AZD2936 + Carboplatin + Rilvegostomig + Trastuzumab Deruxtecan; AZD2936 + Rilvegostomig + Trastuzumab Deruxtecan; Carboplatin + Durvalumab + Trastuzumab Deruxtecan; Carboplatin + Trastuzumab Deruxtecan; Cisplatin + Durvalumab + Trastuzumab Deruxtecan; Durvalumab + Pemetrexed + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan; AZD2936 + Carboplatin + Rilvegostomig + Trastuzumab Deruxtecan; AZD2936 + Rilvegostomig + Trastuzumab Deruxtecan; Carboplatin + Durvalumab + Trastuzumab Deruxtecan; Carboplatin + Trastuzumab Deruxtecan; Cisplatin + Durvalumab + Trastuzumab Deruxtecan; Durvalumab + Pemetrexed + Trastuzumab Deruxtecan; MEDI5752	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; bispecific_PD-L1/CTLA-4_antibody	D967YC00001	A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	3084 - Heidelberg - Research Site - (WITHDRAWN); 5000 - Adelaide - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT04686305
NCT04691804	SHR3162-III-305	Phase 3	RECRUITING	NSW, SA, VIC, WA	2020-12-30	2021-03-18	Abiraterone; Abiraterone + Fuzuloparib + Prednisone; Fuzuloparib; Placebo; Prednisone	glucocorticoid; CYP17A1_inhibitor + PARP_inhibitor + glucocorticoid; PARP_inhibitor; CYP17A1_inhibitor; placebo	Abiraterone + Fuzuloparib + Prednisone; Abiraterone + Fuzuloparib + Prednisone; Placebo	CYP17A1_inhibitor + PARP_inhibitor + glucocorticoid; CYP17A1_inhibitor + PARP_inhibitor + glucocorticoid; placebo	SHR3162-III-305	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Bendigo - Bendigo Health; Concord - Concord Repatriation General Hospital; Fitzroy - St Vincents Hospital Melbourne; Gosford - Gosford Hospital; Kurralta Park - Ashford Cancer Centre Research; Melbourne - The Alfred Hospital; St Albans - Western Health; Sydney - Macquarie University; Wagga Wagga - Riverina Cancer Care Centre; Wahroonga - Sydney Adventist Hospital	https://clinicaltrials.gov/ct2/show/NCT04691804
NCT04699188	KontRASt-01	Phase 1/Phase 2	RECRUITING	VIC	2021-01-05	2021-02-24	JDQ443; JDQ443 + TNO155; JDQ443 + TNO155 + Tislelizumab; JDQ443 + Tislelizumab; TNO155; Tislelizumab	KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; SHP2_inhibitor; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor	JDQ443; JDQ443 + TNO155; JDQ443 + TNO155 + Tislelizumab; JDQ443 + Tislelizumab; JDQ443 + TNO155; JDQ443 + TNO155 + Tislelizumab; JDQ443 + Tislelizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	CJDQ443A12101	A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lung; Cancer of the Lung; Lung Cancer; Neoplasms, Lung; Neoplasms, Pulmonary; Pulmonary Cancer; Pulmonary Neoplasms	3000 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04699188
NCT04702880	CA001-050	Phase 2	RECRUITING	NSW, QLD, VIC, WA	2021-01-07	2021-03-17	BMS-986012; BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin; Carboplatin + Etoposide + Nivolumab; Etoposide; Nivolumab	topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-fucosyl-GM1_monoclonal_antibody	BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin + Etoposide + Nivolumab; BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin + Etoposide + Nivolumab	anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	CA001-050	A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer	Extensive-stage Small Cell Lung Cancer	2145 - Westmead - Local Institution - 0003 - (COMPLETED); 3144 - Malvern - Local Institution - 0001 - (COMPLETED); 3350 - Ballarat Central - Local Institution - 0078 - (WITHDRAWN); 4120 - Greenslopes - Local Institution - 0023; 6150 - Murdoch - Local Institution - 0004	https://clinicaltrials.gov/ct2/show/NCT04702880
NCT04713891	KFCS001	Phase 1	UNKNOWN	NSW	2021-01-15	2021-03-09	Atezolizumab; Atezolizumab + KF-0210; KF-0210	anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor; prostaglandin_EP4_receptor_inhibitor; anti-PD-L1_monoclonal_antibody	Atezolizumab + KF-0210; KF-0210; Atezolizumab + KF-0210	anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor; prostaglandin_EP4_receptor_inhibitor; anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor	KFCS001	A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of KF-0210 in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Colorectal Cancer; Lung Cancer; Squamous Cell Carcinoma of the Esophagus; Gastric Cancer; Bladder Cancer	2031 - Randwick - Scientia Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04713891
NCT04720768	CELEBRATE	Phase 1/Phase 2	RECRUITING	VIC	2021-01-19	2020-06-04	Binimetinib; Binimetinib + Encorafenib + Palbociclib; Encorafenib; Palbociclib	BRAF_V600_inhibitor + CDK4/6_inhibitor + MEK_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor; CDK4/6_inhibitor	Binimetinib + Encorafenib + Palbociclib; Binimetinib + Encorafenib + Palbociclib	BRAF_V600_inhibitor + CDK4/6_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + CDK4/6_inhibitor + MEK_inhibitor	17/021	A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in Patients With BRAF-mutant Metastatic Melanoma (The CELEBRATE Study)	Melanoma; Metastasis	3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - Alfred Health; 3084 - Heidelberg - Austin Hospital; 3128 - Box Hill - Box Hill Hospital	https://clinicaltrials.gov/ct2/show/NCT04720768
NCT04728893	1026-003	Phase 2	RECRUITING	NSW, VIC, WA	2021-01-25	2021-04-05	Nemtabrutinib	BTK_inhibitor	Nemtabrutinib	BTK_inhibitor	1026-003	A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies	Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukaemia	2747 - Sydney - Nepean Hospital-Nepean Cancer Care Centre ( Site 0204); 3128 - Box Hill - Box Hill Hospital ( Site 0203); 6009 - Nedlands - Sir Charles Gairdner Hospital ( Site 0200)	https://clinicaltrials.gov/ct2/show/NCT04728893
NCT04729387	CBYL719K12301	Phase 3	NOT_RECRUITING	NSW, SA, VIC	2021-01-25	2021-07-02	Alpelisib; Alpelisib + Olaparib; Olaparib; Paclitaxel; Paclitaxel + Pegylated liposomal doxorubicin; Pegylated liposomal doxorubicin	PI3K_alpha_inhibitor; PARP_inhibitor; anthracycline + taxane; anthracycline; PARP_inhibitor + PI3K_alpha_inhibitor; taxane	Alpelisib + Olaparib; Paclitaxel + Pegylated liposomal doxorubicin; Alpelisib + Olaparib; Paclitaxel + Pegylated liposomal doxorubicin	PARP_inhibitor + PI3K_alpha_inhibitor; anthracycline + taxane; PARP_inhibitor + PI3K_alpha_inhibitor; anthracycline + taxane	CBYL719K12301	EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer	Ovarian Cancer	2031 - Randwick - Novartis Investigative Site; 3630 - Shepparton - Novartis Investigative Site; 5041 - Bedford Park - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04729387
NCT04739670	BELLA	Phase 2	RECRUITING	NSW, QLD, VIC	2021-02-01	2021-03-01	Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine; Bevacizumab; Carboplatin; Gemcitabine	antimetabolite; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent	Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine; Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	19/002	A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast Cancer	Metastatic Triple Negative Breast Cancer	2065 - St Leonards - Royal North Shore; 4101 - South Brisbane - Mater Health; Melbourne - Monash Health; Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04739670
NCT04771130	BGB-11417-103	Phase 1/Phase 2	RECRUITING	NSW, NZ, QLD, VIC, WA	2021-02-23	2021-05-24	Azacitidine; Azacitidine + BGB-11417; Azacitidine + BGB-11417 + Posaconazole; BGB-11417; Posaconazole	antimetabolite; Bcl2_inhibitor + antimetabolite + azole_antifungal; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; azole_antifungal; Bcl2_inhibitor + antimetabolite; Bcl2_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal	Azacitidine + BGB-11417; Azacitidine + BGB-11417 + Posaconazole; BGB-11417; Azacitidine + BGB-11417; Azacitidine + BGB-11417 + Posaconazole	Bcl2_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal; Bcl2_inhibitor + antimetabolite; Bcl2_inhibitor + antimetabolite + azole_antifungal; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal; Bcl2_inhibitor + antimetabolite; Bcl2_inhibitor + antimetabolite + azole_antifungal	BGB-11417-103	A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies	Acute Myeloid Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasm	0622 - Takapuna - North Shore Hospital; 2139 - Concord - Concord Repatriation General Hospital; 2217 - Kogarah - St George Hospital; 2800 - Orange - Orange Health Hospital; 3004 - Melbourne - The Alfred Hospital; 3065 - Fitzroy - St Vincents Hospital Melbourne; 3084 - Heidelberg - Austin Health; 3168 - Clayton - Monash Health; 4215 - Southport - Gold Coast University Hospital; 4224 - Tugun - John Flynn Private Hospital; 6009 - Nedlands - Linear Clinical Research; 6009 - Nedlands - One Clinical Research; 6021 - Wellington - Wellington Regional Hospital (Ccdhb); 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT04771130
NCT04789096	TUGETHER	Phase 2	RECRUITING	NSW, QLD, SA, TAS, VIC	2021-03-07	2023-03-07	Capecitabine; Capecitabine + Pembrolizumab + Trastuzumab + Tucatinib; Pembrolizumab; Trastuzumab; Tucatinib	anti-PD-1_monoclonal_antibody; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine; fluoropyrimidine; anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation	Capecitabine + Pembrolizumab + Trastuzumab + Tucatinib; Capecitabine + Pembrolizumab + Trastuzumab + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine	BCT 2102	A Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients With Pre-treated Advanced HER2-positive Breast Cancer	Breast Cancer; HER2-positive Breast Cancer	2031 - Randwick - Prince of Wales Hospital; 2109 - Macquarie Park - Macquarie University; 2145 - Westmead - Westmead Hospital; 2250 - Gosford - Gosford Hospital; 2310 - Waratah - Calvary Mater Newcastle; 2450 - Coffs Harbour - Coffs Harbour Health Campus; 2500 - Wollongong - Wollongong Hospital; 2747 - Kingswood - Nepean Cancer Care Centre; 3002 - Parkville - Peter MacCallum Cancer Centre; 3021 - St Albans - Sunshine Hospital; 3084 - Heidelberg - Austin Hospital; 3121 - Richmond - Epworth Richmond Hospital; 4575 - Birtinya - Sunshine Coast University Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT04789096
NCT04794699	IDE397-001	Phase 1	RECRUITING	NSW, SA	2021-03-09	2021-04-14	Docetaxel; Docetaxel + IDE397 + Paclitaxel; IDE397; IDE397 + Sacituzumab Govitecan; Paclitaxel; Pemetrexed; Sacituzumab Govitecan	antimetabolite; MAT2A_inhibitor; anti-Trop2_antibody-drug_conjugate; MAT2A_inhibitor + taxane; MAT2A_inhibitor + anti-Trop2_antibody-drug_conjugate; taxane	Docetaxel + IDE397 + Paclitaxel; IDE397; IDE397 + Sacituzumab Govitecan; Docetaxel + IDE397 + Paclitaxel; IDE397 + Sacituzumab Govitecan; Pemetrexed	MAT2A_inhibitor; MAT2A_inhibitor + anti-Trop2_antibody-drug_conjugate; MAT2A_inhibitor + taxane; MAT2A_inhibitor + anti-Trop2_antibody-drug_conjugate; MAT2A_inhibitor + taxane; antimetabolite	IDE397-001	An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors	Solid Tumor	02010 - Darlinghurst - The Kinghorn Cancer Centre, St Vincent's Health Network Sydney; 05042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT04794699
NCT04799054	TCTLR-101	Phase 1/Phase 2	RECRUITING	NSW, SA, VIC	2021-03-11	2021-03-18	Pembrolizumab; Pembrolizumab + TransCon TLR7/8 agonist; TransCon TLR7/8 agonist	TLR7/8_agonist + anti-PD-1_monoclonal_antibody; TLR7/8_agonist; anti-PD-1_monoclonal_antibody	Pembrolizumab + TransCon TLR7/8 agonist; TransCon TLR7/8 agonist; Pembrolizumab + TransCon TLR7/8 agonist	TLR7/8_agonist; TLR7/8_agonist + anti-PD-1_monoclonal_antibody; TLR7/8_agonist + anti-PD-1_monoclonal_antibody	TCTLR-101	Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Advanced Solid Tumor; Locally Advanced Solid Tumor; Metastatic Solid Tumor; Head and Neck Squamous Cell Carcinoma HNSCC; HPV-associated Cancers; Neoadjuvant Melanoma; Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)	2500 - Wollongong - Ascendis Pharma Investigational Site; 3168 - Clayton - Ascendis Pharma Investigational Site - (WITHDRAWN); 3199 - Frankston - Ascendis Pharma Investigational Site; 5042 - Bedford Park - Ascendis Investigational Site - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT04799054
NCT04801095	WMS1030-101	Phase 1	RECRUITING	VIC, WA	2021-03-14	2021-07-14	WM-S1-030	mutant_receptor_tyrosine_kinase_inhibitor	WM-S1-030	mutant_receptor_tyrosine_kinase_inhibitor	WMS1030-101	A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Metastatic Solid Tumor; Colorectal Cancer; Lung Cancer; Pancreatic Cancer; Cholangiocarcinoma; Head and Neck Cancer	3084 - Heidelberg - Austin Hospital; 3168 - Clayton - Monash Medical Center; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04801095
NCT04802759	CO42867	Phase 1/Phase 2	RECRUITING	SA, VIC, WA	2021-03-16	2021-06-20	Abemaciclib; Abemaciclib + Atezolizumab + Giredestrant; Abemaciclib + Giredestrant; Atezolizumab; Atezolizumab + Giredestrant; Everolimus; Everolimus + Giredestrant; Giredestrant; Giredestrant + Inavolisib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Giredestrant + Samuraciclib; Inavolisib; Ipatasertib; Palbociclib; Pertuzumab; Ribociclib; Samuraciclib	selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; CDK7_inhibitor; PI3K_alpha_inhibitor; mTORC1_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; mTORC1_inhibitor; anti-PD-L1_monoclonal_antibody; pan-AKT_inhibitor; CDK7_inhibitor + selective_estrogen_receptor_degrader; anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader	Abemaciclib + Atezolizumab + Giredestrant; Abemaciclib + Giredestrant; Atezolizumab + Giredestrant; Everolimus + Giredestrant; Giredestrant; Giredestrant + Inavolisib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Giredestrant + Samuraciclib; Abemaciclib + Atezolizumab + Giredestrant; Abemaciclib + Giredestrant; Atezolizumab + Giredestrant; Everolimus + Giredestrant; Giredestrant + Inavolisib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Giredestrant + Samuraciclib; Pertuzumab	CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK7_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK7_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader	CO42867	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)	Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	3000 - Melbourne - Peter Maccallum Cancer Centre; 3199 - Frankston - Peninsula Health-Frankston Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04802759
NCT04810078	CheckMate-67T	Phase 3	RECRUITING	NZ	2021-03-19	2021-05-24	Nivolumab; Nivolumab + rHuPH20; rHuPH20	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase; recombinant_human_hyaluronidase	Nivolumab; Nivolumab + rHuPH20; Nivolumab + rHuPH20	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase	CA209-67T	A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy	Clear Cell Renal Cell Carcinoma	1023 - Auckland - Auckland District Health Board-Auckland City Hospital; 3204 - Hamilton - Waikato Hospital; 4414 - Palmerston North - Palmerston North Hospital	https://clinicaltrials.gov/ct2/show/NCT04810078
NCT04822961	IMP4297-202	Phase 2	NOT_YET_RECRUITING	NSW, QLD, VIC	2021-03-26	2021-12-31	Docetaxel; Placebo; Senaparib	PARP_inhibitor; taxane; placebo	Senaparib; Docetaxel; Placebo	PARP_inhibitor; placebo; taxane	IMP4297-202	A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment	mCRPC	Brisbane - Princess Alexandra Hospital; Melbourne - Cabrini Hospital; Sydney - Macquarie University Hospital; Tugun - John Flynn Hospital	https://clinicaltrials.gov/ct2/show/NCT04822961
NCT04829604	ACE-Breast-03	Phase 2	NOT_RECRUITING	QLD, VIC, WA	2021-04-01	2021-10-26	ARX788; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	ARX788; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	ACE-Breast-03	A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd	HER2 Positive Metastatic Breast Cancer	3135 - Ringwood East - Research Site - (WITHDRAWN); 3168 - Clayton - Research Site - (WITHDRAWN); 3199 - Frankston - Research Site - (COMPLETED); 3220 - Geelong - Research Site - (COMPLETED); 4101 - South Brisbane - Research Site - (WITHDRAWN); 4102 - Woolloongabba - Research Site - (WITHDRAWN); 6009 - Nedlands - Research Site - (COMPLETED); Melbourne - Research Site - (WITHDRAWN)	https://clinicaltrials.gov/ct2/show/NCT04829604
NCT04830124	ARTISTRY-6	Phase 2	RECRUITING	NSW, QLD, SA	2021-04-01	2021-09-27	Nemvaleukin alfa; Nemvaleukin alfa + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; IL-2_fusion_protein; IL-2_fusion_protein + anti-PD-1_monoclonal_antibody	Nemvaleukin alfa; Nemvaleukin alfa + Pembrolizumab; Nemvaleukin alfa + Pembrolizumab	IL-2_fusion_protein; IL-2_fusion_protein + anti-PD-1_monoclonal_antibody; IL-2_fusion_protein + anti-PD-1_monoclonal_antibody	ALKS 4230-006	A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6	Cutaneous Melanoma; Mucosal Melanoma	2298 - Waratah - Calvary Mater Newcastle; 4224 - Tugun - John Flynn Private Hospital; 5011 - Woodville - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT04830124
NCT04830202	C20-503		AVAILABLE	WA	2021-03-31		Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	C20-503	Expanded Access to Telisotuzumab Vedotin	Non-Small Cell Lung Cancer (NSCLC)	6005 - West Perth - Western Heamatology and Oncology Clinics /ID# 243364 - (AVAILABLE)	https://clinicaltrials.gov/ct2/show/NCT04830202
NCT04844073	CP-MVC-101-01	Phase 1/Phase 2	RECRUITING	NSW, SA, VIC	2021-04-13	2021-03-08	MVC-101	bispecific_T-cell_engager,EGFR-targeting	MVC-101	bispecific_T-cell_engager,EGFR-targeting	CP-MVC-101-01	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer	Squamous Cell Cancer of Head and Neck (SCCHN); Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer	2031 - Randwick - Scientia Clinical Research Limited, Corner High & Avoca Street, 5th Floor, Bright Building; 2050 - Camperdown - Chris O'Brien Lifehouse; 3004 - Melbourne - The Alfred Hospital; 3084 - Heidelberg - Austin Hospital, 145 Studley Road, Intensive Care Unit; 3168 - Clayton - Monash Health, Monash Medical Center, 246 Clayton Road; 5042 - Bedford Park - Southern Oncology Clinical Research Unit, 1 Flinders Drive	https://clinicaltrials.gov/ct2/show/NCT04844073
NCT04857372	CIAG933A12101	Phase 1	RECRUITING	VIC	2021-04-20	2021-10-21	IAG933	YAP-TEAD_inhibitor	IAG933	YAP-TEAD_inhibitor	CIAG933A12101	An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors	Mesothelioma	3000 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04857372
NCT04861779	HSK29116-101	Phase 1	RECRUITING	WA	2021-04-22	2021-08-24	HSK29116	BTK_PROTAC_degrader	HSK29116	BTK_PROTAC_degrader	HSK29116-101	A Phase Ia/b Clinical Study on Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Protein Degradation Agent HSK29116 in Subjects With Relapsed or Refractory B-Cell Malignancy	Relapsed/Refractory B-Cell Malignancies	Perth - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04861779
NCT04862663	CAPItello-292	Phase 3	RECRUITING	NSW, WA	2021-04-23	2021-05-10	Abemaciclib; Abemaciclib + Capivasertib + Fulvestrant; Capivasertib; Capivasertib + Fulvestrant + Palbociclib; Capivasertib + Fulvestrant + Palbociclib + Ribociclib; Capivasertib + Fulvestrant + Ribociclib; Fulvestrant; Fulvestrant + Palbociclib + Ribociclib; Palbociclib; Ribociclib	selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; pan-AKT_inhibitor; CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader	Abemaciclib + Capivasertib + Fulvestrant; Capivasertib + Fulvestrant + Palbociclib; Capivasertib + Fulvestrant + Palbociclib + Ribociclib; Capivasertib + Fulvestrant + Ribociclib; Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Capivasertib + Fulvestrant; Capivasertib + Fulvestrant + Palbociclib; Capivasertib + Fulvestrant + Palbociclib + Ribociclib; Capivasertib + Fulvestrant + Ribociclib; Fulvestrant + Palbociclib + Ribociclib	CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	D361DC00001	A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)	Locally Advanced (Inoperable) or Metastatic Breast Cancer	2010 - Darlinghurst - Research Site; 2076 - Wahroonga - Research Site; 2228 - Miranda - Research Site - (TERMINATED); 2298 - Waratah - Research Site; 6009 - Nedlands - Research Site; 6009 - Perth - Research Site	https://clinicaltrials.gov/ct2/show/NCT04862663
NCT04876651	177Lu-TLX591-002	Phase 3	RECRUITING	NSW, NZ, QLD, VIC, WA	2021-05-03	2023-08-29	177Lu-DOTA-rosopatamab	radioligand,PSMA-targeting	177Lu-DOTA-rosopatamab	radioligand,PSMA-targeting	177Lu-TLX591-002	A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug	Metastatic Prostate Cancer	1023 - Auckland - Auckland City Hospital; 2145 - Westmead - Westmead Hospital; 3083 - Melbourne - Austin Health; 3168 - Clayton - Monash Health; 4102 - Woolloongabba - Princess Alexandra Hospital; 6150 - Murdoch - 'GenesisCare Murdoch'	https://clinicaltrials.gov/ct2/show/NCT04876651
NCT04879329	RC48G001	Phase 2	RECRUITING	NSW, Other, QLD, SA, VIC	2021-05-07	2022-05-03	Disitamab vedotin; Disitamab vedotin + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	Disitamab vedotin; Disitamab vedotin + Pembrolizumab; Disitamab vedotin + Pembrolizumab	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	RC48G001	A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2	Urothelial Carcinoma	2065 - St Leonards - Royal North Shore Hospital; 2109 - New South Whales - Macquarie University Hospital; 3199 - Frankston - Peninsula and South East Oncology; 4101 - South Brisbane - Mater Cancer Care Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; 5112 - Elizabeth Vale - Lyell McEwin Hospital	https://clinicaltrials.gov/ct2/show/NCT04879329
NCT04886804	1479-0001	Phase 1	RECRUITING	NSW, VIC	2021-05-12	2021-06-22	Zongertinib	ERBB2_inhibitor,second_generation	Zongertinib	ERBB2_inhibitor,second_generation	1479-0001	Beamion LUNG-1: An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of Zongertinib (BI 1810631) as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations	Neoplasm Metastasis; Non-Small Cell Lung Cancer	2109 - Macquarie Park - Macquarie University; 3144 - Malvern - Cabrini Malvern Hospital	https://clinicaltrials.gov/ct2/show/NCT04886804
NCT04895709	CA052-002	Phase 1/Phase 2	RECRUITING	NSW, QLD, VIC, WA	2021-05-19	2021-05-27	BMS-986340; BMS-986340 + Docetaxel; BMS-986340 + Nivolumab; Docetaxel; Nivolumab	anti-PD-1_monoclonal_antibody; taxane; anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + taxane; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BMS-986340; BMS-986340 + Docetaxel; BMS-986340 + Nivolumab; BMS-986340 + Docetaxel; BMS-986340 + Nivolumab	anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody + taxane; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody + taxane	CA052-002	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors	Cervical Cancer; Gastric/Gastroesophageal Junction Adenocarcinoma; Microsatellite Stable Colorectal Cancer; Non-Small-Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Urothelial Carcinoma; Pancreatic Adenocarcinoma; Melanoma; Ovarian Neoplasms; Triple Negative Breast Neoplasms	2148 - Blacktown - Blacktown Hospital; 2170 - Liverpool - Liverpool Hospital; 3065 - Melbourne - St Vincent's Hospital; 3144 - Malvern - Cabrini Hospital - Malvern; 4102 - Brisbane - Princess Alexandra Hospital; 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04895709
NCT04907851	KEYNOTE-E86	Phase 2	*NOT_RECRUITING	NSW, VIC	2021-05-28	2021-12-10	Denosumab; Denosumab + Pembrolizumab + RXC004; Denosumab + RXC004; Pembrolizumab; RXC004	anti-PD-1_monoclonal_antibody; PORCN_inhibitor + anti-RANK_L_monoclonal_antibody; anti-RANK_L_monoclonal_antibody; PORCN_inhibitor + anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; PORCN_inhibitor	Denosumab + Pembrolizumab + RXC004; Denosumab + RXC004; Denosumab + Pembrolizumab + RXC004; Denosumab + RXC004	PORCN_inhibitor + anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; PORCN_inhibitor + anti-RANK_L_monoclonal_antibody; PORCN_inhibitor + anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; PORCN_inhibitor + anti-RANK_L_monoclonal_antibody	RXC004/0003	A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients With Advanced Solid Tumours That Have Progressed Following Therapy With Current Standard of Care	Advanced Solid Tumours	2500 - Wollongong - Wollongong Hospital; 3304 - Melbourne - The Alfred Hospital - Alfred Health	https://clinicaltrials.gov/ct2/show/NCT04907851
NCT04909125	SVIFT-Nodal-Trial	NA	RECRUITING	NSW	2021-05-26	2021-06-01	Radiotherapy	radiotherapy	Radiotherapy	radiotherapy	SVIFT Nodal Trial	Standard Versus Investigatioinal Fractionation Trial - Nodal Radiation	Breast Cancer; Post Mastectomy	2065 - St Leonards - Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT04909125
NCT04913285	KN-8701	Phase 1	NOT_RECRUITING	NSW, WA	2021-05-28	2021-08-04	Binimetinib; Binimetinib + Exarafenib; Exarafenib	pan-RAF_inhibitor; MEK_inhibitor; MEK_inhibitor + pan-RAF_inhibitor	Binimetinib + Exarafenib; Exarafenib; Binimetinib + Exarafenib	MEK_inhibitor + pan-RAF_inhibitor; pan-RAF_inhibitor; MEK_inhibitor + pan-RAF_inhibitor	KN-8701	A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.	Solid Tumor, Adult; Non-small Cell Lung Cancer; Melanoma	2065 - Wollstonecraft - Melanoma Institute Australia; 6009 - Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04913285
NCT04918810	GUIDE	Phase 2	RECRUITING	NSW, VIC	2021-06-02	2021-11-11	Docetaxel	taxane	Docetaxel	taxane	ANZUP 1903	A Randomised Non-comparative Phase II Trial of Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC)	Castration Resistant Prostatic Cancer	2021 - Darlinghurst - St Vincent's Hospital; 2050 - Camperdown - Chris O'Brien Lifehouse; 2460 - Albury - Border Medical Oncology Research Unit / The Border Cancer Hospital; 2830 - Dubbo - Dubbo Base Hospital; 3199 - Frankston - Frankston Hospital-Peninsula Health; 3630 - Shepparton - Goulburn Valley Health; 3844 - Traralgon - LaTrobe Regional Hospital; Sydney - Concord Repatriation General Hospital	https://clinicaltrials.gov/ct2/show/NCT04918810
NCT04924075	6482-015	Phase 2	RECRUITING	NSW, VIC	2021-06-08	2021-08-12	Belzutifan	HIF2a_inhibitor	Belzutifan	HIF2a_inhibitor	6482-015	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations	Pheochromocytoma/Paraganglioma; Pancreatic Neuroendocrine Tumor; Von Hippel-Lindau Disease; Advanced Gastrointestinal Stromal Tumor; HIF-2α Mutated Cancers	2031 - Randwick - Prince of Wales Hospital-Medical Oncology ( Site 1601); 3050 - Parkville - The Royal Melbourne Hospital ( Site 1602)	https://clinicaltrials.gov/ct2/show/NCT04924075
NCT04925284	XB002-101	Phase 1	RECRUITING	NSW, WA	2021-06-07	2021-06-07	Nivolumab; Nivolumab + XB002; XB002	anti-PD-1_monoclonal_antibody + anti-TF_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-TF_antibody-drug_conjugate	Nivolumab + XB002; XB002; Nivolumab + XB002	anti-PD-1_monoclonal_antibody + anti-TF_antibody-drug_conjugate; anti-TF_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-TF_antibody-drug_conjugate	XB002-101	A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors	Non Small Cell Lung Cancer; Cervical Cancer; SCCHN; Pancreatic Cancer; Esophageal SCC; Metastatic Castration-resistant Prostate Cancer; Triple Negative Breast Cancer; Hormone Receptor-positive Breast Cancer; Epithelial Ovarian Cancer; Endometrial Cancer; Tissue Factor-Expressing Solid Tumors	2010 - Darlinghurst - Exelixis Clinical Site #37; 2065 - Saint Leonards - Exelixis Clinical Site #35; 2170 - Liverpool - Exelixis Clinical Site #44; 2228 - Miranda - Exelixis Clinical Site#75; 6009 - Nedlands - Exelixis Clinical Site#70	https://clinicaltrials.gov/ct2/show/NCT04925284
NCT04925648	PICASSO	Phase 2	RECRUITING	NSW, VIC	2021-06-07	2021-10-18	Darolutamide; Darolutamide + Dasatinib; Dasatinib	YES1_inhibitor + antiandrogen,nonsteroidal,second_generation; BCR-ABL1_inhibitor,second_generation + antiandrogen,nonsteroidal,second_generation; SRC_inhibitor; KIT_inhibitor; PDGFRA_inhibitor; BCR-ABL1_inhibitor,second_generation; SRC_inhibitor + antiandrogen,nonsteroidal,second_generation; KIT_inhibitor + antiandrogen,nonsteroidal,second_generation; PDGFRA_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; YES1_inhibitor	Darolutamide + Dasatinib; Dasatinib; Darolutamide + Dasatinib	BCR-ABL1_inhibitor,second_generation; BCR-ABL1_inhibitor,second_generation + antiandrogen,nonsteroidal,second_generation; KIT_inhibitor; KIT_inhibitor + antiandrogen,nonsteroidal,second_generation; PDGFRA_inhibitor; PDGFRA_inhibitor + antiandrogen,nonsteroidal,second_generation; SRC_inhibitor; SRC_inhibitor + antiandrogen,nonsteroidal,second_generation; YES1_inhibitor; YES1_inhibitor + antiandrogen,nonsteroidal,second_generation; BCR-ABL1_inhibitor,second_generation + antiandrogen,nonsteroidal,second_generation; KIT_inhibitor + antiandrogen,nonsteroidal,second_generation; PDGFRA_inhibitor + antiandrogen,nonsteroidal,second_generation; SRC_inhibitor + antiandrogen,nonsteroidal,second_generation; YES1_inhibitor + antiandrogen,nonsteroidal,second_generation	PICASSO	PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction	Metastatic Prostate Cancer	2010 - Sydney - Kinghorn Cancer Centre, St. Vincent's Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04925648
NCT04928846	M18-868	Phase 3	RECRUITING	VIC	2021-06-14	2022-03-25	Docetaxel; Telisotuzumab Vedotin	taxane; anti-cMET_antibody-drug_conjugate	Docetaxel; Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate; taxane	M18-868	A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer	Non Small Cell Lung Cancer	3084 - Heidelberg - Austin Health /ID# 247507; 3220 - Geelong - Barwon Health /ID# 241920	https://clinicaltrials.gov/ct2/show/NCT04928846
NCT04931342	BOUQUET	Phase 2	NOT_RECRUITING	VIC	2021-06-16	2021-10-07	Abemaciclib; Abemaciclib + Giredestrant; Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Cyclophosphamide; Bevacizumab; Bevacizumab + Inavolisib; Cobimetinib; Cyclophosphamide; Giredestrant; Giredestrant + Inavolisib; Inavolisib; Inavolisib + Letrozole + Palbociclib; Inavolisib + Olaparib; Inavolisib + Palbociclib; Ipatasertib; Ipatasertib + Paclitaxel; Letrozole; Olaparib; Paclitaxel; Palbociclib; Trastuzumab Emtansine	selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; CDK4/6_inhibitor + PI3K_alpha_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + PI3K_alpha_inhibitor; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + PI3K_alpha_inhibitor; pan-AKT_inhibitor; alkylating_agent; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; anti-VEGF_monoclonal_antibody; PI3K_alpha_inhibitor; alkylating_agent + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; aromatase_inhibitor; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; CDK4/6_inhibitor; taxane; MEK_inhibitor; anti-ERBB2_antibody-drug_conjugate; PARP_inhibitor; pan-AKT_inhibitor + taxane	Abemaciclib + Giredestrant; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Cyclophosphamide; Bevacizumab + Inavolisib; Cobimetinib; Giredestrant + Inavolisib; Inavolisib + Letrozole + Palbociclib; Inavolisib + Olaparib; Inavolisib + Palbociclib; Ipatasertib + Paclitaxel; Trastuzumab Emtansine; Abemaciclib + Giredestrant; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Cyclophosphamide; Bevacizumab + Inavolisib; Giredestrant + Inavolisib; Inavolisib + Letrozole + Palbociclib; Inavolisib + Olaparib; Inavolisib + Palbociclib; Ipatasertib + Paclitaxel	CDK4/6_inhibitor + PI3K_alpha_inhibitor; CDK4/6_inhibitor + PI3K_alpha_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; MEK_inhibitor; PARP_inhibitor + PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; alkylating_agent + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; pan-AKT_inhibitor + taxane; CDK4/6_inhibitor + PI3K_alpha_inhibitor; CDK4/6_inhibitor + PI3K_alpha_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; PARP_inhibitor + PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; alkylating_agent + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; pan-AKT_inhibitor + taxane	WO42178	A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors	Ovarian Cancer	3144 - Malvern - Cabrini Hospital; Cabrini Foundation	https://clinicaltrials.gov/ct2/show/NCT04931342
NCT04947189	4CAST	Phase 1/Phase 2	RECRUITING	NSW	2021-06-26	2022-11-01	Dexamethasone; Dexamethasone + Docetaxel + Seviteronel; Docetaxel; Seviteronel	CYP17A1_inhibitor + glucocorticoid + taxane; glucocorticoid; taxane; CYP17A1_inhibitor	Dexamethasone + Docetaxel + Seviteronel; Dexamethasone + Docetaxel + Seviteronel	CYP17A1_inhibitor + glucocorticoid + taxane; CYP17A1_inhibitor + glucocorticoid + taxane	4CAST	4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer	Triple Negative Breast Cancer	2010 - Darlinghurst - Kinghorn Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04947189
NCT04950075	ChonDRAgon	Phase 2	RECRUITING	NSW, QLD, SA	2021-06-30	2021-09-23	INBRX-109; Placebo	DR5_agonistic_antibody; placebo	INBRX-109; Placebo	DR5_agonistic_antibody; placebo	Ph2 INBRX-109 SA CS	A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma	Conventional Chondrosarcoma	2050 - Camperdown - Chris O'Brien Lifehouse; 5000 - Adelaide - Royal Adelaide Hospital; Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT04950075
NCT04956640	LOXO-RAS-20001	Phase 1/Phase 2	RECRUITING	NSW, SA, VIC, WA	2021-07-02	2021-07-19	Carboplatin; Carboplatin + Cetuximab + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Cetuximab; Cetuximab + Olomorasib + Pembrolizumab; Cisplatin; Olomorasib; Pembrolizumab; Pemetrexed	antimetabolite; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor	Carboplatin + Cetuximab + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Cetuximab + Olomorasib + Pembrolizumab; Olomorasib; Carboplatin + Cetuximab + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Cetuximab + Olomorasib + Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	LOXO-RAS-20001	A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors	Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Biliary Tract Neoplasms	2010 - Sydney - St Vincent's Hospital Sydney; 2065 - St Leonards - Royal North Shore Hospital; 3199 - Frankston - Peninsula and Southeast Oncology; 5000 - Adelaide - Cancer Research SA; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04956640
NCT04964375	ABSK043-101	Phase 1	UNKNOWN	NSW, QLD, VIC	2021-07-06	2021-08-31	ABSK-043	PD-L1_inhibitor,oral	ABSK-043	PD-L1_inhibitor,oral	ABSK043-101	A Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor	Neoplasms	4101 - Brisbane - Icon Cancer Centre South Brisbane; Frankston - Peninsula & South Eastern Haematology and Oncology Group; Liverpool - Sydney South West Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04964375
NCT04964934	SERENA-6	Phase 3	RECRUITING	NSW, QLD, WA	2021-07-14	2021-06-30	Abemaciclib; Abemaciclib + Anastrozole + Camizestrant + Letrozole + Palbociclib + Ribociclib; Anastrozole; Camizestrant; Letrozole; Palbociclib; Ribociclib	selective_estrogen_receptor_degrader; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; CDK4/6_inhibitor	Abemaciclib + Anastrozole + Camizestrant + Letrozole + Palbociclib + Ribociclib; Abemaciclib + Anastrozole + Camizestrant + Letrozole + Palbociclib + Ribociclib	CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader	D8534C00001	A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study	ER-Positive HER2-Negative Breast Cancer	2010 - Darlinghurst - Research Site; 4575 - Birtinya - Research Site; 6008 - Subiaco - Research Site - (WITHDRAWN)	https://clinicaltrials.gov/ct2/show/NCT04964934
NCT04969887	MOST-CIRCUIT	Phase 2	*NOT_RECRUITING	NSW, NZ, QLD, SA, TAS, VIC, WA	2021-07-19	2021-08-03	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	ONJ2021-002	Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare Cancers	Advanced Biliary Tract Cancer; Neuroendocrine Tumors; Female Reproductive System Neoplasm; MSI-H Solid Malignant Tumor	2145 - Sydney - Blacktown Hospital; 2298 - Waratah - Calvary Mater Newcastle; 2640 - Albury - Border Medical Oncology Unit; 3084 - Heidelberg - Austin Health; 3630 - Shepparton - Goulburn Valley Health; 4814 - Douglas - Townsville Hospital and Health Service; 4814 - Townsville - Townville Hospital and Health Service; 4870 - Cairns - Cairns and Hinterland Hospital and Health Service; 7000 - Hobart - Royal Hobart Hospital; Adelaide - Royal Adelaide Hospital; Auckland - Auckland City Hospital; Bendigo - Bendigo Health Services; Frankston - Peninsula Health; Geelong - Barwon Health; Orange - Orange Health Service; Parkville - Peter MacCalllum Cancer Centre; Perth - Fiona Stanley Hospital; Warrnambool - South West Healthcare	https://clinicaltrials.gov/ct2/show/NCT04969887
NCT04974398	AK105-304	Phase 3	RECRUITING	NSW, VIC, WA	2021-07-21	2021-08-16	Cisplatin; Cisplatin + Gemcitabine; Cisplatin + Gemcitabine + Penpulimab; Gemcitabine; Penpulimab; Placebo	gemcitabine; anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; placebo; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Cisplatin + Gemcitabine; Cisplatin + Gemcitabine + Penpulimab; Cisplatin + Gemcitabine; Cisplatin + Gemcitabine + Penpulimab; Placebo	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; placebo	AK105-304	A Randomized, Double-blind, Multi-center Phase III Study of Penpulimab (AK105) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma	2010 - Darlinghurst - St Vincent's Public Hospital Sydney; 2065 - St Leonards - Genesis Care North Shore; 3084 - Heidelberg - Sir Charles Gardner; 6009 - Nedlands - Austin Health; Camperdown - Chris O'Brien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT04974398
NCT04975308	EMBER-3	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2021-07-22	2021-10-04	Abemaciclib; Abemaciclib + Imlunestrant; Exemestane; Exemestane + Fulvestrant; Fulvestrant; Imlunestrant	selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; CDK4/6_inhibitor; aromatase_inhibitor + selective_estrogen_receptor_degrader	Abemaciclib + Imlunestrant; Exemestane + Fulvestrant; Imlunestrant; Abemaciclib + Imlunestrant; Exemestane + Fulvestrant	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor + selective_estrogen_receptor_degrader	18175	EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy	Breast Neoplasms; Neoplasm Metastasis	2010 - Darlinghurst - St Vincent's Hospital; 3128 - Box Hill - Box Hill Hospital - (COMPLETED); 3135 - Melbourne - Maroondah Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital - (COMPLETED); 5000 - Adelaide - Cancer Research SA	https://clinicaltrials.gov/ct2/show/NCT04975308
NCT04976634	6482-016	Phase 2	RECRUITING	Auckland, NSW, NZ, VIC	2021-07-16	2021-08-18	Belzutifan; Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; HIF2a_inhibitor	Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab	HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	6482-016	An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors	Carcinoma, Hepatocellular; Colorectal Neoplasms; Pancreatic Ductal Adenocarcinoma; Biliary Tract Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms	1023 - Auckland - Auckland City Hospital-Cancer & Blood Research ( Site 4200); 1023 - Grafton - Auckland City Hospital-Liver Research Unit ( Site 4201); 2145 - Westmead - Westmead Hospital-Department of Medical Oncology ( Site 4001); 2250 - Gosford - Gosford Hospital-Oncology Trials ( Site 4004) - (COMPLETED); 3076 - Epping - Northern Hospital-Department of Medical Oncology ( Site 4003); 3144 - Malvern - Cabrini Hospital - Malvern-Cabrini Institute ( Site 4000) - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT04976634
NCT04985604	DAY101-102	Phase 1/Phase 2	RECRUITING	VIC	2021-07-30	2021-07-15	Pimasertib; Pimasertib + Tovorafenib; Tovorafenib	MEK_inhibitor; RAF_inhibitor,type_2; MEK_inhibitor + RAF_inhibitor,type_2	Pimasertib + Tovorafenib; Tovorafenib; Pimasertib + Tovorafenib	MEK_inhibitor + RAF_inhibitor,type_2; RAF_inhibitor,type_2; MEK_inhibitor + RAF_inhibitor,type_2	DAY101-102	A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations	Melanoma; Solid Tumor; CRAF Gene Amplification; RAF1 Gene Amplification; BRAF Gene Fusion; BRAF Fusion; CRAF Gene Fusion; CRAF Fusion; RAF1 Gene Fusion; RAF1 Fusion; Thyroid Cancer, Papillary; Spitzoid Melanoma; Pilocytic Astrocytoma; Pilocytic Astrocytoma, Adult; Non Small Cell Lung Cancer; Non-Small Cell Adenocarcinoma; Colorectal Cancer; Pancreatic Acinar Carcinoma; Spitzoid Malignant Melanoma; Bladder Cancer; Bladder Urothelial Carcinoma; MAP Kinase Family Gene Mutation; RAS Mutation; RAF Mutation; MEK Mutation	Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04985604
NCT04985721	IMPARP-HRD	Phase 2	RECRUITING	VIC	2021-07-29	2022-02-24	Pamiparib; Pamiparib + Tislelizumab; Tislelizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; PARP_inhibitor	Pamiparib + Tislelizumab; Pamiparib + Tislelizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody	20/044	An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects	Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre; 3065 - Fitzroy - St Vincent's Hospital; 3084 - Heidelberg - Austin Hospital	https://clinicaltrials.gov/ct2/show/NCT04985721
NCT04986852	KEYNOTE-C14	Phase 2	RECRUITING	WA	2021-07-22	2021-09-30	Olinvacimab; Olinvacimab + Pembrolizumab; Pembrolizumab	anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	Olinvacimab + Pembrolizumab; Olinvacimab + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	PMC_TTAC-0001_06 / KEYNOTE-C14	A Phase II, Open-Label, Multicenter Study of Olinvacimab in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer	Metastatic Triple-Negative Breast Cancer	6009 - Nedlands - Hollywood Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04986852
NCT04986865	PROBE	Phase 1	RECRUITING	NSW, SA, VIC	2021-07-23	2021-12-15	ATG-101	bispecific_PD-L1/4-1BB_antibody	ATG-101	bispecific_PD-L1/4-1BB_antibody	ATG-101-001	A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas	Advanced Solid Tumor; Metastatic Solid Tumor; Mature B-cell Non-Hodgkin Lymphoma	2031 - Randwick - Scientia Clinical Research Ltd; 3004 - Melbourne - The Alfred Hospital; 3084 - Heidelberg - Austin Health - Olivia Newton-John Cancer Centre; 5000 - Adelaide - Royal Adelaide Hospital; 8006 - East Melbourne - Peter MacCallum Cancer Centre (PMCC) - Victorian Comprehensive Cancer Centre Location (Peter MacCallum Cancer Centre - East Melbourne)	https://clinicaltrials.gov/ct2/show/NCT04986865
NCT04994132	ARST2031	Phase 3	RECRUITING	NSW, VIC, WA	2021-07-29	2021-09-14	Cyclophosphamide; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine + Vinorelbine; Dactinomycin; Radiotherapy; Vincristine; Vinorelbine	radiotherapy; alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; alkylating_agent; antineoplastic_antibiotic; vinca_alkaloid	Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine + Vinorelbine; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine + Vinorelbine	alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid	ARST2031	A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)	Alveolar Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma; Metastatic Embryonal Rhabdomyosarcoma; Metastatic Rhabdomyosarcoma; Solid Alveolar Rhabdomyosarcoma; Spindle Cell Rhabdomyosarcoma; Spindle Cell/Sclerosing Rhabdomyosarcoma	2145 - Westmead - The Children's Hospital at Westmead; 2310 - Hunter Regional Mail Centre - John Hunter Children's Hospital; 3052 - Parkville - Royal Children's Hospital - (SUSPENDED); 6009 - Perth - Perth Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT04994132
NCT04996875	CGT9486-20-201	Phase 2	RECRUITING	NSW, QLD, VIC	2021-08-06	2021-11-09	CGT9486	KIT_inhibitor	CGT9486	KIT_inhibitor	CGT9486-20-201	A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis	Advanced Systemic Mastocytosis (AdvSM); SM With an Associated Hematologic Neoplasm (SM-AHN); Mast Cell Leukemia (MCL); Aggressive Systemic Mastocytosis (ASM)	2747 - Kingswood - Nepean Hospital; 3051 - Melbourne N. - Peter MacCallum Cancer Centre; 4215 - Southport - Gold Coast University Hospital	https://clinicaltrials.gov/ct2/show/NCT04996875
NCT05007782	GS-US-570-6015	Phase 1	RECRUITING	NSW, VIC	2021-08-11	2021-08-18	Tegafur-gimeracil-oteracil potassium; Zimberelimab	antimetabolite; anti-PD-1_monoclonal_antibody; orotate_phosphoribosyltransferase_inhibitor; DPD_inhibitor	Zimberelimab; Tegafur-gimeracil-oteracil potassium	anti-PD-1_monoclonal_antibody; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	GS-US-570-6015	A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors	Advanced Solid Tumor	2050 - Camperdown - Chris O'Brien Lifehouse; 3168 - Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT05007782
NCT05021120	AK127-101	EARLY_Phase 1	RECRUITING	NSW, VIC	2021-08-24	2021-10-12	AK104; AK104 + AK127; AK127	anti-TIGIT_monoclonal_antibody; bispecific_PD-1/CTLA-4_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/CTLA-4_antibody	AK104 + AK127; AK104 + AK127	anti-TIGIT_monoclonal_antibody + bispecific_PD-1/CTLA-4_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/CTLA-4_antibody	AK127-101	A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours	Advanced or Metastatic Solid Tumours	Adelaide - Ashford Cancer Centre Research; Melbourne - Austin Health; Melbourne - Monash Health; Sydney - Southside Cancer Care Centre - (COMPLETED); Sydney - The Kinghorn Cancer Centre, St Vincents Hospital Sydney	https://clinicaltrials.gov/ct2/show/NCT05021120
NCT05029882	M21-404	Phase 1	RECRUITING	QLD, VIC	2021-08-30	2021-10-13	ABBV-400; ABBV-400 + Bevacizumab; Bevacizumab; Bevacizumab + Trifluridine/Tipiracil; Trifluridine/Tipiracil	antimetabolite; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody; Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor; Trifluridine + anti-VEGF_monoclonal_antibody; anti-cMET_antibody-drug_conjugate; anti-VEGF_monoclonal_antibody + anti-cMET_antibody-drug_conjugate	ABBV-400; ABBV-400 + Bevacizumab; Bevacizumab + Trifluridine/Tipiracil; ABBV-400 + Bevacizumab; Bevacizumab + Trifluridine/Tipiracil	Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + anti-cMET_antibody-drug_conjugate; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor; anti-cMET_antibody-drug_conjugate; Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + anti-cMET_antibody-drug_conjugate; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor	M21-404	A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors	Non-Small Cell Lung Cancer; Advanced Solid Tumors; Gastroesophageal Adenocarcinoma; Colorectal Cancer	3084 - Heidelberg - Austin Health /ID# 247667; 4101 - South Brisbane - Mater Misericordiae Limited /ID# 249995	https://clinicaltrials.gov/ct2/show/NCT05029882
NCT05041309	KT-US-982-5968	Phase 2	ENROLLING_BY_INVITATION	VIC	2021-09-07	2021-12-15	KTE-X19	autologous_CAR-T-cell_therapy,CD19-targeting	KTE-X19	autologous_CAR-T-cell_therapy,CD19-targeting	KT-US-982-5968	Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells	Solid and Hematological Malignancies	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05041309
NCT05043090	SAMETA	Phase 3	RECRUITING	NSW, VIC	2021-09-09	2021-10-28	Durvalumab; Durvalumab + Savolitinib; Savolitinib; Sunitinib	PDGFR_inhibitor; MET_inhibitor,type_1; MET_inhibitor,type_1 + anti-PD-L1_monoclonal_antibody; VEGFR_inhibitor; KIT_inhibitor,first_generation; anti-PD-L1_monoclonal_antibody	Durvalumab; Durvalumab + Savolitinib; Sunitinib; Durvalumab + Savolitinib	KIT_inhibitor,first_generation; MET_inhibitor,type_1 + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-L1_monoclonal_antibody	D5086C00001	A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)	Papillary Renal Cell Carcinoma	2065 - St Leonards - Research Site; 2109 - Macquarie University - Research Site; 3128 - Box Hill - Research Site; 3144 - Malvern - Research Site - (WITHDRAWN)	https://clinicaltrials.gov/ct2/show/NCT05043090
NCT05053854	PARLuNET	Phase 1	RECRUITING	VIC	2021-09-20	2021-12-08	Octreotate; Octreotate + Talazoparib; Talazoparib	PARP_inhibitor; PARP_inhibitor + radionuclide_therapy; radionuclide_therapy	Octreotate + Talazoparib; Octreotate + Talazoparib	PARP_inhibitor + radionuclide_therapy; PARP_inhibitor + radionuclide_therapy	PMC67199	Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor	Neuroendocrine Tumors	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05053854
NCT05067283	1084-001	Phase 1	RECRUITING	Canterbury, NSW, NZ, VIC	2021-10-01	2021-12-17	Carboplatin; Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed; Cetuximab; Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin; Cetuximab + MK-1084; Fluorouracil; Leucovorin; MK-1084; MK-1084 + Pembrolizumab; Oxaliplatin; Pembrolizumab; Pemetrexed	antimetabolite; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; folinic_acid; KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; Fluorouracil; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent	Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed; Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin; Cetuximab + MK-1084; MK-1084; MK-1084 + Pembrolizumab; Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed; Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin; Cetuximab + MK-1084; MK-1084 + Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; Fluorouracil; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	1084-001	A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors	Advanced Solid Tumors	2050 - Camperdown - Chris O'Brien Lifehouse ( Site 0002); 2145 - Westmead - Westmead Hospital-Department of Medical Oncology ( Site 0006); 2170 - Liverpool - Liverpool Hospital-Medical Oncology ( Site 0001); 3168 - Clayton - Monash Health-Oncology Research ( Site 0003); 8011 - Christchurch - New Zealand Clinical Research (Christchurch) ( Site 0004) - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT05067283
NCT05075577	EPI-7386-CS-010	Phase 1/Phase 2	RECRUITING	ACT, Australian Capital Territory, NSW, VIC	2021-10-07	2021-12-21	EPI-7386; EPI-7386 + Enzalutamide; Enzalutamide	antiandrogen,AR_NTD_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,AR_NTD_inhibitor; antiandrogen,nonsteroidal,second_generation	EPI-7386 + Enzalutamide; Enzalutamide; EPI-7386 + Enzalutamide	antiandrogen,AR_NTD_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; antiandrogen,AR_NTD_inhibitor + antiandrogen,nonsteroidal,second_generation	EPI-7386-CS-010	A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2010 - Darlinghurst - St. Vincent's Hospital Sydney; 2050 - Camperdown - Chris O'Brien Lifehouse; 2605 - Garran - The Canberra Hospital; 3128 - Box Hill - Eastern Health	https://clinicaltrials.gov/ct2/show/NCT05075577
NCT05081609	IL-Believe	Phase 1/Phase 2	RECRUITING	QLD, SA	2021-10-05	2022-01-11	Pembrolizumab; TransCon TLR7/8 agonist	TLR7/8_agonist; anti-PD-1_monoclonal_antibody	Pembrolizumab; TransCon TLR7/8 agonist	TLR7/8_agonist; anti-PD-1_monoclonal_antibody	ASND0029	IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Advanced Solid Tumor; Locally Advanced Solid Tumor; Metastatic Solid Tumor; Platinum-resistant Ovarian Cancer; Post Anti-PD-1 Melanoma; 2L+ Cervical Cancer; Neoadjuvant Melanoma; Neoadjuvant Non-Small Cell Lung Cancer; Post Anti-PD-(L)1 Non-Small Cell Lung Cancer; Post Anti-PD-(L)1 Small Cell Lung Cancer	4215 - Southport - Ascendis Pharma Investigational Site; 5000 - Adelaide - Ascendis Pharma Investigational Site	https://clinicaltrials.gov/ct2/show/NCT05081609
NCT05086692	ABILITY-1	Phase 1/Phase 2	RECRUITING	NSW, QLD	2021-10-07	2021-08-27	MDNA11; MDNA11 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; IL-2_superkine + anti-PD-1_monoclonal_antibody; IL-2_superkine	MDNA11 + Pembrolizumab; MDNA11 + Pembrolizumab	IL-2_superkine + anti-PD-1_monoclonal_antibody; IL-2_superkine + anti-PD-1_monoclonal_antibody	MDNA11-01	A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Unresectable Solid Tumor; Clear Cell Renal Cell Carcinoma; Triple Negative Breast Cancer; Non-Small Cell Lung Cancer Squamous; Non-Small Cell Lung Cancer Non-squamous; Colorectal Cancer (MSI-H); Gastric Cancer; Cervical Cancer; Basal Cell Carcinoma; Bladder Cancer; Merkel Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Cutaneous Squamous Cell Carcinoma; Pleural Mesothelioma; Esophageal Cancer; Endometrial Carcinoma; Solid Tumor; Solid Tumor, Adult; MSI-H Solid Malignant Tumor; Cancer With A High Tumor Mutational Burden; Epithelial Ovarian Carcinoma; Primary Peritoneal Cancer; Gastroesophageal Junction (GEJ) Cancer; Acral Melanoma; Mucosal Melanoma; Cutaneous Melanoma; DMMR Solid Malignant Tumor; Fallopian Tube Cancer; Ovarian Cancer; MSI-H Cancer; DMMR Cancer; Pancreas Adenocarcinoma (MSI-H); Skin Cancer	2031 - Randwick - Scientia Clinical Research; 2109 - Sydney - Macquarie University; 4120 - Greenslopes - Gallipoli Medical Research Foundation	https://clinicaltrials.gov/ct2/show/NCT05086692
NCT05094336	MTAP	Phase 1/Phase 2	RECRUITING	NSW	2021-10-14	2022-02-01	AMG 193; AMG 193 + Docetaxel + Pemetrexed; AMG 193 + Pemetrexed; Docetaxel; Pemetrexed	antimetabolite; PRMT5_inhibitor + antimetabolite; PRMT5_inhibitor + antimetabolite + taxane; taxane; PRMT5_inhibitor	AMG 193; AMG 193 + Docetaxel + Pemetrexed; AMG 193 + Pemetrexed; AMG 193 + Docetaxel + Pemetrexed; AMG 193 + Pemetrexed	PRMT5_inhibitor; PRMT5_inhibitor + antimetabolite; PRMT5_inhibitor + antimetabolite + taxane; PRMT5_inhibitor + antimetabolite; PRMT5_inhibitor + antimetabolite + taxane	20210023	A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors	Advanced MTAP-null Solid Tumors	2050 - Camperdown - Chris OBrien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT05094336
NCT05102214	HLX301-001	Phase 1/Phase 2	RECRUITING	NSW, QLD, SA, VIC	2021-10-20	2022-05-03	HLX301	bispecific_PD-L1/TIGIT_antibody	HLX301	bispecific_PD-L1/TIGIT_antibody	HLX301-001	A Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors; Non-small Cell Lung Cancer	4575 - Birtinya - Sunshine Coast University Private Hospital; Adelaide - Southern Oncology Clinical Research Unit; Blacktown - Blacktown Hospital; Brighton - Cabrini Hospital; Camperdown - Chris O'Brien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT05102214
NCT05111626	FORTITUDE-102	Phase 3	RECRUITING	NSW, SA, VIC	2021-10-29	2022-03-14	Bemarituzumab; Bemarituzumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-FGFR2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-FGFR2_monoclonal_antibody	Bemarituzumab + Nivolumab; Nivolumab; Bemarituzumab + Nivolumab	anti-FGFR2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-FGFR2_monoclonal_antibody + anti-PD-1_monoclonal_antibody	20210098	A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression	Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	2065 - St Leonards - GenesisCare -North Shore Oncology; 2298 - Waratah - Calvary Mater Newcastle Hospital; 3084 - Heidelberg - Austin Health, Austin Hospital; 3350 - Ballarat - Ballarat Health Services; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05111626
NCT05116202	BO43328	Phase 1/Phase 2	*PAUSED	NSW, WA	2021-11-02	2022-02-02	Atezolizumab; Atezolizumab + Tiragolumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; RO7247669; RO7247669 + Tiragolumab; Tiragolumab	bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Atezolizumab + Tiragolumab; Ipilimumab + Nivolumab; RO7247669; RO7247669 + Tiragolumab; Atezolizumab + Tiragolumab; Ipilimumab + Nivolumab; RO7247669 + Tiragolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; bispecific_PD-1/LAG3_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody	BO43328	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)	Melanoma	2060 - North Sydney - Melanoma Institute Australia; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT05116202
NCT05117476	CLN-619-001	Phase 1	RECRUITING	VIC, WA	2021-11-02	2021-10-29	CLN-619; CLN-619 + Pembrolizumab; Pembrolizumab	anti-MICA/MICB_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CLN-619; CLN-619 + Pembrolizumab; CLN-619 + Pembrolizumab	anti-MICA/MICB_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CLN-619-001	A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	3004 - Melbourne - Alfred Health; 3168 - Clayton - Monash Health; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05117476
NCT05118789	NVL-520-01	Phase 1/Phase 2	RECRUITING	NSW, VIC	2021-11-03	2022-01-04	NVL-520; Tegafur-gimeracil-oteracil potassium	antimetabolite; orotate_phosphoribosyltransferase_inhibitor; ROS1_inhibitor; DPD_inhibitor	NVL-520; Tegafur-gimeracil-oteracil potassium	ROS1_inhibitor; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	NVL-520-01	A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)	Locally Advanced Solid Tumor; Metastatic Solid Tumor	2050 - Camperdown - Chris O'Brien Lifehouse; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05118789
NCT05123482	D6900C00001	Phase 1/Phase 2	RECRUITING	QLD, VIC, WA	2021-11-05	2021-10-18	AZD2936; AZD2936 + AZD8205 + Rilvegostomig; AZD8205; Rilvegostomig	anti-B7H4_antibody-drug_conjugate; anti-B7H4_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; bispecific_PD-1/TIGIT_antibody	AZD2936 + AZD8205 + Rilvegostomig; AZD8205; AZD2936 + AZD8205 + Rilvegostomig	anti-B7H4_antibody-drug_conjugate; anti-B7H4_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-B7H4_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody	D6900C00001	A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)	Breast Cancer; Biliary Tract Carcinoma; Ovarian Cancer; Endometrial Cancer	3168 - Clayton - Research Site; 4101 - South Brisbane - Research Site - (WITHDRAWN); 6009 - Nedlands - Research Site; VIC 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT05123482
NCT05132582	HER2CLIMB-05	Phase 3	RECRUITING	NSW, Other, SA, VIC, WA	2021-11-12	2022-03-07	Pertuzumab; Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab + Tucatinib; Placebo; Trastuzumab; Tucatinib	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation; placebo	Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab + Tucatinib; Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab + Tucatinib; Placebo	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; placebo	SGNTUC-028	A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)	HER2 Positive Breast Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2109 - Macquarie University - Macquarie University Hospital; 2145 - Sydney - Westmead Hospital; 3084 - Heidelberg - Austin Health; 3128 - Box Hill - Box Hill Hospital; 3199 - Frankston - Peninsula and South East Oncology - (COMPLETED); 5000 - Adelaide - Cancer Research South Australia; 5042 - Bedford Park - Flinders Medical Centre; 6008 - Subiaco - St John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT05132582
NCT05150457	BNA035-101	Phase 1	RECRUITING	NSW, QLD, VIC	2021-12-03	2022-02-08	BNA35	bispecific_EGFR/4-1BB_antibody	BNA35	bispecific_EGFR/4-1BB_antibody	BNA035-101	A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors	Refractory Solid Tumors	2217 - Kogarah - St George Private Hospital; 3065 - Fitzroy - St. Vincents Hospital Melbourne; 4217 - Benowa - Pindara Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05150457
NCT05150691	DB-1303-O-1001	Phase 1/Phase 2	RECRUITING	NSW, QLD	2021-11-26	2022-01-31	DB-1303; DB-1303 + Itraconazole; DB-1303 + Pertuzumab; DB-1303 + Trastuzumab; Itraconazole; Pertuzumab; Trastuzumab	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; SMO_inhibitor; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; SMO_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody	DB-1303; DB-1303 + Itraconazole; DB-1303 + Pertuzumab; DB-1303 + Trastuzumab; DB-1303 + Itraconazole; DB-1303 + Pertuzumab; DB-1303 + Trastuzumab	SMO_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; SMO_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	DB-1303-O-1001	A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors	HER2-positive Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research LTD; 2109 - Sydney - Macquarie Clinical Trials Unit; 4101 - South Brisbane - Integrated Clinical Oncology Network Pty Ltd (Icon)	https://clinicaltrials.gov/ct2/show/NCT05150691
NCT05152147	HERIZON-GEA-01	Phase 3	RECRUITING	NSW, SA, VIC, WA	2021-12-03	2021-12-02	Capecitabine; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Tislelizumab + Zanidatamab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Zanidatamab; Cisplatin; Fluorouracil; Oxaliplatin; Tislelizumab; Trastuzumab; Zanidatamab	fluoropyrimidine; anti-ERBB2_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; anti-PD-1_monoclonal_antibody; bispecific_ERBB2/ERBB2_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; bispecific_ERBB2/ERBB2_antibody	Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Tislelizumab + Zanidatamab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Zanidatamab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Tislelizumab + Zanidatamab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Zanidatamab	anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; bispecific_ERBB2/ERBB2_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; bispecific_ERBB2/ERBB2_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent	ZWI-ZW25-301	A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)	Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma	2170 - Liverpool - Liverpool Hospital; 2640 - Albury - Border Medical Oncology Research Unit - (WITHDRAWN); 3084 - Heidelberg - Austin Health; 5042 - Bedford Park - Flinders Medical Centre; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT05152147
NCT05153239	PM1183-C-008-21	Phase 3	RECRUITING	NSW, VIC, WA	2021-11-29	2022-07-22	Irinotecan; Irinotecan + Lurbinectedin; Irinotecan + Topotecan; Lurbinectedin; Topotecan	DNA_minor_groove-binding_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; DNA_minor_groove-binding_agent	Irinotecan + Lurbinectedin; Irinotecan + Topotecan; Lurbinectedin; Irinotecan + Lurbinectedin; Irinotecan + Topotecan	DNA_minor_groove-binding_agent; DNA_minor_groove-binding_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; DNA_minor_groove-binding_agent + topoisomerase_inhibitor	PM1183-C-008-21	A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)	Relapsed Small Cell Lung Cancer	2050 - Camperdown - The Chris Obrien Lifehouse; 2250 - Gosford - Gosford Hospital GH - Central Coast Cancer Centre; 3128 - Box Hill - Box Hill Hospital Eastern Health Clinical School; 3350 - Ballarat Central - BRICC - Ballarat Health Services; NSW 2086 - Frenchs Forest - Northern Beaches Hospital; NSW 2500 - Wollongong - Cancer Care Wollongong; VIC 3084 - Heidelberg - Austin Hospital- Medical Oncology Unit; WA 6150 - Murdoch - St John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT05153239
NCT05156892	TICTOC	Phase 1	RECRUITING	NSW	2021-12-13	2022-09-04	Itraconazole; Itraconazole + Tamoxifen; Tamoxifen	selective_estrogen_receptor_modulator; SMO_inhibitor; SMO_inhibitor + selective_estrogen_receptor_modulator	Itraconazole + Tamoxifen; Itraconazole + Tamoxifen	SMO_inhibitor + selective_estrogen_receptor_modulator; SMO_inhibitor + selective_estrogen_receptor_modulator	TICTOC	A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Tamoxifen and SUBA-Itraconazole in Patients With Platinum Resistant Recurrent Epithelial Ovarian Cancer	Ovarian Cancer	2010 - Sydney - Kinghorn Cancer Centre, St. Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT05156892
NCT05159388	CL1-95012-001	Phase 1/Phase 2	RECRUITING	NSW, SA, VIC	2021-12-02	2021-09-08	Dexamethasone; PRS-344	glucocorticoid; bispecific_PD-L1/4-1BB_antibody	PRS-344; Dexamethasone	bispecific_PD-L1/4-1BB_antibody; glucocorticoid	CL1-95012-001	A First in Human Phase 1-2 Open-Label, Multicenter, Dose Escalation and Expansion Study of PRS-344/S095012 in Patients With Solid Tumors	Solid Tumor	Camperdown - Chris O'Brian Lifehouse; Malvern - Cabrini Oncology Research; Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05159388
NCT05166577	VT3996-301	Phase 1/Phase 2	RECRUITING	NSW	2021-12-20	2021-10-08	Nanatinostat; Nanatinostat + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody; HDAC_inhibitor,class_1_selective	Nanatinostat; Nanatinostat + Pembrolizumab; Nanatinostat + Pembrolizumab	HDAC_inhibitor,class_1_selective; HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody; HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody	VT3996-301	An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma; EBV-Related Gastric Carcinoma; EBV-Related Leiomyosarcoma; EBV Related Carcinoma; EBV-Related Sarcoma	Blacktown - Blacktown Hospital; Sydney - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT05166577
NCT05169697	YH002004	Phase 1	RECRUITING	NSW, VIC	2021-12-10	2022-02-21	YH001; YH001 + YH002; YH002	anti-OX40_agonistic_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody	YH001 + YH002; YH001 + YH002	anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody	YH002004	A Multicenter, Open-label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2109 - Sydney - Macquarie University Hospital; 2800 - Orange - Orange Health Services; 3144 - Malvern - Cabrini Hospital Malvern; 3199 - Frankston - Peninsula and South Eastern Haematology & Oncology Group	https://clinicaltrials.gov/ct2/show/NCT05169697
NCT05176483	STELLAR-002	Phase 1	RECRUITING	NSW, NZ, QLD	2021-12-15	2021-12-14	Ipilimumab; Ipilimumab + Nivolumab + Zanzalintinib; Nivolumab; Nivolumab + Relatlimab + Zanzalintinib; Nivolumab + Zanzalintinib; Relatlimab; Zanzalintinib	MET/VEGFR2/AXL/MER_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967|[111In]-FPI-1967; MET/VEGFR2/AXL/MER_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967	Ipilimumab + Nivolumab + Zanzalintinib; Nivolumab + Relatlimab + Zanzalintinib; Nivolumab + Zanzalintinib; Zanzalintinib; Ipilimumab + Nivolumab + Zanzalintinib; Nivolumab + Relatlimab + Zanzalintinib; Nivolumab + Zanzalintinib	MET/VEGFR2/AXL/MER_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-PD-1_monoclonal_antibody	XL092-002	A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors	Renal Cell Carcinoma; Metastatic Castration-resistant Prostate Cancer; Urothelial Carcinoma; Solid Tumor; Hepatocellular Carcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Head and Neck Squamous Cell Carcinoma	1023 - Grafton - Exelixis Clinical Site #30; 2065 - Saint Leonards - Exelixis Clinical Site #42; 2109 - Sydney - Exelixis Clinical Site #36; 2640 - Albury - Exelixis Clinical Site #116; 3204 - Hamilton - Exelixis Clinical Site #45; 4102 - Brisbane - Exelixis Clinical Site #16; 4575 - Birtinya - Exelixis Clinical Site #35	https://clinicaltrials.gov/ct2/show/NCT05176483
NCT05176509	YH003005	Phase 1	RECRUITING	NSW, VIC	2021-12-15	2022-04-05	Pembrolizumab; Pembrolizumab + YH001 + YH003; YH001; YH003	anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-CTLA-4_monoclonal_antibody	Pembrolizumab + YH001 + YH003; Pembrolizumab + YH001 + YH003	anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody	YH003005	A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors	Solid Tumor	2148 - Blacktown - Blacktown Cancer and Haematology Centre, Clinical Trials, Block C, Level 3, 18 Blacktown Road; 2217 - Kogarah - "Oncology Clinical Trial Unit St George Private Hospital 1 South Street"; Melbourne - 55 Commercial Rd, Level 2 WBRC; Prahran - Level 3, Suite 7, North Building, Frankston Private, 5 Susono Way, Frankston	https://clinicaltrials.gov/ct2/show/NCT05176509
NCT05180799	BA3071-001	Phase 1/Phase 2	RECRUITING	NSW, SA	2022-01-05	2022-08-03	BA3071; BA3071 + Nivolumab + Pembrolizumab; Nivolumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BA3071; BA3071 + Nivolumab + Pembrolizumab; BA3071 + Nivolumab + Pembrolizumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BA3071-001	A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors	Solid Tumor, Adult; NSCLC; Urothelial Carcinoma; Gastric Cancer; Small Cell Lung Cancer; Hepatocellular Carcinoma; Cervical Carcinoma; Melanoma; Renal Cell Carcinoma; Carcinoma	2228 - Miranda - Cancer Care Foundation; 5000 - Adelaide - Cancer Research South Australia	https://clinicaltrials.gov/ct2/show/NCT05180799
NCT05182931	I-FIRST	Phase 2	RECRUITING	NSW, QLD, SA, VIC, WA	2021-12-20	2022-07-14	Dabrafenib; Dabrafenib + Trametinib; Trametinib	BRAF_V600_inhibitor + MEK_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor	Dabrafenib + Trametinib; Trametinib; Dabrafenib + Trametinib	BRAF_V600_inhibitor + MEK_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	ONJ2021-006	A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)	Thyroid Cancer	3084 - Heidelberg - Austin Health; 3128 - Box Hill - Eastern Health; 3168 - Clayton - Monash Health; 4029 - Brisbane - Royal Brisbane and Women's Hospital; Adelaide - Royal Adelaide Hsopital; Melbourne - Peter MacCallum Cancer Centre; Perth - Sir Charles Gairdner Hospital; Prahran - Alfred Hospital; Sydney - Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT05182931
NCT05187624	BP42573	Phase 1	NOT_RECRUITING	VIC	2022-01-07	2022-04-05	RO7428731	bispecific_T-cell_engager,EGFRvIII-targeting	RO7428731	bispecific_T-cell_engager,EGFRvIII-targeting	BP42573	An Open-label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III	Glioblastoma	3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT05187624
NCT05198752	SWP1001-06	Phase 1	RECRUITING	QLD, VIC	2022-01-19	2022-03-18	SW1115C3	mRNA_personalised_cancer_vaccine	SW1115C3	mRNA_personalised_cancer_vaccine	SWP1001-06	A Phase 1 Clinical Study to Evaluate the Tolerability, Safety,Immunogenicity and Efficacy of the Neoantigen mRNA Personalised Cancer Vaccine SW1115C3 in Patients With Advanced Malignant Solid Tumours	Solid Tumor	Benowa - Pindara Private Hospital; Frankston - Peninsula & South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT05198752
NCT05199753	LM108-01-101	Phase 1/Phase 2	RECRUITING	NSW, QLD, VIC, WA	2022-01-06	2022-03-16	LM-108	anti-CCR8_monoclonal_antibody	LM-108	anti-CCR8_monoclonal_antibody	LM108-01-101	A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours	Advanced Solid Tumor	NSW 2148 - Sydney - Blacktown Hospital; QLD 4101 - South Brisbane - ICON Cancer Centre; QLD 4575 - Birtinya - Sunshine Coast University Private Hospital; VIC 3004 - Melbourne - Alfred Hospital; VIC 3144 - Malvern - Cabrini Health Limited; WA 6009 - Nedlands - One Clinical Research Pty Ltd.	https://clinicaltrials.gov/ct2/show/NCT05199753
NCT05200273	AK114-102	Phase 1	UNKNOWN	SA	2022-01-07	2022-03-15	AK114	anti-IL-1beta_monoclonal_antibody	AK114	anti-IL-1beta_monoclonal_antibody	AK114-102	A Phase 1a, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 in Subjects With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors; Malignancy; Metastasis	Kurralta Park - Ashford Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05200273
NCT05201547	DOMENICA	Phase 3	RECRUITING	ACT, NSW	2022-01-20	2022-04-15	Carboplatin; Carboplatin + Paclitaxel; Dostarlimab; Paclitaxel	anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane	Carboplatin + Paclitaxel; Dostarlimab; Carboplatin + Paclitaxel	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	GINECO-EN105b	Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting	Endometrial Cancer	2298 - Waratah - Calvary Mater Newcastle; 2605 - Garran - Canberra Hospital	https://clinicaltrials.gov/ct2/show/NCT05201547
NCT05203172	C4221026	Phase 4	RECRUITING	VIC	2022-01-10	2022-07-05	Binimetinib; Binimetinib + Cetuximab + Encorafenib; Binimetinib + Encorafenib; Binimetinib + Encorafenib + Ribociclib; Cetuximab; Encorafenib; Ribociclib	anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + CDK4/6_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor; CDK4/6_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; MEK_inhibitor	Binimetinib; Binimetinib + Cetuximab + Encorafenib; Binimetinib + Encorafenib; Binimetinib + Encorafenib + Ribociclib; Encorafenib; Binimetinib + Cetuximab + Encorafenib; Binimetinib + Encorafenib; Binimetinib + Encorafenib + Ribociclib	BRAF_V600_inhibitor; BRAF_V600_inhibitor + CDK4/6_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; MEK_inhibitor; BRAF_V600_inhibitor + CDK4/6_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody	C4221026	ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES	Solid Tumors	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05203172
NCT05205109	ATG-037-001	Phase 1	RECRUITING	NSW, QLD, SA, VIC, WA	2022-01-11	2022-06-07	ATG 037; ATG 037 + Pembrolizumab; Pembrolizumab	CD73_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; CD73_inhibitor	ATG 037 + Pembrolizumab; ATG 037 + Pembrolizumab	CD73_inhibitor + anti-PD-1_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody	ATG-037-001	A Phase I/Ib, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors	2298 - Sydney - Calvary Mater Newcastle; 3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group; 4217 - Benowa - Pindara Private Hospital; 5042 - Bedford Park - Southern Oncology Clinical Research Unit; WA6153 - Mount Pleasant - One Clinical Research Pty Ltd	https://clinicaltrials.gov/ct2/show/NCT05205109
NCT05208047	CGT9486-21-301	Phase 3	RECRUITING	NSW, WA	2022-01-14	2022-04-14	CGT9486; CGT9486 + Sunitinib; Sunitinib	PDGFR_inhibitor; KIT_inhibitor + KIT_inhibitor,first_generation; KIT_inhibitor + PDGFR_inhibitor; VEGFR_inhibitor; KIT_inhibitor,first_generation; KIT_inhibitor + VEGFR_inhibitor; KIT_inhibitor	CGT9486 + Sunitinib; Sunitinib; CGT9486 + Sunitinib	KIT_inhibitor + KIT_inhibitor,first_generation; KIT_inhibitor + PDGFR_inhibitor; KIT_inhibitor + VEGFR_inhibitor; KIT_inhibitor,first_generation; PDGFR_inhibitor; VEGFR_inhibitor; KIT_inhibitor + KIT_inhibitor,first_generation; KIT_inhibitor + PDGFR_inhibitor; KIT_inhibitor + VEGFR_inhibitor	CGT9486-21-301	A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors	Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer	2200 - Bankstown - Bankstown-Lidcombe Hospital; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT05208047
NCT05208944	THIO-101	Phase 2	RECRUITING	QLD, SA, VIC	2022-01-13	2022-06-08	Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	THIO-101	A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO®) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)	Carcinoma, Non-Small-Cell Lung	3065 - Fitzroy - St. Vincent Hospital Melbourne; 4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic; 5000 - Adelaide - Cancer Research SA	https://clinicaltrials.gov/ct2/show/NCT05208944
NCT05215340	TROPION-Lung08	Phase 3	RECRUITING	NSW, SA, VIC	2022-01-18	2022-03-04	Datopotamab deruxtecan; Datopotamab deruxtecan + Pembrolizumab; Pembrolizumab	anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Datopotamab deruxtecan + Pembrolizumab; Pembrolizumab; Datopotamab deruxtecan + Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	DS1062-A-U304	A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)	Metastatic Non Small Cell Lung Cancer	2050 - Camperdown - Chris Obrien Lifehouse; 3084 - Heidelberg - Austin Hospital; 3149 - Mount Waverley - Peninsula and South Eastern Haematology and Oncology Group; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05215340
NCT05217446	SEAMARK	Phase 2	RECRUITING	NSW, QLD, VIC	2022-01-19	2022-07-11	Cetuximab; Cetuximab + Encorafenib + Pembrolizumab; Encorafenib; Pembrolizumab	anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Cetuximab + Encorafenib + Pembrolizumab; Pembrolizumab; Cetuximab + Encorafenib + Pembrolizumab	BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody	C4221022	A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER	Metastatic Colorectal Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - St Leonards - GenesisCare North Shore; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3052 - Parkville - Royal Melbourne Hospital; 3084 - Heidelberg - Austin Health; 4120 - Brisbane - Gallipoli Medical Research Foundation; 4120 - Greenslopes - Greenslopes Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05217446
NCT05220098	TAK-280-1501	Phase 1/Phase 2	RECRUITING	NSW, SA, VIC	2022-02-01	2022-04-22	TAK-280	bispecific_T-cell_engager,B7H3-targeting	TAK-280	bispecific_T-cell_engager,B7H3-targeting	TAK-280-1501	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Unresectable Locally Advanced or Metastatic Cancer	2050 - Camperdown - Chris O'Brien Lifehouse Hospital; 3144 - Malvern - Cabrini Health; 3168 - Clayton - Monash Medical Centre; 5042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT05220098
NCT05221840	PACIFIC-9	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2022-02-02	2022-02-07	Durvalumab; Durvalumab + Monalizumab; Durvalumab + Oleclumab; Monalizumab; Oleclumab; Placebo; Radiotherapy	anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-NKG2A_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; radiotherapy; placebo	Durvalumab; Durvalumab + Monalizumab; Durvalumab + Oleclumab; Durvalumab + Monalizumab; Durvalumab + Oleclumab; Placebo; Radiotherapy	anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; placebo; radiotherapy	D9078C00001	A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy	Non-Small Cell Lung Cancer	2065 - St. Leonards - Research Site - (WITHDRAWN); 2145 - Westmead - Research Site; 2217 - Kogarah - Research Site; 2250 - Gosford - Research Site; 3002 - East Melbourne - Research Site; 3021 - St Albans - Research Site; 3084 - Heidelberg - Research Site; 3128 - Box Hill - Research Site; 4101 - South Brisbane - Research Site; 5112 - Elizabeth Vale - Research Site	https://clinicaltrials.gov/ct2/show/NCT05221840
NCT05245968	NCT05245968	Phase 1	RECRUITING	VIC	2022-02-17	2021-12-01	Imatinib; Imatinib + Pimitespib; Pimitespib; Sunitinib	PDGFR_inhibitor; BCR-ABL1_inhibitor,first_generation + HSP90_inhibitor; BCR-ABL1_inhibitor,first_generation; VEGFR_inhibitor; KIT_inhibitor,first_generation; KIT_inhibitor; PDGFRA_inhibitor; HSP90_inhibitor + PDGFRA_inhibitor; HSP90_inhibitor + KIT_inhibitor; HSP90_inhibitor	Imatinib + Pimitespib; Sunitinib; Imatinib + Pimitespib	BCR-ABL1_inhibitor,first_generation + HSP90_inhibitor; HSP90_inhibitor + KIT_inhibitor; HSP90_inhibitor + PDGFRA_inhibitor; KIT_inhibitor,first_generation; PDGFR_inhibitor; VEGFR_inhibitor; BCR-ABL1_inhibitor,first_generation + HSP90_inhibitor; HSP90_inhibitor + KIT_inhibitor; HSP90_inhibitor + PDGFRA_inhibitor	10058060	A Phase 1 Study of TAS-116 (Pimitespib) in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumor	Gastrointestinal Stromal Tumors	Adelaide - Flinders Medical Center; Melbourne - Alfred Health	https://clinicaltrials.gov/ct2/show/NCT05245968
NCT05252390	NUV-868-01	Phase 1/Phase 2	RECRUITING	NSW, VIC, WA	2022-02-11	2022-03-29	Enzalutamide; Enzalutamide + NUV-868; NUV-868; NUV-868 + Olaparib; Olaparib	BET_inhibitor + antiandrogen,nonsteroidal,second_generation; BET_inhibitor + PARP_inhibitor; PARP_inhibitor; antiandrogen,nonsteroidal,second_generation; BET_inhibitor	Enzalutamide + NUV-868; NUV-868; NUV-868 + Olaparib; Enzalutamide + NUV-868; NUV-868 + Olaparib	BET_inhibitor; BET_inhibitor + PARP_inhibitor; BET_inhibitor + antiandrogen,nonsteroidal,second_generation; BET_inhibitor + PARP_inhibitor; BET_inhibitor + antiandrogen,nonsteroidal,second_generation	NUV-868-01	Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors	Advanced Solid Tumor; Ovarian Cancer; Ovary Cancer; Cancer of Ovary; Cancer of the Ovary; Ovary Neoplasm; Pancreatic Cancer; Pancreas Cancer; Cancer of Pancreas; Cancer of the Pancreas; Pancreas Neoplasm; Prostate Cancer; Prostatic Cancer; Cancer of Prostate; Cancer of the Prostate; Prostate Neoplasm; Castrate Resistant Prostate Cancer; Castration Resistant Prostatic Cancer; Castration Resistant Prostatic Neoplasms; Triple-negative Breast Cancer; Triple Negative Breast Cancer; Triple Negative Breast Neoplasms; Breast Cancer; Breast Carcinoma; Cancer of Breast; Cancer of the Breast; Breast Tumor	2109 - North Ryde - Macquarie University Hospital; 2298 - Waratah - Calvary Mater Hospital Newcastle; 3000 - Melbourne - Peter Maccallum Cancer Centre; 3144 - Malvern - Cabrini Hospital Malvern; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05252390
NCT05253651	MOUNTAINEER-03	Phase 3	RECRUITING	Other, QLD, VIC	2022-02-14	2022-10-24	Bevacizumab; Bevacizumab + Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin; Cetuximab; Fluorouracil; Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib; Leucovorin; Oxaliplatin; Trastuzumab; Tucatinib	anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody; anti-VEGF_monoclonal_antibody; Fluorouracil; ERBB2_inhibitor,third_generation; platinum-based_antineoplastic_agent; folinic_acid; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	Bevacizumab + Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin; Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib; Bevacizumab + Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin; Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	SGNTUC-029	An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer	Colorectal Neoplasms	3004 - Melbourne - The Alfred Hospital; 3065 - Fitzroy - St Vincent's Hospital Melbourne; 4814 - Townsville - Townsville Cancer Center	https://clinicaltrials.gov/ct2/show/NCT05253651
NCT05254171	ASPIRE	Phase 2/Phase 3	RECRUITING	ACT, Australia Capital Territory, NSW, SA, VIC, WA	2022-02-21	2022-08-08	Gemcitabine; Gemcitabine + Ivospemin + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Ivospemin; Nab-paclitaxel; Placebo	antimetabolite + taxane; antimetabolite + polyamine_analogue + taxane; antimetabolite; gemcitabine; polyamine_analogue; taxane; placebo	Gemcitabine + Ivospemin + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Gemcitabine + Ivospemin + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Placebo	antimetabolite + polyamine_analogue + taxane; antimetabolite + taxane; antimetabolite + polyamine_analogue + taxane; antimetabolite + taxane; gemcitabine; placebo	CL-SBP-101-04	A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IV	2485 - Tweed Heads - The Tweed Hospital - (WITHDRAWN); 2605 - Garran - Canberra Region Cancer Centre; 3084 - Heidelberg - Austin Hospital; 5307 - Kurralta Park - Ashford Cancer Centre Research; 6150 - Murdoch - St John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT05254171
NCT05261399	SAFFRON	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2022-02-25	2022-08-03	Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Osimertinib; Osimertinib + Savolitinib; Pemetrexed; Savolitinib	antimetabolite; EGFR_inhibitor,third_generation; MET_inhibitor,type_1; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + MET_inhibitor,type_1	Carboplatin + Cisplatin + Pemetrexed; Osimertinib + Savolitinib; Carboplatin + Cisplatin + Pemetrexed; Osimertinib + Savolitinib	EGFR_inhibitor,third_generation + MET_inhibitor,type_1; antimetabolite + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + MET_inhibitor,type_1; antimetabolite + platinum-based_antineoplastic_agent	D5087C00001	A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).	Carcinoma; Non-Small-Cell Lung	2145 - Westmead - Research Site; 2170 - Liverpool - Research Site; 2298 - Waratah NSW - Research Site; 3168 - Clayton - Research Site; 3220 - Geelong - Research Site - (WITHDRAWN); 4215 - Southport - Research Site; 6160 - Fremantle - Research Site	https://clinicaltrials.gov/ct2/show/NCT05261399
NCT05263180	EMB09X101	Phase 1	RECRUITING	NSW, VIC	2022-02-22	2022-07-25	EMB-09	bispecific_PD-L1/OX40_antibody	EMB-09	bispecific_PD-L1/OX40_antibody	EMB09X101	A First-in-human, Phase I Trial of EMB-09, a Bispecific Antibody Targeting PD-L1 and OX-40 in Patients With Advanced or Metastatic Solid Tumors	Advanced Solid Tumor	Frankston - Peninsula and South Eastern Haematology & Oncology Group; Leonards Hill - GenesisCareNorthShore; Sydney - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT05263180
NCT05267626	CP-AU-007-01	Phase 1/Phase 2	RECRUITING	NSW, SA, VIC	2022-02-23	2022-04-04	AU-007; AU-007 + Aldesleukin; Aldesleukin	anti-IL-2_monoclonal_antibody; IL-2_variant + anti-IL-2_monoclonal_antibody; IL-2_variant	AU-007; AU-007 + Aldesleukin; AU-007 + Aldesleukin	IL-2_variant + anti-IL-2_monoclonal_antibody; anti-IL-2_monoclonal_antibody; IL-2_variant + anti-IL-2_monoclonal_antibody	CP-AU-007-01	A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer	Advanced Solid Tumor; Metastatic Cancer	2228 - Miranda - Southside Cancer Care Centre; 3004 - Melbourne - The Alfred Hospital; 3021 - Saint Albans - Sunshine Hospital; 3084 - Heidelberg - Austin Health; 3168 - Clayton - Monash Health; 3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group; 5042 - Bedford Park - Mark Oliphant Building	https://clinicaltrials.gov/ct2/show/NCT05267626
NCT05269316	IMP9064-101	Phase 1	RECRUITING	NSW, WA	2022-03-03	2022-02-11	IMP9064; Senaparib	PARP_inhibitor; ATR_inhibitor	IMP9064; Senaparib	ATR_inhibitor; PARP_inhibitor	IMP9064-101	A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors	Solid Tumor; Advanced Solid Tumor	2148 - Blacktown - Blacktown Hospital; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT05269316
NCT05277051	GSK4381562-217228	Phase 1	RECRUITING	WA	2022-03-03	2022-03-22	Dostarlimab	anti-PD-1_monoclonal_antibody	Dostarlimab	anti-PD-1_monoclonal_antibody	217228	A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors	Neoplasms	6009 - Nedlands - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT05277051
NCT05277168	SHR-A1904-I-104	Phase 1/Phase 2	RECRUITING	NSW, QLD, VIC, WA	2022-03-03	2022-05-30	SHR-A1904	anti-CLDN18.2_antibody-drug_conjugate	SHR-A1904	anti-CLDN18.2_antibody-drug_conjugate	SHR-A1904-I-104	AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I/IIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS	Advanced Solid Tumors	2031 - Randwick - Scientia Clinical Research Ltd; 2109 - Sydney - Macquarie University; 2145 - Westmead - Westmead Hospital; 3199 - Frankston - Peninsula and South Eastern Haematology & Oncology Group (PASO); 4215 - Southport - Gold Coast Private Hospital; 8000 - Nedlands - One Clinical Research (OCR); Liverpool - Sydney South West Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05277168
NCT05279300	CS5001-101	Phase 1	RECRUITING	NSW, SA, VIC	2022-03-14	2022-03-28	CS5001	anti-ROR1_antibody-drug_conjugate	CS5001	anti-ROR1_antibody-drug_conjugate	CS5001-101	A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas	Advanced Solid Tumor; Advanced Lymphoma	2031 - Randwick - Scientia Clinical Research Limited; Adelaide - Ashford Cancer Centre Research	https://clinicaltrials.gov/ct2/show/NCT05279300
NCT05286801	NCI-2022-01992	Phase 1/Phase 2	RECRUITING	QLD	2022-03-15	2022-11-17	Atezolizumab; Atezolizumab + Tiragolumab; Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab + Tiragolumab; Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	NCI-2022-01992	A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors	Atypical Teratoid/Rhabdoid Tumor; Epithelioid Sarcoma; Kidney Medullary Carcinoma; Malignant Solid Neoplasm; Poorly Differentiated Chordoma; Recurrent Atypical Teratoid/Rhabdoid Tumor; Recurrent Chordoma; Recurrent Epithelioid Sarcoma; Recurrent Kidney Medullary Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Rhabdoid Tumor; Refractory Atypical Teratoid/Rhabdoid Tumor; Refractory Chordoma; Refractory Epithelioid Sarcoma; Refractory Kidney Medullary Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Rhabdoid Tumor; Rhabdoid Tumor	4101 - South Brisbane - Queensland Children's Hospital - (SUSPENDED)	https://clinicaltrials.gov/ct2/show/NCT05286801
NCT05290597	CIBI363A101	Phase 1	RECRUITING	NSW	2022-03-13	2022-08-22	IBI363	anti-PD-1_IL-2-immunocytokine_conjugate	IBI363	anti-PD-1_IL-2-immunocytokine_conjugate	CIBI363A101	A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas	Solid Malignancies or Lymphomas	2500 - Wollongong - Southern Medical Day Care Centre	https://clinicaltrials.gov/ct2/show/NCT05290597
NCT05303532	ROSY-D	Phase 3	ENROLLING_BY_INVITATION	VIC	2022-03-21	2022-04-19	Durvalumab	anti-PD-L1_monoclonal_antibody	Durvalumab	anti-PD-L1_monoclonal_antibody	D4191C00137	ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment	Cancer	3000 - Melbourne - Research Site; 3128 - Box Hill - Research Site	https://clinicaltrials.gov/ct2/show/NCT05303532
NCT05304585	ARST2032	Phase 3	RECRUITING	Auckland, NSW, NZ, WA	2022-03-28	2022-08-04	Cyclophosphamide; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Dactinomycin; Dactinomycin + Vincristine; Radiotherapy; Vincristine	alkylating_agent; antineoplastic_antibiotic; radiotherapy; vinca_alkaloid; antineoplastic_antibiotic + vinca_alkaloid; alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid	Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Dactinomycin + Vincristine; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Dactinomycin + Vincristine	alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; antineoplastic_antibiotic + vinca_alkaloid; alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; antineoplastic_antibiotic + vinca_alkaloid	ARST2032	A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma	Embryonal Rhabdomyosarcoma; Fusion-Negative Alveolar Rhabdomyosarcoma; Spindle Cell/Sclerosing Rhabdomyosarcoma	1145 - Grafton - Starship Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 6009 - Perth - Perth Children's Hospital; 8011 - Christchurch - Christchurch Hospital	https://clinicaltrials.gov/ct2/show/NCT05304585
NCT05306444	CLN-418-001	Phase 1	RECRUITING	NSW	2022-03-22	2022-05-12	CLN-418	bispecific_B7H4/4-1BB_antibody	CLN-418	bispecific_B7H4/4-1BB_antibody	CLN-418-001	A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2217 - Kogarah - St George Private Hospital; 2500 - Wollongong - Southern Medical Day Care Centre	https://clinicaltrials.gov/ct2/show/NCT05306444
NCT05307705	PIKASSO-01	Phase 1	RECRUITING	NSW, SA, VIC	2022-03-25	2022-05-11	Abemaciclib; Abemaciclib + Anastrozole + Exemestane + Fulvestrant + Imlunestrant + LOXO-783 + Letrozole; Anastrozole; Anastrozole + Exemestane + Fulvestrant + Imlunestrant + LOXO-783 + Letrozole; Exemestane; Fulvestrant; Fulvestrant + LOXO-783; Imlunestrant; LOXO-783; LOXO-783 + Paclitaxel; Letrozole; Paclitaxel	PI3Kalpha_H1047R_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + PI3Kalpha_H1047R_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; PI3Kalpha_H1047R_inhibitor; CDK4/6_inhibitor; PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + taxane; taxane	Abemaciclib + Anastrozole + Exemestane + Fulvestrant + Imlunestrant + LOXO-783 + Letrozole; Anastrozole + Exemestane + Fulvestrant + Imlunestrant + LOXO-783 + Letrozole; Fulvestrant + LOXO-783; LOXO-783; LOXO-783 + Paclitaxel; Abemaciclib + Anastrozole + Exemestane + Fulvestrant + Imlunestrant + LOXO-783 + Letrozole; Anastrozole + Exemestane + Fulvestrant + Imlunestrant + LOXO-783 + Letrozole; Fulvestrant + LOXO-783; LOXO-783 + Paclitaxel	CDK4/6_inhibitor + PI3Kalpha_H1047R_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor; PI3Kalpha_H1047R_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + taxane; CDK4/6_inhibitor + PI3Kalpha_H1047R_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + taxane	LOXO-PIK-21001	A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation	Breast Cancer; Solid Tumour	2010 - Sydney - St Vincent's Hospital Sydney; 3000 - Melbourne - Peter MacCallum Cancer Center; 5000 - Adelaide SA - Cancer Research SA	https://clinicaltrials.gov/ct2/show/NCT05307705
NCT05309421	EVX-01-001	Phase 2	RECRUITING	NSW, VIC, WA	2022-04-01	2022-08-30	EVX-01; EVX-01 + Pembrolizumab; Pembrolizumab	autologous_anticancer_vaccine; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + autologous_anticancer_vaccine	EVX-01 + Pembrolizumab; EVX-01 + Pembrolizumab	anti-PD-1_monoclonal_antibody + autologous_anticancer_vaccine; anti-PD-1_monoclonal_antibody + autologous_anticancer_vaccine	EVX-01-001	An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic Melanoma	Melanoma Stage III; Melanoma Stage IV	2065 - Wollstonecraft - Melanoma Institute Australia; 3350 - Ballarat Central - Ballarat Health Services (Grampians Health); 6009 - Nedlands - One Clinical Research; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT05309421
NCT05315700	ORIC-114-01	Phase 1/Phase 2	RECRUITING	NSW, VIC, WA	2022-04-06	2022-03-10	Carboplatin; ORIC-114	ERBB2_inhibitor,exon_20_selective; platinum-based_antineoplastic_agent; EGFR_inhibitor,exon_20_selective	ORIC-114; Carboplatin	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective; platinum-based_antineoplastic_agent	ORIC-114-01	An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration	Solid Tumors	Camperdown - Chris O'Brien Lifehouse; Melbourne - Peter MacCallum Cancer Centre; Nedlands - One Clinical Research, Hollywood Medical Centre; Sydney - Sydney Adventist Health	https://clinicaltrials.gov/ct2/show/NCT05315700
NCT05325866	FORTITUDE-301	Phase 1/Phase 2	RECRUITING	NSW, QLD, VIC, WA	2022-04-06	2022-09-23	Bemarituzumab	anti-FGFR2_monoclonal_antibody	Bemarituzumab	anti-FGFR2_monoclonal_antibody	20210104	A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)	Solid Tumors	2031 - Randwick - Prince of Wales Hospital; 2170 - Liverpool - Liverpool Hospital; 2500 - Wollongong - Wollongong Hospital; 3144 - Malvern - Cabrini Hospital; 4350 - Toowoomba - Toowoomba Hospital; 6150 - Murdoch - St John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT05325866
NCT05327530	MS100070-0119	Phase 2	RECRUITING	NSW, SA, TAS, VIC	2022-04-13	2022-08-17	Avelumab; Avelumab + Sacituzumab Govitecan; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Avelumab; Avelumab + Sacituzumab Govitecan; Avelumab + Sacituzumab Govitecan	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	MS100070_0119	A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)	Locally Advanced or Metastatic Urothelial Carcinoma	Bedford Park - Flinders Medical Centre; Clayton - Monash Medical Centre Clayton; Footscray - Sunshine Hospital - PARENT; Heidelberg - Austin Health; Kurralta Park - Ashford Cancer Centre Research; Liverpool - Liverpool Hospital - PARENT; Newcastle - Calvary Mater Newcastle - PARENT; Southport - Tasman Oncology Research Ltd - Oncology; St Leonards - Royal North Shore Hospital - PARENT; Sydney - Macquarie University Hospital - PARENT; Westmead - The Kinghorn Can Cen	https://clinicaltrials.gov/ct2/show/NCT05327530
NCT05332574	GB263T-FIH001	Phase 1/Phase 2	RECRUITING	NSW, VIC	2022-04-12	2022-05-17	GB263T	trispecific_EGFR/cMET/cMET_antibody	GB263T	trispecific_EGFR/cMET/cMET_antibody	GB263T-FIH001	A Phase I/II, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific EGFR/cMET/cMET Antibody GB263T in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors	NSCLC; Other Solid Tumors	2065 - Saint Leonards - Genesis Care; 2145 - Westmead - Westmead Hospital; 3065 - Melbourne - St Vincent's Hospital Melbourne; 3144 - Malvern - Cabrini Hospital Malvern	https://clinicaltrials.gov/ct2/show/NCT05332574
NCT05337137	RELATIVITY-106	Phase 1/Phase 2	RECRUITING	NSW, SA, VIC, WA	2022-04-13	2022-05-05	Bevacizumab; Bevacizumab + Nivolumab; Bevacizumab + Nivolumab + Relatlimab; Nivolumab; Placebo; Relatlimab	anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; placebo; anti-LAG3_monoclonal_antibody	Bevacizumab + Nivolumab; Bevacizumab + Nivolumab + Relatlimab; Bevacizumab + Nivolumab; Bevacizumab + Nivolumab + Relatlimab; Placebo	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; placebo	CA224-106	A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma	Carcinoma, Hepatocellular	2050 - Camperdown - Local Institution - 0045; 3065 - Melbourne - St. Vincents Hospital; 3084 - Heidelberg - Olivia Newton-John Cancer Research Institute; 5000 - Adelaide - Local Institution - 0022; 6009 - Nedlands - Local Institution - 0017	https://clinicaltrials.gov/ct2/show/NCT05337137
NCT05338346	ATRIUM	Phase 1	NOT_RECRUITING	NSW, QLD, VIC	2022-04-14	2022-07-08	ATG-018	ATR_inhibitor	ATG-018	ATR_inhibitor	ATG-018-001	A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies	Advanced Solid Tumors; Hematological Malignancies	Brisbane - Icon Cancer Centre South Brisbane; Camperdown - Chris O'Brien Lifehouse; Heidelberg - Austin Health; Melbourne - Alfred Health; Sydney - Liverpool Hospital	https://clinicaltrials.gov/ct2/show/NCT05338346
NCT05340374	LuCAB	Phase 1/Phase 2	RECRUITING	VIC	2022-04-14	2022-07-14	Cabazitaxel; Cabazitaxel + Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting; taxane; radioligand,PSMA-targeting + taxane	Cabazitaxel + Lu-177 vipivotide tetraxetan; Cabazitaxel + Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting + taxane; radioligand,PSMA-targeting + taxane	21/018	Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer	Metastatic Castration-resistant Prostate Cancer; mCRPC	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05340374
NCT05348577	CAPItello280	Phase 3	RECRUITING	NSW, QLD, SA	2022-04-21	2022-03-25	Capivasertib; Capivasertib + Docetaxel; Docetaxel; Placebo	pan-AKT_inhibitor + taxane; taxane; placebo; pan-AKT_inhibitor	Capivasertib + Docetaxel; Docetaxel; Capivasertib + Docetaxel; Placebo	pan-AKT_inhibitor + taxane; taxane; pan-AKT_inhibitor + taxane; placebo	D361EC00001	A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)	Prostate Cancer	2076 - Wahroonga - Research Site; 2217 - Kogarah - Research Site; 2228 - Miranda - Research Site; 2800 - Orange - Research Site; 4020 - Redcliffe - Research Site; 4120 - Greenslopes - Research Site; 4575 - Birtinya - Research Site; 5000 - North Adelaide - Research Site	https://clinicaltrials.gov/ct2/show/NCT05348577
NCT05349643	AMB-051-07	Phase 2	RECRUITING	NSW, QLD	2022-04-22	2023-01-26	AMB-05X	anti-CSF1R_monoclonal_antibody	AMB-05X	anti-CSF1R_monoclonal_antibody	AMB-051-07	A Phase 2, Open-Label, Adaptive, Dose-Ranging Study With Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra Articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor	Pigmented Villonodular Synovitis; TGCT; Tenosynovial Giant Cell Tumor	Camperdown - AmMax Bio, Clinical Site; Woolloongabba - AmMax Bio, Clinical Site	https://clinicaltrials.gov/ct2/show/NCT05349643
NCT05352672	R3767-ONC-2011	Phase 3	RECRUITING	QLD, SA, TAS, VIC	2022-04-25	2022-07-14	Cemiplimab; Cemiplimab + Fianlimab; Fianlimab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Cemiplimab; Cemiplimab + Fianlimab; Pembrolizumab; Cemiplimab + Fianlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	R3767-ONC-2011	A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma	Melanoma	03004 - Melbourne - The Alfred Hospital; 03220 - Geelong - Barwon Health Andrew Love Cancer Centre, University Hospital Geelong; 03355 - Wendouree - Ballarat Oncology and Haematology Clinical Trials Unit; 04814 - Townsville - The Townsville Hospital and Health Service; 05006 - Adelaide - Calvary North Adelaide Hospital; 4215 - Southport - Gold Coast University Hospital - (SUSPENDED); 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT05352672
NCT05355298	AMP945-PC-201	Phase 1/Phase 2	RECRUITING	NSW, QLD, VIC	2022-04-27	2022-05-31	AMP945; Gemcitabine; Nab-paclitaxel	antimetabolite; taxane; FAK_inhibitor	AMP945; Gemcitabine; Nab-paclitaxel	FAK_inhibitor; antimetabolite; taxane	AMP945-PC-201	A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients	Pancreatic Cancer; PDAC; Pancreatic Ductal Adenocarcinoma	2065 - St Leonards - GenesisCare; 2145 - Westmead - Westmead Hospital; 3021 - St Albans - Western Health; 3121 - Richmond - Epworth Healthcare; 3128 - Box Hill - Epworth Healthcare; 3168 - Clayton - Monash Health; 4120 - Greenslopes - Gallipolli Medical Research Foundation	https://clinicaltrials.gov/ct2/show/NCT05355298
NCT05356741	AMX-818-001	Phase 1/Phase 2	RECRUITING	NSW, VIC	2022-04-26	2022-04-13	AMX-818; AMX-818 + Pembrolizumab; Pembrolizumab	bispecific_T-cell_engager,ERBB2-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting; anti-PD-1_monoclonal_antibody	AMX-818; AMX-818 + Pembrolizumab; AMX-818 + Pembrolizumab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting; bispecific_T-cell_engager,ERBB2-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting	AMX-818-001	A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of AMX-818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers	Locally Advanced or Metastatic HER2-Expressing Cancers	2031 - Randwick - Investigational site number #101; 3000 - Melbourne - Investigational site number #100	https://clinicaltrials.gov/ct2/show/NCT05356741
NCT05361395	NCT05361395	Phase 1	RECRUITING	NSW	2022-04-29	2022-08-24	Atezolizumab; Atezolizumab + Carboplatin + Etoposide + Tarlatamab; Atezolizumab + Tarlatamab; Carboplatin; Carboplatin + Durvalumab + Etoposide + Tarlatamab; Durvalumab; Durvalumab + Tarlatamab; Etoposide; Tarlatamab	anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent	Atezolizumab + Carboplatin + Etoposide + Tarlatamab; Atezolizumab + Tarlatamab; Carboplatin + Durvalumab + Etoposide + Tarlatamab; Durvalumab + Tarlatamab; Atezolizumab + Carboplatin + Etoposide + Tarlatamab; Atezolizumab + Tarlatamab; Carboplatin + Durvalumab + Etoposide + Tarlatamab; Durvalumab + Tarlatamab	anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	20200469	A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung (DeLLphi-303)	Extensive Stage Small Cell Lung Cancer	2050 - Camperdown - Chris OBrien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT05361395
NCT05364073	FURMO-002	Phase 1	RECRUITING	NSW, VIC	2022-05-03	2022-06-30	Furmonertinib	EGFR_inhibitor,third_generation; ERBB2_inhibitor,exon_20_selective; EGFR_inhibitor,exon_20_selective	Furmonertinib	EGFR_inhibitor,exon_20_selective; EGFR_inhibitor,third_generation; ERBB2_inhibitor,exon_20_selective	FURMO-002	A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations	Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; HER2 Exon 20 Mutations; EGFR Exon 20 Mutations; EGFR Uncommon Mutations, Including G719X and S768I	2065 - St Leonards - ArriVent Investigative Site; 2148 - Blacktown - ArriVent Investigative Site; 3084 - Heidelberg - ArriVent Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05364073
NCT05367440	PETRANHA	Phase 1/Phase 2	RECRUITING	NSW, VIC	2022-05-05	2022-06-02	Abiraterone; Abiraterone + Saruparib; Apalutamide; Apalutamide + Saruparib; Darolutamide; Darolutamide + Saruparib; Enzalutamide; Enzalutamide + Saruparib; Saruparib	PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor; CYP17A1_inhibitor + PARP_inhibitor; CYP17A1_inhibitor; PARP1-selective_inhibitor; CYP17A1_inhibitor + PARP1-selective_inhibitor; antiandrogen,nonsteroidal,second_generation	Abiraterone + Saruparib; Apalutamide + Saruparib; Darolutamide + Saruparib; Enzalutamide + Saruparib; Abiraterone + Saruparib; Apalutamide + Saruparib; Darolutamide + Saruparib; Enzalutamide + Saruparib	CYP17A1_inhibitor + PARP1-selective_inhibitor; CYP17A1_inhibitor + PARP_inhibitor; PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP1-selective_inhibitor; CYP17A1_inhibitor + PARP_inhibitor; PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor + antiandrogen,nonsteroidal,second_generation	D9720C00003	A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)	Metastatic Prostate Cancer	2010 - Darlinghurst - Research Site; 2050 - Camperdown - Research Site; 2065 - St. Leonards - Research Site; 3002 - East Melbourne - Research Site; 3004 - Melbourne - Research Site; 3084 - Heidelberg - Research Site	https://clinicaltrials.gov/ct2/show/NCT05367440
NCT05381909	BGB-24714-101	Phase 1	RECRUITING	NZ, QLD, VIC	2022-05-16	2022-07-06	BGB-24714; BGB-24714 + Carboplatin + Paclitaxel; BGB-24714 + Docetaxel + Paclitaxel; BGB-24714 + Paclitaxel; Carboplatin; Docetaxel; Paclitaxel	SMAC_mimetic; IAP_inhibitor + taxane; IAP_inhibitor; SMAC_mimetic + platinum-based_antineoplastic_agent + taxane; IAP_inhibitor + platinum-based_antineoplastic_agent + taxane; taxane; SMAC_mimetic + taxane; platinum-based_antineoplastic_agent	BGB-24714; BGB-24714 + Carboplatin + Paclitaxel; BGB-24714 + Docetaxel + Paclitaxel; BGB-24714 + Paclitaxel; BGB-24714 + Carboplatin + Paclitaxel; BGB-24714 + Docetaxel + Paclitaxel; BGB-24714 + Paclitaxel	IAP_inhibitor; IAP_inhibitor + platinum-based_antineoplastic_agent + taxane; IAP_inhibitor + taxane; SMAC_mimetic; SMAC_mimetic + platinum-based_antineoplastic_agent + taxane; SMAC_mimetic + taxane; IAP_inhibitor + platinum-based_antineoplastic_agent + taxane; IAP_inhibitor + taxane; SMAC_mimetic + platinum-based_antineoplastic_agent + taxane; SMAC_mimetic + taxane	BGB-24714-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors	Solid Tumor, Adult	1023 - Auckland - Auckland City Hospital; 3084 - Heidelberg - Austin Health; 4101 - South Brisbane - Icon Cancer Care South Brisbane; 4102 - Brisbane - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT05381909
NCT05382286	ASCENT-04	Phase 3	RECRUITING	NSW, QLD, SA, TAS, VIC, WA	2022-05-16	2022-07-25	Carboplatin; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Sacituzumab Govitecan	gemcitabine; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent	Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; gemcitabine	GS-US-592-6173	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1	Triple Negative Breast Cancer; PD-L1 Positive	2060 - North Sydney - Mater Hospital - North Sydney; 2065 - St Leonards - GenesisCare - North Shore; 2217 - Kogarah - Saint George Hospital - Australia; 2640 - Albury - Border Medical Oncology; 3050 - Parkville - Peter MacCallum Cancer Centre; 3084 - Melbourne - Austin Hospital; 3168 - Clayton - Monash Medical Centre; 4101 - South Brisbane - Mater Misericordiae Limited and Mater Research Limited; 4102 - Woolloongabba - Princess Alexandra Hospital; 5000 - Adelaide - Cancer Research SA (CRSA); 6009 - Nedlands - Breast Cancer Research Center - Western Australia; 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT05382286
NCT05382299	ASCENT-03	Phase 3	RECRUITING	NSW, QLD, SA, TAS, VIC, WA	2022-05-16	2022-07-20	Carboplatin; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel; Gemcitabine; Nab-paclitaxel; Paclitaxel; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; taxane; platinum-based_antineoplastic_agent; gemcitabine; antimetabolite + platinum-based_antineoplastic_agent + taxane	Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel; Sacituzumab Govitecan; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel	anti-Trop2_antibody-drug_conjugate; antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent + taxane; gemcitabine	GS-US-592-6238	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1	Triple Negative Breast Cancer; PD-L1 Negative	2060 - North Sydney - Mater Hospital - North Sydney; 2065 - St Leonards - GenesisCare - North Shore; 2217 - Kogarah - Saint George Hospital - Australia; 2640 - Albury - Border Medical Oncology; 3084 - Melbourne - Austin Hospital; 3168 - Clayton - Monash Medical Centre; 4101 - South Brisbane - Mater Misericordiae Limited and Mater Research Limited; 4102 - Woolloongabba - Princess Alexandra Hospital; 5000 - Adelaide - Cancer Research SA (CRSA); 6009 - Nedlands - Breast Cancer Research Center - Western Australia; 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT05382299
NCT05383079	AlphaBet	Phase 1/Phase 2	RECRUITING	VIC	2022-05-16	2022-09-13	Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan + Radium-223; Radium-223	radioligand,PSMA-targeting; radium_223_radionuclide; radioligand,PSMA-targeting + radium_223_radionuclide	Lu-177 vipivotide tetraxetan + Radium-223; Lu-177 vipivotide tetraxetan + Radium-223	radioligand,PSMA-targeting + radium_223_radionuclide; radioligand,PSMA-targeting + radium_223_radionuclide	21/029	Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-resistant Prostate Cancer; mCRPC; Prostate Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05383079
NCT05384626	NVL-655-01	Phase 1/Phase 2	RECRUITING	NSW, QLD, VIC	2022-05-17	2022-06-09	Alectinib; Alectinib + Brigatinib + Ceritinib + Crizotinib + Lorlatinib + NVL-655; Alectinib + Brigatinib + Ceritinib + NVL-655; Brigatinib; Ceritinib; Crizotinib; Lorlatinib; Lorlatinib + NVL-655; NVL-655	ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + MET_inhibitor,type_1; MET_inhibitor,type_1; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1; ALK_inhibitor,fourth_generation + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/RET_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK_inhibitor,third_generation; ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation; ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK_inhibitor,fourth_generation; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation; ALK/ROS1/IGF1R_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor	Alectinib + Brigatinib + Ceritinib + Crizotinib + Lorlatinib + NVL-655; Alectinib + Brigatinib + Ceritinib + NVL-655; Lorlatinib + NVL-655; NVL-655; Alectinib + Brigatinib + Ceritinib + Crizotinib + Lorlatinib + NVL-655; Alectinib + Brigatinib + Ceritinib + NVL-655; Lorlatinib + NVL-655	ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ROS1_inhibitor; ALK_inhibitor,fourth_generation; ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation; ALK_inhibitor,fourth_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/RET_inhibitor + ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,first_generation + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ALK_inhibitor,third_generation + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + MET_inhibitor,type_1 + ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor + ALK_inhibitor,fourth_generation + ALK_inhibitor,second_generation + ROS1_inhibitor; ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation; ALK_inhibitor,fourth_generation + ROS1_inhibitor	NVL-655-01	A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)	Locally Advanced Solid Tumor; Metastatic Solid Tumor	2065 - Saint Leonards - Royal North Shore Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT05384626
NCT05393791	ANZadapt	Phase 2	RECRUITING	NSW, QLD, SA, WA	2022-05-23	2022-11-10	Abiraterone; Abiraterone + Enzalutamide; Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation	Abiraterone + Enzalutamide; Abiraterone + Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	79835	ANZadapt: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer	Prostatic Neoplasms, Castration-Resistant	2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - St Leonards - Genesis Care North Shore; 2076 - Wahroonga - Sydney Adventist Hospital; 2298 - Newcastle - Calvary Mater Newcastle; 2460 - Albury - Border Medical Oncology Research Unit / The Border Cancer Hospital; 4101 - South Brisbane - Mater Hospital Brisbane; 5000 - Adelaide - Royal Adelaide Hospital; 6150 - Murdoch - Fiona Stanly Hospital	https://clinicaltrials.gov/ct2/show/NCT05393791
NCT05399654	INCLINE-101	Phase 1/Phase 2	RECRUITING	WA	2022-05-26	2022-06-28	TAC-001	TLR9_agonistic_antibody_conjugate	TAC-001	TLR9_agonistic_antibody_conjugate	INCLINE-101	A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	6009 - Nedlands - Clinical Site	https://clinicaltrials.gov/ct2/show/NCT05399654
NCT05410145	D3S-001-100	Phase 1/Phase 2	RECRUITING	NSW, VIC, WA	2022-06-06	2022-08-03	Carboplatin; Carboplatin + Cisplatin + D3S-001 + Pemetrexed; Cetuximab; Cetuximab + D3S-001; Cisplatin; D3S-001; D3S-001 + Pembrolizumab; Pembrolizumab; Pemetrexed	antimetabolite; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor	Carboplatin + Cisplatin + D3S-001 + Pemetrexed; Cetuximab + D3S-001; D3S-001; D3S-001 + Pembrolizumab; Carboplatin + Cisplatin + D3S-001 + Pemetrexed; Cetuximab + D3S-001; D3S-001 + Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent	D3S-001-100	A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation	KRAS P.G12C	2109 - Sydney - D3 Bio Investigative Site; 3144 - Malvern - D3 Bio Investigative Site; 6009 - Nedlands - D3 Bio Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05410145
NCT05411133	A001	Phase 1	RECRUITING	NSW, VIC	2022-06-05	2022-05-30	ARB202	bispecific_T-cell_engager,CDH17-targeting	ARB202	bispecific_T-cell_engager,CDH17-targeting	A001	A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies	Gastrointestinal Cancer; Cholangiocarcinoma; Liver Cancer; Colorectal Adenocarcinoma; Pancreatic Cancer; Gastric Cancer; Esophageal Adenocarcinoma; Gastroesophageal Junction	Adelaide - Southern Oncology Clinical Research Unit; Sydney - St George Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05411133
NCT05415072	CDYP688A12101	Phase 1/Phase 2	RECRUITING	NSW, VIC	2022-06-08	2022-07-04	DYP688; DYP688 + Tebentafusp; Tebentafusp	GNAQ/GNA11_inhibitor; GNAQ/GNA11_inhibitor + anti-CD3/scFv_fusion_protein,gp100-targeting; anti-CD3/scFv_fusion_protein,gp100-targeting	DYP688; DYP688 + Tebentafusp; DYP688 + Tebentafusp	GNAQ/GNA11_inhibitor; GNAQ/GNA11_inhibitor + anti-CD3/scFv_fusion_protein,gp100-targeting; GNAQ/GNA11_inhibitor + anti-CD3/scFv_fusion_protein,gp100-targeting	CDYP688A12101	A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas	Metastatic Uveal Melanoma	2145 - Westmead - Novartis Investigative Site; 3000 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05415072
NCT05417594	CERTIS1	Phase 1/Phase 2	RECRUITING	NSW, VIC	2022-06-09	2022-08-04	AZD9574; AZD9574 + Datopotamab deruxtecan; AZD9574 + Temozolomide; AZD9574 + Trastuzumab Deruxtecan; Datopotamab deruxtecan; Temozolomide; Trastuzumab Deruxtecan	alkylating_agent; anti-ERBB2_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-Trop2_antibody-drug_conjugate; PARP1-selective_inhibitor + alkylating_agent; PARP1-selective_inhibitor; anti-Trop2_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate	AZD9574; AZD9574 + Datopotamab deruxtecan; AZD9574 + Temozolomide; AZD9574 + Trastuzumab Deruxtecan; AZD9574 + Datopotamab deruxtecan; AZD9574 + Temozolomide; AZD9574 + Trastuzumab Deruxtecan	PARP1-selective_inhibitor; PARP1-selective_inhibitor + alkylating_agent; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-Trop2_antibody-drug_conjugate; PARP1-selective_inhibitor + alkylating_agent; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-Trop2_antibody-drug_conjugate	D8410C00001	A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)	Advanced Solid Malignancies	2010 - Darlinghurst - Research Site; 2031 - Randwick - Research Site; 2050 - Camperdown - Research Site; 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT05417594
NCT05419375	BX43361	Phase 2	RECRUITING	NSW, NZ, VIC, WA	2022-06-13	2022-07-22					BX43361	Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors	Solid Tumors	1023 - Auckland - Auckland City Hospital, Cancer and Blood Research; 2050 - Camperdown - Lifehouse; 2065 - St Leonards - Northern Cancer Institute - (WITHDRAWN); 2145 - Westmead - Westmead Hospital; Medical Oncology and Pallative Care - (WITHDRAWN); 3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology; 6009 - Nedlands - One Clinical Research - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT05419375
NCT05419388	BP43963	Phase 1/Phase 2	NOT_RECRUITING	NSW, NZ, QLD, WA	2022-06-13	2022-08-15	RO7247669	bispecific_PD-1/LAG3_antibody	RO7247669	bispecific_PD-1/LAG3_antibody	BP43963	A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma	Melanoma	1023 - Auckland - Auckland City Hospital, Cancer and Blood Research; 2060 - North Sydney - Melanoma Institute Australia; 2450 - Coffs Harbour - Coffs Harbour Health Campus; 4102 - Woolloongabba - Princess Alexandra Hospital; Cancer Trials Unit; 6002 - Wellington - Wellington Hospital; Regional Oncology Unit; 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05419388
NCT05425940	STELLAR-303	Phase 3	RECRUITING	NSW, NZ, SA, VIC	2022-06-16	2022-09-07	Atezolizumab; Atezolizumab + Zanzalintinib; Regorafenib; Zanzalintinib	MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967|[111In]-FPI-1967; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Zanzalintinib; Regorafenib; Atezolizumab + Zanzalintinib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-PD-L1_monoclonal_antibody	XL092-303	A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer	Colorectal Cancer	1023 - Auckland - Exelixis Clinical Site #57; 2200 - Bankstown - Exelixis Clinical Site #53; 2444 - Port Macquarie - Exelixis Clinical Site #27; 2640 - Albury - Exelixis Clinical Site #83; 3002 - Melbourne - Exelixis Clinical Site #19; 3021 - Melbourne - Exelixis Clinical Site #23; 3084 - Heidelberg - Exelixis Clinical Site #97; 3204 - Hamilton - Exelixis Clinical Site #69; 5011 - Woodville South - Exelixis Clinical Site #64; 5042 - Bedford Park - Exelixis Clinical Site #117; 6021 - Wellington - Exelixis Clinical Site #104; 9016 - Dunedin - Exelixis Clinical Site #49	https://clinicaltrials.gov/ct2/show/NCT05425940
NCT05428735	DRAGON-2	NA	RECRUITING	VIC	2022-06-17	2022-04-01					NL80303.068.22	An International Multicenter Randomized Controlled Trial to Compare Combined Portal and Hepatic Vein Embolization (PVE/HVE) With PVE Alone in Patients With Colorectal Liver Cancer Metastases (CRLM) and a Small Future Liver Remnant (FLR)	Colorectal Cancer Liver Metastases (CRLM); Small Future Liver Remnant (FLR)	3168 - Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT05428735
NCT05440786	NCT05440786	Phase 2	RECRUITING	NSW, VIC	2022-06-28	2022-09-20	Abemaciclib; Abemaciclib + Irinotecan + Temozolomide; Irinotecan; Irinotecan + Temozolomide; Temozolomide	alkylating_agent; CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; CDK4/6_inhibitor	Abemaciclib + Irinotecan + Temozolomide; Irinotecan + Temozolomide; Abemaciclib + Irinotecan + Temozolomide; Irinotecan + Temozolomide	CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor	18434	A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma	Sarcoma, Ewing; Neoplasm Metastasis	2145 - Westmead - The Children's Hospital at Westmead; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3052 - Melbourne - Royal Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT05440786
NCT05450744	IPAX-2	Phase 1	RECRUITING	NZ, QLD, SA, VIC	2022-07-06	2023-04-01	131I-IPA; 131I-TLX-101	radioligand,LAT1/2-targeting; radioiodine_conjugate	131I-IPA; 131I-TLX-101	radioiodine_conjugate; radioligand,LAT1/2-targeting	131I-TLX-101-002 (IPAX-2)	A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma	Neoplastic Disease; Glioblastoma; Glioblastoma Multiforme	Adelaide - Royal Adelaide Hospital; Auckland - Mercy Hospital; Gold Coast - Gold Coast University Hospital; Melbourne - Olivia Newton John Cancer Research Institute/Austin Health	https://clinicaltrials.gov/ct2/show/NCT05450744
NCT05458219	CIBI343A101	Phase 1	RECRUITING	QLD	2022-07-11	2022-10-26	IBI343	anti-CLDN18.2_antibody-drug_conjugate	IBI343	anti-CLDN18.2_antibody-drug_conjugate	CIBI343A101	A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors	Locally Advanced Unresectable or Metastatic Solid Tumors	4217 - Benowa - Pindara Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05458219
NCT05459129	CO43613	Phase 1/Phase 2	RECRUITING	SA, WA	2022-07-12	2023-04-13	Atezolizumab; Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab; Carboplatin; Paclitaxel; Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab; Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	CO43613	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)	Squamous Cell Carcinoma of the Head and Neck	5000 - Adelaide - Cancer Research SA; 6009 - Perth - Sir Charles Gairdner Hospital; Medical Oncology - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT05459129
NCT05462236	AUM001-2001-MK3475-D65	Phase 2	RECRUITING	NSW, QLD, VIC	2022-07-13	2023-04-14	AUM001; Irinotecan; Irinotecan + Pembrolizumab; Pembrolizumab	MNK_inhibitor; anti-PD-1_monoclonal_antibody; topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + topoisomerase_inhibitor	Irinotecan + Pembrolizumab; AUM001; Irinotecan + Pembrolizumab	anti-PD-1_monoclonal_antibody + topoisomerase_inhibitor; MNK_inhibitor; anti-PD-1_monoclonal_antibody + topoisomerase_inhibitor	AUM001-2001-MK3475-D65	A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2500 - Wollongong - Prince of Wales Hospital; 3144 - Malvern - Cabrini Hospital; 3355 - Wendouree - Ballarat Oncology and Haematology; 4217 - Benowa - Pindara Private Hospital, Gold Coast Cancer Care	https://clinicaltrials.gov/ct2/show/NCT05462236
NCT05466799	TRIPP-FFX	Phase 2	RECRUITING	SA, VIC	2022-07-18	2023-04-26	Leucovorin; OncoSil	brachytherapy; folinic_acid	OncoSil; Leucovorin	brachytherapy; folinic_acid	ONCO01P04	An Open-label, Multi-centre, Randomized Study of TaRgeted Intratumoural Placement of P-32 (OncoSil™) in Addition to FOLFIRINOX Chemotherapy vs FOLFIRINOX Alone in Patients With Unresectable Locally Advanced Pancreatic Adenocarcinoma.	Locally Advanced Pancreatic Cancer	Adelaide - Royal Adelaide Hospital; Richmond - Epworth Healthcare	https://clinicaltrials.gov/ct2/show/NCT05466799
NCT05468697	6482-024	Phase 1/Phase 2	RECRUITING	NSW	2022-07-18	2022-08-10	Belzutifan; Belzutifan + Palbociclib; Palbociclib; Thiotepa	alkylating_agent; CDK4/6_inhibitor + HIF2a_inhibitor; CDK4/6_inhibitor; HIF2a_inhibitor	Belzutifan; Belzutifan + Palbociclib; Belzutifan + Palbociclib; Thiotepa	CDK4/6_inhibitor + HIF2a_inhibitor; HIF2a_inhibitor; CDK4/6_inhibitor + HIF2a_inhibitor; alkylating_agent	6482-024	A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma	Renal Cell Carcinoma	2109 - Macquarie University - Macquarie University-MQ Health Clinical Trials Unit ( Site 2001)	https://clinicaltrials.gov/ct2/show/NCT05468697
NCT05480865	Argonaut	Phase 1	RECRUITING	NSW, SA, VIC, WA	2022-07-27	2022-07-06	BBP-398; BBP-398 + Sotorasib; Sotorasib	SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	BBP-398 + Sotorasib; BBP-398 + Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor	NAV-1003	A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation	Solid Tumor, Adult; Metastatic Solid Tumor; Metastatic NSCLC; Non Small Cell Lung Cancer	3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group; 5000 - Adelaide - Cancer Research SA; 5042 - Adelaide - Southern Oncology Clinical Research Unit; 6008 - Subiaco - St John of God Subiaco Hospital; 6009 - Perth - One Clinical Research; NSW 2800 - Orange - Orange Health Service	https://clinicaltrials.gov/ct2/show/NCT05480865
NCT05487235	GO43712	Phase 1	RECRUITING	NSW, NZ, SA, VIC, WA	2022-08-02	2022-08-17	Atezolizumab; Atezolizumab + RLY-1971; RLY-1971	anti-PD-L1_monoclonal_antibody; SHP2_inhibitor + anti-PD-L1_monoclonal_antibody; SHP2_inhibitor	Atezolizumab + RLY-1971; Atezolizumab + RLY-1971	SHP2_inhibitor + anti-PD-L1_monoclonal_antibody; SHP2_inhibitor + anti-PD-L1_monoclonal_antibody	GO43712	A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumors; Metastatic Solid Tumors	1124 - Auckland - Auckland City Hospital; 2010 - Darlinghurst - St Vincent's Hospital Sydney; 3084 - Heidelberg - Austin Hospital; 3690 - Wodonga - Border Medical Oncology; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - One Clinical Research Perth	https://clinicaltrials.gov/ct2/show/NCT05487235
NCT05494918	JSKN003-101	Phase 1	RECRUITING	WA	2022-08-08	2022-09-02	JSKN003	anti-ERBB2_antibody-drug_conjugate	JSKN003	anti-ERBB2_antibody-drug_conjugate	JSKN003-101	A Phase I, Multi-center, Open-label, Dose Escalation, First-In-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of JSKN003 in Subjects With Advanced or Metastatic Solid Malignant Tumors	Advanced Solid Tumors; Metastatic Solid Tumors	6009 - Perth - Breast Cancer Research Centre	https://clinicaltrials.gov/ct2/show/NCT05494918
NCT05498597	AMT-151-01	Phase 1	RECRUITING	NSW, QLD, SA, VIC, WA	2022-08-10	2023-01-25	AMT-151	anti-FR-alpha_antibody-drug_conjugate	AMT-151	anti-FR-alpha_antibody-drug_conjugate	AMT-151-01	First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours	Advanced Solid Tumor; Advanced Cancer; Advanced Carcinoma; Ovarian Cancer; Ovarian Carcinoma; Ovarian Epithelial Cancer; Ovarian Endometrioid Adenocarcinoma; Endometrial Cancer; Endometrial Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Lung Adenocarcinoma; Triple Negative Breast Cancer; Pancreatic Ductal Adenocarcinoma; Malignant Pleural Mesothelioma; Ovarian Clear Cell Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Mucinous Adenocarcinoma	Adelaide - Cancer Research SA; Brisbane - ICON Cancer Centre; Malvern - Cabrini Malvern Hospital; Perth - One Clinical Research (OCR); South Brisbane - Mater Cancer Care Centre; Sydney - Chris O'Brien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT05498597
NCT05500508	AMXT1501-102	Phase 1/Phase 2	RECRUITING	NSW	2022-08-12	2022-11-29	AMXT-1501	polyamine_transport_inhibitor	AMXT-1501	polyamine_transport_inhibitor	AMXT1501-102	A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer	Cancer; Solid Tumor; Solid Carcinoma; Advanced Cancer; DIPG Brain Tumor; Ovary Cancer; Breast Cancer; Papillary Thyroid Cancer; Head and Neck Cancer; Gastric Cancer; Nsclc; Mesotheliomas Pleural; Mesothelioma Peritoneum; Esophageal Cancer; Diffuse Midline Glioma, H3 K27M-Mutant; Endometrial Cancer; Cervical Cancer; Melanoma; Colorectal Cancer; Glioma, Malignant	Sydney - Kids Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05500508
NCT05501886	VIKTORIA-1	Phase 3	RECRUITING	NSW, QLD, SA, TAS, VIC, WA	2022-08-12	2022-09-30	Alpelisib; Alpelisib + Fulvestrant; Fulvestrant; Fulvestrant + Gedatolisib; Fulvestrant + Gedatolisib + Palbociclib; Gedatolisib; Palbociclib	selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor	Alpelisib + Fulvestrant; Fulvestrant; Fulvestrant + Gedatolisib; Fulvestrant + Gedatolisib + Palbociclib; Alpelisib + Fulvestrant; Fulvestrant + Gedatolisib; Fulvestrant + Gedatolisib + Palbociclib	CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader	CELC-G-301	Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy	Breast Cancer	Adelaide - Adelaide Oncology & Haematology; Fitzroy - St Vincent's Hospital (Melbourne) Ltd; Frankston - Peninsula & South Eastern Hematology and Oncology Group (PSEHOG); Nedlands - Hollywood Private Hospital, Breast Cancer Research Centre; South Brisbane - Mater Hospital Brisbane, Mater Cancer Care Centre; Southport - Icon Cancer Centre- Southport; Wahroonga - Sydney Adventist Hospital; Woodville - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05501886
NCT05504291	ARET2121	Phase 2	RECRUITING	WA	2022-08-15	2022-11-04	Carboplatin; Carboplatin + Etoposide + Melphalan + Vincristine; Etoposide; Melphalan; Vincristine	alkylating_agent; topoisomerase_inhibitor; alkylating_agent + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; platinum-based_antineoplastic_agent; vinca_alkaloid	Carboplatin + Etoposide + Melphalan + Vincristine; Carboplatin + Etoposide + Melphalan + Vincristine	alkylating_agent + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid	ARET2121	Intravitreal Melphalan for Intraocular Retinoblastoma	Bilateral Retinoblastoma; Childhood Intraocular Retinoblastoma; Group D Retinoblastoma; Stage I Retinoblastoma; Unilateral Retinoblastoma	6009 - Perth - Perth Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT05504291
NCT05508906	OP-1250-003	Phase 1	RECRUITING	NSW, WA	2022-08-18	2022-08-31	Alpelisib; Alpelisib + Palazestrant; Palazestrant; Palazestrant + Ribociclib; Ribociclib	PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + complete_estrogen_receptor_antagonist; complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; CDK4/6_inhibitor	Alpelisib + Palazestrant; Palazestrant + Ribociclib; Alpelisib + Palazestrant; Palazestrant + Ribociclib	CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; PI3K_alpha_inhibitor + complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; PI3K_alpha_inhibitor + complete_estrogen_receptor_antagonist	OP-1250-003	A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination With the CDK4/6 Inhibitor Ribociclib or With the PI3K Inhibitor Alpelisib in Adult Subjects With Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer	Metastatic Breast Cancer; Advanced Breast Cancer; HR-positive Breast Cancer; HER2-negative Breast Cancer	2109 - New South Wales - Macquarie Health; 6009 - Nedlands - Breast Cancer Research Center- Western Australia	https://clinicaltrials.gov/ct2/show/NCT05508906
NCT05509985	ASKG315-101	Phase 1	NOT_YET_RECRUITING	NSW, VIC	2022-08-18	2023-08-09	ASKG315; Pembrolizumab	IL-15_prodrug; anti-PD-1_monoclonal_antibody	ASKG315; Pembrolizumab	IL-15_prodrug; anti-PD-1_monoclonal_antibody	ASKG315-101	A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumors	Melbourne - The Alfred Hospital; Sydney - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT05509985
NCT05512377	1403-0011	Phase 2	RECRUITING	NSW, QLD, SA, VIC	2022-08-22	2022-11-25	Brigimadlin	MDM2_inhibitor	Brigimadlin	MDM2_inhibitor	1403-0011	Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours	Pancreatic Neoplasms; Solid Tumors; Biliary Tract Cancer; Lung Neoplasms; Bladder Cancer	2031 - Randwick - Prince of Wales Hospital; 3084 - Heidelberg - Austin Health; 4101 - South Brisbane - ICON; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT05512377
NCT05519449	PSMA-007-001	Phase 1	RECRUITING	NSW, SA, WA	2022-08-25	2022-09-15	JANX007	PSMA-tumor-activated_T-cell_engager	JANX007	PSMA-tumor-activated_T-cell_engager	PSMA-007-001	A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Castration Resistant Prostatic Cancer	2050 - Camperdown - Chris O'Brien Lifehouse (COBLH); 5042 - Bedford Park - Southern Oncology Clinical Research Unit (SoCRU); 6009 - Nedlands - Linear Clinical Research Ltd.	https://clinicaltrials.gov/ct2/show/NCT05519449
NCT05523947	YH32367-101	Phase 1/Phase 2	RECRUITING	NSW, VIC, WA	2022-08-29	2022-08-26	YH32367	bispecific_ERBB2/4-1BB_antibody	YH32367	bispecific_ERBB2/4-1BB_antibody	YH32367-101	A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors	HER2-Positive Solid Tumor	Adelaide - Southern Oncology Clinical Research Unit; Melbourne - Austin Health; Perth - Breast Cancer Research Centre - WA - (WITHDRAWN); Sydney - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT05523947
NCT05525247	SLC-3010-001	Phase 1/Phase 2	RECRUITING	NSW, Perth, WA	2022-08-30	2022-12-21	Gemcitabine	antimetabolite; gemcitabine	Gemcitabine	antimetabolite; gemcitabine	SLC-3010-001	A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination With Various Anticancer Therapies in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2298 - Waratah - Selecxine Investigator site; 6153 - Brentwood - Selecxine Investigator site	https://clinicaltrials.gov/ct2/show/NCT05525247
NCT05533697	mRNA-4359-P101	Phase 1/Phase 2	RECRUITING	NSW, VIC, WA	2022-09-07	2022-08-18	Pembrolizumab; Pembrolizumab + mRNA-4359; mRNA-4359	anti-PD-1_monoclonal_antibody; mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting	Pembrolizumab + mRNA-4359; mRNA-4359; Pembrolizumab + mRNA-4359	anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting	mRNA-4359-P101	Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors	Advanced Solid Tumors	2065 - Wollstonecraft - Melanoma Institute Australia; 2228 - Miranda - Southside Cancer Center; 3084 - Melbourne - Austin Hospital; 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05533697
NCT05544552	SURF301	Phase 1/Phase 2	RECRUITING	NSW, QLD, VIC, WA	2022-09-15	2022-11-22	TYRA-300	FGFR3_inhibitor	TYRA-300	FGFR3_inhibitor	TYR300-101	A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)	Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor; Urothelial Carcinoma; Solid Tumor, Adult; Bladder Cancer; Non-muscle-invasive Bladder Cancer; FGFR3 Gene Mutation; FGFR3 Gene Alteration; Advanced Solid Tumor; Advanced Urothelial Carcinoma; Urinary Tract Cancer; Urinary Tract Tumor; Urinary Tract Carcinoma	2109 - Macquarie Park - Macquarie University; 3000 - Melbourne - Peter MacCallum Cancer Research Unit; 3084 - Heidelberg - Austin Health; 4102 - Woolloongabba - Princess Alexandra Hospital; 4215 - Southport - Tasman Oncology; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT05544552
NCT05549297	IMCgp100-203	Phase 2/Phase 3	RECRUITING	NSW, QLD, VIC	2022-09-19	2022-12-19	Pembrolizumab; Pembrolizumab + Tebentafusp; Tebentafusp	anti-PD-1_monoclonal_antibody; anti-CD3/scFv_fusion_protein,gp100-targeting + anti-PD-1_monoclonal_antibody; anti-CD3/scFv_fusion_protein,gp100-targeting	Pembrolizumab + Tebentafusp; Tebentafusp; Pembrolizumab + Tebentafusp	anti-CD3/scFv_fusion_protein,gp100-targeting; anti-CD3/scFv_fusion_protein,gp100-targeting + anti-PD-1_monoclonal_antibody; anti-CD3/scFv_fusion_protein,gp100-targeting + anti-PD-1_monoclonal_antibody	IMCgp100-203	Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)	Advanced Melanoma	2065 - Wollstonecraft - Melanoma Institute Australia; 3004 - Melbourne - Alfred Health; 4102 - Woolloongabba - Princess Alexandra Hospital; 4120 - Greenslopes - Gallipoli Medical Research Foundation (GMRF)	https://clinicaltrials.gov/ct2/show/NCT05549297
NCT05555732	DS1062-A-U303	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2022-09-22	2023-01-11	Carboplatin; Carboplatin + Cisplatin + Datopotamab deruxtecan + Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Datopotamab deruxtecan; Datopotamab deruxtecan + Pembrolizumab; Pembrolizumab; Pemetrexed	antimetabolite; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Datopotamab deruxtecan + Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Datopotamab deruxtecan + Pembrolizumab; Carboplatin + Cisplatin + Datopotamab deruxtecan + Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Datopotamab deruxtecan + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	DS1062-A-U303	A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)	Metastatic Non Small Cell Lung Cancer	2500 - Wollongong - Southern Medical Day Care Centre; 3199 - Frankston - PSEHOG (Peninsula and South Eastern Haematology and Oncology Group); 5000 - Adelaide - CRSA/ St Andrews Hospital; 5042 - Bedford Park - Flinders Medical Centre (Fmc); QLD 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT05555732
NCT05570227	MetaMel	NA	RECRUITING	VIC	2022-10-04	2023-06-27					21/164	Identification of Metabolic Phenotypes Associated With Prognosis and Therapeutic Response in Patients With Melanoma	Melanoma	3002 - Melbourne - Peter Mac Callum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05570227
NCT05577416	AB-218-IIT-201	EARLY_Phase 1	RECRUITING	VIC	2022-10-11	2022-10-11	Safusidenib	IDH1_R132_inhibitor	Safusidenib	IDH1_R132_inhibitor	2022.003	A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma	Glioma	Melbourne - Royal Melbourne Hospital	https://clinicaltrials.gov/ct2/show/NCT05577416
NCT05577715	CA116-003	Phase 2	RECRUITING	NSW, VIC, WA	2022-10-10	2022-11-14	Farletuzumab Ecteribulin	anti-FR-alpha_antibody-drug_conjugate	Farletuzumab Ecteribulin	anti-FR-alpha_antibody-drug_conjugate	CA116-003	A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies	Carcinoma, Non-Small-Cell Lung	1871 - Liverpool - Local Institution - 0032; 2500 - Wollongong - Local Institution - 0040; 3350 - Ballarat Central - Local Institution - 0012; 6150 - Murdoch - Local Institution - 0022	https://clinicaltrials.gov/ct2/show/NCT05577715
NCT05580770	MEKRAF-AST-101	Phase 1/Phase 2	RECRUITING	NSW, VIC	2022-10-11	2023-02-03	BGB-3245; BGB-3245 + Mirdametinib; Mirdametinib	MEK_inhibitor + RAF_dimer_inhibitor; RAF_dimer_inhibitor; MEK_inhibitor	BGB-3245 + Mirdametinib; BGB-3245 + Mirdametinib	MEK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor	MEKRAF-AST-101	A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2298 - Waratah - Calvary Mater Newcastle; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05580770
NCT05581004	GO43860	Phase 1	RECRUITING	NSW, VIC, WA	2022-10-12	2022-10-20	Atezolizumab; Atezolizumab + RO7502175; RO7502175	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + unknown_drug_class; unknown_drug_class	Atezolizumab + RO7502175; RO7502175; Atezolizumab + RO7502175	anti-PD-L1_monoclonal_antibody + unknown_drug_class; unknown_drug_class; anti-PD-L1_monoclonal_antibody + unknown_drug_class	GO43860	A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors; NSCLC; HNSCC; Melanoma; TNBC; Esophageal Cancer; Gastric Cancer; Cervical Cancer; Urothelial Carcinoma; Clear Cell RCC; HCC	2010 - Darlinghurst - Kinghorn Cancer Centre; St Vincents Hospital; 3168 - Clayton - Monash Health Monash Medical Centre; 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT05581004
NCT05598151	HM-EZHI-101	Phase 1	RECRUITING	VIC	2022-10-24	2023-01-11	HM97662	EZH1/2_inhibitor	HM97662	EZH1/2_inhibitor	HM-EZHI-101	A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	Adelaide - Cancer Research SA; Ballarat - Grampians Health; Clayton - Monash Medical Centre; Frankston - Peninsula and Southeast Oncology	https://clinicaltrials.gov/ct2/show/NCT05598151
NCT05599984	M23-385	Phase 1	RECRUITING	NSW, VIC	2022-10-28	2022-12-05	Budigalimab; Carboplatin; Carboplatin + Cisplatin; Cisplatin	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent	Budigalimab; Carboplatin + Cisplatin; Carboplatin + Cisplatin	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent	M23-385	A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors	Advanced Solid Tumors	2010 - Darlinghurst - The Kinghorn Cancer Centre /ID# 260874; 2050 - Camperdown - Chris O'Brien Lifehouse /ID# 259087; 3000 - Melbourne - Peter MacCallum Cancer Ctr /ID# 259197; 3084 - Heidelberg - Austin Health and Ludwig Institute for Cancer Research /ID# 255174	https://clinicaltrials.gov/ct2/show/NCT05599984
NCT05605522	FPI-2059-101	Phase 1	RECRUITING	NSW	2022-10-31	2023-02-07					FPI-2059-101	A Phase 1 Study of [225Ac]-FPI-2059 in Adult Participants With NTSR1-Expressing Advanced, Metastatic and/or Recurrent Solid Tumours	Pancreatic Ductal Adenocarcinoma (PDAC); Squamous Cell Carcinoma of Head and Neck; Colorectal Cancer; Gastric Cancer; Ewing Sarcoma; NTSR1 Expressing Solid Tumours; Neuroendocrine Differentiated (NED) Prostate Cancer	2145 - Sydney - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT05605522
NCT05607498	EMB07X101	Phase 1	RECRUITING	VIC, WA	2022-11-03	2023-03-01	EMB-07	bispecific_PD-L1/OX40_antibody; bispecific_T-cell_engager,ROR1-targeting	EMB-07	bispecific_PD-L1/OX40_antibody; bispecific_T-cell_engager,ROR1-targeting	EMB07X101	A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma	Advanced/Metastatic Solid Tumors; Relapse/Refractory Lymphoma	Frankston - Peninsula and South Eastern Haematology and Oncology Group; Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05607498
NCT05607550	FURMO-004	Phase 3	RECRUITING	NSW, QLD, VIC	2022-11-04	2023-06-01	Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Furmonertinib; Pemetrexed	antimetabolite; EGFR_inhibitor,third_generation; ERBB2_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; EGFR_inhibitor,exon_20_selective	Carboplatin + Cisplatin + Pemetrexed; Furmonertinib; Carboplatin + Cisplatin + Pemetrexed	EGFR_inhibitor,exon_20_selective; EGFR_inhibitor,third_generation; ERBB2_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	FURMO-004	A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)	Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations	2148 - Blacktown - Arrivent Investigative Site; 3084 - Heidelberg - ArriVent Investigative Site; 4102 - Woolloongabba - Arrivent Investigative Site; NSW 2065 - St Leonards - Arrivent Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05607550
NCT05609370	BGB-A317-LBL-007-201	Phase 1/Phase 2	RECRUITING	NSW, QLD, SA, VIC, WA	2022-11-01	2023-01-29	Bevacizumab; Bevacizumab + Capecitabine + Fluorouracil + LBL-007; Bevacizumab + Capecitabine + Fluorouracil + LBL-007 + Tislelizumab; Bevacizumab + Capecitabine + LBL-007 + Tislelizumab; Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab; Capecitabine; Fluorouracil; LBL-007; Tislelizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; fluoropyrimidine; anti-VEGF_monoclonal_antibody; Fluorouracil; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine	Bevacizumab + Capecitabine + Fluorouracil + LBL-007; Bevacizumab + Capecitabine + Fluorouracil + LBL-007 + Tislelizumab; Bevacizumab + Capecitabine + LBL-007 + Tislelizumab; Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab; Bevacizumab + Capecitabine + Fluorouracil + LBL-007; Bevacizumab + Capecitabine + Fluorouracil + LBL-007 + Tislelizumab; Bevacizumab + Capecitabine + LBL-007 + Tislelizumab; Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-LAG3_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; Fluorouracil; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-LAG3_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine	BGB-A317-LBL-007-201	A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	2148 - Blacktown - Blacktown Cancer and Haematology Centre; 2298 - Waratah - Calvary Mater Newcastle; 2640 - East Albury - Border Medical Oncology; 2650 - Wagga Wagga - Riverina Cancer Care Centre; 2800 - Orange - Orange Health Service (Central West Cancer Care Centre); 3004 - Melbourne - The Alfred Hospital; 3084 - Heidelberg - Austin Health; 3168 - Clayton - Monash Health; 4101 - South Brisbane - Icon Cancer Care South Brisbane; 4217 - Benowa - Pindara Private Hospital; 5042 - Bedford Park - Flinders Centre For Innovation in Cancer (Fcic); 6009 - Nedlands - One Clinical Research; 6150 - Murdoch - St John of God, Murdoch	https://clinicaltrials.gov/ct2/show/NCT05609370
NCT05609968	3475-D46	Phase 3	RECRUITING	NSW, SA, VIC	2022-11-02	2023-02-06	Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Pembrolizumab + Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	3475-D46	An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)	Carcinoma, Non-Small-Cell Lung	2800 - Orange - Orange Hospital-Clinical Trials Unit ( Site 0600); 3199 - Frankston - Frankston Hospital-Oncology and Haematology ( Site 0601); 5000 - Adelaide - Cancer Research SA-St Andrews Hospital ( Site 0603)	https://clinicaltrials.gov/ct2/show/NCT05609968
NCT05611931	XPORT-EC-042	Phase 3	RECRUITING	NSW, QLD, SA, TAS, VIC	2022-11-03	2023-04-18	Placebo; Selinexor	placebo; selective_inhibitor_of_nuclear_export	Selinexor; Placebo	selective_inhibitor_of_nuclear_export; placebo	XPORT-EC-042	A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma	Endometrial Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2145 - Wentworthville - Westmead Hospital; 2250 - Gosford - Central Coast LHD - Gosford & Wyong Hospitals; 2305 - New Lambton Heights - Newcastle Private Hospital; 2640 - Albury East - Border Medical Oncology and Haematology; 3000 - Melbourne - Peter MacCallum Cancer Centre/RWH/RMH; 3128 - Box Hill - Box Hill Hospital - Eastern Health (Oncology); 3144 - Malvern - Cabrini Health; 3168 - Clayton - Monash Health; 3199 - Frankston - Frankston Hospital; 4215 - Southport - ICON Cancer Centre Southport; 4350 - Toowoomba - Toowoomba Hospital; 5000 - Southport - The Royal Adelaide Hospital; 7000 - Hobart - Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT05611931
NCT05613088	CA116-001	Phase 2	RECRUITING	NSW, QLD, VIC, WA	2022-11-04	2023-02-01	Farletuzumab Ecteribulin; Paclitaxel; Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Pegylated liposomal doxorubicin; Topotecan	anti-FR-alpha_antibody-drug_conjugate; taxane; topoisomerase_inhibitor; anthracycline + taxane + topoisomerase_inhibitor; anthracycline	Farletuzumab Ecteribulin; Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Paclitaxel + Pegylated liposomal doxorubicin + Topotecan	anthracycline + taxane + topoisomerase_inhibitor; anti-FR-alpha_antibody-drug_conjugate; anthracycline + taxane + topoisomerase_inhibitor	CA116-001	A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Neoplasms, Ovarian	2065 - Sydney - GenesisCare - North Shore; 2298 - Waratah - Calvary Mater Newcastle; 3144 - Malvern - Cabrini Hospital - Malvern; 3168 - Clayton - Monash Medical Centre Clayton; 4032 - Chermside - Icon Cancer Centre - Chermside; 6009 - Nedlands - Sir Charles Gairdner Hospital; 6009 - Perth - Sir Charles Gairdner Hospital (SCGH) - WA Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05613088
NCT05614258	ADG206-1001	Phase 1	RECRUITING	SA, VIC	2022-11-09	2023-02-13	ADG206	anti-4-1BB_agonistic_antibody	ADG206	anti-4-1BB_agonistic_antibody	ADG206-1001	A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	3168 - Clayton - Monash Health; 5037 - Kurralta Park - Ashford Cancer Centre Research	https://clinicaltrials.gov/ct2/show/NCT05614258
NCT05614739	LOXO-FG3-22001	Phase 1	RECRUITING	NSW	2022-11-07	2023-01-12	LOXO-435; LOXO-435 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; FGFR3_inhibitor + anti-PD-1_monoclonal_antibody; FGFR3_inhibitor	LOXO-435; LOXO-435 + Pembrolizumab; LOXO-435 + Pembrolizumab	FGFR3_inhibitor; FGFR3_inhibitor + anti-PD-1_monoclonal_antibody; FGFR3_inhibitor + anti-PD-1_monoclonal_antibody	LOXO-FG3-22001	An Open-Label, Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations	Urinary Bladder Neoplasms; Neoplasm Metastasis; Ureteral Neoplasms	2065 - Saint Leonards - Royal North Shore Hospital; NSW 2010 - Darlinghurst - Kinghorn Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05614739
NCT05619913	EPOCH	Phase 2	RECRUITING	NSW, QLD, VIC	2022-11-09	2023-05-22	Eribulin; Eribulin + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + macrocyclic_ketone_analogue; anti-PD-1_monoclonal_antibody; macrocyclic_ketone_analogue	Eribulin; Eribulin + Pembrolizumab; Eribulin + Pembrolizumab	anti-PD-1_monoclonal_antibody + macrocyclic_ketone_analogue; macrocyclic_ketone_analogue; anti-PD-1_monoclonal_antibody + macrocyclic_ketone_analogue	ANZGOG 1828/2021	The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma	Ovarian Carcinosarcoma; Uterine Carcinosarcoma	8006 - Melbourne - Peter MacCallum Cancer Centre; Clayton - Monash Health; Herston - Royal Brisbane and Women's Hospital; Randwick - Prince of Wales Hospital	https://clinicaltrials.gov/ct2/show/NCT05619913
NCT05625399	RELATIVITY-127	Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2022-11-15	2023-03-06	Nivolumab; Nivolumab + Relatlimab; Nivolumab + Relatlimab + rHuPH20; Relatlimab; rHuPH20	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase; recombinant_human_hyaluronidase; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Nivolumab + Relatlimab; Nivolumab + Relatlimab + rHuPH20; Nivolumab + Relatlimab; Nivolumab + Relatlimab + rHuPH20	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase	CA224-127	A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma	Melanoma	2065 - Wollstonecraft - University of Sydney - Melanoma Institute Australia MIA; 2145 - Westmead - Westmead Hospital; 2298 - Waratah - Local Institution - 0184; 2444 - Port Macquarie - Port Macquarie Base Hospital; 2450 - Coffs Harbour - North Coast Area Health Service NCAHS - The North Coast Cancer Institute NCCI - Coffs Harbour Health Campus; 2650 - Wagga Wagga - Riverina Cancer Care Centre; 2800 - Orange - Orange Health Service; 3004 - Melbourne - The Alfred Hospital; 3084 - Heidelberg - Austin Hospital - Medical Oncology Unit; 3128 - Box Hill - Box Hill Hospital-Eastern Health; 3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre; 3844 - Traralgon - Latrobe Regional Health; 4575 - Birtinya - Sunshine Coast University Private Hospital; 5011 - Woodville South - Local Institution - 0183 - (WITHDRAWN); 6009 - Nedlands - One Clinical Research; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT05625399
NCT05625412	IM043-004	Phase 1	RECRUITING	NSW, QLD, VIC	2022-11-15	2022-12-09	BMS-986360; BMS-986360 + Capecitabine; BMS-986360 + Docetaxel; BMS-986360 + Nivolumab; Capecitabine; Docetaxel; Nivolumab	JNK_inhibitor + anti-PD-1_monoclonal_antibody; fluoropyrimidine; anti-PD-1_monoclonal_antibody; JNK_inhibitor + fluoropyrimidine; taxane; JNK_inhibitor + taxane; JNK_inhibitor	BMS-986360; BMS-986360 + Capecitabine; BMS-986360 + Docetaxel; BMS-986360 + Nivolumab; BMS-986360 + Capecitabine; BMS-986360 + Docetaxel; BMS-986360 + Nivolumab	JNK_inhibitor; JNK_inhibitor + anti-PD-1_monoclonal_antibody; JNK_inhibitor + fluoropyrimidine; JNK_inhibitor + taxane; JNK_inhibitor + anti-PD-1_monoclonal_antibody; JNK_inhibitor + fluoropyrimidine; JNK_inhibitor + taxane	IM043-004	A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors	Advanced Solid Tumors	2010 - Darlinghurst - St Vincent's Hospital - The Kinghorn Cancer Center; 2065 - St Leonards - GenesisCare North Shore; 3199 - Frankston - Frankston Hospital; 4120 - Brisbane - Gallipoli Medical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT05625412
NCT05635708	BGB-LC-201	Phase 2	RECRUITING	NSW, WA	2022-11-23	2023-03-07	BGB-15025; BGB-15025 + Carboplatin + Cisplatin + Paclitaxel + Pemetrexed + Tislelizumab; BGB-15025 + Tislelizumab; BGB-A445; BGB-A445 + Carboplatin + Cisplatin + Paclitaxel + Pemetrexed + Tislelizumab; BGB-A445 + Tislelizumab; Carboplatin; Carboplatin + Cisplatin + LBL-007 + Paclitaxel + Pemetrexed + Tislelizumab; Carboplatin + Cisplatin + Paclitaxel + Pemetrexed + Tislelizumab; Cisplatin; LBL-007; LBL-007 + Tislelizumab; Paclitaxel; Pemetrexed; Tislelizumab	antimetabolite; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; HPK1_inhibitor; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; HPK1_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; taxane; anti-LAG3_monoclonal_antibody; HPK1_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BGB-15025 + Carboplatin + Cisplatin + Paclitaxel + Pemetrexed + Tislelizumab; BGB-15025 + Tislelizumab; BGB-A445 + Carboplatin + Cisplatin + Paclitaxel + Pemetrexed + Tislelizumab; BGB-A445 + Tislelizumab; Carboplatin + Cisplatin + LBL-007 + Paclitaxel + Pemetrexed + Tislelizumab; Carboplatin + Cisplatin + Paclitaxel + Pemetrexed + Tislelizumab; LBL-007 + Tislelizumab; Tislelizumab; BGB-15025 + Carboplatin + Cisplatin + Paclitaxel + Pemetrexed + Tislelizumab; BGB-15025 + Tislelizumab; BGB-A445 + Carboplatin + Cisplatin + Paclitaxel + Pemetrexed + Tislelizumab; BGB-A445 + Tislelizumab; Carboplatin + Cisplatin + LBL-007 + Paclitaxel + Pemetrexed + Tislelizumab; Carboplatin + Cisplatin + Paclitaxel + Pemetrexed + Tislelizumab; LBL-007 + Tislelizumab	HPK1_inhibitor + anti-PD-1_monoclonal_antibody; HPK1_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; HPK1_inhibitor + anti-PD-1_monoclonal_antibody; HPK1_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	BGB-LC-201	Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer	2050 - Camperdown - Chris Obrien Lifehouse; 2086 - Frenchs Forest - Northern Beaches Hospital; 2148 - Blacktown - Blacktown Cancer and Haematology Centre; 2444 - Port Macquarie - Port Macquarie Base Hospital; 6008 - Subiaco - St John of God Health Care; 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05635708
NCT05636215	CIBI354A101	Phase 1/Phase 2	NOT_YET_RECRUITING	NSW, QLD, VIC	2022-11-23	2023-01-01	IBI354	anti-ERBB2_antibody-drug_conjugate	IBI354	anti-ERBB2_antibody-drug_conjugate	CIBI354A101	A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors	Locally Advanced Unresectable or Metastatic Solid Tumors	2031 - Randwick - Scientia Clinical Research Ltd; 3168 - Clayton - Monash Health; 4575 - Sunshine Coast - Sunshine Coast University Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05636215
NCT05642949	MHB036C-CP001EN	Phase 1/Phase 2	NOT_YET_RECRUITING	QLD, SA, VIC	2022-11-30	2023-01-23	MHB036C	anti-Trop2_antibody-drug_conjugate	MHB036C	anti-Trop2_antibody-drug_conjugate	MHB036C-CP001EN	Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors	Advanced Solid Tumor	3144 - Melbourne - Cabrini Health; 4217 - Gold Coast - Pindara Private Hospital; 5042 - Adelaide - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT05642949
NCT05645692	BO44157	Phase 2	RECRUITING	NSW, SA	2022-12-07	2023-04-13	Atezolizumab; Tiragolumab; Tiragolumab + Tobemstomig; Tobemstomig	bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody	Atezolizumab; Tiragolumab + Tobemstomig; Tobemstomig; Tiragolumab + Tobemstomig	anti-PD-L1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody	BO44157	A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy	Urothelial Cancer	2113 - Macquarie Park - Macquarie University Hospital; 5037 - Kurralta Park - ICON Cancer Care Adelaide; 5112 - Adelaide - Lyell McEwin Hospital	https://clinicaltrials.gov/ct2/show/NCT05645692
NCT05646862	INAVO121	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2022-12-02	2023-06-07	Alpelisib; Alpelisib + Fulvestrant; Fulvestrant; Fulvestrant + Inavolisib; Inavolisib	selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader	Alpelisib + Fulvestrant; Fulvestrant + Inavolisib; Alpelisib + Fulvestrant; Fulvestrant + Inavolisib	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader	WO43919	A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy	Breast Cancer	2010 - Darlinghurst - Kinghorn Cancer Centre; St Vincents Hospital; 2139 - Concord - Concord Repatriation General Hospital; Concord Cancer Centre; 2250 - Gosford - Gosford Hospital; Cancer Care Services; 2450 - Coffs Harbour - Coffs Harbour Health Campus; 2560 - Campbelltown - Campbelltown Hospital; Macarthur Cancer Therapy Centre; 3550 - Bendigo - Bendigo Cancer Centre; 4066 - Auchenflower - Icon Cancer Care Wesley; 4556 - Sippy Downs - University of the Sunshine Coast; 6009 - Perth - Sir Charles Gairdner Hospital; Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT05646862
NCT05647122	EGRET	Phase 1	RECRUITING	NSW, VIC	2022-12-02	2022-12-22	AZD9592; AZD9592 + Bevacizumab + Fluorouracil + Leucovorin; AZD9592 + Osimertinib; Bevacizumab; Fluorouracil; Leucovorin; Osimertinib	EGFR_inhibitor,third_generation; anti-VEGF_monoclonal_antibody + bispecific_cMET/EGFR_antibody + fluoropyrimidine + folinic_acid; anti-VEGF_monoclonal_antibody; Fluorouracil; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; folinic_acid; bispecific_cMET/EGFR_antibody	AZD9592; AZD9592 + Bevacizumab + Fluorouracil + Leucovorin; AZD9592 + Osimertinib; AZD9592 + Bevacizumab + Fluorouracil + Leucovorin; AZD9592 + Osimertinib	EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; anti-VEGF_monoclonal_antibody + bispecific_cMET/EGFR_antibody + fluoropyrimidine + folinic_acid; bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; Fluorouracil; anti-VEGF_monoclonal_antibody + bispecific_cMET/EGFR_antibody + fluoropyrimidine + folinic_acid	D9350C00001	A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors	Advanced Solid Tumours; Carcinoma Non-small Cell Lung; Head and Neck Neoplasms; Colorectal Neoplasms	2217 - Kogarah - Research Site; 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT05647122
NCT05650879	HER2	Phase 1	RECRUITING	NSW, WA	2022-12-06	2023-03-20	ELVN-002; ELVN-002 + Trastuzumab Deruxtecan; ELVN-002 + Trastuzumab Emtansine; Trastuzumab Deruxtecan; Trastuzumab Emtansine	ERBB2_inhibitor,exon_20_selective; anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,exon_20_selective + anti-ERBB2_antibody-drug_conjugate	ELVN-002; ELVN-002 + Trastuzumab Deruxtecan; ELVN-002 + Trastuzumab Emtansine; ELVN-002 + Trastuzumab Deruxtecan; ELVN-002 + Trastuzumab Emtansine	ERBB2_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective + anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,exon_20_selective + anti-ERBB2_antibody-drug_conjugate	ELVN-002-001	A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer	HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer; HER2 Gene Mutation; HER2 Amplification	2010 - Darlinghurst - Blacktown Hospital; 2145 - Westmead - Macquarie University Hospital; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT05650879
NCT05652855	MHB088C-CP001EN	Phase 1/Phase 2	NOT_YET_RECRUITING	QLD, SA, VIC	2022-12-07	2023-01-23	MHB088C	anti-B7H3_antibody-drug_conjugate	MHB088C	anti-B7H3_antibody-drug_conjugate	MHB088C-CP001EN	Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	3144 - Melbourne - Cabrini Health; 4217 - Gold Coast - Pindara Private Hospital; 5042 - Adelaide - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT05652855
NCT05652868	MYTX-011-01	Phase 1	RECRUITING	NSW, SA	2022-12-07	2023-03-23	MYTX-011	anti-cMET_antibody-drug_conjugate	MYTX-011	anti-cMET_antibody-drug_conjugate	MYTX-011-01	A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01	NSCLC; NSCLC Stage IV; NSCLC Stage IIIB; Non-Small Cell Lung Cancer; Advanced Non-Small Cell Squamous Lung Cancer; Advanced Non-Small Cell Lung Cancer; Advanced Non-Small Cell Non-Squamous Lung Cancer	2050 - Camperdown - KisMET-01 Clinical Site; 2148 - Blacktown - KisMET-01 Clinical Site; 5000 - Adelaide - Queen Elizabeth Hospital; 5011 - Adelaide - KisMET-01 Clinical Site	https://clinicaltrials.gov/ct2/show/NCT05652868
NCT05654623	VERITAC-2	Phase 3	RECRUITING	QLD, TAS, VIC	2022-12-08	2023-03-03	ARV-471; Fulvestrant	selective_estrogen_receptor_degrader; ER_PROTAC_degrader	ARV-471; Fulvestrant	ER_PROTAC_degrader; selective_estrogen_receptor_degrader	C4891001	A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)	Advanced Breast Cancer	3144 - Malvern - Cabrini Hospital - Malvern; 3186 - Brighton - Cabrini Hospital -Brighton; 3220 - Geelong - Barwon Health; 4575 - Birtinya - Sunshine Coast University Private Hospital; 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT05654623
NCT05668988	DZ2022E0005	Phase 3	RECRUITING	NSW, VIC, WA	2022-12-20	2022-12-13	Carboplatin; Carboplatin + Pemetrexed; Pemetrexed; Sunvozertinib	antimetabolite; ERBB2_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; EGFR_inhibitor,exon_20_selective	Carboplatin + Pemetrexed; Sunvozertinib; Carboplatin + Pemetrexed	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	DZ2022E0005	A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation	Non-small Cell Lung Cancer	Concord - WK28 Investigative Site; Melbourne - WK28 Investigative Site; Nedlands - WK28 Investigative Site; Randwick - WK28 Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05668988
NCT05671510	PRESERVE-003	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2022-12-31	2023-06-28	Docetaxel; ONC392	taxane; anti-CTLA-4_monoclonal_antibody	Docetaxel; ONC392	taxane; anti-CTLA-4_monoclonal_antibody	PRESERVE-003	Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors	Non Small Cell Lung Cancer	2200 - Bankstown - Bankstown Hospital - 3305; 4006 - Newstead - Mater - 3301; 5000 - Adelaide - Cancer Research SA - 3303; New Lambton Heights - Newcastle Private Hospital - 3302	https://clinicaltrials.gov/ct2/show/NCT05671510
NCT05676931	EDGE-Lung	Phase 2	RECRUITING	NSW, QLD, SA, VIC	2023-01-05	2023-02-01	Docetaxel; Docetaxel + Domvanalimab + Zimberelimab; Docetaxel + Zimberelimab; Domvanalimab; Domvanalimab + Zimberelimab; Zimberelimab	anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane	Docetaxel + Domvanalimab + Zimberelimab; Docetaxel + Zimberelimab; Domvanalimab + Zimberelimab; Zimberelimab; Docetaxel + Domvanalimab + Zimberelimab; Docetaxel + Zimberelimab; Domvanalimab + Zimberelimab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane	EDGE-Lung	A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer	Advanced Non-Small Cell Lung Cancer	Adelaide - Cancer Research SA; Albury - Border Cancer Hospital; Benowa - Pindara Private Hospital; Coffs Harbour - Coffs Harbour Health Campus	https://clinicaltrials.gov/ct2/show/NCT05676931
NCT05678673	STELLAR-304	Phase 3	RECRUITING	QLD	2022-12-23	2023-01-01	Nivolumab; Nivolumab + Zanzalintinib; Sunitinib; Zanzalintinib	PDGFR_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor; VEGFR_inhibitor; KIT_inhibitor,first_generation; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967|[111In]-FPI-1967; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Nivolumab + Zanzalintinib; Sunitinib; Nivolumab + Zanzalintinib	KIT_inhibitor,first_generation; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor; VEGFR_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor111In-FPI-1967 + [111In]-FPI-1967 + anti-PD-1_monoclonal_antibody	XL092-304	A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma	Non-Clear Cell Renal Cell Carcinoma	4032 - Chermside - Exelixis Clinical Site #14; 4101 - South Brisbane - Exelixis Clinical Site #29	https://clinicaltrials.gov/ct2/show/NCT05678673
NCT05694936	VADER	Phase 2	RECRUITING	NSW, SA, VIC	2023-01-19	2023-01-23	Cetuximab; Cetuximab + Panitumumab; Cetuximab + Panitumumab + Sodium Valproate; Panitumumab; Sodium Valproate	anti-EGFR_monoclonal_antibody; HDAC_inhibitor + anti-EGFR_monoclonal_antibody; HDAC_inhibitor	Cetuximab + Panitumumab; Cetuximab + Panitumumab + Sodium Valproate; Cetuximab + Panitumumab; Cetuximab + Panitumumab + Sodium Valproate	HDAC_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody; HDAC_inhibitor + anti-EGFR_monoclonal_antibody	VADER	A Phase II Randomised Controlled Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (CRC)	Metastatic Colorectal Cancer	2065 - Saint Leonards - Royal North Shore Hospital; 3000 - Melbourne - Peter MacCallum Cancer Institute; 3084 - Melbourne - Austin Health; 3128 - Box Hill - Eastern Health; 3199 - Frankston - Peninsula Health; 3280 - Warrnambool - South West Healthcare; 3350 - Ballarat Central - Eben-Marie Garzina; 5000 - Adelaide - Queen Elizabeth Hospital; 5042 - Bedford Park - Southern Adelaide Local Health Network Incorporated	https://clinicaltrials.gov/ct2/show/NCT05694936
NCT05696626	ELAINEIII	Phase 3	RECRUITING	NSW, QLD	2023-01-13	2023-10-31	Abemaciclib; Abemaciclib + Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Lasofoxifene + Palbociclib + Ribociclib; Fulvestrant; Lasofoxifene; Palbociclib; Ribociclib	selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_modulator; selective_estrogen_receptor_modulator; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor	Abemaciclib + Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Lasofoxifene + Palbociclib + Ribociclib; Abemaciclib + Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Lasofoxifene + Palbociclib + Ribociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_modulator; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_modulator	SMX 22-002	An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Metastatic Breast Cancer	Blacktown - Blacktown Hospital; Concord - Concord Repatriation General Hospital; South Brisbane - Mater Misericordiae Ltd, South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05696626
NCT05712889	VNC-236-101	Phase 1	RECRUITING	NSW, QLD, SA, Southern Australia	2023-01-25	2023-01-24	VIP236	small-molecule-drug-conjugate,alpha-V-beta-3-targeting	VIP236	small-molecule-drug-conjugate,alpha-V-beta-3-targeting	VNC-236-101	An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity and Pharmacokinetics of VIP236 Monotherapy in Subjects With Advanced Cancer	Neoplasms	2109 - Macquarie Park - Macquarie University; 4101 - Brisbane - ICON Brisbane; 5037 - Adelaide - ICON Adelaide	https://clinicaltrials.gov/ct2/show/NCT05712889
NCT05718895	CLINCH	Phase 1	RECRUITING	QLD, VIC	2023-01-30	2023-03-27	ATG 022	anti-CLDN18.2_antibody-drug_conjugate	ATG 022	anti-CLDN18.2_antibody-drug_conjugate	ATG-022-ST-001	An Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	Adelaide - Cancer Research SA Pty Ltd; Malvern - Cabrini Health Limited; South Brisbane - Integrated Clinical Oncology Network Pty Ltd (Icon)	https://clinicaltrials.gov/ct2/show/NCT05718895
NCT05720130	TheraPb-ADVC001	Phase 1/Phase 2	RECRUITING	QLD	2023-02-07	2023-03-15	212Pb-ADVC001; Abiraterone; Abiraterone + Enzalutamide; Enzalutamide	radioligand,PSMA-targeting; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation	Abiraterone + Enzalutamide; 212Pb-ADVC001; Abiraterone + Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; radioligand,PSMA-targeting	TheraPb-ADVC001	TheraPb: Phase I/IIa Dose Escalation and Toxicity Study of [212Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma	Prostatic Neoplasms; Castration-Resistant	4029 - Brisbane - Royal Brisbane & Women's Hospital; 4102 - Brisbane - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT05720130
NCT05725291	AMT-116-01	Phase 1	RECRUITING	QLD	2023-02-02	2023-06-28	AMT-116	anti-CD44v9_antibody-drug_conjugate	AMT-116	anti-CD44v9_antibody-drug_conjugate	AMT-116-01	First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	Brisbane - ICON Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05725291
NCT05727176	FOENIX-CCA4	Phase 2	RECRUITING	NSW, VIC	2023-02-03	2023-05-12	Futibatinib	pan-FGFR_inhibitor,irreversible	Futibatinib	pan-FGFR_inhibitor,irreversible	TAS-120-205	Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements	Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangement	2010 - Sydney - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre; 3004 - Melbourne - Alfred Health, Medical Oncology Unit, Second floor William Buckland Radiotherapy Center	https://clinicaltrials.gov/ct2/show/NCT05727176
NCT05727904	IOV-MEL-301	Phase 3	RECRUITING	QLD, VIC, WA	2023-02-06	2023-03-30	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	IOV-MEL-301	A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma	Metastatic Melanoma; Unresectable Melanoma; Melanoma	3000 - Melbourne - Peter MacCallum Cancer Centre; 4120 - Greenslopes - Greenslopes Private Hospital; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT05727904
NCT05735080	INX-315-01	Phase 1/Phase 2	RECRUITING	QLD, VIC	2023-02-09	2023-03-28	INX-315	CDK2_inhibitor	INX-315	CDK2_inhibitor	INX-315-01	A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer	Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Ovarian Cancer; CCNE1 Amplification; Solid Tumor; Advanced Cancer; Metastatic Cancer	3052 - Parkville - Peter MacCallum Cancer Center; 4101 - South Brisbane - Mater Hospital	https://clinicaltrials.gov/ct2/show/NCT05735080
NCT05740566	DeLLphi-304	Phase 3	RECRUITING	NSW, VIC	2023-02-21	2023-05-31	Amrubicin; Amrubicin + Lurbinectedin + Topotecan; Lurbinectedin; Tarlatamab; Topotecan	bispecific_T-cell_engager,DLL3-targeting; topoisomerase_inhibitor; anthracycline; DNA_minor_groove-binding_agent + anthracycline + topoisomerase_inhibitor; DNA_minor_groove-binding_agent	Amrubicin + Lurbinectedin + Topotecan; Tarlatamab; Amrubicin + Lurbinectedin + Topotecan	DNA_minor_groove-binding_agent + anthracycline + topoisomerase_inhibitor; bispecific_T-cell_engager,DLL3-targeting; DNA_minor_groove-binding_agent + anthracycline + topoisomerase_inhibitor	20210004	A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy	Small Cell Lung Cancer (SCLC)	2170 - Liverpool - Liverpool Hospital; 2298 - Waratah - Calvary Mater Newcastle Hospital; 3004 - Melbourne - The Alfred Hospital; 3168 - Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT05740566
NCT05743036	ZN-c3-016	Phase 1/Phase 2	RECRUITING	SA, VIC	2023-02-15	2023-02-27	Azenosertib; Azenosertib + Cetuximab + Encorafenib; Cetuximab; Encorafenib	anti-EGFR_monoclonal_antibody; WEE1_inhibitor; BRAF_V600_inhibitor; BRAF_V600_inhibitor + WEE1_inhibitor + anti-EGFR_monoclonal_antibody	Azenosertib + Cetuximab + Encorafenib; Azenosertib + Cetuximab + Encorafenib	BRAF_V600_inhibitor + WEE1_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + WEE1_inhibitor + anti-EGFR_monoclonal_antibody	ZN-c3-016	A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination With Encorafenib and Cetuximab in Adults With Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05743036
NCT05756907	SB221	Phase 1/Phase 2	RECRUITING	NSW, SA	2023-02-23	2023-09-15	Atezolizumab; Atezolizumab + SON-1010; SON-1010	anti-PD-L1_monoclonal_antibody; IL-12_variant + anti-PD-L1_monoclonal_antibody; IL-12_variant	Atezolizumab + SON-1010; SON-1010; Atezolizumab + SON-1010	IL-12_variant; IL-12_variant + anti-PD-L1_monoclonal_antibody; IL-12_variant + anti-PD-L1_monoclonal_antibody	SB221	A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer	Advanced Solid Tumor; Platinum-resistant Ovarian Cancer	2148 - Blacktown - Blacktown Mt Druitt Hospital; 2640 - Albury - The Border Cancer Hospital; 5037 - Kurralta Park - Ashford Cancer Centre Research	https://clinicaltrials.gov/ct2/show/NCT05756907
NCT05759728	CNA3103-001	Phase 1/Phase 2	RECRUITING	SA	2023-02-26	2023-10-24	CNA3103	autologous_CAR-T-cell_therapy,LGR5-targeting	CNA3103	autologous_CAR-T-cell_therapy,LGR5-targeting	CNA3103-001	A Phase 1/2a, Multicenter, Open-Label, Dose Escalation and Expansion Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Adult Subjects With Metastatic Colorectal Cancer	Colorectal Cancer Metastatic	5000 - Adelaide - Carina Biotech Investigators	https://clinicaltrials.gov/ct2/show/NCT05759728
NCT05763004	IOS-1002-201	Phase 1	RECRUITING	VIC, WA	2023-02-28	2023-03-15	Pembrolizumab; Tegafur-gimeracil-oteracil potassium	antimetabolite; anti-PD-1_monoclonal_antibody; orotate_phosphoribosyltransferase_inhibitor; DPD_inhibitor	Pembrolizumab; Tegafur-gimeracil-oteracil potassium	anti-PD-1_monoclonal_antibody; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	IOS-1002-201	A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS 1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors	Solid Tumor, Adult	Clayton - Monash Health Medical Center; Heidelberg - Austin Health / Cancer Clinical Trials Center; Melbourne - Alfread Health; Melbourne - Peter MacCallum Cancer Center; Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05763004
NCT05774873	CIBI334A101	Phase 1/Phase 2	RECRUITING	NSW	2023-03-07	2023-08-09	IBI334	bispecific_EGFR/B7H3_antibody	IBI334	bispecific_EGFR/B7H3_antibody	CIBI334A101	A Phase I/II Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumors	2145 - Waratah - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT05774873
NCT05785754	DCSZ11-101	Phase 1	RECRUITING	NSW, SA, VIC, WA	2023-03-14	2023-06-28	DCSZ11; DCSZ11 + Pembrolizumab; Pembrolizumab	anti-CD93_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CD93_monoclonal_antibody + anti-PD-1_monoclonal_antibody	DCSZ11; DCSZ11 + Pembrolizumab; DCSZ11 + Pembrolizumab	anti-CD93_monoclonal_antibody; anti-CD93_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD93_monoclonal_antibody + anti-PD-1_monoclonal_antibody	DCSZ11-101	A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	2010 - Sydney - St Vicent's Hospital; 2031 - Randwick - Scientia Clinical Research; 3144 - Malvern - Cabrini Hospital; 3168 - Clayton - Monash Health; 5011 - Woodville South - The Queen Elizabeth Hospital (TQEH); 5042 - Bedford Park - Southern Oncology Clinical Research Unit (SOCRU); 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT05785754
NCT05785767	R3767-ONC-2235	Phase 2/Phase 3	RECRUITING	NSW, VIC	2023-03-14	2023-06-30	Cemiplimab; Cemiplimab + Fianlimab; Fianlimab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Cemiplimab; Cemiplimab + Fianlimab; Cemiplimab + Fianlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	R3767-ONC-2235	A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%	Advanced Non-Small Cell Lung Cancer	2109 - Macquarie Park - Macquarie University Health Science Center (MQ Health); 2650 - Wagga Wagga - Riverina Cancer Care Centre (RCCC); 3350 - Ballarat - Ballarat Regional Integrated Cancer Centre (BRICC); 3550 - Bendigo - Bendigo Hospital; NSW 2500 - Wollongong - Southern Medical Day Care Centre	https://clinicaltrials.gov/ct2/show/NCT05785767
NCT05789082	Krascendo-170	Phase 1/Phase 2	RECRUITING	NSW, VIC	2023-03-28	2023-06-20	Carboplatin; Carboplatin + Cisplatin + Divarasib + Pembrolizumab + Pemetrexed; Cisplatin; Divarasib; Divarasib + Pembrolizumab; Pembrolizumab; Pemetrexed	antimetabolite; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor	Carboplatin + Cisplatin + Divarasib + Pembrolizumab + Pemetrexed; Divarasib + Pembrolizumab; Carboplatin + Cisplatin + Divarasib + Pembrolizumab + Pemetrexed; Divarasib + Pembrolizumab	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	BO44426	A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation	Non-Small Cell Lung Cancer	2139 - Concord - Concord Repatriation General Hospital; Concord Cancer Centre; 3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology; 3004 - Melbourne - Alfred Health	https://clinicaltrials.gov/ct2/show/NCT05789082
NCT05797168	FONTANA	Phase 1/Phase 2	RECRUITING	NSW, VIC	2023-03-21	2023-06-05	AZD5335; AZD5335 + Saruparib; Saruparib	PARP1-selective_inhibitor + anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate; PARP_inhibitor + anti-FR-alpha_antibody-drug_conjugate; PARP_inhibitor	AZD5335; AZD5335 + Saruparib; AZD5335 + Saruparib	PARP1-selective_inhibitor + anti-FR-alpha_antibody-drug_conjugate; PARP_inhibitor + anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-FR-alpha_antibody-drug_conjugate; PARP_inhibitor + anti-FR-alpha_antibody-drug_conjugate	D8990C00001	FONTANA: A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors.	Ovarian Cancer; Lung Adenocarcinoma	2170 - Liverpool - Research Site; 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT05797168
NCT05800015	R3767-ONC-2236	Phase 2/Phase 3	RECRUITING	NSW, VIC, WA	2023-03-23	2023-08-08	Carboplatin; Carboplatin + Cemiplimab + Cisplatin + Fianlimab + Paclitaxel + Pemetrexed; Carboplatin + Cemiplimab + Cisplatin + Paclitaxel + Pemetrexed; Cemiplimab; Cisplatin; Fianlimab; Paclitaxel; Pemetrexed	antimetabolite; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-LAG3_monoclonal_antibody	Carboplatin + Cemiplimab + Cisplatin + Fianlimab + Paclitaxel + Pemetrexed; Carboplatin + Cemiplimab + Cisplatin + Paclitaxel + Pemetrexed; Carboplatin + Cemiplimab + Cisplatin + Fianlimab + Paclitaxel + Pemetrexed; Carboplatin + Cemiplimab + Cisplatin + Paclitaxel + Pemetrexed	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	R3767-ONC-2236	A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels	Non-small Cell Lung Cancer	2109 - Macquarie Park - Macquarie University Health Science Center (MQ Health); 3065 - Fitzroy - St Vincents Hospital; 3350 - Ballarat - Ballarat Regional Integrated Cancer Centre (BRICC); 3550 - Bendigo - Bendigo Hospital; 6150 - Murdoch - St John of God Murdoch Hospital; NSW 2500 - Wollongong - Southern Medical Day Care Centre	https://clinicaltrials.gov/ct2/show/NCT05800015
NCT05800665	GO44537	Phase 1	RECRUITING	NSW, VIC	2023-03-24	2023-05-02	RO-7656594	unknown_drug_class	RO-7656594	unknown_drug_class	GO44537	A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer	Advanced Prostate Cancer; Metastatic Prostate Cancer	2010 - Darlinghurst - St Vincent's Hospital Sydney; 3084 - Heidelberg - Austin Hospital	https://clinicaltrials.gov/ct2/show/NCT05800665
NCT05800964	NCT05800964	Phase 1	RECRUITING	NSW, VIC	2023-03-24	2023-06-13	AMG 305	bispecific_T-cell_engager,MSLN-targeting	AMG 305	bispecific_T-cell_engager,MSLN-targeting	20220073	Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	2050 - Camperdown - Chris OBrien Lifehouse; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05800964
NCT05805501	BO43936	Phase 2	RECRUITING	QLD, SA	2023-03-28	2023-04-21	Axitinib; Axitinib + Pembrolizumab; Axitinib + Tiragolumab + Tobemstomig; Axitinib + Tobemstomig; Pembrolizumab; Tiragolumab; Tobemstomig	bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor; VEGFR/PDGFR_inhibitor + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; KIT_inhibitor,ATP-competitive; anti-PD-1_monoclonal_antibody	Axitinib + Pembrolizumab; Axitinib + Tiragolumab + Tobemstomig; Axitinib + Tobemstomig; Axitinib + Pembrolizumab; Axitinib + Tiragolumab + Tobemstomig; Axitinib + Tobemstomig	KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + bispecific_PD-1/LAG3_antibody	BO43936	A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma	Renal Cell Carcinoma	4575 - Birtinya - Sunshine Coast University Hospital; The Adem Crosby Centre; 5037 - Kurralta Park - ICON Cancer Care Adelaide	https://clinicaltrials.gov/ct2/show/NCT05805501
NCT05807035	CAN001	Phase 1	RECRUITING	SA	2023-04-07	2023-02-10	Radvax	autologous_anticancer_vaccine	Radvax	autologous_anticancer_vaccine	CAN001	A Phase I Trial of Autologous Tumour Vaccine for Advanced Solid Cancers	Solid Tumor	5046 - Adelaide - ARASMI	https://clinicaltrials.gov/ct2/show/NCT05807035
NCT05816252	SKB264-II-04	Phase 2	RECRUITING	NSW, VIC	2023-04-14	2023-04-19	Carboplatin; Carboplatin + Pembrolizumab + Sacituzumab tirumotecan; Carboplatin + Sacituzumab tirumotecan; Osimertinib; Osimertinib + Sacituzumab tirumotecan; Pembrolizumab; Pembrolizumab + Sacituzumab tirumotecan; Sacituzumab tirumotecan	EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; EGFR_inhibitor,third_generation; anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent	Carboplatin + Pembrolizumab + Sacituzumab tirumotecan; Carboplatin + Sacituzumab tirumotecan; Osimertinib + Sacituzumab tirumotecan; Pembrolizumab + Sacituzumab tirumotecan; Carboplatin + Pembrolizumab + Sacituzumab tirumotecan; Carboplatin + Sacituzumab tirumotecan; Osimertinib + Sacituzumab tirumotecan; Pembrolizumab + Sacituzumab tirumotecan	EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent	SKB264-II-04	A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer	Non-small Cell Lung Cancer	2010 - Darlinghurst - St Vincent's Hospital - Kinghorn Cancer Centre; 3004 - Melbourne - Paula Fox Melanoma and Cancer Centre; 3280 - Warrnambool - South West Oncology	https://clinicaltrials.gov/ct2/show/NCT05816252
NCT05818683	CR109321	Phase 1	RECRUITING	NSW, QLD, VIC	2023-04-06	2023-04-26	Abiraterone; Abiraterone + Apalutamide + Cabazitaxel + Cetrelimab + Darolutamide + Docetaxel + Enzalutamide + JNJ-78278343 + Prednisone; Apalutamide; Cabazitaxel; Cetrelimab; Darolutamide; Docetaxel; Enzalutamide; JNJ-78278343; Prednisone	CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,KLK2-targeting + glucocorticoid + taxane; CYP17A1_inhibitor; glucocorticoid; anti-PD-1_monoclonal_antibody; taxane; bispecific_T-cell_engager,KLK2-targeting; antiandrogen,nonsteroidal,second_generation	Abiraterone + Apalutamide + Cabazitaxel + Cetrelimab + Darolutamide + Docetaxel + Enzalutamide + JNJ-78278343 + Prednisone; Abiraterone + Apalutamide + Cabazitaxel + Cetrelimab + Darolutamide + Docetaxel + Enzalutamide + JNJ-78278343 + Prednisone	CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,KLK2-targeting + glucocorticoid + taxane; CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,KLK2-targeting + glucocorticoid + taxane	CR109321	A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-resistant Prostate Neoplasms	2109 - Macquarie University - Macquarie University; 3000 - Melbourne - Peter MacCallum Cancer Centre; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT05818683
NCT05840211	ASCENT-07	Phase 3	RECRUITING	ME, NSW, QLD, SA, TAS, VIC, WA	2023-04-21	2023-05-08	Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel; Paclitaxel; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; fluoropyrimidine; taxane; fluoropyrimidine + taxane	Capecitabine + Nab-paclitaxel + Paclitaxel; Sacituzumab Govitecan; Capecitabine + Nab-paclitaxel + Paclitaxel	anti-Trop2_antibody-drug_conjugate; fluoropyrimidine + taxane; fluoropyrimidine + taxane	GS-US-598-6168	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy	Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer	2010 - Darlinghurst - St Vincent's Hospital Sydney; 2065 - St Leonards - GenesisCare North Shore (Oncology); 2170 - Liverpool - Liverpool Hospital; 3021 - St Albans - Sunshine Hospital (Western Health); 3084 - Melbourne - Austin Health; 4029 - Queensland - Royal Brisbane and Women's Hospital; 4066 - Auchenflower - Icon Cancer Centre Wesley; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - Breast Cancer Research Centre - WA; 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT05840211
NCT05848011	CP-MGD019-02	Phase 2	RECRUITING	VIC	2023-05-04	2023-09-28	Docetaxel; Docetaxel + Lorigerlimab + Prednisone; Lorigerlimab; Prednisone	bispecific_PD-1×CTLA-4_dual-affinity_responsive_target_molecule; glucocorticoid; taxane; bispecific_PD-1×CTLA-4_dual-affinity_responsive_target_molecule + glucocorticoid + taxane	Docetaxel + Lorigerlimab + Prednisone; Docetaxel + Lorigerlimab + Prednisone	bispecific_PD-1×CTLA-4_dual-affinity_responsive_target_molecule + glucocorticoid + taxane; bispecific_PD-1×CTLA-4_dual-affinity_responsive_target_molecule + glucocorticoid + taxane	CP-MGD019-02	A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer	Androgen-Independent Prostatic Cancer; Androgen-Independent Prostatic Neoplasms; Prostate Cancer Recurrent; Androgen-Insensitive Prostatic Cance; Androgen-Resistant Prostatic Cancer; Hormone Refractory Prostatic Cancer; Immunotherapy; Immune Checkpoint Inhibitor; Inhibitory Checkpoint Molecule	North Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05848011
NCT05852691	CO44194	Phase 2	RECRUITING	SA, VIC, WA	2023-05-02	2023-07-18	Nab-paclitaxel; Nab-paclitaxel + Pembrolizumab; Nab-paclitaxel + Tobemstomig; Pembrolizumab; RO7247669; Tobemstomig	bispecific_PD-1/LAG3_antibody; bispecific_PD-1/LAG3_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; taxane	Nab-paclitaxel + Pembrolizumab; Nab-paclitaxel + Tobemstomig; Nab-paclitaxel + Pembrolizumab; Nab-paclitaxel + Tobemstomig; RO7247669	anti-PD-1_monoclonal_antibody + taxane; bispecific_PD-1/LAG3_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane; bispecific_PD-1/LAG3_antibody + taxane	CO44194	A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer	Breast Cancer	5037 - Kurralta Park - ICON Cancer Care Adelaide; 6149 - Bull Creek - Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit; St Albans - Sunshine Hospital; Oncology Research	https://clinicaltrials.gov/ct2/show/NCT05852691
NCT05855200	AZUR-2	Phase 3	RECRUITING	NSW, QLD, VIC	2023-05-03	2023-08-02	Dostarlimab	anti-PD-1_monoclonal_antibody	Dostarlimab	anti-PD-1_monoclonal_antibody	219606	A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer	Colonic Neoplasms; Neoplasms, Colon	2065 - St Leonards - GSK Investigational Site; 2298 - Waratah - GSK Investigational Site; 3084 - Heidelberg - GSK Investigational Site; 4102 - Woolloongabba - GSK Investigational Site; VIC 3004 - Melbourne - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT05855200
NCT05858164	NCT05858164	Phase 1	RECRUITING	NSW, QLD	2023-05-05	2023-08-07	BAY2862789	DGK-alpha_inhibitor	BAY2862789	DGK-alpha_inhibitor	22231	An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Alpha Inhibitor (DGKαi) BAY 2862789 in Participants With Advanced Solid Tumors	Advanced Solid Tumors; Non-small Cell Lung Cancer	2010 - Darlinghurst - The Kinghorn Cancer Centre - Medical Oncology Department; 4106 - Woollongabba - Princess Alexandra Hospital Australia	https://clinicaltrials.gov/ct2/show/NCT05858164
NCT05858736	PRESERVE-009	Phase 1	RECRUITING	NSW, QLD, SA	2023-05-12	2023-07-11	AI-025; ONC392	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	AI-025; ONC392	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	AI-061-AU-01	Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study	Melanoma; Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer; Cervical Cancer; Renal Cell Carcinoma; Bladder Cancer; Esophageal Cancer; Gastric Cancer; Gastroesophageal-junction Cancer; Colorectal Cancer; Anal Cancer; Hepatocellular Carcinoma; Bile Duct Cancer	2010 - Darlinghurst - St. Vincent's Private Hospital; 4006 - Brisbane - Mater Misericordiae Ltd.; 4120 - Southport - Tasman Oncology Research; 5000 - Adelaide - Cancer Research SA; 5042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT05858736
NCT05867121	GO44010	Phase 1	RECRUITING	NSW, NZ, SA	2023-05-10	2023-10-02	Atezolizumab; Atezolizumab + Gemcitabine + Nab-paclitaxel + RO7496353; Atezolizumab + RO7496353; Capecitabine; Capecitabine + Nivolumab + Oxaliplatin + RO7496353 + Tegafur-gimeracil-oteracil potassium; Gemcitabine; Nab-paclitaxel; Nivolumab; Oxaliplatin; RO7496353; Tegafur-gimeracil-oteracil potassium	antimetabolite; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + orotate_phosphoribosyltransferase_inhibitor + platinum-based_antineoplastic_agent; gemcitabine; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent; taxane; anti-TGF-beta_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; fluoropyrimidine; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; DPD_inhibitor + anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent	Atezolizumab + Gemcitabine + Nab-paclitaxel + RO7496353; Atezolizumab + RO7496353; Capecitabine + Nivolumab + Oxaliplatin + RO7496353 + Tegafur-gimeracil-oteracil potassium; Atezolizumab + Gemcitabine + Nab-paclitaxel + RO7496353; Atezolizumab + RO7496353; Capecitabine + Nivolumab + Oxaliplatin + RO7496353 + Tegafur-gimeracil-oteracil potassium	DPD_inhibitor + anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + orotate_phosphoribosyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; DPD_inhibitor + anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + orotate_phosphoribosyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; gemcitabine	GO44010	A Phase Ib, Open-Label, Multicenter Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors	Metastatic Solid Tumor; Non-small Cell Lung Cancer; Gastric Cancer; Pancreatic Ductal Adenocarcinoma	1023 - Auckland - Auckland City Hospital; 2010 - Darlinghurst - St Vincent'S Hospital; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT05867121
NCT05867303	RC198-G001	Phase 1	RECRUITING	QLD, SA, VIC	2023-05-17	2023-06-05	RC198	undisclosed_fusion_protein	RC198	undisclosed_fusion_protein	RC198-G001	A Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Immunogenetic and Efficacy of RC198 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors	Melanoma; Urothelial Carcinoma; Renal Cell Carcinoma; Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Carcinoma	3144 - Malvern - Cabrini Hospital Malvern; 4066 - Auchenflower - ICON Cancer Centre Wesley; 5042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT05867303
NCT05868174	177Lu-TLX250-001	Phase 1	RECRUITING	NSW, QLD, VIC, WA	2023-05-11	2023-05-23	177Lu-TLX250; 177Lu-TLX250 + Peposertib; Peposertib	DNA-dependent_protein_kinase_inhibitor; 177Lu-anti-CA9-radioconjugate + DNA-dependent_protein_kinase_inhibitor; 177Lu-anti-CA9-radioconjugate	177Lu-TLX250 + Peposertib; 177Lu-TLX250 + Peposertib	177Lu-anti-CA9-radioconjugate + DNA-dependent_protein_kinase_inhibitor; 177Lu-anti-CA9-radioconjugate + DNA-dependent_protein_kinase_inhibitor	177Lu-TLX250-001	A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors	Solid Tumor, Adult; Advanced Solid Tumor; Advanced Renal Cell Carcinoma	Adelaide - Ashford (Icon) Cancer Centre; Brisbane - Princess Alexandra Hospital; Melbourne - Austin Health; North Ryde - Macquarie University; Perth - GenesisCare Murdoch	https://clinicaltrials.gov/ct2/show/NCT05868174
NCT05870748	STRO-002-GM3	Phase 2/Phase 3	RECRUITING	NSW	2023-05-12	2023-07-12	Gemcitabine; Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Paclitaxel; Pegfilgrastim; Pegylated liposomal doxorubicin; Topotecan	anthracycline + antimetabolite + taxane + topoisomerase_inhibitor; topoisomerase_inhibitor; gemcitabine; granulocyte_colony_stimulating_factor; anthracycline; taxane	Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Pegfilgrastim; Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan	anthracycline + antimetabolite + taxane + topoisomerase_inhibitor; granulocyte_colony_stimulating_factor; anthracycline + antimetabolite + taxane + topoisomerase_inhibitor; gemcitabine	STRO-002-GM3	REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)	Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer	2031 - Randwick - Prince of Wales Hospital; 2050 - Camperdown - Chris O'Brien Lifehouse; 2145 - Westmead - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT05870748
NCT05872295	IKS014-01	Phase 1	RECRUITING	NSW, VIC, WA	2023-05-14	2023-09-14	IKS014	anti-ERBB2_antibody-drug_conjugate	IKS014	anti-ERBB2_antibody-drug_conjugate	IKS014-01	A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors	Breast Cancer; Gastric Cancer; Gastroesophageal-junction Cancer	2139 - Concord - Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit; 2145 - Westmead - Westmead Hospital; 3004 - Melbourne - Alfred Health; 3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group (PSEHOG); 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05872295
NCT05876754	ProvIDHe	Phase 3	RECRUITING	NSW, QLD, SA, WA	2023-05-17	2023-05-03	Ivosidenib	IDH1_R132_inhibitor	Ivosidenib	IDH1_R132_inhibitor	DIM-95031-002	An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma	Cholangiocarcinoma	Brisbane - Royal brisbane & Women's Hospital; Fitzroy - St Vincent's Hospital; Subiaco - St John of God Hospital - Bendat Family Comprehensive Cancer Centre (BFCCC); Sydney - Kinghorn Cancer Centre; Woodville - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05876754
NCT05878288	DISCERN	Phase 2	RECRUITING	VIC	2023-05-17	2023-05-26	Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	HREC/88736/PMCC-2022-326880	Comprehensive and Deep Profiling in Cutaneous Squamous Cell Carcinomas to Unravel Treatment Efficacy in Immunotherapy Treated Patients	Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma of the Head and Neck; Neoplasms; Non-melanoma Skin Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05878288
NCT05879822	INCB-99280-211	Phase 2	RECRUITING	NZ	2023-05-19	2023-10-30	INCB099280	PD-L1_inhibitor,oral	INCB099280	PD-L1_inhibitor,oral	INCB 99280-211	A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive	Advanced Solid Tumor	03010 - Rotorua - Rotorua Hospital; 09016 - Dunedin - Dunedin Hospital	https://clinicaltrials.gov/ct2/show/NCT05879822
NCT05884398	LIBERTAS	Phase 3	RECRUITING	NSW, QLD, VIC	2023-05-23	2023-08-31	Apalutamide	antiandrogen,nonsteroidal,second_generation	Apalutamide	antiandrogen,nonsteroidal,second_generation	CR109327	A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Metastatic Castrate-sensitive Prostate Cancer	2109 - Macquarie University - Macquarie University Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 4101 - South Brisbane - Mater Misericordiae Hospital	https://clinicaltrials.gov/ct2/show/NCT05884398
NCT05886868	BL0020-101	Phase 1	RECRUITING	NSW, QLD	2023-05-24	2023-10-24	BL0020	unknown_drug_class	BL0020	unknown_drug_class	BL0020-101	A Phase I, International, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BL0020 as A Single Agent in Patients With Advanced Solid Tumors	Advanced Solid Tumor	Birtinya - Sunshine Coast University Private Hospital; Sydney - Cancer Care Foundation Limited; Sydney - Scientia Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05886868
NCT05886920	D3S-002-100	Phase 1	RECRUITING	NSW, SA, WA	2023-05-24	2023-07-10	D3S-002	ERK_inhibitor	D3S-002	ERK_inhibitor	D3S-002-100	A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations	Advanced Solid Tumors With MAPK Pathway Mutations	2148 - Blacktown - D3 Bio Investigative Site; 5042 - Bedford Park - D3 Bio Investigative Site; 6009 - Nedlands - D3 Bio Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05886920
NCT05888844	INCB-99280-212	Phase 2	RECRUITING	NSW, NZ, QLD, VIC	2023-05-24	2023-10-09	INCB099280	PD-L1_inhibitor,oral	INCB099280	PD-L1_inhibitor,oral	INCB 99280-212	A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Squamous Cell Carcinoma	Cutaneous Squamous Cell Carcinoma	02640 - Albury - Border Medical Oncology Research Unit; 03128 - Box Hill - Box Hill Hospital; 03168 - Clayton - Monash Medical Centre Clayton; 03200 - Hamilton - Waikato Hospital; 03550 - Bendigo - Bendigo Hospital - (WITHDRAWN); 04102 - Woolloongabba - Princess Alexandra Hospital Australia; 04814 - Townsville - Townsville Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05888844
NCT05891171	ARC-25	Phase 1	RECRUITING	VIC	2023-05-26	2023-10-13	Carboplatin; Carboplatin + Pemetrexed + Zimberelimab; Fluorouracil; Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab; Leucovorin; Oxaliplatin; Pemetrexed; Zimberelimab	antimetabolite; anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; folinic_acid	Carboplatin + Pemetrexed + Zimberelimab; Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab; Carboplatin + Pemetrexed + Zimberelimab; Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	ARC-25	A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Advanced Cancer; Advanced Malignancies; Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Gastroesophageal-junction Cancer (GEJ); Head and Neck Squamous Cell Carcinoma (HNSCC); Non-Small Cell Lung Cancer (NSCLC); Ovarian Cancer; Renal Cell Carcinoma (RCC); Triple Negative Breast Cancer (TNBC)	Adelaide - Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05891171
NCT05894239	WO44263	Phase 3	RECRUITING	NSW, QLD, WA	2023-06-07	2023-07-28	Inavolisib; Placebo	PI3K_alpha_inhibitor; placebo	Inavolisib; Placebo	PI3K_alpha_inhibitor; placebo	WO44263	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer	Metastatic Breast Cancer	2010 - Darlinghurst - Kinghorn Cancer Centre; St Vincents Hospital; 2250 - Gosford - Gosford Hospital; Cancer Care Services; 4556 - Sippy Downs - University of the Sunshine Coast; 6009 - Perth - Sir Charles Gairdner Hospital; Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT05894239
NCT05904886	SKYSCRAPER-14	Phase 3	RECRUITING	NZ	2023-06-14	2023-09-14	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Tiragolumab; Bevacizumab; Placebo; Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; placebo	Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Tiragolumab; Placebo	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; placebo	CO44668	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma	Carcinoma, Hepatocellular	1023 - Auckland - Auckland City Hospital; 6021 - Wellington - Wellington Hospital; 8011 - Christchurch - Christchurch Hospital; Gastroenterology Dept	https://clinicaltrials.gov/ct2/show/NCT05904886
NCT05906862	AMT-253-01	Phase 1	RECRUITING	NSW, QLD, SA, VIC	2023-06-07	2023-11-06	AMT-253	anti-MUC18_antibody-drug_conjugate	AMT-253	anti-MUC18_antibody-drug_conjugate	AMT-253-01	First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors	Advanced Solid Tumor	Adelaide - Southern Oncology Clinical Research; Brisbane - ICON Cancer Centre; Malvern - Cabrini Malvern Hospital; Sydney - Blacktown; Sydney - Chris O'Brien Lifehouse; Sydney - Maquarie University Hospital; VIC 3004 - Melbourne - Alfred Hospital	https://clinicaltrials.gov/ct2/show/NCT05906862
NCT05907304	SEACRAFT-1	Phase 1	RECRUITING	NSW, VIC, WA	2023-06-07	2023-08-17	Naporafenib; Naporafenib + Trametinib; Trametinib	MEK_inhibitor + RAF_dimer_inhibitor; RAF_dimer_inhibitor; MEK_inhibitor	Naporafenib + Trametinib; Naporafenib + Trametinib	MEK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor	ERAS-254-01	An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations	Advanced or Metastatic Solid Tumors	Macquarie Park - Macquarie University; Melbourne - St. Vincent's Hospital; Perth - Linear Clinical Research, LTD	https://clinicaltrials.gov/ct2/show/NCT05907304
NCT05907954	IDE196-009	Phase 2	RECRUITING	NSW, VIC	2023-06-14	2023-07-03	Darovasertib	PKC_inhibitor	Darovasertib	PKC_inhibitor	IDE196-009	(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma	Uveal Melanoma	2010 - Sydney - St. Vincent's Health Sydney; 3004 - Melbourne - Alfred Health	https://clinicaltrials.gov/ct2/show/NCT05907954
NCT05909904	BGB-HNSCC-201	Phase 2	RECRUITING	NSW, QLD, SA, VIC, WA	2023-06-09	2023-07-21	BGB-A425; BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab; LBL-007; LBL-007 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-TIM3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab; LBL-007 + Tislelizumab; Tislelizumab; BGB-A425 + LBL-007 + Tislelizumab; BGB-A425 + Tislelizumab; LBL-007 + Tislelizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody	BGB-HNSCC-201	A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer	2065 - St Leonards - North Shore Private Hospital; 2747 - Kingswood - Nepean Hospital; 3677 - Wangaratta - Northeast Health Wangaratta; 4120 - Greenslopes - Greenslopes Private Hospital; 5000 - Adelaide - Cancer Research South Australia; 6150 - Murdoch - St John of God, Murdoch	https://clinicaltrials.gov/ct2/show/NCT05909904
NCT05910827	HMBD-001-103	Phase 1/Phase 2	RECRUITING	NSW, QLD, SA, VIC, WA	2023-06-16	2024-02-06	Cetuximab; Cetuximab + Docetaxel + HMBD-001; Docetaxel; Docetaxel + HMBD-001; HMBD-001	anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation + taxane; anti-EGFR_monoclonal_antibody; anti-ERBB3_monoclonal_antibody,third_generation + taxane; taxane; anti-ERBB3_monoclonal_antibody,third_generation	Cetuximab + Docetaxel + HMBD-001; Docetaxel + HMBD-001; Cetuximab + Docetaxel + HMBD-001; Docetaxel + HMBD-001	anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation + taxane; anti-ERBB3_monoclonal_antibody,third_generation + taxane; anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation + taxane; anti-ERBB3_monoclonal_antibody,third_generation + taxane	HMBD-001-103	A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-small Cell Lung Cancers	Advanced or Metastatic Squamous Non-Small Cell Lung Cancer	2065 - Sydney - GenesisCare North Shore; 3144 - Malvern - Cabrini Health; 4101 - Brisbane - ICON Cancer Centre South Brisbane; 5042 - Adelaide - Southern Oncology Clinical Research Unit; 6009 - Perth - Linear Clinical Research; Frankston - Peninsula & South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT05910827
NCT05911295	SGNDV-001	Phase 3	RECRUITING	NSW, Other, QLD, SA, VIC	2023-06-09	2023-09-22	Carboplatin; Carboplatin + Cisplatin + Gemcitabine; Cisplatin; Disitamab vedotin; Disitamab vedotin + Pembrolizumab; Gemcitabine; Pembrolizumab	anti-ERBB2_antibody-drug_conjugate; gemcitabine; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Gemcitabine; Disitamab vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Disitamab vedotin + Pembrolizumab	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	SGNDV-001	An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)	Urothelial Carcinoma	2109 - Brisbane - Macquarie University Hospital; 3199 - Frankston - Peninsula and South East Oncology; 4032 - Chermside - Icon Cancer Care Chermside; 5112 - Elizabeth Vale - Lyell McEwin Hospital	https://clinicaltrials.gov/ct2/show/NCT05911295
NCT05914116	DB-1311-O-1001	Phase 1/Phase 2	RECRUITING	NSW, WA	2023-06-13	2023-09-05	DB-1311	anti-B7H3_antibody-drug_conjugate	DB-1311	anti-B7H3_antibody-drug_conjugate	DB-1311-O-1001	A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors	Advanced Solid Tumors	2031 - Sydney - Site 201; 6009 - Nedlands - Site 202	https://clinicaltrials.gov/ct2/show/NCT05914116
NCT05919537	HMBD-001-102	Phase 1	RECRUITING	NSW, QLD, SA, VIC, WA	2023-06-16	2023-09-06	Docetaxel; Docetaxel + HMBD-001; Gemcitabine; Gemcitabine + HMBD-001 + Nab-paclitaxel; HMBD-001; Nab-paclitaxel	anti-ERBB3_monoclonal_antibody,third_generation + antimetabolite + taxane; anti-ERBB3_monoclonal_antibody,third_generation + taxane; gemcitabine; anti-ERBB3_monoclonal_antibody,third_generation; taxane	Docetaxel + HMBD-001; Gemcitabine + HMBD-001 + Nab-paclitaxel; HMBD-001; Docetaxel + HMBD-001; Gemcitabine + HMBD-001 + Nab-paclitaxel	anti-ERBB3_monoclonal_antibody,third_generation; anti-ERBB3_monoclonal_antibody,third_generation + antimetabolite + taxane; anti-ERBB3_monoclonal_antibody,third_generation + taxane; anti-ERBB3_monoclonal_antibody,third_generation + antimetabolite + taxane; anti-ERBB3_monoclonal_antibody,third_generation + taxane; gemcitabine	HMBD-001-102	A Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions or Selected HER3 Mutations	Non-Small Cell Lung Cancer; Pancreatic Cancer; Locally Advanced Solid Tumor; Metastatic Solid Tumor	2065 - Sydney - GenesisCare North Shore; 3144 - Malvern - Cabrini Health; 4101 - Brisbane - ICON Cancer Centre South Brisbane; 5042 - Adelaide - Southern Oncology Clinical Research Unit; 6009 - Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05919537
NCT05920356	NCT05920356	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2023-06-26	2023-11-16	Carboplatin; Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Sotorasib; Pembrolizumab; Pemetrexed; Sotorasib	antimetabolite; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Sotorasib; Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	20190341	A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)	Non-Small Cell Lung Cancer (NSCLC)	2065 - St Leonards - GenesisCare -North Shore Oncology; 2139 - Concord - Concord Repatriation General Hospital; 2560 - Campbelltown - Campbelltown Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - The Alfred Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 4350 - Toowoomba - Toowoomba Hospital; 5000 - Adelaide - Cancer Research South Australia	https://clinicaltrials.gov/ct2/show/NCT05920356
NCT05923008	CIBI130A101	Phase 1/Phase 2	RECRUITING	QLD	2023-06-19	2023-11-14	IBI130	anti-Trop2_monoclonal_antibody	IBI130	anti-Trop2_monoclonal_antibody	CIBI130A101	A Phase 1/2, Multicenter, Open-label Study of IBI130 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	4575 - Birtinya - Sunshine Coast University	https://clinicaltrials.gov/ct2/show/NCT05923008
NCT05935098	BGB-A317-A3055-101	Phase 1	RECRUITING	NSW, QLD, WA	2023-07-05	2023-08-21	BGB-A3055; BGB-A3055 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BGB-A3055; BGB-A3055 + Tislelizumab; BGB-A3055 + Tislelizumab	anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BGB-A317-A3055-101	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors	Advanced Solid Tumor; Metastatic Solid Tumor; Solid Tumor	2050 - Camperdown - Chris Obrien Lifehouse; 4101 - South Brisbane - Icon Cancer Care South Brisbane; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05935098
NCT05947851	1026-010	Phase 3	RECRUITING	SA, VIC	2023-07-07	2023-08-08	Nemtabrutinib; Nemtabrutinib + Venetoclax; Rituximab; Rituximab + Venetoclax; Venetoclax	BTK_inhibitor + Bcl2_inhibitor; BTK_inhibitor; anti-CD20_monoclonal_antibody; Bcl2_inhibitor + anti-CD20_monoclonal_antibody; Bcl2_inhibitor	Nemtabrutinib + Venetoclax; Rituximab + Venetoclax; Nemtabrutinib + Venetoclax; Rituximab + Venetoclax	BTK_inhibitor + Bcl2_inhibitor; Bcl2_inhibitor + anti-CD20_monoclonal_antibody; BTK_inhibitor + Bcl2_inhibitor; Bcl2_inhibitor + anti-CD20_monoclonal_antibody	1026-010	A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)	Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic; Small-Cell Lymphoma; Lymphoma, Small Lymphocytic; CLL; SLL	3021 - Melbourne - Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 1103); 5000 - Adelaide - Royal Adelaide Hospital ( Site 1104)	https://clinicaltrials.gov/ct2/show/NCT05947851
NCT05954871	GO44272	Phase 1	RECRUITING	NSW, SA, VIC	2023-07-12	2024-01-08	Cetuximab; Cetuximab + RLY-1971; Osimertinib; Osimertinib + RLY-1971; RLY-1971	anti-EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody; SHP2_inhibitor; EGFR_inhibitor,third_generation	Cetuximab + RLY-1971; Osimertinib + RLY-1971; Cetuximab + RLY-1971; Osimertinib + RLY-1971	EGFR_inhibitor,third_generation + SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody	GO44272	A Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Patients With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Patients With Metastatic Colorectal Cancer	Colorectal Cancer; Non-Small Cell Lung Cancer	3000 - Melbourne - Peter Maccallum Cancer Centre; 3065 - Fitzroy - St Vincent's Hospital Melbourne; 3690 - Wodonga - Border Medical Oncology; 5011 - Woodville - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05954871
NCT05957081	MarkV-01	Phase 1	NOT_YET_RECRUITING	QLD, VIC	2023-07-19	2023-11-28	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	MarkV-01	A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	3004 - Melbourne - Alfred Health; 3144 - Malvern - Cabrini Health Limited; 3350 - Ballarat - Ballarat Regional Integrated Cancer Centre (Grampians Health); 4217 - Benowa - Australian Hospital Care (Pindara) PTY LTD. Trading as Pindara Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05957081
NCT05957536	D3L-001-100	Phase 1	RECRUITING	NSW, VIC	2023-07-20	2023-09-19					D3L-001-100	A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors.	HER-2 Positive Advanced Solid Tumors	2109 - Sydney - D3 Bio Investigative Site; 3144 - Malvern - D3 Bio Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05957536
NCT05967689	REZILIENT2	Phase 2	RECRUITING	NSW, WA	2023-07-21	2023-07-27	TAS6417	EGFR_inhibitor,exon_20_selective	TAS6417	EGFR_inhibitor,exon_20_selective	TAS6417-201	An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.	Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations	2065 - Saint Leonards - GenesisCare - North Shore; 2200 - Bankstown - Bankstown-Lidcombe Hospital; 6027 - Joondalup - Joondalup Health Campus	https://clinicaltrials.gov/ct2/show/NCT05967689
NCT05969041	MYE-Symphony	Phase 1	RECRUITING	NSW, SA, VIC, WA	2023-07-28	2023-08-02	MT-302	Trop2-targeting_lipid-nanoparticles	MT-302	Trop2-targeting_lipid-nanoparticles	MTX-TROP2-302	MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors	Epithelial Tumors, Malignant	2010 - Darlinghurst - St Vincent's Public Hospital Sydney; 2031 - Randwick - Scientia Clinical Research Ltd; 2145 - Westmead - Westmead Hospital; 3144 - Malvern - Cabrini Health; 5042 - Bedford Park - Souther Oncology Clinical Research Unit (SOCRU); 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT05969041
NCT05975073	NCT05975073	Phase 1/Phase 2	RECRUITING	SA, VIC	2023-07-27	2023-07-27	AMG 193; AMG 193 + IDE397; IDE397; Pemetrexed	antimetabolite; MAT2A_inhibitor + PRMT5_inhibitor; PRMT5_inhibitor; MAT2A_inhibitor	AMG 193 + IDE397; AMG 193 + IDE397; Pemetrexed	MAT2A_inhibitor + PRMT5_inhibitor; MAT2A_inhibitor + PRMT5_inhibitor; antimetabolite	20220127	A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors	MTAP-null Non-Small-Cell Lung Cancer; MTAP-null Solid Tumors	3168 - Clayton - Monash Medical Centre; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05975073
NCT05981703	BGB-A317-26808-101	Phase 1	RECRUITING	NSW, NZ, SA, WA	2023-07-31	2023-09-07	Tislelizumab	anti-PD-1_monoclonal_antibody	Tislelizumab	anti-PD-1_monoclonal_antibody	BGB-A317-26808-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Solid Tumor	1023 - Auckland - Auckland City Hospital; 2109 - North Ryde - Macquarie University; 2228 - Miranda - Southside Cancer Care; 5037 - Kurralta Park - Ashford Cancer Centre Research; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05981703
NCT05984277	eVOLVE-Lung02	Phase 3	RECRUITING	NSW, QLD, VIC	2023-08-02	2023-10-24	Carboplatin; Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Paclitaxel + Pemetrexed; MEDI5752; Paclitaxel; Pembrolizumab; Pemetrexed	bispecific_PD-L1/CTLA-4_antibody; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Paclitaxel + Pemetrexed; Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Paclitaxel + Pemetrexed; MEDI5752	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent + taxane; bispecific_PD-L1/CTLA-4_antibody	D798AC00001	A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).	Metastatic Non-small Cell Lung Cancer	3065 - Fitzroy - Research Site; 3084 - Heidelberg - Research Site; 3168 - Clayton - Research Site; 4101 - South Brisbane - Research Site; NSW 2145 - Sydney - Research Site	https://clinicaltrials.gov/ct2/show/NCT05984277
NCT05987332	IDE196-002	Phase 2/Phase 3	RECRUITING	NSW, QLD, VIC, WA	2023-08-03	2023-10-31	Crizotinib; Crizotinib + Darovasertib; Dacarbazine; Dacarbazine + Ipilimumab + Nivolumab + Pembrolizumab; Darovasertib; Ipilimumab; Nivolumab; Pembrolizumab	MET_inhibitor,type_1; MET_inhibitor,type_1 + PKC_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor; ALK_inhibitor,first_generation; alkylating_agent; PKC_inhibitor + ROS1_inhibitor; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; alkylating_agent + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ROS1_inhibitor; PKC_inhibitor	Crizotinib + Darovasertib; Dacarbazine + Ipilimumab + Nivolumab + Pembrolizumab; Crizotinib + Darovasertib; Dacarbazine + Ipilimumab + Nivolumab + Pembrolizumab	ALK_inhibitor,first_generation + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; alkylating_agent + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ALK_inhibitor,first_generation + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; alkylating_agent + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	IDE196-002	IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)	Metastatic Uveal Melanoma	2145 - Sydney - Westmead Hospital; 3168 - Melbourne - Alfred Health; 4102 - Brisbane - Princess Alexander Hospital; 6009 - Perth - Sir Charles Gairdner Hospital; Adelaide - Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05987332
NCT05991349	CIBI129A101	Phase 1/Phase 2	RECRUITING	NSW	2023-08-06	2024-03-12	IBI129	anti-B7H3_antibody-drug_conjugate	IBI129	anti-B7H3_antibody-drug_conjugate	CIBI129A101	A Phase 1/2 Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	2217 - Sydney - St George private Hospital	https://clinicaltrials.gov/ct2/show/NCT05991349
NCT05997615	TCD17896	Phase 1/Phase 2	RECRUITING	NSW, VIC	2023-08-11	2023-08-10	AMX-500	unknown_drug_class	AMX-500	unknown_drug_class	TCD17896	A Phase 1, First-in-human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)	Hormone-refractory Prostate Cancer	2010 - New South Wales - Investigational Site Number: 101; 3000 - Victoria - Investigational Site Number: 100	https://clinicaltrials.gov/ct2/show/NCT05997615
NCT06003231	SGNDV-005	Phase 2	RECRUITING	NSW, Other, VIC	2023-08-15	2023-11-14	Disitamab vedotin	anti-ERBB2_antibody-drug_conjugate	Disitamab vedotin	anti-ERBB2_antibody-drug_conjugate	SGNDV-005	A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2	Carcinoma, Squamous Cell of Head and Neck; Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Endometrial Neoplasms	2109 - Brisbane - Macquarie University Hospital; 2148 - Blacktown NSW - Blacktown Hospital; 3199 - Frankston - Peninsula and South East Oncology	https://clinicaltrials.gov/ct2/show/NCT06003231
NCT06003621	MoST-TAP	Phase 2	RECRUITING	NSW, QLD, VIC, WA	2023-08-15	2023-12-15	Atezolizumab; Atezolizumab + Tiragolumab; Tiragolumab	anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Atezolizumab + Tiragolumab; Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	ML43743	A Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients With Advanced Solid Tumours.	Solid Tumor, Adult	2444 - Port Macquarie - Port Macquarie Base Hospital; 2450 - Coffs Harbour - Coffs Harbour Health Campus; 2640 - Albury - Border Medical Oncology Research Unit; 2640 - Albury - Ramsay Health Care Australia Pty Ltd trading as The Border Cancer Hospital; 2800 - Orange - Orange Base Hospital; 3220 - Geelong - Barwon Health; 3550 - Bendigo - Bendigo Health; 4350 - Toowoomba - Toowoomba Hospital; 4870 - Cairns - Cairns Hospital; 6150 - Perth - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT06003621
NCT06007482	ES009-1001	Phase 1	RECRUITING	NSW, VIC	2023-08-21	2023-09-07	ES009	anti-LILRB2_monoclonal_antibody	ES009	anti-LILRB2_monoclonal_antibody	ES009-1001	An Open-Label, Multicenter, First-in-Human, Phase 1 Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumor	Frankston - Peninsula and South Eastern Oncology and Haematology Group; Kogarah - St George Private Hospital; Randwick - Scientia Clinical Research; Sunshine Coast - Sunshine Coast University Private Hospital	https://clinicaltrials.gov/ct2/show/NCT06007482
NCT06007690	CoMpass	Phase 3	RECRUITING	QLD, VIC	2023-08-17	2023-12-06	Placebo	placebo	Placebo	placebo	AU-011-301	A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma	Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma; Ocular Melanoma	3002 - East Melbourne - Eye Research Australia; 4000 - Brisbane - Terrace Eye Centre	https://clinicaltrials.gov/ct2/show/NCT06007690
NCT06016738	OPERA-01	Phase 3	RECRUITING	NSW, SA, VIC, WA	2023-08-29	2023-11-16	Anastrozole; Anastrozole + Exemestane + Fulvestrant + Letrozole; Exemestane; Fulvestrant; Letrozole; Palazestrant	selective_estrogen_receptor_degrader; aromatase_inhibitor; complete_estrogen_receptor_antagonist; aromatase_inhibitor + selective_estrogen_receptor_degrader	Anastrozole + Exemestane + Fulvestrant + Letrozole; Palazestrant; Anastrozole + Exemestane + Fulvestrant + Letrozole	aromatase_inhibitor + selective_estrogen_receptor_degrader; complete_estrogen_receptor_antagonist; aromatase_inhibitor + selective_estrogen_receptor_degrader	OP-1250-301	A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)	Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma	2145 - Westmead - Clinical Trial Site; 2250 - Gosford - Clinical Trial Site; 3168 - Clayton - Clinical Trial Site; 3355 - Ballarat Central - Clinical Trial Site; 3630 - Shepparton - Clinical Trial Site; 5000 - Adelaide - Clinical Trial Site; 6009 - Nedlands - Clinical Trial Site	https://clinicaltrials.gov/ct2/show/NCT06016738
NCT06018337	DB-1303-O-3002	Phase 3	RECRUITING	NSW, SA	2023-08-25	2024-01-18	Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel; DB-1303; Nab-paclitaxel; Paclitaxel	fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate; taxane; fluoropyrimidine + taxane	Capecitabine + Nab-paclitaxel + Paclitaxel; DB-1303; Capecitabine + Nab-paclitaxel + Paclitaxel	anti-ERBB2_antibody-drug_conjugate; fluoropyrimidine + taxane; fluoropyrimidine + taxane	DB-1303-O-3002	A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)	Metastatic Breast Cancer	2155 - Adelaide - Research Site	https://clinicaltrials.gov/ct2/show/NCT06018337
NCT06031441	GO44431	Phase 1	RECRUITING	NSW, VIC	2023-09-04	2023-11-27	Atezolizumab; Atezolizumab + RO7566802; RO7566802	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + unknown_drug_class; unknown_drug_class	Atezolizumab + RO7566802; Atezolizumab + RO7566802	anti-PD-L1_monoclonal_antibody + unknown_drug_class; anti-PD-L1_monoclonal_antibody + unknown_drug_class	GO44431	A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced Solid Tumors; Recurrent Solid Tumors; Metastatic Solid Tumors	2010 - Darlinghurst - St Vincent's Hospital Sydney; 3000 - Melbourne - Peter Maccallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06031441
NCT06036836	4280A-010	Phase 2	RECRUITING	NSW, QLD, VIC, WA	2023-09-07	2023-09-29	Favezelimab; Favezelimab + Lenvatinib + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Favezelimab + Lenvatinib + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; Pembrolizumab; Favezelimab + Lenvatinib + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	4280A-010	A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)	Solid Tumor; Cutaneous Squamous Cell Carcinoma; Endometrial Cancer	2010 - Darlinghurst - St Vincent's Hospital-The Kinghorn Cancer Centre ( Site 0005); 2065 - St Leonards - Royal North Shore Hospital ( Site 0008); 2148 - Sydney - Blacktown Hospital ( Site 0003); 3004 - Melbourne - The Alfred Hospital ( Site 0004); 4029 - Brisbane - Royal Brisbane and Women's Hospital ( Site 0002); 6150 - Murdock - Fiona Stanley Hospital ( Site 0006)	https://clinicaltrials.gov/ct2/show/NCT06036836
NCT06058793	1403-0019	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2023-09-22	2023-12-12	Brigimadlin	MDM2_inhibitor	Brigimadlin	MDM2_inhibitor	1403-0019	Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma	Liposarcoma, Dedifferentiated	2031 - Randwick - Prince of Wales Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT06058793
NCT06063681	StingrayTx	Phase 1	RECRUITING	NSW, VIC	2023-09-23	2023-10-12	SR-8541A	ENPP1_inhibitor	SR-8541A	ENPP1_inhibitor	StingrayTx	Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy in Subjects With Advanced/Metastatic Solid Tumors	Advanced / Metastatic Solid Tumor	2031 - Randwick - Scientia Clinical Research Ltd; 3168 - Clayton - Monash Health; 3199 - Frankston - Peninsula & South Eastern Haematology & Oncology Group	https://clinicaltrials.gov/ct2/show/NCT06063681
NCT06064877	FIERCE-HN	Phase 3	RECRUITING	NSW, QLD, WA	2023-09-26	2024-01-11	Cetuximab; Cetuximab + Ficlatuzumab; Ficlatuzumab; Placebo	anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-HGF_monoclonal_antibody; placebo; anti-HGF_monoclonal_antibody	Cetuximab + Ficlatuzumab; Cetuximab + Ficlatuzumab; Placebo	anti-EGFR_monoclonal_antibody + anti-HGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-HGF_monoclonal_antibody; placebo	AV-299-23-301	A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)	Metastatic Head-and-neck Squamous-cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma	2010 - Sydney - St. Vincent's Hospital; 2217 - Kogarah - St George Hospital; 4102 - Brisbane - Princess Alexandra Hospital; 6150 - Murdoch - St. John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT06064877
NCT06065748	CO44657	Phase 3	RECRUITING	NSW, NZ, QLD, SA, VIC	2023-09-26	2023-12-11	Abemaciclib; Abemaciclib + Fulvestrant + LHRH Agonist + Palbociclib + Ribociclib; Abemaciclib + Giredestrant + LHRH Agonist + Palbociclib + Ribociclib; Fulvestrant; Giredestrant; LHRH Agonist; Palbociclib; Ribociclib	selective_estrogen_receptor_degrader; CDK4/6_inhibitor + LHRH_agonist + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; LHRH_agonist	Abemaciclib + Fulvestrant + LHRH Agonist + Palbociclib + Ribociclib; Abemaciclib + Giredestrant + LHRH Agonist + Palbociclib + Ribociclib; Abemaciclib + Fulvestrant + LHRH Agonist + Palbociclib + Ribociclib; Abemaciclib + Giredestrant + LHRH Agonist + Palbociclib + Ribociclib	CDK4/6_inhibitor + LHRH_agonist + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + LHRH_agonist + selective_estrogen_receptor_degrader	CO44657	A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy	Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer	2060 - North Sydney - Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research; 2086 - Frenchs Forest - Northern Beaches Hospital; 2747 - Kingswood - Nepean Hospital; Nepean Cancer Care Centre; 3021 - St Albans - Sunshine Hospital; 3220 - Geelong - Barwon Health; 3280 - Warrnambool - South West Healthcare; 4101 - South Brisbane - Mater Misericordiae Limited; 4442 - Palmerston North - Palmerston North Hospital; Regional Cancer Treatment Service; 4556 - Sippy Downs - University of the Sunshine Coast; 5000 - Adelaide - Cancer Research SA	https://clinicaltrials.gov/ct2/show/NCT06065748
NCT06072781	RAMP-301	Phase 3	RECRUITING	NSW, QLD, SA	2023-10-02	2024-03-18	Anastrozole; Anastrozole + Letrozole + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Avutometinib; Avutometinib + Defactinib; Defactinib; Letrozole; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	RAF/MEK_clamp; FAK_inhibitor; topoisomerase_inhibitor; aromatase_inhibitor; anthracycline; anthracycline + aromatase_inhibitor + taxane + topoisomerase_inhibitor; FAK_inhibitor + RAF/MEK_clamp; taxane	Anastrozole + Letrozole + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Avutometinib + Defactinib; Anastrozole + Letrozole + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Avutometinib + Defactinib	FAK_inhibitor + RAF/MEK_clamp; anthracycline + aromatase_inhibitor + taxane + topoisomerase_inhibitor; FAK_inhibitor + RAF/MEK_clamp; anthracycline + aromatase_inhibitor + taxane + topoisomerase_inhibitor	VS-6766-301	A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)	Low Grade Serous Ovarian Cancer	2031 - Randwick - Prince of Wales Hospital; 4066 - Auchenflower - Icon Cancer Centre Wesley; 5000 - Adelaide - Cancer Research South Australia	https://clinicaltrials.gov/ct2/show/NCT06072781
NCT06074497	KGX101ST101	Phase 1	NOT_YET_RECRUITING	QLD, VIC	2023-10-03	2023-11-02	KGX101	IL-12_Fc-fusion_protein	KGX101	IL-12_Fc-fusion_protein	KGX101ST101	A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation Trial of KGX101 Administered as a Monotherapy to Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group; 4575 - Birtinya - Sunshine Coast University Private Hospital	https://clinicaltrials.gov/ct2/show/NCT06074497
NCT06074588	2870-004	Phase 3	RECRUITING	NSW, VIC	2023-10-03	2023-11-12	Dexamethasone; Dexamethasone + Sacituzumab tirumotecan; Docetaxel; Docetaxel + Pemetrexed; Pemetrexed; Sacituzumab tirumotecan	antimetabolite + taxane; antimetabolite; anti-Trop2_antibody-drug_conjugate + glucocorticoid; anti-Trop2_antibody-drug_conjugate; glucocorticoid; taxane	Dexamethasone + Sacituzumab tirumotecan; Docetaxel + Pemetrexed; Dexamethasone + Sacituzumab tirumotecan; Docetaxel + Pemetrexed	anti-Trop2_antibody-drug_conjugate + glucocorticoid; antimetabolite + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; antimetabolite + taxane	2870-004	A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations	Non-small Cell Lung Cancer (NSCLC)	2145 - Westmead - Westmead Hospital-Department of Medical Oncology ( Site 3000); 2217 - Kogarah - St. George Private Hospital ( Site 3004); 3021 - Melbourne - Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 3003); 3168 - Clayton - Monash Health-Oncology Research ( Site 3001)	https://clinicaltrials.gov/ct2/show/NCT06074588
NCT06082960	GS-US-521-6317	Phase 1	RECRUITING	VIC	2023-10-09	2023-10-09	GS-9911; GS-9911 + Zimberelimab; Zimberelimab	anti-PD-1_monoclonal_antibody; DGK-alpha_inhibitor; DGK-alpha_inhibitor + anti-PD-1_monoclonal_antibody	GS-9911; GS-9911 + Zimberelimab; GS-9911 + Zimberelimab	DGK-alpha_inhibitor; DGK-alpha_inhibitor + anti-PD-1_monoclonal_antibody; DGK-alpha_inhibitor + anti-PD-1_monoclonal_antibody	GS-US-521-6317	A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors	Solid Tumors	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06082960
NCT06092580	AWT020-001	Phase 1	RECRUITING	QLD, SA, VIC	2023-10-18	2023-09-15	AWT020	anti-PD1-IL2_fusion_protein	AWT020	anti-PD1-IL2_fusion_protein	AWT020-001	A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer	Advanced Cancer	4101 - South Brisbane - ICON Cancer Center South Brisbane; 5042 - Bedford Park - Southern Oncology Clinical Research Unit (SOCRU); Melbourne - Alfred Health	https://clinicaltrials.gov/ct2/show/NCT06092580
NCT06097728	eVOLVE-Meso	Phase 3	RECRUITING	QLD, VIC, WA	2023-10-18	2023-11-09	Carboplatin; Carboplatin + Cisplatin + Ipilimumab + Nivolumab + Pemetrexed; Carboplatin + Pemetrexed; Cisplatin; Ipilimumab; MEDI5752; Nivolumab; Pemetrexed	bispecific_PD-L1/CTLA-4_antibody; antimetabolite; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Ipilimumab + Nivolumab + Pemetrexed; Carboplatin + Pemetrexed; Carboplatin + Cisplatin + Ipilimumab + Nivolumab + Pemetrexed; Carboplatin + Pemetrexed; MEDI5752	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; bispecific_PD-L1/CTLA-4_antibody	D7988C00001	A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)	Unresectable Pleural Mesothelioma	3000 - Melbourne - Research Site; 3168 - Clayton - Research Site; 4032 - Chermside - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT06097728
NCT06099782	3475A-F11	Phase 2	RECRUITING	NSW, NZ, VIC	2023-10-19	2023-12-26	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	3475A-F11	A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types (MK-3475A-F11)	Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Melanoma	1023 - Auckland - Auckland City Hospital-Cancer & Blood Research ( Site 1051); 2444 - Port Macquarie - Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 1001); 3199 - Frankston - Frankston Hospital-Oncology and Haematology ( Site 1007); 6035 - Wellington - Bowen Hospital ( Site 1050)	https://clinicaltrials.gov/ct2/show/NCT06099782
NCT06103864	D7630C00001	Phase 3	RECRUITING	NSW, VIC, WA	2023-10-23	2023-11-23	Carboplatin; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Datopotamab deruxtecan; Durvalumab; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab	antimetabolite; gemcitabine; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent	Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Durvalumab; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Datopotamab deruxtecan	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-Trop2_antibody-drug_conjugate; gemcitabine	D7630C00001	A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)	Breast Cancer	2010 - Darlinghurst - Research Site; 2050 - Camperdown - Research Site; 2298 - Waratah - Research Site; 3000 - Melbourne - Research Site; 3084 - Heidelberg - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT06103864
NCT06105632	C4391022	Phase 3	RECRUITING	NSW, QLD	2023-10-24	2024-01-09	Everolimus; Everolimus + Exemestane + Fulvestrant; Exemestane; Fulvestrant; Fulvestrant + PF-07220060; PF-07220060	selective_estrogen_receptor_degrader; aromatase_inhibitor; CDK4_selective_inhibitor; mTORC1_inhibitor; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor + mTORC1_inhibitor + selective_estrogen_receptor_degrader	Everolimus + Exemestane + Fulvestrant; Fulvestrant + PF-07220060; Everolimus + Exemestane + Fulvestrant; Fulvestrant + PF-07220060	CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor + mTORC1_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor + mTORC1_inhibitor + selective_estrogen_receptor_degrader	C4391022	AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY	Advanced or Metastatic Breast Cancer	2109 - North Ryde - Macquarie University; 4812 - Rosslea - Icon Cancer Centre Townsville; 4812 - Townsville - Icon Cancer Centre Townsville	https://clinicaltrials.gov/ct2/show/NCT06105632
NCT06108479	DF6215-001	Phase 1	RECRUITING	VIC	2023-10-25	2023-11-28					DF6215-001	A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors	Solid Tumor, Adult	3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT06108479
NCT06112314	PRISM-MEL-301	Phase 3	RECRUITING	NSW, QLD	2023-10-31	2023-12-18	IMC-F106C; IMC-F106C + Nivolumab; Nivolumab; Nivolumab + Relatlimab; Relatlimab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting; anti-PD-1_monoclonal_antibody; bispecific_T-cell_engager,PRAME-targeting; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	IMC-F106C + Nivolumab; Nivolumab + Relatlimab; IMC-F106C + Nivolumab; Nivolumab + Relatlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting	IMC-F106C-301	A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301	Advanced Melanoma	4120 - Greenslopes - Gallipoli Medical Research Foundation (Greenslopes Private Hospital); Wollstonecraft - University of Sydney - Melanoma Institute Australia (MIA) - The Poche Centre; Woolloongabba - The University of Queensland (UQ) - Princess Alexandra Hospital (PAH)	https://clinicaltrials.gov/ct2/show/NCT06112314
NCT06117774	DeLLphi-306	Phase 3	RECRUITING	NSW, WA	2023-10-31	2024-02-20	Placebo; Radiotherapy; Tarlatamab	radiotherapy; bispecific_T-cell_engager,DLL3-targeting; placebo	Tarlatamab; Placebo; Radiotherapy	bispecific_T-cell_engager,DLL3-targeting; placebo; radiotherapy	20230016	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy	Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer	2444 - Port Macquarie - Port Macquarie Base Hospital; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT06117774
NCT06119581	SUNRAY-01	Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2023-11-01	2023-12-21	Carboplatin; Carboplatin + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Olomorasib; Olomorasib + Pembrolizumab; Pembrolizumab; Pemetrexed; Placebo	antimetabolite; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor	Carboplatin + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Olomorasib + Pembrolizumab; Pembrolizumab; Carboplatin + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Olomorasib + Pembrolizumab; Placebo	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; placebo	18612	SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression	Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis	2250 - Gosford - Gosford Hospital; 3065 - Melbourne - St Vincent's Hospital; 3350 - Ballarat Central - Ballarat Health Services; 3630 - Shepparton - Goulburn Valley Health; 4066 - Auchenflower - Icon Cancer Centre Wesley; 4215 - Southport - Gold Coast University Hospital; 4575 - Birtinya - Sunshine Coast University Hospital; 4740 - Mackay - Mackay Base Hospital; 4814 - Townsville - The Townsville Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 6009 - Perth - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT06119581
NCT06120283	BGB-43395-101	Phase 1	RECRUITING	NSW, VIC	2023-11-01	2023-12-01	BGB-43395; BGB-43395 + Fulvestrant; BGB-43395 + Fulvestrant + Letrozole; Fulvestrant; Letrozole	selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; CDK4_selective_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor	BGB-43395 + Fulvestrant; BGB-43395 + Fulvestrant + Letrozole; BGB-43395 + Fulvestrant; BGB-43395 + Fulvestrant + Letrozole	CDK4_selective_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader	BGB-43395-101	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Non-small Cell Lung Cancer	2109 - North Ryde - Macquarie University; 2148 - Blacktown - Blacktown Cancer and Haematology Centre; 3000 - Melbourne - Peter Maccallum Cancer Centre; 3084 - Heidelberg - Austin Health	https://clinicaltrials.gov/ct2/show/NCT06120283
NCT06120491	EvoPAR-PR01	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2023-11-06	2023-11-21	Abiraterone; Abiraterone + Darolutamide + Enzalutamide; Abiraterone + Darolutamide + Enzalutamide + Saruparib; Darolutamide; Enzalutamide; Placebo; Saruparib	CYP17A1_inhibitor + PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; PARP1-selective_inhibitor; placebo; antiandrogen,nonsteroidal,second_generation	Abiraterone + Darolutamide + Enzalutamide; Abiraterone + Darolutamide + Enzalutamide + Saruparib; Abiraterone + Darolutamide + Enzalutamide; Abiraterone + Darolutamide + Enzalutamide + Saruparib; Placebo	CYP17A1_inhibitor + PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; placebo	D9723C00001	A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)	Metastatic Castration-Sensitive Prostate Cancer	2010 - Darlinghurst - Research Site; 2031 - Randwick - Research Site; 3000 - Melbourne - Research Site; 4032 - Chermside - Research Site; 4101 - South Brisbane - Research Site; 4812 - Hyde Park - Research Site; 5037 - Kurralta Park - Research Site	https://clinicaltrials.gov/ct2/show/NCT06120491
NCT06130553	PRIMROSE	Phase 1/Phase 2	RECRUITING	VIC	2023-11-08	2024-01-18	AZD3470; Pemetrexed	antimetabolite; PRMT5_inhibitor	AZD3470; Pemetrexed	PRMT5_inhibitor; antimetabolite	D9970C00001	PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours That Are MTAP Deficient	Advanced Solid Tumours That Are MTAP Deficient	3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06130553
NCT06131398	NCT06131398	Phase 1	RECRUITING	SA	2023-11-09	2024-03-07	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	20220028	A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT06131398
NCT06132958	2870-005	Phase 3	RECRUITING	NSW, QLD, VIC	2023-11-10	2023-12-06	Dexamethasone; Dexamethasone + Sacituzumab tirumotecan; Doxorubicin; Doxorubicin + Paclitaxel; Paclitaxel; Sacituzumab tirumotecan	anthracycline + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; anti-Trop2_antibody-drug_conjugate; glucocorticoid; taxane; doxorubicin	Dexamethasone + Sacituzumab tirumotecan; Doxorubicin + Paclitaxel; Dexamethasone + Sacituzumab tirumotecan; Doxorubicin + Paclitaxel	anthracycline + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; anthracycline + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; doxorubicin	2870-005	A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)	Endometrial Cancer	2065 - St Leonards - GenesisCare North Shore ( Site 1103); 2148 - Blacktown - Blacktown Hospital ( Site 1101); 3002 - East Melbourne - Epworth Freemasons ( Site 1104); 3199 - Frankston - Frankston Hospital ( Site 1105); 4029 - Brisbane - Royal Brisbane and Women's Hospital ( Site 1102)	https://clinicaltrials.gov/ct2/show/NCT06132958
NCT06136624	5684-003	Phase 3	RECRUITING	NSW, QLD, VIC	2023-11-13	2023-12-31	Abiraterone; Abiraterone + Enzalutamide + Prednisone; Dexamethasone; Dexamethasone + Opevesostat; Enzalutamide; Opevesostat; Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; CYP11A1_inhibitor; CYP17A1_inhibitor; glucocorticoid; antiandrogen,nonsteroidal,second_generation; CYP11A1_inhibitor + glucocorticoid	Abiraterone + Enzalutamide + Prednisone; Dexamethasone + Opevesostat; Abiraterone + Enzalutamide + Prednisone; Dexamethasone + Opevesostat	CYP11A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; CYP11A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid	5684-003	A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy	Prostate Cancer Metastatic	2109 - Macquarie University - Macquarie University-MQ Health Clinical Trials Unit ( Site 0234); 2145 - Westmead - Westmead Hospital-Department of Medical Oncology ( Site 0232); 2830 - Dubbo - Dubbo Hospital ( Site 0235); 3000 - Melbourne - Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0230); 4102 - Brisbane - Princess Alexandra Hospital-Cancer Care Serices ( Site 0237)	https://clinicaltrials.gov/ct2/show/NCT06136624
NCT06136650	5684-004	Phase 3	RECRUITING	NSW, NZ, QLD, VIC	2023-11-13	2023-12-18	Abiraterone; Abiraterone + Enzalutamide + Prednisone; Dexamethasone; Dexamethasone + Opevesostat; Enzalutamide; Opevesostat; Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; CYP11A1_inhibitor; CYP17A1_inhibitor; glucocorticoid; antiandrogen,nonsteroidal,second_generation; CYP11A1_inhibitor + glucocorticoid	Abiraterone + Enzalutamide + Prednisone; Dexamethasone + Opevesostat; Abiraterone + Enzalutamide + Prednisone; Dexamethasone + Opevesostat	CYP11A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; CYP11A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid	5684-004	A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)	Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms	1023 - Auckland - Auckland City Hospital-Cancer & Blood Research ( Site 1033); 2109 - Macquarie University - Macquarie University-MQ Health Clinical Trials Unit ( Site 0214); 2145 - Westmead - Westmead Hospital-Department of Medical Oncology ( Site 0212); 3000 - Melbourne - Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0210); 4029 - Brisbane - Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si	https://clinicaltrials.gov/ct2/show/NCT06136650
NCT06151574	1479-0008	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2023-11-22	2024-01-15	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Pembrolizumab; Pemetrexed; Zongertinib	antimetabolite; ERBB2_inhibitor,second_generation; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Zongertinib; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed	ERBB2_inhibitor,second_generation; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	1479-0008	Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations	Lung Cancer, Non-squamous, Non-small Cell	2065 - St Leonards - Royal North Shore Hospital; 3084 - Heidelberg - Austin Health; 4102 - Woolloongabba - Princess Alexandra Hospital; 6008 - Subiaco - St John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT06151574
NCT06157541	TCaP	Phase 1/Phase 2	RECRUITING	QLD, VIC	2023-11-26	2024-02-08	Ifosfamide; Pembrolizumab	alkylating_agent; anti-PD-1_monoclonal_antibody	Pembrolizumab; Ifosfamide	anti-PD-1_monoclonal_antibody; alkylating_agent	P3894 / MSD-MK3475-E78	Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Multiforme	Glioblastoma Multiforme; Astrocytoma, Grade IV	3084 - Heidelberg - Austin Hospital; 4006 - Bowen Hills - Newro Foundation; 4006 - Herston - Royal Brisbane and Women's Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT06157541
NCT06162572	SPLFIO-174	Phase 1/Phase 2	NOT_YET_RECRUITING	NSW, SA, VIC	2023-12-07	2024-06-07	Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	SPLFIO-174	A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression	Non-small Cell Lung Cancer (NSCLC)	2640 - Albury - Albury Wodonga Regional Cancer Centre; Border Medical Oncology Research Unit; 3021 - St Albans - Sunshine Hospital; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT06162572
NCT06170190	CIBI133A101	Phase 1/Phase 2	RECRUITING	NSW	2023-12-06	2024-01-16	IBI133	anti-ERBB3_monoclonal_antibody	IBI133	anti-ERBB3_monoclonal_antibody	CIBI133A101	A Multicentre, Open-label, Phase 1/2 Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours	Locally Advanced Unresectable or Metastatic Solid Tumors	2170 - Liverpool - Liverpool Hospital	https://clinicaltrials.gov/ct2/show/NCT06170190
NCT06170788	2870-007	Phase 3	RECRUITING	NSW, VIC	2023-12-06	2023-12-15	Dexamethasone; Dexamethasone + Pembrolizumab + Sacituzumab tirumotecan; Pembrolizumab; Sacituzumab tirumotecan	anti-Trop2_antibody-drug_conjugate; glucocorticoid; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + glucocorticoid	Dexamethasone + Pembrolizumab + Sacituzumab tirumotecan; Pembrolizumab; Dexamethasone + Pembrolizumab + Sacituzumab tirumotecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + glucocorticoid; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + glucocorticoid	2870-007	A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50%	Non-small Cell Lung Cancer (NSCLC)	2145 - Westmead - Westmead Hospital-Department of Medical Oncology ( Site 3000); 2444 - Port Macquarie - Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3002); 3076 - Epping - Northern Hospital ( Site 3003); 3350 - Ballarat Central - Grampians Health-Medical Oncology ( Site 3001)	https://clinicaltrials.gov/ct2/show/NCT06170788
NCT06174987	ROMast-001	Phase 3	RECRUITING	SA, VIC	2023-12-08	2024-01-05	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	ROMast-001	A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Advanced Cancer; Metastatic Cancer	3168 - Melbourne - Monash Medical Center - (WITHDRAWN); 5042 - Bedford Park - Flinders Medical Center	https://clinicaltrials.gov/ct2/show/NCT06174987
NCT06179160	INCB161734-101	Phase 1	RECRUITING	NSW, VIC, WA	2023-12-20	2024-01-04	Cetuximab; Cetuximab + INCB161734 + Retifanlimab; INCB161734; Retifanlimab	anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody; KRAS_G12D_inhibitor; KRAS_G12D_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Cetuximab + INCB161734 + Retifanlimab; INCB161734; Cetuximab + INCB161734 + Retifanlimab	KRAS_G12D_inhibitor; KRAS_G12D_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KRAS_G12D_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody	INCB161734-101	A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	Solid Tumors	02010 - Darlinghurst - St Vincent'S Hospital Sydney; 02050 - Camperdown - Chris Obrien Lifehouse; 03004 - Melbourne - The Alfred Hospital; 06009 - Nedlands - Linear Clinical Research; 3051 - North Melbourne - Peter Maccallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06179160
NCT06179511	D9470C00001	Phase 1/Phase 2	RECRUITING	VIC	2023-12-19	2024-01-31	AZD9829	anti-CD123_antibody-drug_conjugate	AZD9829	anti-CD123_antibody-drug_conjugate	D9470C00001	A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies	Hematological Malignancies	3084 - Heidelberg - Research Site; VIC 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06179511
NCT06184035	Tumorad	Phase 1/Phase 2	RECRUITING	SA, VIC	2023-12-14	2023-11-30					Tumorad-01	A Phase I/IIa, Dose Escalation and Dose Expansion, First-in-human, Open-label, Multicenter, Single-arm Study Evaluating the Safety, Tolerability, Dosimetry, and Early Efficacy of [177Lu]Lu-SN201 in Participants With Progressive or Treatment-refractory Locally Advanced Unresectable, Metastatic or Recurrent Solid Tumors	Solid Tumor; Metastatic Cancer; Unresectable Solid Tumor; Recurrent Solid Tumor; Locally Advanced Solid Tumor; Refractory Cancer	3065 - Melbourne - St Vincent Hospital Melbourne; 5000 - Adelaide - Cancer Research South Adelaide	https://clinicaltrials.gov/ct2/show/NCT06184035
NCT06188208	VVD-130850-01	Phase 1	RECRUITING	QLD, VIC	2023-12-31	2024-01-05	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	VVD-130850-01	A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 Inhibitor VVD-130850 as Single Agent and in Combination With Checkpoint Inhibition in Participants With Advanced Solid and Hematologic Tumors	Advanced Solid Tumors; Advanced Hematologic Tumors	Adelaide - Cancer Research South Australia; South Brisbane - ICON Cancer Research	https://clinicaltrials.gov/ct2/show/NCT06188208
NCT06188520	CYCAD-1	Phase 1/Phase 2	RECRUITING	VIC	2023-12-18	2023-12-05	AZD8421; AZD8421 + Abemaciclib + Camizestrant; AZD8421 + Camizestrant + Palbociclib; AZD8421 + Camizestrant + Ribociclib; Abemaciclib; Camizestrant; Palbociclib; Ribociclib	selective_estrogen_receptor_degrader; CDK2_inhibitor; CDK4/6_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader	AZD8421; AZD8421 + Abemaciclib + Camizestrant; AZD8421 + Camizestrant + Palbociclib; AZD8421 + Camizestrant + Ribociclib; AZD8421 + Abemaciclib + Camizestrant; AZD8421 + Camizestrant + Palbociclib; AZD8421 + Camizestrant + Ribociclib	CDK2_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader	D8470C00001	A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors	ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC)	3002 - East Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06188520
NCT06188702	CL1-95035-001	Phase 1	RECRUITING	NSW, VIC	2024-01-02	2024-04-29	Pemetrexed	antimetabolite	Pemetrexed	antimetabolite	CL1-95035-001	A Phase 1, Open-label, Multicenter Clinical Trial of S095035 (MAT2A Inhibitor) in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP	MTAP-deleted Solid Tumors	2031 - Randwick - Scientia Clinical Research; 3004 - Prahran - The Alfred	https://clinicaltrials.gov/ct2/show/NCT06188702
NCT06194877	BGB-3245-EGFR-001	Phase 1	RECRUITING	NSW, VIC	2023-12-22	2024-04-18	BGB-3245; BGB-3245 + Panitumumab; Panitumumab	anti-EGFR_monoclonal_antibody; RAF_dimer_inhibitor + anti-EGFR_monoclonal_antibody; RAF_dimer_inhibitor	BGB-3245 + Panitumumab; BGB-3245 + Panitumumab	RAF_dimer_inhibitor + anti-EGFR_monoclonal_antibody; RAF_dimer_inhibitor + anti-EGFR_monoclonal_antibody	BGB-3245-EGFR-001	A Phase 1b, Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 With Panitumumab in Patients With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers	Colorectal Cancer; Pancreatic Ductal Cancer; Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers	2145 - Westmead - Westmead Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06194877
NCT06198426	CIBI3004A101	Phase 1/Phase 2	NOT_YET_RECRUITING	NSW	2024-01-08	2024-05-01	IBI3004	unknown_drug_class	IBI3004	unknown_drug_class	CIBI3004A101	A Phase 1/2, Multicenter, Open-label Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	2770 - Randwick - Scientia Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT06198426
NCT06199908	AMT-562-01	Phase 1	NOT_YET_RECRUITING	NSW, VIC	2024-01-08	2024-03-31	AMT-562	anti-ERBB3_antibody-drug_conjugate	AMT-562	anti-ERBB3_antibody-drug_conjugate	AMT-562-01	First-in-Human, Phase 1 Study of AMT-562 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	Malvern - Cabrini Malvern Hospital; North Ryde - Macquarie University Hospital	https://clinicaltrials.gov/ct2/show/NCT06199908
NCT06203210	IDeate-Lung02	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2024-01-02	2024-05-21	Amrubicin; Amrubicin + Lurbinectedin + Topotecan; Lurbinectedin; Topotecan	topoisomerase_inhibitor; anthracycline; DNA_minor_groove-binding_agent + anthracycline + topoisomerase_inhibitor; DNA_minor_groove-binding_agent	Amrubicin + Lurbinectedin + Topotecan; Amrubicin + Lurbinectedin + Topotecan	DNA_minor_groove-binding_agent + anthracycline + topoisomerase_inhibitor; DNA_minor_groove-binding_agent + anthracycline + topoisomerase_inhibitor	DS7300-188	A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)	Small Cell Lung Cancer	2050 - Camperdown - Chris Oâbrien Lifehouse; 3021 - St Albans - Sunshine Hospital; 3350 - Ballarat - Ballarat Base Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 4814 - Townsville - Townsville Cancer Centre; 6008 - Subiaco - St John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT06203210
NCT06208657	OPTIMISE	Phase 1/Phase 2	NOT_YET_RECRUITING	NSW, QLD, SA, VIC, WA	2024-01-05	2024-03	Irinotecan; Irinotecan + Paxalisib + Temozolomide; Paxalisib; Pimasertib; Temozolomide	alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor; alkylating_agent; MEK_inhibitor; topoisomerase_inhibitor; dual_PI3K/mTOR_inhibitor	Irinotecan + Paxalisib + Temozolomide; Pimasertib; Irinotecan + Paxalisib + Temozolomide	MEK_inhibitor; alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor; alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor	OPTIMISE	Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer	Childhood Cancer; Childhood Solid Tumor; Childhood Brain Tumor; Recurrent Cancer; Refractory Cancer	Adelaide - Women's and Children's Hospital; Brisbane - Queensland Children's Hospital; Melbourne - Monash Children's Hospital; Melbourne - Royal Children's Hospital; Newcastle - John Hunter Children's Hospital; Perth - Perth Children's Hospital; Sydney - Sydney Children's Hospital, Randwick; Sydney - The Children's Hospital at Westmead	https://clinicaltrials.gov/ct2/show/NCT06208657
NCT06219941	D9800C00001	Phase 2	RECRUITING	NSW, VIC, WA	2024-01-12	2023-12-13	AZD0901; AZD0901 + Fluorouracil + Gemcitabine + Irinotecan + Leucovorin + Liposomal Irinotecan; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Liposomal Irinotecan	topoisomerase_inhibitor; gemcitabine; anti-CLDN18.2_antibody-drug_conjugate + antimetabolite + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; folinic_acid; anti-CLDN18.2_antibody-drug_conjugate	AZD0901; AZD0901 + Fluorouracil + Gemcitabine + Irinotecan + Leucovorin + Liposomal Irinotecan; AZD0901 + Fluorouracil + Gemcitabine + Irinotecan + Leucovorin + Liposomal Irinotecan	anti-CLDN18.2_antibody-drug_conjugate; anti-CLDN18.2_antibody-drug_conjugate + antimetabolite + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; anti-CLDN18.2_antibody-drug_conjugate + antimetabolite + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; gemcitabine	D9800C00001	A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2.	Gastric Cancer; Gastroesophageal Junction Cancer; Pancreatic Adenocarcinoma	2031 - Randwick - Research Site; 3000 - Melbourne - Research Site; WA6150 - Murdoch - Research Site	https://clinicaltrials.gov/ct2/show/NCT06219941
NCT06220864	SNV1521-101	Phase 1	RECRUITING	NSW, WA	2024-01-23	2024-02-23					SNV1521-101	A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors	Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research; 6009 - Crawley - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06220864
NCT06225596	BT8009-230	Phase 2/Phase 3	RECRUITING	QLD, SA	2024-01-24	2024-01-24	Avelumab; Avelumab + Carboplatin + Cisplatin + Gemcitabine; BT8009; BT8009 + Pembrolizumab; Carboplatin; Cisplatin; Gemcitabine; Pembrolizumab	gemcitabine; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bicycle_toxin_conjugate,NECTIN4-targeting; anti-PD-1_monoclonal_antibody; bicycle_toxin_conjugate,NECTIN4-targeting; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Avelumab + Carboplatin + Cisplatin + Gemcitabine; BT8009; BT8009 + Pembrolizumab; Avelumab + Carboplatin + Cisplatin + Gemcitabine; BT8009 + Pembrolizumab	anti-PD-1_monoclonal_antibody + bicycle_toxin_conjugate,NECTIN4-targeting; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; bicycle_toxin_conjugate,NECTIN4-targeting; anti-PD-1_monoclonal_antibody + bicycle_toxin_conjugate,NECTIN4-targeting; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	BT8009-230	A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)	Metastatic Urothelial Cancer	2310 - Hunter - Calvary Mater Newcastle; 4066 - South Brisbane - Icon Cancer Centre; 5000 - Adelaide - Cancer Research SA	https://clinicaltrials.gov/ct2/show/NCT06225596
NCT06226766	JSKN033-101	Phase 1/Phase 2	RECRUITING	NSW	2024-01-18	2024-01-18	Envafolimab; JSKN003	anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate	Envafolimab; JSKN003	anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody	JSKN033-101	Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors	Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06226766
NCT06233942	BG-C9074-101	Phase 1	RECRUITING	NSW, VIC, WA	2024-01-23	2024-04-12	Tislelizumab	anti-PD-1_monoclonal_antibody	Tislelizumab	anti-PD-1_monoclonal_antibody	BG-C9074-101	Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors	Advanced Solid Tumor	2109 - North Ryde - Macquarie University; 2500 - Wollongong - Cancer Care Wollongong; 3000 - Melbourne - Peter Maccallum Cancer Centre; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06233942
NCT06238479	LOXO-ENC-23001	Phase 1	RECRUITING	SA	2024-01-26	2024-03-05	LY4101174	anti-NECTIN4_antibody-drug_conjugate	LY4101174	anti-NECTIN4_antibody-drug_conjugate	LOXO-ENC-23001	A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors	Metastatic Solid Tumor; Recurrent Solid Tumor; Advanced Solid Tumor; Urinary Bladder Neoplasm; Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Esophageal Cancer; Pancreatic Cancer; Ovarian Cancer; Cervical Cancer; Head and Neck Squamous Cell Carcinoma; Prostate Cancer; Renal Pelvis Cancer; Bladder Cancer	5037 - Kurralta Park - Icon Cancer Centre Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT06238479
NCT06242470	CP-MGC026-01	Phase 1	RECRUITING	VIC	2024-02-01	2024-03-06	MGC026	anti-B7H3_antibody-drug_conjugate	MGC026	anti-B7H3_antibody-drug_conjugate	CP-MGC026-01	A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors	Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer; Squamous Cell Carcinoma of Head and Neck; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Castration Resistant Prostatic Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Gastro-esophageal Cancer; Pancreas Cancer; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma; Platinum-resistant Ovarian Cancer	Heidelberg - Austin Health- Olivia Newton John Cancer Center	https://clinicaltrials.gov/ct2/show/NCT06242470
NCT06242691	1200-002	Phase 1/Phase 2	RECRUITING	VIC	2024-01-26	2024-02-28	Dexamethasone	glucocorticoid	Dexamethasone	glucocorticoid	1200-002	A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors	Advanced Solid Tumors	3004 - Melbourne - The Alfred Hospital ( Site 0103)	https://clinicaltrials.gov/ct2/show/NCT06242691
NCT06253130	EIK1003-001	Phase 1/Phase 2	RECRUITING	NSW, QLD, VIC	2024-02-02	2023-12-11	IMP1734	PARP1-selective_inhibitor	IMP1734	PARP1-selective_inhibitor	EIK1003-001 (IMP1734-101)	A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research Ltd; 2109 - Sydney - Macquarie University; 3199 - Frankston - Peninsula and south eastern haematology and oncology group; 4101 - South Brisbane - Mater Cancer Care Centre, Mater Misericordiae Limited; 4102 - Woolloongabba - Princess Alexandra Hospital; 4125 - Southport - Gold Coast Private Hospital	https://clinicaltrials.gov/ct2/show/NCT06253130
NCT06256588	JADE	Phase 3	RECRUITING	NSW, QLD, VIC	2024-02-05	2024-03-21	Dostarlimab; Placebo	anti-PD-1_monoclonal_antibody; placebo	Dostarlimab; Placebo	anti-PD-1_monoclonal_antibody; placebo	221530	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Neoplasms, Head and Neck	2148 - Blacktown - GSK Investigational Site; 3004 - Melbourne - GSK Investigational Site; 3220 - Geelong - GSK Investigational Site; 3350 - Ballarat - GSK Investigational Site; 4029 - Herston - GSK Investigational Site; 4814 - Douglas - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT06256588
NCT06257264	BG-68501-101	Phase 1	RECRUITING	NSW	2024-02-05	2024-02-28	BG-68501; BG-68501 + Fulvestrant; Fulvestrant	selective_estrogen_receptor_degrader; CDK2_inhibitor; CDK2_inhibitor + selective_estrogen_receptor_degrader	BG-68501 + Fulvestrant; BG-68501 + Fulvestrant	CDK2_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + selective_estrogen_receptor_degrader	BG-68501-101	A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors	Breast Cancer; Small Cell Lung Cancer; Ovarian Cancer; Gastric Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced Solid Tumor; Endometrial Cancer; Prostate Cancer	2065 - St Leonards - Genesiscare North Shore; 2148 - Blacktown - Blacktown Cancer and Haematology Centre	https://clinicaltrials.gov/ct2/show/NCT06257264
NCT06267729	APOLLO	Phase 1/Phase 2	RECRUITING	VIC	2024-02-19	2024-03-12	AZD0754	allogeneic_CAR-T-cell_therapy,STEAP2-targeting	AZD0754	allogeneic_CAR-T-cell_therapy,STEAP2-targeting	D9660C00001	A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO	Metastatic Prostate Cancer	3002 - East Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06267729
NCT06302426	INI-4001-101	Phase 1	NOT_YET_RECRUITING	NSW, VIC	2024-03-04	2024-03-29	Atezolizumab; Atezolizumab + Avelumab + Cemiplimab + Durvalumab + INI-4001 + Nivolumab + Pembrolizumab; Avelumab; Cemiplimab; Durvalumab; INI-4001; Nivolumab; Pembrolizumab	anti-PD-L1_monoclonal_antibody; TLR7/8_agonist; anti-PD-1_monoclonal_antibody; TLR7/8_agonist + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Atezolizumab + Avelumab + Cemiplimab + Durvalumab + INI-4001 + Nivolumab + Pembrolizumab; Atezolizumab + Avelumab + Cemiplimab + Durvalumab + INI-4001 + Nivolumab + Pembrolizumab	TLR7/8_agonist + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; TLR7/8_agonist + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	INI-4001-101	An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours	Advanced Solid Tumor	2640 - Albury - The Border Cancer Hospital; 3144 - Malvern - Cabrini Hospital	https://clinicaltrials.gov/ct2/show/NCT06302426
NCT06305962	177Lu-RAD204.2023.0001	EARLY_Phase 1	RECRUITING	NSW, QLD, WA	2024-03-07	2024-06	177Lu-RAD204	177Lu-anti-PD-L1_radioconjugate	177Lu-RAD204	177Lu-anti-PD-L1_radioconjugate	177Lu-RAD204.2023.0001	Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Non-small Cell Lung Cancer	PDL1 Gene Mutation; Non Small Cell Lung Cancer	2500 - Wollongong - Wollongong Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 6009 - Nedlands - Hollywood Private Hospital	https://clinicaltrials.gov/ct2/show/NCT06305962
NCT06307015	DE-RADIATE	NA	NOT_YET_RECRUITING	NSW	2024-03-06	2024-04	Radiotherapy	radiotherapy	Radiotherapy	radiotherapy	2023/ETH02441	De-escalation of Radiation Dose in HPV-associated Oropharyngeal Squamous Cell Carcinoma Utilising FMISO PET and Magnetic Resonance Imaging as Non-Invasive Biomarkers of Hypoxia (DE-RADIATE)	HPV Positive Oropharyngeal Squamous Cell Carcinoma	2065 - Saint Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT06307015
NCT06318273	M24-742	Phase 1	RECRUITING	VIC	2024-03-13	2024-03-08	ABBV-969	anti-PSMA∕STEAP1_antibody_drug_conjugate	ABBV-969	anti-PSMA∕STEAP1_antibody_drug_conjugate	M24-742	A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-Resistant Prostate Cancer	3065 - Fitzroy - St Vincent's Hospital /ID# 264293	https://clinicaltrials.gov/ct2/show/NCT06318273
NCT06325748	SENTI-202-101	Phase 1	RECRUITING	NSW, VIC	2024-03-19	2024-04-22	Fludarabine	antimetabolite	Fludarabine	antimetabolite	SENTI-202-101	SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Hematological Malignancies	AML/MDS; CD33 Expressing Hematological Malignancies; FLT3 Expressing Hematological Malignancies	2050 - Camperdown - Royal Prince Alfred Hospital; 3000 - Melbourne - Peter MacCallum Cancer Center	https://clinicaltrials.gov/ct2/show/NCT06325748
NCT06326411	NST-628	Phase 1	RECRUITING	NSW, QLD, SA, WA	2024-03-21	2024-04-09	NST-628	pan-RAF/MEK_glue	NST-628	pan-RAF/MEK_glue	NST-628-001	A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors	Oncology; MEK Mutation; RAF Gene Mutation; Ras (KRAS or NRAS) Gene Mutation; Melanoma; NSCLC; Glioma; Solid Tumor, Adult; MAPK Pathway Gene Mutation	120 - Greenslopes - Gallipoli Medical Research Centre- Greenslopes Private Hospital; 2010 - Sidney - The Kinghorn Cancer Center, St. Vincent's Health Network; 2031 - Rand - Scientia Clinical Research, Ltd; 5042 - Adelaide - Southern Oncology Research Unit; 6009 - Nedlands - One Clinical Research, Pty Ltd	https://clinicaltrials.gov/ct2/show/NCT06326411
NCT06336148	ACTM-838-01	Phase 1	NOT_YET_RECRUITING	NSW, SA, VIC	2024-03-22	2024-04	ACTM-838	IL-15/STING_variant,S.Typhimurium-attenuated_bacterial_cancer_therapy	ACTM-838	IL-15/STING_variant,S.Typhimurium-attenuated_bacterial_cancer_therapy	ACTM-838-01	A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients With Advanced Solid Tumors	Solid Tumor	2145 - Westmead - Westmead Hospital, Cnr Hawkesbury Road and Darcy Road, Site No: 200; 3004 - Melbourne - Alfred Hospital, 55 Commercial Road, Site No: 201; 5042 - Bedford Park - Southern Oncology Clinical Research Unit, Level 3, Mark Oliphant Building, 5 Laffer Drive, Site No: 202	https://clinicaltrials.gov/ct2/show/NCT06336148
NCT06337084	MNPR-101-D001	Phase 1	RECRUITING	VIC	2024-03-28	2024-04-10					MNPR-101-D001	Open Label Pilot Study Evaluating Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors	Solid Tumor, Adult; Bladder Cancer; Urothelial Carcinoma; Triple-negative Breast Cancer; Lung Cancer; Colorectal Cancer; Gastric Cancer; Ovarian Cancer; Pancreatic Cancer	3051 - North Melbourne - Melbourne Theranostic Innovation Centre (MTIC)	https://clinicaltrials.gov/ct2/show/NCT06337084
NCT06341647	AB-201-01	Phase 1	NOT_YET_RECRUITING	VIC	2024-03-26	2024-08-31	AB-201; AB-201 + Cyclophosphamide + Fludarabine; Cyclophosphamide; Fludarabine	antimetabolite; alkylating_agent; alkylating_agent + allogeneic_CAR-NK-cell_therapy,ERBB2-targeting + antimetabolite; allogeneic_CAR-NK-cell_therapy,ERBB2-targeting	AB-201 + Cyclophosphamide + Fludarabine; AB-201 + Cyclophosphamide + Fludarabine	alkylating_agent + allogeneic_CAR-NK-cell_therapy,ERBB2-targeting + antimetabolite; alkylating_agent + allogeneic_CAR-NK-cell_therapy,ERBB2-targeting + antimetabolite	AB-201-01	A Multicenter, Open-label, Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced Human Epidermal Growth Factor Receptor 2 Positive(HER2+) Solid Tumors	Breast Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - The Alfred Hosptial	https://clinicaltrials.gov/ct2/show/NCT06341647
NCT06343402	TBBO8520-101	Phase 1	RECRUITING	VIC	2024-04-01	2024-05-22	Pembrolizumab; Tegafur-gimeracil-oteracil potassium	antimetabolite; anti-PD-1_monoclonal_antibody; orotate_phosphoribosyltransferase_inhibitor; DPD_inhibitor	Pembrolizumab; Tegafur-gimeracil-oteracil potassium	anti-PD-1_monoclonal_antibody; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	TBBO8520-101	A Phase 1a/1b Open-Label Study of BBO-8520 Monotherapy and BBO-8520 in Combination With Pembrolizumab in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - the ONKORAS-101 Study	Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; NSCLC; KRAS G12C; Metastatic Lung Cancer; Advanced Lung Carcinoma	3051 - Melbourne - Peter MacCallum Cancer Centre; 3199 - Frankston - Peninsula & South Eastern Hematology and Oncology Group (PAS)	https://clinicaltrials.gov/ct2/show/NCT06343402
NCT06345079	STOPNET	Phase 2	NOT_YET_RECRUITING	QLD	2024-04-01	2024-07	Octreotide	somatostatin_analog	Octreotide	somatostatin_analog	AG0219NET	A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (STOPNET)	Neuroendocrine Tumors	4006 - Brisbane - Royal Brisbane Women's Hospital	https://clinicaltrials.gov/ct2/show/NCT06345079
NCT06349408	CIBI3001A101	Phase 1/Phase 2	NOT_YET_RECRUITING	NSW	2024-04-01	2024-05-30	IBI3001	anti-EGFR/B7H3_antibody-drug_conjugate	IBI3001	anti-EGFR/B7H3_antibody-drug_conjugate	CIBI3001A101	A Phase 1/2 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors	Locally Advanced Solid Tumor	2500 - Wollongong - Wollongong Public	https://clinicaltrials.gov/ct2/show/NCT06349408
NCT06350097	TROPION-Lung14	Phase 3	RECRUITING	NSW, VIC	2024-04-02	2024-04-29	Datopotamab deruxtecan; Datopotamab deruxtecan + Osimertinib; Osimertinib	anti-Trop2_antibody-drug_conjugate; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; EGFR_inhibitor,third_generation	Datopotamab deruxtecan + Osimertinib; Osimertinib; Datopotamab deruxtecan + Osimertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate	D516NC00001	A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer	Non-small Cell Lung Cancer	2145 - Westmead - Research Site; 2217 - Kogarah - Research Site; 3168 - Clayton - Research Site	https://clinicaltrials.gov/ct2/show/NCT06350097
NCT06351904	RAG-01-01	Phase 1	RECRUITING	NSW, VIC	2024-04-02	2024-04-03	Bacillus Calmette-Guérin	BCG_vaccine	Bacillus Calmette-Guérin	BCG_vaccine	RAG-01-01	A Phase Ⅰ, Open Label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy	Non-Muscle-Invasive Bladder Cancer (NMIBC)	2065 - St Leonards - GenesisCare North Shore; 3050 - Melbourne - The Royal Melbourne Hospital; 3199 - Melbourne - Peninsula & South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT06351904
NCT06353386	5684-01A	Phase 1/Phase 2	RECRUITING	NSW, QLD, VIC	2024-04-03	2024-05-20	Cabazitaxel; Cabazitaxel + Dexamethasone + Opevesostat + Prednisone; Dexamethasone; Dexamethasone + Docetaxel + Opevesostat + Prednisone; Dexamethasone + Olaparib + Opevesostat; Dexamethasone + Opevesostat; Docetaxel; Olaparib; Opevesostat; Prednisone	CYP11A1_inhibitor + PARP_inhibitor + glucocorticoid; CYP11A1_inhibitor; PARP_inhibitor; CYP11A1_inhibitor + glucocorticoid + taxane; glucocorticoid; taxane; CYP11A1_inhibitor + glucocorticoid	Cabazitaxel + Dexamethasone + Opevesostat + Prednisone; Dexamethasone + Docetaxel + Opevesostat + Prednisone; Dexamethasone + Olaparib + Opevesostat; Dexamethasone + Opevesostat; Cabazitaxel + Dexamethasone + Opevesostat + Prednisone; Dexamethasone + Docetaxel + Opevesostat + Prednisone; Dexamethasone + Olaparib + Opevesostat; Dexamethasone + Opevesostat	CYP11A1_inhibitor + PARP_inhibitor + glucocorticoid; CYP11A1_inhibitor + glucocorticoid; CYP11A1_inhibitor + glucocorticoid + taxane; CYP11A1_inhibitor + PARP_inhibitor + glucocorticoid; CYP11A1_inhibitor + glucocorticoid; CYP11A1_inhibitor + glucocorticoid + taxane	5684-01A	MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)	Prostatic Neoplasms, Castration-Resistant	2109 - Macquarie University - Macquarie University-MQ Health Clinical Trials Unit ( Site 0108); 3000 - Melbourne - Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0110); 4120 - Greenslopes - Gallipoli Medical Research Ltd-GMRF CTU ( Site 0107)	https://clinicaltrials.gov/ct2/show/NCT06353386
NCT06357533	TROPION-Lung10	Phase 3	RECRUITING	QLD, VIC	2024-04-05	2024-04-11	Datopotamab deruxtecan; Datopotamab deruxtecan + Rilvegostomig; Pembrolizumab; Rilvegostomig	anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; bispecific_PD-1/TIGIT_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody	Datopotamab deruxtecan + Rilvegostomig; Pembrolizumab; Rilvegostomig; Datopotamab deruxtecan + Rilvegostomig	anti-PD-1_monoclonal_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; bispecific_PD-1/TIGIT_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody	D7632C00001	A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)	Non-Small Cell Lung Cancer	3000 - Melbourne - Research Site; 3168 - Clayton - Research Site; QL 4101 - South Brisbane - Research Site	https://clinicaltrials.gov/ct2/show/NCT06357533
NCT06365853	IMGN853-0424	Phase 2	NOT_YET_RECRUITING	VIC	2024-04-10	2024-06-30	Mirvetuximab Soravtansine; Mirvetuximab Soravtansine + Prednisolone; Prednisolone	anti-FR-alpha_antibody-drug_conjugate + glucocorticoid; anti-FR-alpha_antibody-drug_conjugate; glucocorticoid	Mirvetuximab Soravtansine; Mirvetuximab Soravtansine + Prednisolone; Mirvetuximab Soravtansine + Prednisolone	anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate + glucocorticoid; anti-FR-alpha_antibody-drug_conjugate + glucocorticoid	IMGN853-0424	A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression	Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive	Clayton - Monash University - Monash Medical Centre (MMC) - Clayton	https://clinicaltrials.gov/ct2/show/NCT06365853
NCT06372574	GO44669	Phase 1	RECRUITING	VIC	2024-04-15	2024-07-01	RO7617991; RO7617991 + Tocilizumab; Tocilizumab	anti-IL-6_monoclonal_antibody + unknown_drug_class; unknown_drug_class; anti-IL-6_monoclonal_antibody	RO7617991 + Tocilizumab; RO7617991 + Tocilizumab	anti-IL-6_monoclonal_antibody + unknown_drug_class; anti-IL-6_monoclonal_antibody + unknown_drug_class	GO44669	A Phase I, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7617991 in HLA-A*02-Positive Patients With Locally Advanced and/or Metastatic MAGE-A4-Positive Solid Tumors	Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult	3002 - East Melbourne - Peter MacCallum Cancer Centre-Box Hill	https://clinicaltrials.gov/ct2/show/NCT06372574
NCT06400485	AMT-676-01	EARLY_Phase 1	NOT_YET_RECRUITING	NSW, New South wWales, QLD, VIC, WA	2024-05-01	2024-06-01	AMT-676	anti-CDH17_antibody-drug_conjugate	AMT-676	anti-CDH17_antibody-drug_conjugate	AMT-676-01	First-in-Human, Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	Greenslopes - Gallipoli Medical Research Foundation; Macquarie - Macquarie University Hospital; Melbourne - Cabrini Hospital; Nedlands - Linear Research; Randwick - SCIENTIA Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT06400485
NCT06418061	CIBI3005A101	Phase 1	NOT_YET_RECRUITING	WA	2024-05-13	2024-06-30	IBI3005	unknown_drug_class,bispecific_antibody	IBI3005	unknown_drug_class,bispecific_antibody	CIBI3005A101	A Phase 1, Multicenter, Open-label Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumors	6009 - Nedlands - One Clinical Research Pty Ltd	https://clinicaltrials.gov/ct2/show/NCT06418061
NCT06431594	GSK5733584-222730	Phase 1	NOT_YET_RECRUITING	NSW	2024-05-22	2024-06-21	GSK5733584	anti-B7H4_antibody-drug_conjugate	GSK5733584	anti-B7H4_antibody-drug_conjugate	222730	A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects With Advanced Solid Tumors	Solid Tumors	2109 - Sydney - GSK Investigational Site; 2148 - Blacktown - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT06431594
NCT06441747	BIL-PPP	Phase 2	NOT_YET_RECRUITING	NSW, QLD, SA, VIC, WA	2024-05-29	2024-08	Durvalumab; Durvalumab + Olaparib; Olaparib	anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; PARP_inhibitor	Durvalumab + Olaparib; Durvalumab + Olaparib	PARP_inhibitor + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody	BIL-PPP	Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)	Cholangiocarcinoma	2050 - Camperdown - Chris O'Brien Lifehouse; 2145 - Westmead - Westmead Hospital; 2500 - Wollongong - Wollongong Hospital; 3021 - Saint Albans - Western Health; 3084 - Melbourne - Austin Health; 3168 - Clayton - Monash Medical Centre; 4006 - Brisbane - Royal Brisbane Women's Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; Bedford Park - Flinders Medical Centre; Perth - St John of God Hospital, Subiaco	https://clinicaltrials.gov/ct2/show/NCT06441747
NCT06452277	SOHO-02	Phase 3	NOT_YET_RECRUITING	ACT, NSW	2024-06-05	2024-06-24	BAY2927088; Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Pembrolizumab; Pemetrexed	antimetabolite; anti-PD-1_monoclonal_antibody; ERBB2_inhibitor,exon_20_selective; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; EGFR_inhibitor,exon_20_selective	BAY2927088; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	22615	A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations	Advanced Non-small Cell Lung Cancer; HER2 Mutation	2170 - Liverpool - Blacktown Cancer & Haematology Centre; 2298 - Waratah - Calvary Mater Hospital Newcastle; 2605 - Garran - The Canberra Hospital (TCH) - Canberra Region Cancer Centre (CRCC)	https://clinicaltrials.gov/ct2/show/NCT06452277
NCT06478693	MTX-GPC3-303	Phase 1	RECRUITING	NSW, QLD, VIC, WA	2024-06-24	2024-07-01	MT-303	GPC3-targeting_lipid-nanoparticles	MT-303	GPC3-targeting_lipid-nanoparticles	MTX-GPC3-303	A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma	Hepatocellular Carcinoma	2010 - Sydney - St Vincent's Hospital; 3004 - Melbourne - The Alfred Hospital; 4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd; 6150 - Murdoch - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06478693
